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Abstract 
Background 
UK care home residents are prescribed an average of 8-10 medicines daily with evidence that 
inappropriate prescribing is prevalent leading to problematic polypharmacy. This increases the 
risk of adverse drug events that negatively affect resident outcomes, quality-of-life and have 
financial costs to the NHS. Deprescribing (the cessation of inappropriate medicines) can reduce 
inappropriate prescribing, however, there are significant barriers to its implementation in this 
setting. Identifying and understanding barriers and facilitators of stopping inappropriate 
medicines is necessary to improve the implementation of deprescribing in care homes. 
Method 
A literature review was conducted to synthesise existing evidence. Semi-structured interviews 
were conducted with residents, relatives, care home staff, GPs and pharmacists. Themes and 
explanations were developed using Framework Analysis. Theoretical models of behaviour 
change were applied to identify candidate components for a novel intervention for deprescribing 
in care homes. 
Findings 
The literature review highlighted a lack of evidence regarding residents’ and relatives’ attitudes 
to deprescribing, and a lack of depth regarding barriers and facilitators to deprescribing. Three 
themes were identified from the empirical data: 1) individuals involved in the deprescribing 
process; 2) social barriers; 3) logistical barriers. Theme 1 highlighted the complexity of the 
deprescribing process and themes 2&3 identified and explained systematic barriers and 
facilitators to deprescribing. Social barriers included a reluctance to discuss life expectancy and 
healthcare professionals’ perceptions of residents and relatives. Logistical barriers included the 
unavailability of key stakeholders and navigating health and social care systems. 
Potential intervention components included; demonstrating the behaviour of deprescribing, 
providing feedback on its outcomes plus provision of prompts. 
Conclusions 
This thesis has provided novel, in-depth explanation and insight of the barriers and facilitators to 
deprescribing from the perspective of key stakeholders. This was utilised to identify potential 
components of a deprescribing behaviour change intervention for implementation and 
evaluation in care homes. 
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Chapter 1 Introduction 
There are approximately 400,000 people aged 65 years old or older living in nursing or 
residential homes in the United Kingdom (UK) (Age UK, 2019).  Nursing homes provide 24-hour 
nursing care from registered nurses, and residential homes are staffed by carers who provide 
personal care only to residents.  Both of these come under the umbrella term “care homes”, and 
are considered when the term care home is used throughout this thesis.  Care homes may be a 
single, privately owned home, part of a privately owned chain, or owned by a local council or a 
charitable organisation. 
Globally, the number of older people is increasing and thus the population of care homes is 
likely to increase. By 2050, it is predicted that the proportion of people aged over 60 in the world 
will double to reach 22% from 900 to 2,100 million people (World Health Organisation, 2016).  In 
Europe 34% of the population will be over 60 years old (World Health Organisation, 2016).  The 
population of those over 60 is also set to rise rapidly in countries with a younger population, with 
an increase of 100 million in this population of Africa by 2050 (World Health Organisation, 
2016).  Consequently, there is likely to be an increased demand for long-term care facilities for 
older people.  Care of older people differs around the world, and the World Health Organisation 
(WHO) is undertaking comprehensive research that aims to improve the health of older people 
worldwide.  This includes an investigation of the settings and providers of long term care for 
older people, which can range from family members in a home environment to qualified nurses 
in a specialised facility (World Health Organisation, 2016).  
Of particular relevance to this thesis are the provision of care to older people in countries in 
which deprescribing research has been undertaken.  This includes the UK, Australia, the United 
States, New Zealand and Belgium, a country in Europe and a member of European Union.  
Most of these countries have adopted a variation of residential and nursing homes as 
terminology, however Australia and New Zealand both refer to care homes with different terms.  
In Australia, residential aged care homes is the preferred terminology, while in New Zealand, 
residential homes are referred to as rest homes, and nursing homes are called long stay 
hospitals (Australian Government Department of Health, 2020; New Zealand Government, 
2020a).  241,723 people received care in a residential aged care facility in Australia in the year 
2017-2018 (Australian Government Department of Health, 2020).  Care homes also operate 
similarly across the US, Canada, New Zealand, Australia and Europe, with care homes being 
owned and operated by a mixture of government bodies, private companies and not-for-profit 
organisations (Australian Government Department of Health, 2020; New Zealand Government, 
2020b, Government of Canada, 2020; Eurofund, 2017; U. S Department of Health and Human 
Services, 2019).  Most care homes in the US and Europe are operated for profit by private 
17 
 
 
companies, with 69% of nursing homes and 81% of care homes in the US being operated in this 
way (Eurofund, 2017;U.S Department of Health and Human Services, 2019) .  However, in 
Australia the majority of care is provided by not-for-profit organisations and there are more not-
for-profit care homes being opened in Belgium than there are ones that are run-for-profit 
(Australian Government Department of Health, 2020; Eurofund, 2017).  The extent to which the 
Governments of various countries are involved in care homes differs, too.  In the UK, Australia 
and the US some aspects of care, such as regulation, are determined centrally by the 
Government with other responsibilities devolved to localised bodies (Care Quality Commission, 
2017; Australian Government Department of Health, 2020; U.S Department of Health and 
Human Services, 2019).  In Canada, the central Government has no responsibility for care 
homes and each territory is responsible for the operation of care homes in their area 
(Government of Canada, 2020).  As a result, the terminology utilised to refer to care homes 
differs from region to region and therefore, comparing Canadian care homes to other countries 
is challenging (Government of Canada, 2020). 
People living in this setting often have more complicated medical histories than other patients, 
as the complexity of their illnesses can lead to care home admission when their conditions can 
no longer be managed at home (Baylis and Perks-Baker, 2017).  Care home residents typically 
have multiple health conditions and complications such as cognitive impairment; it is estimated 
that 70% of care home residents in the UK live with dementia or other cognitive impairment 
(Age UK, 2019).  In the UK, Gordon et al (2014) reported that care home residents lived with an 
average of six medical diagnoses, which included conditions such as dementia, hypertension, 
Type 2 diabetes and renal failure.  To treat or prevent illness, care home residents are 
prescribed an average of 8-10 medicines every day (Barber et al., 2009).  Taking multiple 
medicines (polypharmacy) can increase a resident’s risk of adverse drug reactions, drug 
interactions, falls and hospital admissions, all of which can affect their quality-of-life (Alldred et 
al, 2016; Barber et al, 2009; Age UK, 2019) 
This introductory chapter provides the context for this thesis.  The concepts of polypharmacy 
and deprescribing are introduced, which includes characterisation of deprescribing as a 
behaviour.  Deprescribing is characterised as a behaviour throughout this thesis, and behaviour 
change psychology was applied to provide an understanding of deprescribing.  This chapter 
also describes the setting for this study: care homes in England, which includes a description of 
care homes and their position in the health and social care system.  Finally, the policies which 
are informing practice in England regarding care homes and inappropriate prescribing are 
introduced to provide the wider context of this empirical research.  
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1.1 Polypharmacy and suboptimal prescribing care homes: 
background to the thesis 
1.1.1 Defining polypharmacy 
Polypharmacy means “multiple medicines”, and it has been demonstrated that polypharmacy 
can cause harm, as will be described in detail below.  It is a concept for which there are many 
definitions.  Masnoon et al (2017) conducted a systematic review examining the multiple 
definitions of polypharmacy and collated 138 definitions of polypharmacy, with the majority of 
these (81%) being numerical definitions.  Of these, almost half (46%) referred to polypharmacy 
as being more than five medicines with the others ranging from two to eleven medicines.  The 
remaining definitions were numerical, but specific to a setting or condition (11%), or descriptive 
(8%).  Masnoon et al (2017) noted that numerical definitions of polypharmacy were not always 
relevant in a clinical setting, because polypharmacy may sometimes be necessary to treat 
multiple co-morbidities.  Instead, there has been a shift towards defining polypharmacy as 
“appropriate” and “inappropriate”, or “problematic”.  However, only 6.4% of definitions included 
in Masnoon et al’s (2017) study made such distinctions. 
The King’s Fund report on polypharmacy and medicines optimisation also made the distinction 
between appropriate and problematic polypharmacy (Duerden et al, 2013).  It was 
acknowledged that polypharmacy may be beneficial, provided that the medicines were 
optimised and the treatment aimed to maintain quality of life and improve longevity (Duerden et 
al, 2013).  The definition of problematic polypharmacy included the inappropriate prescription of 
multiple medicines, as well as instances where the potential benefit of a medicine was not 
realised.  The King’s Fund also assigned meaning to problematic medicines by describing when 
a medicine may be inappropriate described in Figure 1:  
- The treatments are not evidence-based 
- The risk of harm from treatments is likely to outweigh benefit,  
- A drug combination is hazardous because of interactions  
- The overall demands of medicine-taking, or ‘pill burden’, are unacceptable to the patient, 
which may affect adherence 
- Medicines are being prescribed to treat the adverse effects of other medicines where 
alternative solutions are available to reduce the number of medicines (this may include 
medicines prescribed to treat the adverse effects of a medicine where the initial 
medicine has been stopped) 
 
 
Inappropriate prescribing is prevalent in older people, especially those who live in care homes, 
and so it is highly likely that there are people living in care homes with problematic 
Figure 1: Inappropriate polypharmacy as defined by the King's Fund (Duerden et al, 2013) 
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polypharmacy (Shah et al, 2013; Stafford et al, 2011).  Stafford et al (2011) reported that 
inappropriate prescribing, defined by application of the Beers and McLeod criteria (lists of 
medicines which may be inappropriate to prescribe to older people) to resident’s medicines, was 
widespread in Australian care homes (Poudel et al, 2013).  In the UK, Barber et al (2009) 
reported that there was a high rate of prescribing and monitoring errors in care homes: 39% of 
residents were subject to a prescribing error, and 24% of these were deemed to be prescribed 
an unnecessary medicine.  Furthermore, 18% of residents prescribed a medicine with 
monitoring requirements were not being met (Barber et al, 2009).  Such prescribing errors led to 
care home residents receiving inappropriate medicines and being exposed to harm from these 
medicines. 
Polypharmacy in older people has been associated with adverse drug reactions, falls, mortality, 
and an increased length of hospital admission (Masnoon et al, 2017; Milton et al, 2008).  
However, it is difficult to determine whether these outcomes are caused by polypharmacy or the 
patient’s pre-existing condition(s) (Wastesson et al, 2018).  The impact of polypharmacy on 
such clinical outcomes is also difficult to determine due to the observational design of studies.  
Wastesson et al (2018) noted that the effect of a participant’s illness on the outcome of a trial of 
a medicine, “confounding by indication”, was usually accounted for through study design and 
statistical analysis (Kyriacou and Lewis, 2016).  However, people taking multiple medicines 
typically have more than one condition, which increases the challenge of accounting for bias 
caused by confounding by indication.  Wastesson et al (2018) suggested that “confounding by 
multimorbidity” may be more appropriate for polypharmacy studies, and that existing studies did 
not sufficiently account for this bias.  Studies of polypharmacy also displayed a preference 
towards a numerical definition of polypharmacy, which lacked the nuance of a more descriptive 
definition which accounted for appropriate polypharmacy.  This made it difficult to determine the 
effect of polypharmacy alone on a trial participant’s outcomes, and to determine the negative 
effects which polypharmacy was responsible for.  Nevertheless, stopping inappropriate 
medicines may reduce the risk of a patient experiencing harm from a medicine that they did not 
need to take.  
1.1.2 Causes of polypharmacy 
A common cause of polypharmacy, especially in older people, is multimorbidity with studies 
suggesting that greater than 50% of older people live with at least two long-term conditions 
(Jokanovic et al, 2015).  Treatment for each long-term condition is typically by single-disease 
guidance which recommend medicines to treat each condition (Wastesson et al, 2018).  
However, there is little guidance available to aid clinicians treating those with more than one 
condition.  Consequently, for example, an older person who had experienced a myocardial 
infarction and lived with Type 2 diabetes and dementia would be treated according to three 
different guidelines.  This can lead to problematic polypharmacy, as medicines prescribed for 
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the different conditions interact with each other, the patient’s conditions and the patient’s 
physiological status (drug-drug interactions and drug-disease interactions) (Wastesson et al, 
2018).  Randomised controlled trials do not typically involve people who have been diagnosed 
with, and are being treated, for other conditions and so there is a lack of evidence about how to 
treat multimorbid patients (Wastesson et al, 2018). 
The issues that can be caused by following guidelines for multiple conditions in multimorbid 
patients were highlighted by Dumbreck et al (2015).  Dumbreck et al (2015) conducted a 
systematic examination of the potential drug-drug and drug-disease interactions which may 
occur when medicines are prescribed according to the UK guidance for 12 common conditions.  
The medicines recommended as first- or second-line treatment by the National Institute for 
Health and Care Excellence (NICE) in the UK for conditions including Type 2 diabetes, 
depression and heart failure.  Prescribing medicines for Type 2 diabetes, according to the 
guideline, and the 11 other conditions included in the study gave rise to 32 potentially serious 
drug disease interactions (Dumbreck et al, 2015).  The majority (84%) of these interactions 
referred to interactions between medicines and poor kidney function.  Furthermore, 133 drug-
drug interactions were identified between medicines prescribed for type 2 diabetes and the 11 
other conditions included in the study, of which 19% were potentially serious (Dumbreck et al, 
2015).  The NICE guidelines rarely alerted clinicians to the potential of drug interactions 
(Dumbreck et al, 2015).   
Poor management of medicines can lead to polypharmacy, especially as a person becomes 
older (Masnoon et al, 2017).  Older people taking multiple medicines are susceptible to both 
pharmacokinetic and pharmacodynamic drug interactions and advanced age impacts upon 
these in several ways.  For example, changes in renal function may affect the elimination of a 
medicine and changes in hepatic function may affect the way a medicine is metabolised (Klotz, 
2009).  Older people also have less muscle mass and more fat tissue than younger people, 
which affects the distribution of medicines in the body (Petrovic et al, 2003; Klotz, 2009).  This 
can increase the half-life of medicines such as benzodiazepines leading to prolonged effects 
compared with younger people.   
1.1.3 Polypharmacy policies and guidance in the UK 
There are several policies, reports and reviews in the UK which inform the use of medicines in 
care homes, as well as several policies to inform the management of polypharmacy.  In 2018, 
the UK government announced the National Overprescribing Review to examine the factors 
contributing to the large amount of medicines prescribed in the UK, including the problematic 
polypharmacy experienced by individuals.  The remit of the Review is presented in Figure 2 
below: (Department of Health and Social Care, 2018):   
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- Problematic polypharmacy 
- The transfer of information between primary and secondary care 
- The management of non-reviewed repeat prescriptions 
- The role of technology 
- Alternatives to medicines, such as social prescribing 
 
 
This review will address multiple issues related to problematic pharmacy raised throughout this 
chapter, and the thesis as a whole.  The commissioning of this review provides support to the 
central tenet of this thesis: problematic polypharmacy is a national issue, and that research is 
required in order to determine how it should be reduced. 
Whilst there is no current UK policy on deprescribing, there is policy relating to polypharmacy 
and medicines optimisation through medicine review.  However, medicines optimisation has a 
wider remit than deprescribing.  As well as stopping medicines, medicines optimisation also 
includes the initiation of appropriate medicines, the reduction and increasing of doses and the 
monitoring of medicines (Scottish Government Polypharmacy Model of Care Group, 2018).  The 
Scottish government produced guidance which is also utilised by healthcare professionals in 
England (Scottish Government Polypharmacy Model of Care Group, 2018).  This guidance 
presents the seven steps to appropriate polypharmacy: steps which should be considered 
during a medicine review and could lead to deprescribing.  These are presented in Figure 3: 
 
Step 1. Identify what matters to the patient 
Step 2. Identify essential drug therapy 
Step 3. Does the patient take unnecessary drug therapy? 
Step 4. Are therapeutic objectives being achieved? 
Step 5. Is the patient at risk of adverse drug reactions (ADRs) or suffers actual ADRs? 
Step 6. Is drug therapy cost effective? 
Step 7. Is the patient willing and able to take drug therapy as intended? 
 
 
The Royal Pharmaceutical Society (RPS) have also produced guidance on medicines 
optimisation which could inform the process in care homes, and lead to a reduction in 
inappropriate prescribing in this setting (Royal Pharmaceutical Society, 2020).  The RPS’ and 
Scottish Government’s polypharmacy guidance both place the patient at the heart of decision-
making and encourage healthcare professionals to try to understand the patient’s experience, 
Figure 3: NHS Scotland's 7 steps to appropriate polypharmacy (Scottish Government 
Polypharmacy Model of Care Group, 2018) 
Figure 2: Remit of the National Overprescribing Review (Department of Health 
and Social Care, 2018) 
i r  : Th  remit of the National Overprescribing Review (ref) 
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priorities and ability to use medicines as a part of their review.  England’s National Health 
Service (NHS) reflects that the patient should be at the centre at, and involved in, decision-
making.  By 2023/24, the NHS aims to implement a comprehensive model for personalised 
care, and shared decision-making is a part of this.  The NHS defines shared decision-making as 
requiring two experts to share responsibility for decisions (NHS England, 2020):  
- The healthcare professional, who understands treatment risks and benefits 
- The patient, who is an expert in their beliefs, priorities and social circumstances. 
As the NHS aims to deliver the comprehensive model, healthcare professionals are being 
directed to provide shared decision-making and to encourage patients to contribute to the 
decision as an equal (NHS England, 2020). 
Both sets of guidance also aim to ensure that medicines use is safe.  The Scottish 
Government’s polypharmacy guidance breaks down the steps of a medicines review and aids 
the healthcare professional in the undertaking of individual reviews.  The RPS guidance 
encourages the healthcare professional to reflect on their practice, and to consider what is 
important when doing a medicines review.  When viewed together, they provide a structure to 
facilitate healthcare professionals performing medicines optimisation.  This could include those 
who are working in care homes, attempting to reduce inappropriate prescribing. 
1.2 Deprescribing: one potential solution 
Recently, there has been an increasing amount of interest and research into optimising 
medicine regimens and “deprescribing” in care homes.  This is likely due to the prevalence of 
problematic polypharmacy in this setting and the associated adverse outcomes, as described 
above.  Deprescribing is a relatively new term which, according to Reeve et al. (2015) and 
Alldred (2014), was first used in 2003 by (Woodward, 2003).  Since then, the term has been 
defined as variations of “drug discontinuation” (Scott et al., 2013).  The following definition was 
the result of a systematic review which was conducted in order to define the word deprescribing:  
 “the process of a trial of withdrawal of inappropriate medications supervised by a 
healthcare professional with the goal of managing polypharmacy and improving 
outcomes" (Reeve et al, 2015, pp1262).   
This “process” part of the definition includes identifying medicines which should be stopped, 
devising a deprescribing regime and offering ongoing support to the patient (Reeve et al, 2015; 
Woodward, 2003).  
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Page et al (2018) went further than producing a definition, and described deprescribing as a 
concept with seven critical attributes, which are presented in Figure 4: 
1. Withdrawing medications: specifically, the withdrawal of regular (not short term) 
medicines.  
2. De-escalation of polypharmacy: healthcare professionals may want to deprescribe to 
minimise the perceived negative effects of polypharmacy; medicine users may want to 
reduce the number of medicines they take to increase adherence or to counter negative 
attitudes to medicines. 
3. Intended outcomes: this highlights that deprescribing is an intentional act, undertaken to 
improve outcomes.   
4. Structured and iterative process: deprescribing is a methodical process, which was 
highlighted as early as 2003 by Woodward.  Numerous acronyms and tools have been 
developed to facilitate this process, such as the Screening Tool Of Older People's 
Prescriptions (STOPP) criteria (O'Mahony et al, 2014). 
5. Intervention: deprescribing should be an active intervention to ensure appropriate 
prescribing, it is not the result of a patient choosing to stop their medicine, or a 
prescribing mistake. 
6. Risk to benefit: ensures that the appropriateness of each medicine is considered, 
including their risk to benefit ratio. 
7. Patient-centred care: ensures that the requirements of each individual patient is 
considered when deprescribing, and that it is not a process focussed on healthcare 
professionals.  This is a factor which is lacking from the definition proposed by Reeve et 
al (2014). 
 
 
Whilst Page et al (2018) did not propose a simple definition of deprescribing, they did provide a 
full and accurate description of the process as intended when the term “deprescribing” was 
utilised in this thesis.  Therefore, these attributes should be considered as the process of 
deprescribing which was the focus of the empirical work. 
1.2.1 Potential benefits of deprescribing 
There are many examples in the literature of deprescribing reducing the number of potentially 
inappropriate medicines and therefore reducing the burden of medicines a patient must take 
(Potter et al, 2016; Mckean et al 2015).  Potentially inappropriate medicines may, by definition, 
cause harm to a patient and so stopping them reduce the harm caused (Reeve et al, 2014).  It is 
also possible that reducing polypharmacy could reduce the potentially harmful effects of 
Figure 4: The seven critical attributes of deprescribing as defined by Page et al (2018) 
Figure : The seven critical attributes of deprescribing as described by Page et al 
(2018) 
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polypharmacy, including: pharmacokinetic and pharmacodynamic drug interactions, adverse 
effects and the adverse events, such as falls and hospital admissions, which arise from these.  
There is evidence that stopping inappropriate medicines from certain medication classes results 
in clinically meaningful outcomes.  It has been demonstrated that cessation of benzodiazepines 
resulted in improved cognitive function, falls could be reduced by stopping medicines which can 
contribute to falling (for example: diuretic, antidepressant and antihypertensive drugs), and 
hypertension can be improved by stopping non-steroidal anti-inflammatory medicines (Reeve et 
al, 2014; de Jong et al, 2013).  Specifically in care home residents, reduced mortality was 
demonstrated when antipsychotic medicines were stopped in residents with Alzheimer’s 
disease.  Ballard et al (2009) conducted a randomised, placebo controlled, parallel, two-group 
treatment discontinuation trial and reported that the cumulative probability of survival in the 
group who continued treatment with antipsychotic medicines was 70% (95%CI 58%-80%), and 
77% (95%CI 64-85) in those who stopped treatment. 
Iyer et al (2008) conducted a systematic review of medication withdrawal trials in people aged 
65 years old and older.  The review comprised the findings of 31 studies, including trials of 
stopping diuretic, antihypertensive, antidepressant and antipsychotic medicines.  Few adverse 
or withdrawal effects were reported across the review, and there was evidence of benefits.  For 
example stopping benzodiazepines was reported to improve cognitive function with no 
difference in sleep parameters between those who stopped benzodiazepines and those who did 
not (Iyer et al, 2008). 
There are also potential cost savings to deprescribing in care homes.  The RPS calculated that 
£135 million could be saved by having a pharmacist work in every care home (Royal 
Pharmaceutical Society, 2016).  Of this, £60 million was estimated to be saved through 
medicines optimisation, with the remaining £75 million saved through reduced hospital 
admissions.  At a time when the NHS is under pressure to reduce costs, savings made through 
medicines optimisation including deprescribing in care homes have the potential to offer 
significant individual, organisational and societal benefits. 
1.2.2 Potential risks of deprescribing 
As well as the potential benefits of deprescribing, there are also associated risks.  Not all trials 
of deprescribing in older people have shown benefits, and cessation of a potentially 
inappropriate medicine does not always result in a reversal of harm.  For example, it was shown 
that cessation of anticholinergic medicines did not significantly improve or worsen cognitive 
function.  Kersten et al (2013) conducted a randomised, controlled, single blinded trial of care 
home residents and investigated the relationship between their cognitive function and their 
anticholinergic drug score (ADS).  Participants were asked at baseline, four weeks and eight 
weeks to recall ten words immediately.  After eight weeks, the difference in immediate word 
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recall between the control group and the group which had their ADS score reduced by a median 
of two was 0.54 words (95%CI 0.91-2.05) (Kersten et al, 2013).  
Further risks of deprescribing include the fact that patients may experience withdrawal effects or 
a recurrence of the condition the medicine was prescribed for (Reeve et al, 2014).  There are 
few studies which investigate the effect of withdrawing medicines in care home residents.  
Cerety et al (1993) conducted a retrospective review of the medical records of 175 nursing 
home residents and found that 34% of these residents experienced a total of 94 adverse 
reaction after medicines were stopped.  Iyer et al (2008) reported in their review of medication 
withdrawal trials in people aged 65 years old and older that some adverse effects were seen in 
some trials; for example, stopping antipsychotic treatment led to poor sleep and worsened 
nocturnal symptoms of the condition the for which the medicine was prescribed.  Reeve et al 
(2014) suggested that adverse effects caused by withdrawal of medicines can be minimised by 
tapering the medicine, rather than abruptly stopping it.   
A recurrence of the condition being treated is also a possibility, as demonstrated by a study of 
the effects of stopping antihypertensive medicines (Nelson et al, 2003).  It was found that whilst 
36% of 503 older people whose antihypertensive medicines were stopped were normotensive 
after one year, a further 54% of people required their antihypertensives restarting for the original 
indication (Nelson et al, 2003).  Restarting the medicine resolved the recurrence of the condition 
being treated, which is likely to be a solution to this problem. 
A concern may arise whereby conditions may not be improved by restarting a medicine, and 
dementia is a potential example of this which is likely to affect care home residents.  There is 
limited evidence available to guide the use of acetylcholinesterase inhibitors and memantine 
used for the treatment of dementia, and it is unclear when these should be deprescribed 
(Parsons et al, 2010).  Trials of these medicines typically last for a maximum of 12 months, and 
so their benefit beyond this time is uncertain (Parsons et al, 2010).  There is evidence to 
suggest that stopping these medicines can result in a decline in the patient’s condition, and it is 
unclear whether restarting the medicine results in an improvement (Parsons et al, 2010).  The 
lack of evidence of the benefit of these medicines beyond 12 months, coupled with the risk that 
stopping them may cause an irreversible decline in the patient’s condition, can deter healthcare 
professionals from deprescribing these medicines. 
There is also uncertainty regarding medicines which have a long “time to benefit”, as these may 
not be beneficial for older people (Holmes et al, 2013).  For example, statins prescribed for the 
prevention of myocardial infarction have a time to benefit of 2 to 5 years (Holmes et al, 2013).  
Therefore, older people who are unlikely to live for longer than two years, due to their advanced 
age or a terminal diagnosis, may not live long enough to realise the benefit of the medicine.  
They may still, however, experience harm from the medicine caused by adverse effects, or 
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pharmacokinetic or pharmacodynamic drug interactions.  Lack of guidance concerning such 
uncertainties may also deter healthcare professionals from deprescribing. 
1.2.3 Other solutions to inappropriate medicines use in care homes 
It is important to note that deprescribing is one potential solution to inappropriate polypharmacy 
and other potential solutions include those in Figure 5 below (Molokhia and Majeed, 2017): 
- More and improved guidance for treating multimorbid patients who require multiple 
medicines, including risk prediction tools to quantify the risks associated with taking 
certain medicines. 
- Enhanced systems for monitoring patients and their medicines: this may be facilitated 
by electronic records, prescribing and systems.  It may also be facilitated by 
incorporating other healthcare professionals into the process of medicines 
management, such as pharmacists and nurses. 
- Focussing on high risk groups, such as those with co-morbidities, older people and care 
home residents. 
- Rapid identification of patients taking multiple medicines, facilitated by electronic 
systems 
- Medicines reconciliation: rapid transfer of patient information between care settings, 
ensuring that changes to medicines are maintained when the patient moves to a 
different care setting 
- Artificial intelligence and other digital innovations 
 
 
Despite these alternative solutions to the important problem of inappropriate polypharmacy, 
deprescribing was selected as the focus for this thesis as it is an emerging area in which there 
is a lack of research, particularly in care homes in the UK.  Whilst there are risks, there are also 
many potential benefits.  The primary care landscape in the UK is changing, and more initiatives 
are being announced to improve the health of those in care homes in care homes (see section 
1.3.4).  This includes involving more of the multi-disciplinary team in reviewing the medicines of 
care home residents, and increasing the presence of healthcare professionals in care homes.  
As these initiatives are introduced, and more people start reviewing the medicines of care home 
residents more regularly, deprescribing is an approach which should be investigated to 
determine its potential use and benefit in care homes in the UK.  This includes investigation of 
its feasibility, including attitudes towards the concept and barriers and facilitators to the process.  
These will be addressed by this thesis in order to determine whether deprescribing in care 
homes is beneficial, and how it could be facilitated.  Behaviour change psychology will be 
utilised to characterise deprescribing as a behaviour and determine how it may be improved 
Figure 5: Alternative solutions to inappropriate polypharmacy, as proposed by Molokhia 
and Majeed (2017) 
Figure : Alternative solutions t  inappropriate prescribing as described by Molokhia and 
Majeed (2017) pp XX 
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1.3 Care homes in the UK 
In addition to the complications caused by the residents’ conditions, living in a care home adds 
extra layers of communication and complexity to the deprescribing process.  This is because 
residents may be unable to partake in shared decision- making or knowledge exchange due to 
cognitive impairment, and their relatives may need, or wish, to be involved as an advocate.  
Care home staff are also involved where they would not be for a community dwelling patient.  
Pharmacists working in care homes may have to liaise with the GP to enact deprescribing, and 
hospital specialists may also need to be contacted before a decision is made.  Consequently, 
the involvement of multiple stakeholders is one example of why deprescribing is more complex 
in a care home.  It is also complicated by the structure of the health and social care system in 
the UK. 
1.3.1 Medicines management in care homes 
The medicines of care home residents are typically managed by care home staff, from the 
ordering to the administration of a medicine (Barber et al, 2009).  Care home staff manage the 
ordering of medicines, usually in collaboration with a local community pharmacy (Barber et al, 
2009).  The medicines are then dispensed by a community pharmacy, either in their original 
manufacturer’s packaging or as monitored dosage systems (MDS) (Barber et al, 2009).  MDS 
are dispensed by pharmacy staff and consist of a weekly tray for each resident (Barber et al, 
2009).  Care home staff typically administer medicines to residents ,multiple times a day, similar 
to a “medicines round” in a hospital.  However, residents with the capacity to administer their 
own medicines should be allowed and enabled to do this (National Institute for Health and Care 
Excellence, 2014).  Not being responsible for managing their medicines means that care home 
residents usually have little responsibility for their own medicines. 
Similarly, care home staff are often responsible for liaising with GP practices to arrange GP 
appointments for residents (Social Care Institute for Excellence, 2013).  As a result of this, care 
home residents lack agency over their own care as they are reliant on others to arrange GP 
care for them.  In addition to this, there is no single way of providing primary care to care home 
residents.  When a resident moves into a care home, they may stay registered with their own 
GP.  Alternatively, they may be encouraged to re-register with a local practice or with a practice 
which provides a service to the care home.   As a result, care home staff may correspond with a 
number of GP practices on behalf of their residents; there is evidence to suggest that care 
homes in the UK have residents registered to a mean of 3.8 (range 1-14) GP practices per care 
home (Barber et al, 2009).  As GP practices often have different systems of operating, care 
home staff have multiple systems to navigate which may present different barriers to accessing 
primary care for a resident.
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1.3.2 Policies informing the use of medicines in care homes 
Policies informing the use of medicines in care homes include: 
- NICE: Quality standard QS85 and NICE guidance SC1, both entitled “managing 
medicines in care homes (National Institute for Health and Care Excellence, 2014; 
National Institute for Health and Care Excellence, 2015) 
- RPS: The right medicine: Improving care in care homes (Royal Pharmaceutical Society, 
2016) 
- General Pharmaceutical Council (GPhC): Pharmacy and care homes (Webber, 2015) 
- Social Care Institute for Excellence (SCIE) Guide 52: GP services for older people: a 
guide for care home managers (Social Care Institute for Excellence, 2013)  
The NICE guidance and quality standard cover all aspects of medicine use in care homes, from 
the ordering to the review and administration, and is aimed at anyone involved in medicines in 
care homes, including care home staff, GPs and community pharmacists (National Institute for 
Health and Care Excellence, 2014; National Institute for Health and Care Excellence, 2015).  
The NICE Quality Statement states that residents should have their medicines reviewed at least 
annually.  The NICE guidance goes further, stating that medication reviews should be 
conducted by a named healthcare professional, and that they should involve the resident and a 
multidisciplinary team.  The guidance also describes what a medicines review should include; 
however, deprescribing is not explicitly mentioned in these stages. 
The RPS and GPhC guidance are specific to pharmacists and pharmacy practice and provide 
information about the role of pharmacists in care homes and guidance for pharmacists working 
in these settings (Royal Pharmaceutical Society, 2016; Webber. 2015).  Finally, the SCIE 
guidance provides guidance for care home staff liaising with GP practices to obtain GP services 
for residents in their care.  This includes outlining the care that residents are entitled to, 
including medicine reviews (Social Care Institute for Excellence, 2013).  
1.3.2.1 The roles of Care Quality Commission and Quality Outcomes Framework 
The Care Quality Commission (CQC) is a regulatory body responsible for monitoring, inspecting 
and regulating health and care providers, including care homes, in the UK to ensure they are 
safe and of a high quality (Care Quality Commission, 2020).  Each care home in the UK must be 
registered with the CQC and have a named responsible person as a condition of their 
registration (Care Quality Commission, 2020).  The CQC inspects care homes and issues a 
report and rating detailing the strengths and areas of improvement for care homes (Care Quality 
Commission, 2020).  Care homes may be rated either inadequate, requires improvement, good 
or excellent.  Those rated inadequate are subject to extra inspections and targets aimed to 
increase the quality and safety of care they provide (Care Quality Commission, 2020). 
The Quality Outcomes Framework (QOF) is a voluntary reward scheme for GP surgeries in 
England that aims to reward and encourage good practice (NHS Digital, 2020).  GP practices 
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are rewarded for their performance against 77 indicators: 65 indicators from 19 clinical areas 
such as heart failure, seven public health indicators such as adult obesity and five indicators 
from two additional public health services (cervical screening and contraception) (NHS Digital, 
2020).  The higher the score across the indicators, the larger a financial reward the practice will 
receive (NHS Digital, 2020). 
1.3.3 Roles of healthcare professionals in the care of care home residents 
There are multiple people involved in the care of care home residents.  As well as the resident 
themselves, there is also care home staff, GPs, primary care pharmacists and relatives.  
Hospital specialists may also be involved in a resident’s care, as well as other professionals 
such as physiotherapists, speech and language therapists, dieticians, social workers, 
community pharmacists, opticians and dentists.  These people must co-ordinate in order to 
ensure that the resident is receiving the best possible care.  The key stakeholders identified in 
the deprescribing process were the resident, relatives, GPs, care home staff and primary care 
pharmacists.  Their roles in care homes in England are described below and were investigated 
further by the empirical research. 
Whilst care home staff are responsible for the routine care of care home residents, GPs are 
responsible for their medical care: diagnosing and treating acute issues, the medical 
management of long-term conditions and the prescribing of medicines (Social Care Institute for 
Excellence, 2013).  They may be responsible for one, some or all the residents in a care home.  
If responsible for all the residents, they typically visit the care home routinely through a funded 
scheme (Social Care Institute for Excellence, 2013).  If they are responsible for fewer residents, 
this may not be in place.  NICE have stated that all care home residents should have their 
medicines reviewed at least annually and at present GPs and primary care pharmacists, where 
employed for this purpose, are responsible for conducting these (National Institute for Health 
and Care Excellence, 2015).   
There are emerging roles for pharmacists in primary care and in care homes.  In 2015, NHS 
England launched the Clinical Pharmacists in General Practice Programme which has seen the 
full time equivalent of 1000 pharmacists working in general practice (Baqir and Joshua, 2018).  
Pharmacists also work for Clinical Commissioning Groups (CCGs), or for other providers 
subcontracted to provide NHS medicines services, and the roles of both groups of pharmacists 
includes conducting medicine reviews.  Some pharmacists are employed by CCGs specifically 
to review the medicines of care home residents (Baqir and Joshua, 2018).   
Pharmacists working in primary care work closely with GPs, and those who are not qualified as 
independent prescribers will refer their prescribing or deprescribing recommendations to a GP 
to be implemented (Baqir and Joshua, 2018).  Pharmacists who are independent prescribers 
may prescribe or deprescribe medicines during a review autonomously. 
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Care home residents may also receive secondary care, either during a hospital admission or 
through care from a specialist team based in secondary care.  Secondary care adds another 
group of healthcare professionals who may review the resident’s medicines and make, and/or 
enact, prescribing and deprescribing decisions.  This adds another potential layer of complexity 
to the deprescribing process. 
1.3.4 Primary care initiatives 
Currently, several changes are being implemented in the NHS which reflect the increased 
interest in medicines optimisation and reducing problematic pharmacy.  Both the NHS Long 
Term Plan and the GP Five Year Forward View include aims to medicines optimisation and care 
home residents in order to improve the care provided to residents and minimise inappropriate 
prescribing (NHS, 2019). 
The NHS Long Term Plan, which will shape the next ten years of healthcare provision in the UK, 
includes changes to how care home residents will receive primary care provision.  A key part of 
the NHS Long Term Plan is the creation of Primary Care Networks (PCNs) which are the 
affiliation of local providers, including GP surgeries and community pharmacies, which will work 
together to serve their local area (Primary Care Strategy and NHS Contracts Team, 2019).  
Each PCN must deliver five Direct Enhanced Services (DES) as part of the GP contract.  Two of 
these DES include care home residents and are applicable to this thesis (Primary Care Strategy 
and NHS Contracts Team, 2019): 
- Structured medication review and medicines optimisation 
- Enhanced health in care homes 
These DES will be provided through changes to the way primary care is provided to care 
homes.  Some of these changes are continuations or expansion of services which are currently 
available, such as pharmacist-led medicine reviews, whilst others are novel, such as the 
provision of weekly visits to care homes by a named healthcare professional (Primary Care 
Strategy and NHS Contracts Team, 2019). 
The Medicines Optimisation in Care Homes (MOCH) programme was an example of the 
expansion and continuation of a service already available in some areas to care homes (Baqir 
and Joshua, 2018).  Pharmacists and pharmacy technicians were employed and trained through 
this programme to optimise medicines in care homes, which included a reduction in problematic 
polypharmacy and the deprescribing of inappropriate medicines.  This was provided amongst 
other activities designed to optimise medicines use in care homes, for example the training of 
care home staff by pharmacy professionals and improving medicine systems in care homes.  
NHS England funded 600 places on the training pathway which facilitated the MOCH 
programme, which turn addressed problematic polypharmacy in care homes (Baqir and Joshua, 
2018). 
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The Enhanced Health in Care Homes DES aims to ensure that people living in care homes 
experience the same access to healthcare as those who reside in the community (Primary Care 
Strategy and NHS Contracts Team, 2019).  This includes improving the quality and safety of 
care provided by care homes and improving suboptimal prescribing.  This will be provided 
through the identification of a clinical lead who will ensure, amongst other factors, that the 
improvements displayed in Figure 6 below are implemented (Primary Care Strategy and NHS 
Contracts Team, 2019): 
- Every care home resident has a named clinical team for provision of community 
services, 
- A multidisciplinary team (MDT) is established who will develop and monitor personalised 
care plans for care home residents 
- Establish protocols for information sharing and the use of shared care records,  
- Each care home will experience a weekly MDT “home round” led by an appropriate 
clinician, which fortnightly must be a GP or geriatrician.   
- Each care home resident has a personalised care plan within seven days of admission 
to the home, which will be reviewed annually.   
- Structured medicine reviews are provided for each care home resident. 
 
 
The DES which aims to improve medicines optimisation and ensure structured medication 
reviews includes various strategies aimed at improving the access of patients to regular, 
structured medication reviews (Primary Care Strategy and NHS Contracts Team, 2019).  This 
includes supporting other healthcare professionals to assist with the medicines optimisation 
process, and identifying patients such as care home residents who would benefit from a 
structured medicines review (Primary Care Strategy and NHS Contracts Team, 2019).  The 
provision of these two DES should ensure that care home residents experience improved 
provision of primary care services, and that problematic polypharmacy and suboptimal 
prescribing in care homes is reduced. 
1.4 Deprescribing: a behaviour 
This thesis aims to investigate deprescribing as a behaviour, and to identify behaviour change 
techniques which may improve deprescribing in care homes.  In the context of behaviour 
change, a behaviour has been defined as: 
“Anything a person does in response to internal or external events. Actions may be 
overt (motor or verbal) and directly measurable, or covert (activities not viewable 
e.g., physiological responses) and indirectly measurable; behaviours are physical 
events that occur in the body and are controlled by the brain” (Michie et al, 2013) 
This definition was agreed by a multidisciplinary group during a Delphi process in relation to 
psychology, sociology, anthropology and economics.  It may not be immediately obvious why 
Figure 6: Improvements to primary care provision in care homes as outlined in the 
Enhanced Health in Care Homes DES (Primary Care Strategy and NHS Contracts Team, 
2019) 
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this definition is relevant to this healthcare study; however, it can be applied to deprescribing in 
the following ways: 
- Deprescribing is something that a healthcare professional does in response to internal 
events, such as their thought processes during a medicine review, or an external event, 
such as a change in the resident’s condition. 
- Overt deprescribing actions are the actions of stopping inappropriate medicines; this is 
a measurable outcome of deprescribing behaviour. 
- Covert deprescribing actions are emotions or influences felt during the deprescribing 
process. 
- Deprescribing is a physical event controlled by the brain. 
There is precedent for the conceptualisation of deprescribing as a behaviour.  Ailabouni et al 
(2016) and Scott et al (2019) employed behaviour change psychology and the Theoretical 
Domains Framework (TDF) to investigate the phenomenon of deprescribing.  Cadogan et al 
(2015) also employed behaviour change techniques as a method of addressing inappropriate 
polypharmacy in primary care (Cadogan et al., 2015).  In addition to this prescribing, the 
opposite of deprescribing, is widely regarded as a behaviour and behaviour change psychology, 
including the TDF, have been utilised to investigate this (Anderson et al, 2014; Cockburn and 
Pit, 1997).   
Furthermore, an international symposium on deprescribing guidelines identified behaviour 
change as a necessary part of the implementation of deprescribing guidelines (Farrell et al., 
2019).  It was stated that behaviour change psychology would provide insights into 
deprescribing behaviour and would assist with the successful implementation of deprescribing 
intervention (Farrell et al., 2019).  This thesis aims to address this, and will utilise the 
Theoretical Domains Framework to explore deprescribing as a behaviour.   
The Theoretical Domains Framework was selected as a theoretical basis for this study as it is a 
composite framework of multiple behaviour change theories (Cane et al, 2012).  A detailed 
description of the TDF is beyond the remit of this chapter; this can be found in Chapter 3 section 
3.2 and Chapter 5 section 5.2.  However, the Theoretical Domains Framework was applied to 
the findings of the literature review (Chapter 2, sections 2.4.6 and 2.6.3) and the findings of the 
empirical work (Chapter 5).  The TDF was then utilised to identify possible components of a 
behaviour change intervention which may improve deprescribing behaviours in care homes. 
1.5 Overview of this thesis 
This thesis aimed to use qualitative methods to gain an in-depth understanding into why care 
home residents in the UK are experiencing problematic polypharmacy and how deprescribing, 
one potential solution, in care homes can be facilitated.  Behaviour change psychology was 
employed to identify techniques which may be implemented to change the deprescribing 
behaviours of healthcare professionals.  Though it is beyond the scope of this thesis, it is 
intended that the identified techniques will form the foundation of a resident-centred behaviour 
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change intervention for use in care homes.  The intervention would be co-designed with 
residents, relatives, GPs, pharmacists and care home staff. 
The thesis will address the following aim and objectives in six chapters: 
Aim 
To investigate the barriers and facilitators to deprescribing for older people living in care homes. 
Objectives 
- To examine the existing evidence of barriers and facilitators to deprescribing 
unnecessary medicines for older people living in care homes 
- To investigate how the deprescribing process happens in care homes, including the 
roles and responsibilities of those involved 
- To explore how older people living in care homes, and their relatives, perceive their 
medicines (or medicines taken by the resident) and their attitudes to deprescribing 
- To explore the attitudes of healthcare professionals towards deprescribing in care 
homes, including identification of perceived barriers and facilitators to deprescribing. 
- To use the evidence and findings to identify behaviour change techniques that may 
inform the development of a novel intervention.  
This chapter has provided the background to the thesis including details about how care homes 
are structured and how medicines are managed in UK care homes and why deprescribing has 
been defined as a behaviour. 
The second chapter is the literature review, which consists of a systematic literature search 
followed by a narrative synthesis of the findings.  The Theoretical Domains Framework (TDF) is 
introduced in this chapter and is applied to the findings of the literature review. 
The third chapter, methodology and methods, provides the rationale for the methods employed 
to conduct the empirical study before explaining how the study was conducted.  This includes 
detail about the pragmatic approach taken to the study and the theoretical underpinnings, 
followed by presentation of and discussion around the sampling, data and quality assurance 
processes.  This chapter also incorporates the ethical approval processes that were undertaken 
before data collection began. 
Chapter 4 is the findings chapter, where the qualitative findings of the qualitative study are 
presented narratively.  This is followed by Chapter 5, where the TDF is applied to the qualitative 
findings.  These findings are then incorporated with the barriers described in the literature 
review and mapped to the Behaviour Change Wheel (BCW) in Chapter 5 to select behaviour 
change techniques which may be used to develop a novel deprescribing intervention. 
The final chapter, Chapter 6, brings together the whole thesis to discuss deprescribing in care 
homes, contextualising the findings in the wider literature and explaining how they could inform 
policy and practice.
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1.6 Summary 
There is a wealth of evidence that suggests that older people, and particularly those in care 
homes, are susceptible to inappropriate prescribing which may consequently be causing harm.  
Whilst there are some initiatives that have recently been announced to address this, there is a 
paucity of research into one of the solutions: deprescribing, especially set in care homes, in the 
UK.  This thesis aimed to address this, through an investigation of the attitudes to, and barriers 
and facilitators of, deprescribing in this setting.  This chapter provided the background to this 
thesis: definitions of key the key terms deprescribing and polypharmacy, a description of the 
structure of care homes and medicines management within UK care homes and insight into why 
deprescribing is important in care homes.  Deprescribing was then characterised as a 
behaviour, which provided a rationale for the use of behaviour change psychology and 
techniques throughout the study.  The policy and guidance that informs current practice 
regarding medicines use in the UK was also outlined, followed by the aims and objectives of the 
study and the thesis structure.  The following chapter is the literature review that explores and 
synthesises the current evidence around deprescribing in care homes. 
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Chapter 2 Literature review with narrative synthesis of barriers and 
facilitators to deprescribing in care homes 
2.1 Introduction 
This chapter presents the literature review: a narrative synthesis of barriers and facilitators to 
deprescribing in care homes.  This chapter will address the following objective of the overall 
thesis: 
- To examine the existing evidence of barriers and facilitators to deprescribing for older 
people living in care homes. 
Firstly, the research question and aim of the literature review will be presented, followed by the 
methodology employed.  This includes the rationale for why narrative synthesis was undertaken, 
as well as how the Theoretical Domains Framework (TDF) was incorporated into the review.  
The methods section (2.2) explains how Popay et al’s (2006) guidance on conducting narrative 
synthesis was followed to conduct the review.  This is followed by the results section (2.5), 
which outlines the studies included in the review and their critical appraisal.  The findings are 
presented following Popay et al’s (2006) guidance, and this section includes how the findings 
were extracted and mapped to the TDF.  Finally, the findings and their TDF mapping are 
examined and explained in the discussion. 
2.2 Research question and aim of the literature review 
Research question 
What barriers and facilitators to deprescribing for older people living in care homes have been 
identified and described in the existing literature?   
Aim 
To describe the barriers and facilitators to deprescribing in care homes, as perceived by care 
home residents, relatives, healthcare professionals and care home staff. 
To map the barriers to deprescribing in care homes identified by healthcare professionals and 
care home staff to the TDF. 
2.3 Methodology 
In order to conduct a rigorous literature review, a clear, transparent and replicable method 
should be followed to ensure that all eligible papers are identified, included and critically 
appraised, and that their findings are appropriately reported (Higgins and Green, 2011).  Once 
the studies for inclusion have been identified following a systematic process, their findings must 
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be synthesised in order for them to be reported.  There are multiple approaches to synthesising 
findings, and selection of the most appropriate approach involves consideration of the type of 
data that was being sought.  In order to gain insight into the existing literature and to guide the 
choice of approach for this literature review, a scoping and mapping exercise was conducted.  
This exercise piloted the search strategy and inclusion and exclusion criteria that were used for 
the finalised literature review.   
The mapping exercise identified that both qualitative and quantitative studies had been 
conducted to investigate barriers and facilitators to deprescribing in care homes.  It was 
therefore decided that a range of study designs would be considered eligible for inclusion in the 
review, including quantitative, qualitative and mixed methods studies.  The inclusion of multiple 
study types made the findings unsuitable for presenting as a quantitative review, such as a 
meta-analysis (Higgins and Green, 2011).  However, it was not appropriate to use a purely 
qualitative method of synthesis such as meta-synthesis, meta-ethnography or thematic 
synthesis to present the findings either (Barnett-Page and Thomas, 2009).   
Consequently, it was decided that a narrative synthesis would be the most appropriate method.  
Narrative synthesis employs words as the main method of presenting the findings, although 
numerical or statistical analysis may be utilised if necessary (Popay et al, 2006).  This allows for 
the inclusion of heterogeneous and mixed methods study designs and the summarising of 
qualitative and quantitative findings, which was deemed necessary for this review (Ryan and 
Cochrane Consumers and Communication Review Group, 2013)   
The guidance on the conduct of narrative synthesis in systematic reviews (Popay et al., 2006) 
was developed in response to the need for methodological guidance for undertaking literature 
reviews with narrative syntheses, and was used to guide the conduct of this literature review.  
Use of the guidance lends rigour to the narrative synthesis process and is recommended by the 
Cochrane Collaboration (Ryan and Cochrane Consumers and Communication Review Group, 
2013).  While the guidance focuses on the use of narrative synthesis in evaluating the effects 
and implementation of interventions, Popay et al (2006) acknowledged that it can be used for a 
wide range of research questions, such as the question posed by this literature review.  
To ensure a consistent and rigorous approach, each study included in the review was appraised 
using an appropriate critical appraisal tool.  This ensured studies of similar designs were 
subjected to the same appraisal methods, which minimised variation in the appraisal and 
presentation of studies and allowed fair conclusions to be drawn.  Due to the paucity of literature 
identified in the mapping exercise, it was decided not to exclude studies based on this quality 
assessment (see section 2.5.3), however the critical appraisal was used to analyse, evaluate 
and guide the findings and conclusion.
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2.3.1 Theoretical Domains Framework 
The findings from the literature review were also synthesised using the Theoretical Domains 
Framework (TDF).  Employing the TDF in the literature review allowed the findings of the 
literature review to be integrated with the findings of the empirical research with the work 
undertaken to identify potential intervention components (Chapter 5).  It also ensured that the 
TDF was embedded into the study, from the initial informative phase (the literature review) to 
the design and reporting of the empirical work.  Furthermore, Atkins et al (2017) stated that the 
TDF may be incorporated into systematic reviews, although the methods for this were not 
described. 
For more information regarding the Theoretical Domains Framework and the rationale for 
applying it to this study, please see Chapter 3 section 3.2.3 and Chapter 5, section 5.2. 
2.4 Methods 
The guidance on the conduct of narrative synthesis in systematic reviews (Popay et al, 2006) 
refers to six stages which were followed in order to complete this review, as shown in Figure 7: 
1. Identifying the review focus, searching for and mapping the available evidence 
2. Specifying the review question 
3. Identifying studies to include in the review 
4. Data extraction and study quality appraisal 
5. The synthesis (in this review, this included mapping the findings to the TDF) 
6. Reporting of the results and dissemination (not included in this review) 
 
 
2.4.1 Identifying the review focus, searching for and mapping the available 
evidence 
The first stage refers to the identification of the review focus and to search for and map the 
available evidence to refine the research question and identify study designs.  This stage was 
undertaken as the mapping and scoping exercise, prior to the literature search that informed this 
review.  It revealed a small number of studies examining the barriers and facilitators to 
deprescribing in care homes – three were identified at the time of the mapping exercise (Ellis et 
al 2014, Kalogianis et al 2016, Harriman et al 2014), with Azermai et al (2013) identified as a 
potentially eligible study, amongst others.  The study designs were varied, including surveys, 
mixed methods studies and qualitative methodologies.  This confirmed that narrative synthesis 
was an appropriate choice for this review, as findings from at least three different study designs 
required synthesis.   
Figure 7: The six stages in conducting a narrative synthesis, as defined by Popay et al 
(2006) 
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The initial mapping exercise allowed for inclusion of papers relating to barriers and facilitators to 
deprescribing, as well as papers concerning interventions designed to test deprescribing in care 
homes.  However, it became apparent that the results were not focussed enough.  This was 
because there were numerous papers detailing deprescribing interventions that had been 
trialled in care homes, but these papers did not discuss the barriers and facilitators to 
deprescribing and were therefore irrelevant to the focus of this review.  Consequently, the 
inclusion and exclusion criteria were refined, and it was decided that articles evaluating and 
testing deprescribing interventions in care homes would not be included in this review.   
2.4.2 Specifying the review question: What barriers and facilitators to 
deprescribing for older people living in care homes have been 
identified and described in the existing literature?”   
The SPIDER (sample, phenomenon of interest, design, evaluation, research type) tool was 
utilised to design the research question and inclusion and exclusion criteria for this literature 
review (Cooke et al, 2012).  SPIDER facilitates searches for qualitative and mixed methods 
studies in healthcare research.   
The “design” and “research type” aspects of the SPIDER acronym did not lend themselves to 
constructing the research question, as all study designs were considered for inclusion.  
Therefore, the “sample”, “phenomenon of interest”, and “evaluation” parts were used: 
● Sample: older people living in care homes 
● Phenomenon of interest: deprescribing  
● Evaluation: barriers and facilitators 
This created the question, “What barriers and facilitators to deprescribing for older people living 
in care homes have been identified and described in the existing literature?”  This question was 
specific, answerable and included all the information being sought by the review. 
2.4.3 Inclusion and exclusion criteria 
The inclusion and exclusion criteria were set using the SPIDER acronym, as described above 
(Cooke et al., 2012). 
2.4.3.1 Inclusion criteria 
Sample:  
a) Older people who were prescribed medicines and were residents of care homes, and 
their relatives 
b) Care home staff, doctors and other healthcare professionals involved in the prescribing 
and/or administration of medicines to these patients. 
Phenomenon of interest: 
a) The process of deprescribing inappropriate medicines in care homes 
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Design: 
a) Interviews, focus groups, questionnaires, surveys or observational studies 
 
Evaluation: 
a) Views, experiences, attitudes, beliefs, perceptions, barriers, facilitators 
Research type: 
a) Qualitative, quantitative or mixed methods. 
In addition to the above criteria, in order to be included the articles must have been: 
- Available in English 
- Accessible as a full text article. 
2.4.3.2 Exclusion criteria: 
a) Articles that did not focus on older people living in care homes (e.g. articles concerning 
younger people or hospices). 
b) Articles that did not focus on deprescribing, the cessation of medicines (e.g. articles 
about medicines optimisation, which has a wider definition) 
The following databases were searched on the 5th January 2017: Embase, Medline, CINAHL, 
PsychInfo and International Pharmaceutical Abstracts (IPA).  These databases were selected 
as they contain information regarding articles published that are related to medicine, health and 
allied health professionals so are likely to include studies related to stopping medicines and care 
home residents.  PsychInfo was selected as it includes health behaviour studies, which are of 
particular interest for this thesis.  The searches were limited to results in the English language, 
and those published after the year 2000.  This was because the mapping exercise did not 
identify any relevant studies from before 2000, and deprescribing is a term that has only been in 
use since 2003 (Reeve et al, 2015).  There has also been an increase in interest in 
polypharmacy in care homes over the past two decades, and an increase in polypharmacy itself 
over this time (Reeve et al, 2015).  Hand searching the references of included articles was 
undertaken.   
The search strategy (Appendix A) included synonyms for the terms “care home” (for example, 
nursing home, long term care facility) and “deprescribing” (for example, 
cessation/withdrawal/stopping of medicines).  Truncations (*), relevant words close to one 
another (nX, adjX) and other Boolean operators were used to ensure the search included as 
many variations of the search terms as possible.   
The findings from systematic reviews were not included in this review.  Instead, the reference 
lists of systematic reviews were hand searched to identify primary studies suitable for inclusion.  
The full texts of primary studies identified in the reference lists that were deemed potentially 
relevant to the review being conducted were sought, read and included if they met the inclusion 
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criteria.  Primary studies were sought as opposed to the reviews which incorporated their results 
to ensure that the primary data, free of the influences, opinions and biases of review authors, 
was utilised in the narrative synthesis.  In addition to hand searching the references of 
systematic reviews, hand searching of the reference lists of all included studies was undertaken 
to identify eligible studies. 
2.4.4 Title, abstract and full text screening 
Endnote version 8, later updated to version 9, was used to collate articles.  This allowed for the 
search results to be organised, and facilitated the title, abstract and full text screening of the 
search results.  After duplicates were removed, the titles of the search results were read and 
assessed for potential inclusion into the literature review.  Many articles were discounted at this 
stage due to clear irrelevance to the topic.  The abstracts were then compared against the 
inclusion and exclusion criteria and if it appeared that the article could be eligible, or if there was 
insufficient information in the abstract to determine eligibility, then the full text was sought.  The 
full text was then read by the author and compared against the inclusion and exclusion criteria 
before determining whether it was suitable for inclusion.  If it was unclear whether an article 
should be included, this was discussed with the supervisory team and a decision was made.  
Details of papers which were not included after discussion are in Appendix B. 
2.4.5 Data extraction and study quality appraisal 
The author designed and utilised a data extraction table which was utilised to systemically 
extract data from the included studies (Table 1).  The data extraction table allowed for collection 
of key information from the study, and included factors identified by the critical appraisal tools as 
important for determining study quality, such as details regarding the sample, data collection 
methods and study design.  The table allowed for the same information to be extracted from 
each included article, which aided comparison of the articles and increased transparency and 
rigour.   
Critical appraisal of each paper was undertaken using a critical appraisal tool appropriate for the 
study design.  The studies included in the review were either qualitative, surveys, or mixed 
methods studies comprising both a qualitative and a survey aspect.  Therefore, the Critical 
Appraisal Skills Programme (CASP) tool for qualitative research (Critical Appraisal Skills 
Programme, 2014) and/or the Centre for Evidence Based Management’s (CEBM) tool for 
appraising survey quality (Centre for Evidence Based Management, 2014) were utilised when 
undertaking the critical appraisal of included studies.  Mixed methods studies were appraised 
using both tools.   
Critical appraisal tools are recommended by the Cochrane collaboration (Cochrane UK, online, 
2019).  Such tools are especially recommended for novice researchers to aid them in exploring 
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all aspects study quality.  The CASP and CEBM tools were selected because they allowed for 
assessment of the key points required when assessing the quality of studies.  For example, the 
CASP tool prompts researchers to assess the credibility, transferability, dependability and 
confirmability of the study in question, whilst the CEBM tool encourages consideration of how 
statistics, sample size and recruitment methods may have introduced bias to the sample 
(Critical Appraisal Skills Programme, 2014; Centre for Evidence Based Management, 2014).  
For the findings of the critical appraisals included in this literature reviews, see section 2.5.3. 
2.4.6 Synthesis of results 
Results were synthesised using recommendations from Popay et al’s (2006) guidance.  Textual 
descriptions of the findings and data to be included, as well as Table 1, assisted in visualising 
the data.  Discussion with the supervisory team and colleagues also shaped the synthesis.  
Following this process, the findings were extracted from the studies and synthesised as follows. 
2.4.6.1 Use of the Theoretical Domains Framework 
The barriers to deprescribing as described by healthcare professionals were extracted from the 
findings to be synthesised and mapped to the Theoretical Domains Framework.  As described in 
Chapter 1.4, deprescribing was characterised as a behaviour in order to gain a deeper 
understanding of it.  This allowed for the application of frameworks which provide insight into 
factors of behaviour, such as the Theoretical Domains Framework (TDF).  A full description of 
the TDF is beyond the remit of this chapter and this can be found in Chapter 3.2.3 and Chapter 
5.2.  In summary, the TDF is a composite of health behaviour frameworks, the use of which 
provides a more detailed understanding of the behaviour in question.  The TDF consists of 14 
domains, each representing an factor theorised to influence behaviour.  Once the barriers to 
deprescribing presented by the articles included in the literature review had been identified, they 
were then mapped to the TDF thus providing insight into why the barriers occurred.  This 
information was then utilised to understand how behaviour might be improved.  The healthcare 
professional barriers identified in the literature (not the systematic reviews) were synthesised 
and mapped to the Theoretical Domains Framework (TDF), as described transparently below.  
The results of this mapping are presented in section 2.6.3. 
1. Synthesised barriers to deprescribing were then created, by extracting barriers from the 
literature and grouping similar ones together.  Examples of these synthesised barriers 
were influence of the resident’s health, systemic barriers to communication and 
emotions felt towards deprescribing. 
2. The synthesised barriers were mapped to the TDF through discussion between the 
author and the member of the supervisory team.  The author mapped the barriers, and 
then discussed the mapping with the member of the supervisory team who suggested 
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alternative domains where appropriate.  Disagreements were resolved through 
discussion.  
As the TDF was applied to both the literature review and empirical findings, details of the TDF 
mapping quality assurance procedures offered by a member of the supervisory team with 
expertise in the TDF use (CE) are detailed in section 5.2.2.2 which covers the mapping of the 
empirical findings to the TDF.  The same quality assurances procedures were used at this stage 
also.   
The validated version of the TDF, as presented by Cane et al (2012), was utilised throughout 
this thesis.  The validated version of the TDF can be found in Appendix C.  Appendix C also 
presents Table 53, which links the TDF to deprescribing. 
2.4.6.2 Narrative synthesis of other findings 
Once the barriers to deprescribing as perceived by healthcare professionals had been extracted 
from the articles included in the literature review, the remaining findings were presented as 
follows.  These findings consisted of factors important to residents, relatives, healthcare 
professionals and care home staff when deprescribing in care homes, and facilitators to the 
process.  The findings were then tabulated and separated into two groups to be described and 
presented narratively (section 2.6.1 and 2.6.2): 
● Deprescribing factors identified by residents and relatives 
● Deprescribing factors identified by healthcare professionals and care home staff 
2.4.7 Repeat of the search 
The saved searches from January 2017 were repeated on each database on 25th July 2019 to 
ensure that relevant articles published since the last search were included in the review.   
2.5 Results 
The searches from the 5th January 2017 yielded a total of 2123 results, which were narrowed 
down to 25 articles for full text review (see Figure 8).  Articles identified through hand searching 
came from journal alerts (subscription to BMC geriatrics) and reviewing the references of 
included articles.  Three further articles were identified for inclusion when the search was re-run 
on 25th July 2019.  The PRISMA guidelines (Moher et al, 2009) were used to produce the 
PRISMA diagram in Figure 8, detailing how included articles were selected.
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Figure 8: PRISMA diagram presenting inclusion and exclusion of studies for literature 
review of barriers and facilitators to deprescribing 
Ten articles which were sought for full text review were not obtainable.  Seven of these articles 
existed as an abstract only, and searches for full texts based on the abstracts were not 
successful.  Three articles could not be obtained after emailing the authors or via searches and 
requests made via ResearchGate.  17 articles were discarded after full text review: 
- 14 articles did not include any barriers or facilitators to deprescribing in care homes.  Six 
of these were intervention assessments, the other eight consisted of review articles, 
retrospective studies other study designs which did not explore barriers and facilitators 
to deprescribing in care homes. 
- One article was a study protocol with no findings. 
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- Two articles did not discuss deprescribing in care homes. 
Table 51, Appendix B provides details of papers which were not included after discussion 
between the author and the supervisory team. 
Four systematic reviews were also identified as being relevant to the study.  Anderson et al 
(2014) reviewed the barriers and facilitators to deprescribing as perceived by healthcare 
professionals, and Reeve et al (2013) published a review of the barriers and facilitators to 
deprescribing as perceived by patients.  Neither of these reviews were specific to the care home 
setting and the challenges that are faced by those living in care homes, and those caring for 
residents.   
Bokhof and Junius-Walker (2016) and Lundby et al (2019) conducted systematic reviews of 
qualitative studies investigating GP and patient attitudes to reducing polypharmacy, and the 
views of healthcare professionals towards deprescribing in older adults with a limited life 
expectancy respectively.  However, neither Lundby et al (2019) or Bokhof and Junius Walker 
(2016) focused specifically on care homes, and they only consider the views of GPs and 
patients.  This excludes other health and social care staff and does not allow for the views of 
residents and their relatives to be presented either.  For these reasons, whilst relevant primary 
studies from the reviews by Anderson et al (2014), Reeve et al (2013), Bokhof and Junius 
Walker (2016) and Lundby et al (2019) were included in the review being conducted, the 
reviews themselves were utilised only in the contextualisation of the literature review findings in 
section 2.7.  
2.5.1 Written summary of included articles 
Nine articles were identified and eligible to include in the literature review.  Of these nine, four 
studies concerned the deprescribing of antipsychotic medicines only (Azermai et al, 2013; Ellis 
et al, 2014; Mavrodaris et al, 2013; Simmons et al, 2017).  The other five studies included did 
not limit their study to a class of medicines (Ailabouni et al, 2016; Palagyi et al, 2016; Harriman 
et al, 2014; Turner et al, 2016; Kalogianis et al, 2015).  Only one study, by Mavrodaris et al 
(2013), was conducted in the UK.  The other included studies were conducted in the US (Ellis et 
al, 2014; Simmons et al, 2017), Belgium (Azermai et al, 2013), Canada (Harriman et al, 2014), 
New Zealand (Ailabouni et al, 2016) and Australia (Turner et al, 2016; Palagyi et al, 2016; 
Kalogianis et al, 2017).   
Four of the studies included were described by the authors as qualitative studies (Ailabouni et 
al, 2016; Turner et al, 2016; Simmons et al, 2017; Palagyi et al, 2016).  Ailabouni et al (2016) 
conducted semi-structured interviews with GPs, Turner et al (2016) utilised the nominal group 
technique method, Simmons et al (2017) employed focus groups and Palagyi et al (2016) 
incorporated both interviews and focus groups into their study design.  The remaining studies 
were survey studies, or mixed methods studies incorporating a survey (Kalogianis et al, 2015; 
Azermai et al, 2013; Ellis et al, 2014; Harriman et al, 2014; Mavrodaris et al, 2013).  Mavrodaris 
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et al (2013) and Ellis et al (2014) incorporated qualitative methods into their research by 
including open-ended questions in their surveys, which were analysed qualitatively.  The 
quantitative aspects of these studies, and of the other survey studies included in the review, 
were descriptively analysed.   
Only three studies (Kalogianis et al, 2015; Palagyi et al, 2016; Turner et al, 2016) incorporated 
the views of care home residents into their studies.  Palagyi et al (2016) and Turner et al (2016) 
also included the relatives of care home residents, pharmacists, care home staff and GPs in 
their studies.  Simmons et al (2017) and Ellis et al (2014) recruited only care home staff, and 
Azermai et al (2013) and Mavrodaris et al (2013) recruited both care home staff and GPs.  
Ailabouni et al (2016) and Harriman et al (2014) examined only the views of GPs.  GPs were the 
most group included in the most studies.  All studies focused on deprescribing in care homes, 
except for Mavrodaris et al (2013) who also considered deprescribing antipsychotic medicines in 
community dwelling patients.  Mavrodaris et al (2013) was included as it was the only study 
which considered deprescribing in care homes that was conducted in the UK; only the findings 
that were clearly applicable to the care home setting were included in the review. 
Table 1 summarises the articles included in the literature review.  The key findings stated in 
Table 1 are taken from the abstract of each study, which summarises the findings the authors 
thought were most important.   
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2.5.2 Overview and key findings of included studies 
Table 1: Overview and key findings of included studies 
Lead 
author 
Year 
published 
Country Study design Objectives Medicine 
type 
Participants 
and setting 
Analysis 
method 
Key findings 
Azermai 2013 Belgium Mixed 
methods: 
expert group 
meeting 
which 
informed the 
development 
of a 
quantitative 
survey  
Explore the 
willingness of 
GPs and 
nurses to 
discontinue 
antipsychotics, 
and the 
barriers 
encountered 
Antipsychotic  Survey: GPs 
and nurses 
caring for 51 
care home 
residents who 
took 
antipsychotic 
medicines 
Survey: Mean 
scores for 
barriers were 
calculated with 
some statistical 
analysis. 
 
Barriers to 
deprescribing: 
fear of the 
resident 
causing harm 
to themselves 
or others, 
increased 
workload for 
staff. 
Ellis 2014 USA Mixed 
methods: 
survey  
Investigate the 
barriers and 
facilitators to 
reducing the 
use of 
antipsychotic 
drugs for older 
people living in 
Antipsychotic 276 nursing 
home staff 
recruited from a 
conference 
delegation. 
Quantitative 
and qualitative 
(theme-based 
content 
analysis) 
methods used. 
Themes: 
“Changes in 
practice” and 
“relevant to 
needed 
assistance” 
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Lead 
author 
Year 
published 
Country Study design Objectives Medicine 
type 
Participants 
and setting 
Analysis 
method 
Key findings 
care homes in 
Florida. 
Mavrodari
s 
2013 UK Mixed 
methods: 
survey 
Investigate 
antipsychotic 
prescribing 
practices and 
patient review 
in primary care 
and care 
homes. 
Antipsychotic 60 GPs from a 
pool of 144 GP 
practices and 28 
care home staff 
Open question 
responses 
analysed with 
thematic 
analysis. 
75% GPs 
“occasionally” 
stop 
antipsychotic 
medicines due 
to concerns 
about stopping 
medicines 
without 
secondary care 
input and 
resistance from 
care home 
staff. 
Harriman 2014 Canada Quantitative: 
survey 
Investigate the 
attitudes of 
doctors 
towards 
deprescribing 
All 30 family 
physicians 
caring for 10 or 
more frail, 
elderly patients 
Descriptive 
analysis.  The 
results were 
“combined and 
analysed for 
Barriers to 
deprescribing 
reported: 
medicines 
prescribed by 
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Lead 
author 
Year 
published 
Country Study design Objectives Medicine 
type 
Participants 
and setting 
Analysis 
method 
Key findings 
for older 
people living in 
care homes. 
living in care 
homes 
frequency of 
response”. 
another 
prescriber, 
organisational 
factors and fear 
of adverse 
effects 
Kalogiani
s 
2015 Australia Quantitative 
survey 
Investigate 
whether care 
home 
residents in 
Australia were 
willing to have 
their 
medications 
deprescribed. 
All 236 care home 
residents 
Descriptive 
analysis. 
40.5% 
residents 
reported a 
desire to stop 
taking one or 
more of their 
medicines, 
78.9% would 
be willing to 
stop medicines 
if their doctor 
suggested it 
Palagyi 2016 Australia Qualitative: 
Focus groups 
and semi-
To investigate 
perceptions of 
medicine use 
All 25 residents, 16 
relatives, 19 
care home staff 
Not specified Participants 
displayed 
passivity 
 
 
 
49 
Lead 
author 
Year 
published 
Country Study design Objectives Medicine 
type 
Participants 
and setting 
Analysis 
method 
Key findings 
structured 
interviews 
and 
deprescribing 
in care homes. 
from three care 
homes, 8 GPs 
and 4 
pharmacists 
 
towards 
deprescribing.  
GPs preferred 
the “path of 
least 
resistance” 
reporting 
barriers such 
as time 
constraints, 
organisation of 
care and 
system 
barriers. 
Turner 2016 Australia Qualitative: 
Nominal 
group 
technique.  
Each group 
ranked the 
deprescribing 
Determine the 
most important 
deprescribing 
factors for 
GPs, nurses, 
pharmacists, 
residents and 
All 19 GPs, 12 
nurses, 14 
pharmacists and 
11 care home 
residents and 
their 
representatives.   
Nominal group 
technique. 
No groups had 
the same 
priorities.  Top 
priorities were: 
wellbeing of the 
resident, 
clinical 
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Lead 
author 
Year 
published 
Country Study design Objectives Medicine 
type 
Participants 
and setting 
Analysis 
method 
Key findings 
factors they 
thought were 
important. 
their 
representativ-
es  
appropriatenes
s of therapy, 
GP receptivity 
to 
deprescribing, 
evidence for 
deprescribing  
Ailabouni 2016 New 
Zealand 
Qualitative: 
semi-
structured 
interviews 
Investigate GP 
perceived 
challenges to 
deprescribing 
in residential 
care and the 
possible 
enablers that 
support GPs to 
implement 
deprescribing.  
All 10 GPs Themes 
identified with 
iterative building 
of coding list.  
TDF and 
constant 
comparison 
techniques 
involved. 
Four themes: 
The recognition 
of the problem; 
behaviour 
change factors; 
prescribing 
factors: social 
influences and 
policy and 
processes; 
enablers. 
Simmons 2017 USA Qualitative: 
focus groups 
To explore 
nursing home 
staff 
Antipsychotic 29 care home 
staff  
Coding of each 
statement using 
a hierarchical 
Facilitators: 
improvement in 
quality of life 
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Lead 
author 
Year 
published 
Country Study design Objectives Medicine 
type 
Participants 
and setting 
Analysis 
method 
Key findings 
perceptions of 
antipsychotic 
medication 
use and 
identify 
barriers and 
facilitators to 
deprescribing. 
coding system.  
Coded data 
used to 
summarise the 
quotes and 
identify 
significant 
themes 
and family 
satisfaction, 
reduction in 
falls.  Barriers: 
family 
resistance, fear 
of adverse 
effects, issues 
with non-
pharmacologic
al alternatives, 
risk aversion 
and safety 
concerns. 
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2.5.3 Critical appraisal of included articles 
The quality of the included studies was assessed using the CASP tool for qualitative research 
(Critical Appraisal Skills Programme, 2014) and the CEBM survey appraisal tool (Centre for 
Evidence Based Management, 2014).  A written narrative is presented below. 
The qualitative studies (Palagyi et al 2016, Turner et al 2016, Ailabouni et al 2016) were well 
conducted in that the data collection methods were well reasoned and explained.  Palagyi et al 
(2016) and Ailabouni et al (2016) described their process of analysis clearly, while this was less 
well explained by Turner et al (2016).  Palagyi et al (2016) and Ailabouni et al (2016) provided 
meaningful findings, which were supported by evidence in the form of quotes.  The description 
of the analysis process Palagyi et al (2016) and Ailabouni et al (2016) employed, coupled with 
the supporting evidence, improved the credibility of their findings.  The findings presented by 
Turner et al (2016) lacked depth and supporting evidence, though this was largely due to the 
methodology utilised, which produced a list of findings rather than an in-depth exploration of the 
issues identified by participants.  Both Turner et al (2016) and Palagyi et al (2016) did not report 
the relationships between the researcher and the participants and the researcher’s place in the 
study, which may reduce confidence in the credibility of their findings.  Ailabouni et al (2016) 
had, however, briefly explained the researcher’s background which allowed the reader to 
consider how this may have affected their interpretation of the data.  Ailabouni et al (2016) also 
presented a completed COREQ 32 checklist (Tong et al., 2007) which improved the credibility 
and dependability of the research.  These papers were judged to provide valuable data for the 
review. 
Simmons et al (2018) also presented the results of a qualitative study, an investigation into 
nursing staff’s views on reducing the use of antipsychotic medicines in care homes.  Focus 
groups were utilised to investigate the topic; however, their use was not justified so it was not 
clear whether this was the most appropriate data collection method (Simmons et al, 2018).  In 
addition, there was no description for the inclusion of homes or participants, and so 
transferability of the findings was limited (Simmons et al, 2018; Hannes et al, 2011).  The 
method of data analysis was also unclear, which limited the credibility, and the lack of reflexivity 
impacted upon the confirmability of the study (Simmons et al, 2018; Hannes et al, 2011).  
Overall, this study was judged to be of a lower quality than other studies included in this review, 
though the findings were included in order to gain a breadth of understanding of the topic.  The 
findings were, however, given less emphasis in the findings and discussion sections of this 
chapter. 
Azermai et al (2013) conducted a survey investigating the barriers and facilitators to 
deprescribing antipsychotic medicines in care homes, as perceived by GPs and care home 
staff.  An initial qualitative phase was used to inform the development of the survey, which then 
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formed the main focus of the study.  Perhaps because it formed only the initial part of the study, 
the qualitative phase of the study was not as well described or reasoned.  Again, the 
relationship between the researcher and participants was not considered, and it was not clear 
how rigorously the data collection process was conducted and whether this was appropriate.  
This reduced the value of the findings of the survey phase of the study.  The survey was, 
however, validated by a sample of nurses, GPs and pharmacists which did increase the content 
validity of the survey.  There was little detail provided concerning how the survey was 
conducted, for example context was lacking in relation to the sample and whether it was 
representative and there was only descriptive analysis.  The study still contributed to a little 
studied field, but there was insufficient detail regarding the methods to decide upon its quality. 
Ellis et al (2015) conducted a survey, but collected data through open ended questions which 
were analysed using qualitative methods.  The survey was not validated prior to use, and it was 
unclear whether the sample was representative of the population.  The surveys were distributed 
at a conference session, and there were more managerial participants than general care staff 
participants which limited the findings towards the opinions of managers which may differ from 
other care staff.  Surveys which appeared to have been completed by participants from the 
same care home were discarded.  It was noted, though, that the authors could not be sure that 
the discarded surveys were duplicates which could have resulted in a loss of data.  However, 
the analysis methods were clearly explained and triangulation took place, both of which 
increase the credibility of the results.  While there are methodological flaws with the study which 
may affect its validity, the findings appear to have been analysed appropriately and it provides a 
useful contribution to the literature review, despite its limitations.  
Mavrodaris et al (2013) and Harriman et al (2014) also conducted survey-based studies.  Only 
Harriman et al (2014) addressed the context of their sample, acknowledging that it was too 
small and lacked power for statistical analysis.  Other details relating to sample size and context 
were missing from the two papers which limited the generalisability of the findings (Mavrodaris 
et al, 2013; Harriman et al, 2014).  The methods of the papers were described clearly, which 
increased reliability.  Mavrodaris et al (2013) presented their results both quantitatively and 
qualitatively, with the analysis methods explained clearly with evidence of triangulation, which 
enhanced credibility.  However, both studies had methodological issues and their sample sizes 
were too small for inferential tests which would have determined whether the results were 
significant.  Harriman et al (2014) was included in the literature review as it provided further 
insight into GPs’ views on deprescribing.  Mavrodaris et al (2013) was included in the literature 
review as it was the only study identified that was conducted in the UK, which meant the 
findings were more applicable to the UK setting. 
The final survey study included in the literature review was Kalogianis et al (2016).  There were 
methodological inconsistencies in this study, for example the data collection methods were 
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unclear, and the survey was not validated for use in this participant group (Kalogianis et al, 
2016).  Kalogianis et al (2016) was the only paper to conduct statistical analysis of their findings, 
but the confidence intervals and P values presented were large which signified that the results 
were uncertain and imprecise.  This was the poorest quality survey study included in this 
literature review, but it was included to provide context for the findings of other studies included 
in this review.  In this way, less weight was ascribed to the findings of this study than of the 
other studies included. 
2.6 Literature review findings:  narrative synthesis 
As highlighted in Table 1, only three of the seven included articles featured the views and 
opinions of residents and relatives, compared with six studies in which healthcare professionals 
and care home staff partook.  Therefore, the findings were weighted towards the views of 
healthcare professionals and care home staff, with limited information available relating to the 
views of residents and relatives.  The findings were therefore separated in order to gain a clear 
picture of the factors that were important to residents and relatives, and those important to 
healthcare professionals.  This allowed the views of residents and relatives to be clearly 
displayed, understood and utilised to design interview schedules for the empirical research.  
The views of healthcare professionals and care home staff could then be considered with the 
findings of the TDF mapping exercise throughout this thesis, both during the design of interview 
schedules and the selection of potential intervention components. 
Despite the fact that three papers were solely about the discontinuation of antipsychotics, 
unless otherwise stated they have been analysed and synthesised with the other five studies.  
This was because all the papers reported similar barriers and facilitators to deprescribing. 
2.6.1 Deprescribing factors identified by residents and relatives 
While there were limited findings related to residents and relatives provided by the included 
studies, one finding reported by multiple studies was that the residents’ attitude to healthcare 
professionals was likely to impact their beliefs about their medicines and deprescribing (Palagyi 
et al 2016, Kalogianis et al 2016, Turner et al 2016)  With regard to care home staff, residents 
and relatives feared that irregular (for example, new or temporary nursing staff) did not know the 
resident’s history, and that this may affect their ability to advocate for the resident (Turner et al 
2016).  
However, the most significant influence impact that any health or social care staff member had 
on the resident or relative was the doctor, and it was the doctor who was most likely to influence 
a resident’s feelings about deprescribing.  This was highlighted by Palagyi et al (2016), who 
reported a theme named “respect the GP and do as I am told”.  Palagyi et al (2016) suggested 
that this deference to the GP’s opinion, also reported by Turner et al (2016), led to the residents 
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displaying little interest toward their medicines, described by Palagyi et al (2016) as “apathy”.  
Kalogianis et al (2016) also reported that residents were willing to put their trust in the GP and 
agree with their suggestions, displaying little resistance to change.  
“The doctor has got the training and knowledge so we have to go with their 
recommendation”.  Relative, Palagyi et al (2016) pp7. 
Palagyi et al (2016) attributed this to the resident not experiencing any perceived harm or 
detrimental effects from their medicines, and so they did not think to question them.  It was also 
reported that residents and relatives often believed that medicines were “keeping the resident 
alive”, which may also meant they were reluctant to consider stopping them (Palagyi et al, 
2016).   
Healthcare professionals perceived barriers to communicating with residents, and residents and 
relatives participating in Turner et al’s (2016) study appeared aware of this.  Turner et al (2016) 
reported the finding that residents and relatives worried that their voice was not heard during the 
deprescribing process.  This implied that residents and relatives wish to be involved in the 
deprescribing process.  However, residents did not view themselves as a barrier in Kalogianis et 
al’s (2016) study: 40.5% of residents reported being willing to stop a medicine, rising to 78.9% if 
the doctor thought it was necessary.  In addition to this, 56% of residents were willing to take 
more medicines if needed.  This suggested little resistance from residents to deprescribing 
suggestions and, as Palagyi et al (2016) and Turner et al (2016) also discovered, that residents 
were content to agree with the doctor’s recommendations.   
Residents and relatives were keen to avoid deprescribing having a negative impact on the 
resident’s quality of life, with residents participating in Turner et al (2016) especially keen for the 
resident’s wellbeing to be recognised as a key factor in deprescribing (Azermai et al 2014, 
Palagyi et al 2016).   
There was also tension reported in the included articles between the resident/relative and 
healthcare professional goals of care for the resident.  Healthcare professionals focused on 
quality of life, whilst residents and relatives perceived medicines to be prescribed for longevity 
(Palagyi et al 2016).  It was also reported that GPs viewed care home residents as in the last 
stage of their lives and therefore sometimes unsuitable for major interventions, whereas 
relatives were perceived to view the home as a 24-hour healthcare facility that should work like 
a hospital.  These differences of opinion are likely to have influenced the residents’ and 
relatives’ views of deprescribing. 
The final barrier to deprescribing focussed on care home residents’ knowledge of their 
medicines.  Turner et al (2016), Ellis et al (2015) and Palagyi et al (2016) reported that 
healthcare professionals and care home staff believed that residents lacked knowledge of their 
medicines and that this was a barrier to deprescribing.  Conversely, residents responding to 
Kalogianis et al’s (2016) survey disagreed that residents lacked knowledge of medicines, as 
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67% of participants stated that they had good knowledge of their medicines.  However, 
Kalogianis et al (2016) did not define what constituted a “good” knowledge of medicines, which 
limited the application of this finding to the wider literature.  
2.6.2 Deprescribing factors identified by healthcare professionals and care 
home staff 
The barriers and facilitators to deprescribing in care homes as described by healthcare 
professionals were extracted from the included articles and displayed in Table 2.  They were 
then synthesised and mapped to the TDF.  Other deprescribing factors reported by healthcare 
professionals are described below. 
Firstly, there appeared to be a difference in the way healthcare professionals perceived and 
enacted their behaviour.  Ellis et al (2015), Mavrodaris et al (2013), Harriman et al (2014) and 
Azermai et al (2014) all discovered that GPs reported being willing to deprescribe, however 
Azermai et al (2014) reported that deprescribing was only happening “occasionally” and 
discontinuation of anti-psychotic medicines was considered in more residents than was actually 
attempted.  GPs were also more likely to reduce doses than to stop a medicine altogether.  
Furthermore, Harriman et al (2014) found that while the majority (75%) of surveyed GPs stated 
that they were “not reluctant” to deprescribe, local data suggested that GPs were not 
deprescribing.  These results demonstrated a dissonance between the perceptions of GPs and 
their behaviour, and despite believing that they did, and were willing to, deprescribe, they were 
not enacting this behaviour.  The reasons for the difference between the GPs perceptions of 
and actual deprescribing activity are not explored by any of the articles, though the multiple 
barriers to deprescribing reported across all articles and collated in this review provide 
explanation for why deprescribing is not occurring. 
As well as individuals perceiving their own thoughts and actions differently, healthcare 
professionals and care home staff had different perceptions of each other’s willingness to 
deprescribe (Turner et al 2016, Mavrodaris et al 2013).  Mavrodaris et al (2013) discussed the 
perceptions GPs and care home staff held of each other.  It was found that GPs and care home 
staff perceived each other to be unwilling to stop antipsychotic medicines (Mavrodaris et al, 
2013).  This was uniquely described as “a culture of blaming”, which may provide insight into 
how GPs and care home staff perceive each other in the UK (Mavrodaris et al, 2013).  Nurses 
participating in Turner et al’s (2016) study reported that the GP being receptive of their 
suggestions was a key factor in deprescribing, and feared their role in deprescribing may be 
dismissed by GPs.  This suggests that the attitude of GPs towards nurses affects the nurses’ 
willingness to be involved in deprescribing.   
A facilitator to deprescribing identified by healthcare professionals, care home staff and 
residents and relatives was the burden of administration of medicines, highlighted by Turner et 
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al (2016) and Palagyi et al (2016).  Residents with complex or high numbers of medicines were 
considered, and reported by themselves, to be more willing to stop medicines (Turner et al, 
2016).  Palagyi et al (2016) described how medication burden can be a facilitator from the care 
staff’s point of view, as administering and managing medicines was time consuming, and thus 
provided an impetus to initiate the deprescribing process. 
2.6.3 Extraction and mapping of literature-identified healthcare 
professional barriers to deprescribing to the TDF 
Firstly, the barriers to deprescribing identified in the nine studies included in the literature review 
were extracted.  Similar barriers were grouped and synthesised to produce a list of synthesised 
barriers to deprescribing.  These synthesised barriers were then mapped to the TDF.  Table 2 
shows the results of this process, and the rationale for these mapping decisions is provided 
below Table 2. 
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Table 2: Extraction, synthesis and mapping to the TDF of barriers extracted from primary 
studies in the literature review 
Barriers extracted from 
studies 
Synthesised barrier Description Studies citing this 
barrier 
TDF domains mapped 
to 
Previous unsuccessful 
deprescribing attempt (Azermai 
et al, 2014),)  
Cognitive impairment prohibits 
patient involvement in 
deprescribing decision, 
(Ailabouni et al, 2016; Harriman) 
Difficulty balancing the resident’s 
health conditions with 
deprescribing (Ailabouni et al, 
2016) 
Influence of the 
resident’s health 
 
Barriers related to the 
health conditions the 
resident lives with.  
Azermai et al (2014), 
Ailabouni et al (2016), 
Harriman et al (2014) 
Environmental context 
and resources 
 
Family is resistant (Azermai et 
al, 2014; Simmons et al, 2018; 
Palagyi et al, 2016) 
Residents may resist change 
(Ailabouni et al, 2016) 
Care home staff resist 
deprescribing (Mavrodaris et al, 
2013) 
Opposition of others to 
deprescribing  
 
Perceiving that others, 
particularly residents 
and relatives, may be 
opposed to 
deprescribing acts as a 
barrier to stopping 
medicines. 
Azermai et al (2014), 
Ailabouni et al (2016), 
Mavrodaris et al (2013), 
Simmons et al (2018), 
Palagyi et al (2016) 
Social influences 
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Barriers extracted from 
studies 
Synthesised barrier Description Studies citing this 
barrier 
TDF domains mapped 
to 
Reduction to the resident’s 
quality of life (Azermai et al, 
2014) 
Return/worsening of symptoms, 
or occurrence of adverse 
reactions (Simmons et al, 2018; 
Azermai et al, 2014) 
Negative beliefs about 
consequences for the 
resident 
 
Concern about various 
negative consequences 
for the resident, 
including deterioration. 
Azermai et al (2014), 
Harriman et al (2014), 
Simmons et al (2018), 
Turner et al (2016) 
Beliefs about 
consequences 
Potential for legal consequences 
(Palagyi et al, 2016) 
Higher workload (Azermai et al, 
2014) 
Negative beliefs about 
consequences for 
health and social care 
staff 
Concern regarding 
negative consequences 
which would impact 
health and social care 
staff. 
Palagyi et al (2016), 
Azermai et al (2014), 
Beliefs about 
consequences 
Fear of the resident’s health 
deteriorating after deprescribing 
(Ailabouni et al, 2016; Turner et 
al, 2016) 
Fear of how the resident and 
relatives would view 
deprescribing (Ailabouni et al, 
2016) 
Emotions felt towards 
deprescribing  
Consequences 
described as “fears” by 
article authors 
Ailabouni et al (2016), 
Turner et al (2016) 
Emotions 
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Barriers extracted from 
studies 
Synthesised barrier Description Studies citing this 
barrier 
TDF domains mapped 
to 
GPs unwilling to increase 
frustrating communications with 
care homes (Palagyi et al, 2016)  
Shortage of skilled staff in CH 
(Palagyi, et al, 2016; Ellis et al, 
2015) 
Shortage of GPs willing to work 
in care homes (Palagyi et al, 
2016) 
Staffing issues 
 
Barriers attributed to a 
lack of skilled people 
able to participate in the 
work. 
Ellis et al (2015), 
Palagyi, et al (2016) 
Environmental context 
and resources 
Skills 
Education needed for care home 
staff, doctors and relatives (Ellis 
et al, 2015; Simmons et al, 
2018; Mavrodaris et al, 2013; 
Palagyi et al, 2016; Ailabouni et 
al, 2016) 
Lack of education and 
training  
 
 Ellis et al (2015), 
Simmons et al (2018), 
Palagyi, et al (2016), 
Ailabouni et al (2016) 
Knowledge 
Need for reimbursement (Ellis et 
al, 2015) 
Lack of funding (Ailabouni et al, 
2016) 
Lack of funding 
 
 Ellis et al (2015), 
Ailabouni et al (2016) 
Environmental 
consequence and 
resources 
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Barriers extracted from 
studies 
Synthesised barrier Description Studies citing this 
barrier 
TDF domains mapped 
to 
Family unavailability and time 
constraints (Harriman et al, 
2014; Ellis et al, 2015) 
Paperwork is inefficient, 
inadequate and increases scope 
for error (Ailabouni et al, 2016) 
GPs unwilling to increase 
frustrating communications with 
care homes (Palagyi et al, 2016)  
Poor co-ordination between 
specialist and general care 
providers (Palagyi et al, 2016; 
Turner et al, 2016) 
Systemic barriers to 
communication 
 
Barriers to 
communication 
attributed to healthcare 
systems rather than 
interpersonal factors. 
Harriman et al (2014), 
Ailabouni et al (2016), 
Palagyi et al (2016), 
Ellis et al (2015) 
Environmental 
consequence and 
resources 
Difficulty in balancing multiple 
factors involved in deprescribing, 
such as the risk/benefit of a 
medicine and the resident’s 
existing health conditions 
(Ailabouni et al, 2016) 
Skill deficiencies 
 
Issues with applying 
knowledge. 
Ailabouni et al (2016) 
Skills 
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Barriers extracted from 
studies 
Synthesised barrier Description Studies citing this 
barrier 
TDF domains mapped 
to 
Lack of ability to apply evidence 
to residents (Ailabouni et al, 
2016) 
Lack of access to user friendly, 
evidence based deprescribing 
guidelines and protocols 
(Ailabouni et al, 2016; Palagyi et 
al, 2016) 
Lack of evidence and 
guidance 
 
 Ailabouni et al (2016), 
Palagyi et al (2016) 
Knowledge 
Environmental context 
and resources 
Lack of standard medication 
charts/electronic system for care 
homes (Palagyi et al, 2016) 
Inadequate system of providing 
medicine reviews (Palagyi et al, 
2016) 
Care home work is costly, time 
consuming and frustrating 
(Palagyi et al, 2016) 
Systemic barriers to 
deprescribing 
 
Barriers to deprescribing 
caused by healthcare 
systems and ways of 
working imposed on 
participants. 
Palagyi et al (2016) 
Environmental context 
and resources 
GPs varied in their confidence to 
make deprescribing decisions 
(Palagyi et al, 2016) 
Confidence to 
deprescribe 
 
 Palagyi et al (2016) 
Beliefs about 
capabilities 
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Barriers extracted from 
studies 
Synthesised barrier Description Studies citing this 
barrier 
TDF domains mapped 
to 
Differences in expectations and 
goals of care between GPs and 
relatives (Palagyi et al, 2016) 
Goals of care 
 
 Palagyi et al (2016) 
Social influences 
Lack of time to deprescribe due 
to competing tasks and time 
constraints (Ailabouni et al, 
2016; Ellis et al, 2015) 
Care home work is costly, time 
consuming and frustrating 
(Palagyi et al, 2016) 
GP services are provided to care 
homes on a part time basis 
(Palagyi et al, 2016) 
High workload of careers 
(Palagyi et al, 2016) 
Doctor unable to discuss 
deprescribing due to time 
constraints (Harriman et al, 
2014) 
Lack of time Lack of time to engage 
in care home work and 
deprescribing was 
frequently cited as a 
barrier to deprescribing. 
Ailabouni et al (2016), 
Ellis et al (2015), 
Palagyi et al (2016) 
Environmental context 
and resources 
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Barriers extracted from 
studies 
Synthesised barrier Description Studies citing this 
barrier 
TDF domains mapped 
to 
GPs and care home staff lack 
deprescribing knowledge 
(Ailabouni et al, 2016) 
Residents’ and relatives’ lack 
knowledge of medicines (Palagyi 
et al, 2016; Turner et al. 2016) 
Knowledge 
deficiencies of GPs, 
care home staff, 
residents and relatives 
 Ailabouni et al (2016), 
Palagyi et al (2016) 
Knowledge 
Uncertainty of roles (Mavrodaris 
et al, 2013) 
Uncertainty of roles 
 
Uncertainty regarding 
who was responsible for 
the management of 
medicines started in 
hospital. 
Mavrodaris et al (2013) 
Social/professional 
role and identity 
GPs reluctant to stop medicines 
started by other prescribers 
(Ailabouni et al, 2016; Harriman 
et al, 2014) 
Influence of other 
prescribers 
The influence of the 
other prescriber rather 
than an uncertainty of 
roles which prevented 
deprescribing 
Harriman et al (2014), 
Ailabouni et al (2016) 
Social influences 
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Table 3: Mapping of barriers related to antipsychotic medicines only 
Barriers extracted from 
studies 
Synthesised barrier Description Studies citing this 
barrier 
TDF domains mapped to 
● Inadequate non 
pharmacological 
alternatives (Azermai 
et al, 2014; Simmons 
et al, 2018) 
● Lack of resource 
(staff, funding) for 
non-pharmacological 
alternatives 
(Mavrodaris et al, 
2013) 
Lack of viable non-
pharmacological 
alternatives  
 
A lack of viable non-
pharmacological 
alternatives to 
antipsychotic medicines, 
including the staff and 
funding required, is a 
barrier to stopping this 
class of medicines.  
Azermai et al (2014), 
Mavrodaris et al (2013), 
Simmons et al (2018) 
Environmental context 
and resources 
● Resident risk of harm 
to themselves, staff, 
other residents 
(Azermai et al (2014) 
Risk of harm Specific risk of resident 
causing harm due to 
recurrence of psychosis 
after stopping 
antipsychotic medicines 
Azermai et al (2014), Beliefs about 
consequences 
66 
 
 
2.6.3.1 Rationale for the mapping of the synthesised barriers in Table 2 
This section provides the rationale for the mapping decisions presented in Table 2. 
2.6.3.1.1 Environmental context and resources 
The most common domain that literature-identified barriers were mapped to was Environmental 
Context and Resources.  Cane et al (2012) defined this domain as:  
“any circumstances of a person’s situation or environment that discourages or 
encourages the development of skills and abilities, independence, social 
competence and adaptive behaviour” (Cane et al, 2012, pp14).   
In terms of deprescribing, as shown in Appendix C table 53, this domain was defined to mean 
contextual, resource and material limitations which impeded deprescribing.  The following 
synthesised barriers were assigned to this domain: 
- Influence of the resident’s health 
- Staffing issues 
- Lack of evidence and guidance 
- Lack of funding 
- Systemic barriers to communication 
- Systemic barriers to deprescribing 
- Lack of time 
Influence of the resident’s health referred to barriers to deprescribing that were related to the 
resident’s health conditions, for example cognitive impairment limiting their involvement in 
decision-making or a previous unsuccessful deprescribing attempt that resulted in a negative 
consequence.  This barrier was assigned to this domain after discussion.  It was first assigned 
to Social Influences, as it refers to the influence that another, in this case the resident, had on 
the prescriber’s behaviour.  However, it was felt that Environmental Context and Resources was 
a more appropriate domain.  This was because the domain Social Influences refers to 
interpersonal factors, or how one person’s behaviour affects another’s, rather than how a patient 
factor may influence a behaviour.  Assigning the barrier to Environmental Context and 
Resources acknowledges that the health of the resident is a context within which prescribers 
work; a resident who cannot communicate is a more challenging context for the prescriber to 
work with than a resident who can communicate. 
Staffing issues was one of only three synthesised barriers which was assigned to two domains 
of the TDF.  This was because there were two closely linked factors that were reported and 
synthesised as staffing issues: a shortage of staff in general, and more specifically a shortage of 
skilled staff, for example registered nurses.  These two factors were too closely entwined to 
separate, so this barrier was assigned to both the Environmental Context and Resources and 
Skills domains.  The Environmental Context and Resources domain reflects the shortage of staff 
as a resource, and the Skills domain reflects the lack of skilled staff. 
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The synthesised barrier lack of evidence and guidance was also assigned to two domains of the 
TDF.  The Knowledge domain was appropriate because evidence and guidance provides 
knowledge to prescribers which aids them with deprescribing in care homes.  The 
Environmental Context and Resources domain was appropriate because healthcare 
professionals may have difficulties accessing evidence, or the evidence may not exist.  This is 
an example of the environment not being conducive to deprescribing behaviour, as it is beyond 
the scope of the individual healthcare professional to create the evidence base  they require. 
The final synthesised barriers assigned to the Environmental Context and Resources domain 
are more obviously associated with this domain.  Lack of funding and time refers to lack of 
resources, and systemic barriers to communication and deprescribing are barriers related to the 
environment within which the healthcare professionals work.  Examples of systemic barriers are 
insufficient communications or medicine reviews, unavailability of people whose opinion is 
sought and a lack of standardised medical record keeping in care homes.   
It is worth considering that “lack of time” as a barrier, frequently cited by participants in the 
studies, may be masking other deficiencies which may be more appropriately mapped to other 
domains.  For example, rather than a lack of time, the issue might be insufficient time 
management skills, which would fall under the Skills domain.  It could also be that healthcare 
professionals prioritise other work over deprescribing, which suggests a goal conflict.  This 
would then fall under the Goals domain.  However, the original studies presented that the barrier 
was simply a lack of time rather than anything else, and as time is a resource, this barrier was 
assigned to the Environmental Context and Resources domain.   
2.6.3.1.2 Knowledge and skills 
The Knowledge and Skills domains are separate domains of the TDF, but are closely related 
and were therefore considered together (Fleming et al, 2014).  Whilst the Knowledge domain is 
concerned with what the participant knows, the Skills domain refers to the application of what 
the participant knows.  The literature-identified barriers that were mapped to the Knowledge and 
Skills domains were:   
- Lack of evidence and guidance 
- Lack of education and training 
- Knowledge deficiencies 
The Knowledge domain was defined for the purpose of this study to incorporate all aspects of 
knowing how to deprescribe.  The rationale for including the barrier “lack of evidence and 
guidance” in the Knowledge domain is described above (evidence informs knowledge), and the 
barrier “knowledge deficiencies” clearly fits into this domain.  “Lack of education and training” 
was assigned to both the Knowledge and Skills domains.  This was because some of the 
education required referred to gaining knowledge, such as knowledge of the risks of medicines, 
and some was more related to skills, for example managing the behaviour of agitated residents.   
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The Skills domain was also assigned to three barriers.  The “skills deficiency” barrier 
demonstrates the difference between knowledge and skill.  An identified skill deficiency was that 
prescribers lacked the ability to apply their deprescribing knowledge to residents, which was a 
problem with their skill rather than their knowledge.  The rationale for including the barrier 
“staffing issues” in the Skills domain was described above, as it was also assigned to 
Environmental Context and Resources.  It was assigned to the Skills domain as a lack of skilled 
staff in particular was a barrier to deprescribing.  
2.6.3.1.3 Social influences 
The Social Influences domain was defined by Cane et al (2012) to refer to the: 
 “interpersonal processes that can cause individuals to change their thoughts, 
feelings and behaviours”. (Cane et al, 2012, pp14) 
In this study, it includes how the influence of patients, carers and others involved in the 
resident’s care affect the deprescribing behaviours of healthcare professionals.  Three barriers 
were assigned to this domain: 
- Opposition of others to deprescribing 
- Influence of other prescribers 
- Goals of care 
The first two barriers listed above refer directly to the influence of others, be it a relative who is 
opposed to deprescribing or a hospital doctor the healthcare professional does not want to 
disagree with.  It is this influence of the other person on the prescriber which changes their 
behaviour and forms the barrier to deprescribing.  This is a social, interpersonal barrier.   
The final barrier assigned to the Social Influences domain was the “goals of care” barrier.  At 
first, this was assigned to the Goals domain of the TDF as it referred to how GPs and relatives 
perceived the Goals of the resident’s care.  However, it was moved to the Social Influences 
domain because the actual barrier to deprescribing was the perception that GPs held of the 
relatives.  GPs believed that relatives had conflicting views concerning the role of the care home 
and the residents’ goals of care, and it was this which affected their behaviour and prevented 
deprescribing.  Therefore, the barrier goals of care was assigned to the Social Influences 
barrier. 
2.6.3.1.4 Other domains 
Two barriers, both regarding the perceived negative consequences of deprescribing, were 
assigned to the Beliefs About Consequences domain.  The Beliefs About Consequences 
domain in this study refers to what prescribers believe the outcomes of their actions will be, and 
several potential negative consequences were identified by the included studies.  Examples of 
potential negative consequences of deprescribing include causing harm to the resident or the 
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healthcare professional facing litigation due to deprescribing.  Consideration of the negative 
consequences of deprescribing clearly falls into the Beliefs About Consequences domain. 
After discussion, barriers regarding the fear of consequences were separated from the general 
beliefs about consequences and assigned to the Emotions domain of the TDF.  This was 
because one study stated that participants were fearful of the consequences of deprescribing, 
rather than just aware of the consequences of deprescribing (Ailabouni et al, 2016).  Therefore, 
it can be interpreted that it was an emotion, fear, which was preventing them from 
deprescribing.  One study also noted that GPs were “frustrated” by care home work (Palagyi et 
al, 2016), another emotion suitable for assigning to this domain. 
Two domains of the TDF were used only once.  Palagyi et al (2016) reported the varying 
degrees of confidence prescribers had to deprescribe, which refers to their beliefs about their 
own capabilities.  It was therefore assigned to this domain.  Finally, Mavrodaris et al (2013) 
identified that uncertainty of roles, and who was responsible for a medicine prescribed by 
secondary care, was a barrier to deprescribing.  This was assigned to the Social/Professional 
Role and Identity domain of the TDF, because it relates to how the prescriber’s behaviour is 
affected by what they understand their role in the resident’s care to be. 
2.6.3.1.5 Antipsychotic medicines 
Two synthesised barriers were raised only in relation to antipsychotic medicines, and these are 
presented in a separate table (Table 3).  This was because they may not be applicable to all 
medicines.  A lack of non-pharmacological alternatives to antipsychotics was frequently cited as 
a barrier to stopping them.  This was attributed to a lack of efficacy, funding and staff to manage 
the non-pharmacological alternatives.  For this reason, this barrier was assigned to 
Environmental Context and Resources.  There were also specific beliefs about the 
consequences of stopping antipsychotic medicines, which related to a belief that stopping the 
medicine could enable the resident to cause harm to themselves or others.  This belief about 
consequences prevented deprescribing of antipsychotic medicines, and was assigned to the 
belief about consequences domain. 
2.7 Discussion of the findings of the literature review 
2.7.1 Introduction 
This literature review aimed to investigate the barriers and facilitators to deprescribing in care 
homes.  Nine articles were identified as eligible to include in the review.  Of these, four were 
described as qualitative and the remaining were survey studies, or mixed methods studies 
which included surveys.  Four of the included studies discussed the deprescribing of 
antipsychotic medicines only, while the remaining studies were not limited to a single class of 
medicines.   
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The studies included focussed on the views and opinions of healthcare professionals, with only 
one study providing qualitative insight into the views of residents and relatives.  Two more 
studies provided limited quantitative insight into the deprescribing beliefs of residents and 
relatives.  The findings were therefore synthesised in two groups: factors residents and relatives 
believe are important when deprescribing, and those considered important by healthcare 
professionals and care home staff.  The barriers were then extracted from the healthcare 
professional and care home staff findings, synthesised and mapped to the domains of the TDF.  
The healthcare professional barriers were mapped to the TDF as they will be the users of any 
intervention. There was also a lack of resident and relative findings to map at this stage.   
This discussion will contextualise the findings of this review with the findings of four existing 
systematic reviews, which are described below.  The mapping of the barriers to the TDF is 
discussed in Chapter 5.4, following the mapping of the empirical findings to the TDF and 
Behaviour Change Wheel (BCW).   
2.7.2 Systematic reviews incorporated into the discussion 
Reeve et al (2013) summarised the barriers and facilitators to deprescribing from the 
perspective of patients, combining the results of twenty-one papers to generate five themes.  
The first three themes are barriers and facilitators to deprescribing, while the fourth theme is a 
facilitator and the fifth a barrier to the process (Reeve et al, 2013, pp798): 
- Disagreement/agreement with “appropriateness” of deprescribing 
- Absence/presence of a “process” for deprescribing 
- Negative/positive “influences” to deprescribing  
- Dislike of medicines 
- Fear of deprescribing 
Anderson et al (2014) conducted a similar review, though they examined prescriber barriers and 
facilitators.  This included 22 papers, whose results were described in four themes (Anderson et 
al 2014): 
- Awareness: level of insight a prescriber has into the appropriateness of their prescribing 
- Inertia: failure to act, despite awareness that there is evidence of inappropriate 
prescribing 
- Self-efficacy: how factors such as a prescriber’s knowledge level, attitudes and 
influences affect their beliefs or confidence to deprescribe 
- Feasibility: factors external to the prescriber, such as patients and other healthcare 
professionals, which are perceived to affect a prescriber’s ability to deprescribe. 
Lundby et al (2019) conducted a systematic review into the attitude of healthcare professionals 
towards deprescribing for older people with limited life expectancy.  Eight studies were included, 
and the findings were presented in four themes: 
- Patient and relative involvement, including the barriers to involvement of these groups 
such as cognitive impairment and the avoidance of discussing end of life issues. 
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- The importance of teamwork, including the relationships between different healthcare 
professionals and factors involving specialist prescribers. 
- Healthcare professional’s self-assurance and skills, including knowledge, evidence, 
confidence to deprescribe and concerns regarding deprescribing. 
- The impact of organisational factors, such as continuity of care, workload, time and 
guidance. 
Bokhof and Junius-Walker’s (2016) qualitative synthesis investigated reducing polypharmacy 
from the perspectives of GPs and older people.  14 qualitative studies were included, and 11 
key concepts were described in the study: 
Patient views: 
- Experimenting with multiple medicines to get to know them: patients reported stopping 
some or all of their medicines to test their efficacy or investigate side effects 
- Attitudes and beliefs about medicines, such as like or dislike of medicines or fear of 
dependency 
- Personal experiences with medicines, such as the cost or perceived efficacy or harm of 
medicines 
- Necessity of priority-based treatment decisions in the face of multimorbidity: some 
patients described prioritising their medicines when they had multiple medical conditions. 
- Relationship GP affecting reasonable medication management: this key concept 
included the trust the patient had in the GP, and that GPs rarely knew of the changes 
patients made to their medicines. 
- System-related contributors to polypharmacy, including issues around consultations, the 
pharmaceutical industry and past healthcare experiences.   
GP views: 
- Assumptions of elderly patients, such as a perception that patients do not understand 
their medicines or beliefs regarding what patients thought of their medicines 
- Interface prescribing problems contribute to polypharmacy, including issues around 
ensuring continuity of care. 
- Evidence-based guidelines contribute to polypharmacy.  This key concept examined the 
conflict GPs described between following guidance and individualising medical care. 
- Failure to meet the challenge of complex decision-making: GPs felt they did not have the 
resources they required to deprescribe, such as time or evidence.   
- Proposals for solutions: describes the solutions GPs had considered to reduce 
medicines use, such as prioritising medicines and amending targets. 
There were numerous similarities between the findings of Anderson et al (2014), Reeve et al 
(2013), Lundby et al (2019) and Bokhof and Junius Walker (2016), and the findings of the nine 
papers included in this review.  This suggests that prescribers face similar barriers to 
deprescribing for all patients all settings, not just to deprescribing for older people in care 
homes.   
2.7.3 Deprescribing factors identified by residents and relatives 
A similarity between the findings of Reeve et al’s (2013) study and the findings reported in 
section 2.6 was that patients believe medicines are beneficial.  Reeve et al (2016) reported that 
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medicines were usually described as beneficial by the patients interviewed, and they were 
therefore reluctant to stop them.  This was similar to the findings of Palagyi et al (2016), who 
reported that residents and relatives believed that medicines were beneficial in that they were 
“keeping the resident alive”.  Reeve et al (2016) and Bokhof and Junius-Walker (2016) also 
reported that the continuation of medicines by a doctor was proof that the medicine was 
necessary, which may also be a reason that care home residents and their relatives believe in 
the necessity of medicines. 
Whilst Bokhof and Junius-Walker (2016) described a similar attitude to medicines, they also 
described that some older patients are sceptical and unsure of their medicines benefits.  This 
opposing view was described by Reeve et al (2013) to act as a facilitator to deprescribing.  
Patients were more willing to consider stopping medicines if they did not believe them to be 
beneficial any more or they had experience of side effects (Reeve et al, 2013).  This reflects the 
necessity-concerns framework, which is a conceptual model that can be utilised to understand 
patient adherence to medicine (Horne et al, 2013).  It suggests that a patient’s decision 
regarding whether to adhere to their medicines is influenced by their judgements of the 
medicine’s benefits, and the potential harms of the medicines (Horne et al, 2013).   
Palagyi et al (2016), Turner et al (2016) and Azermai et al (2014) all reported that the resident’s 
wellbeing was important when deprescribing, and that residents and relatives did not wish for 
deprescribing to cause harm.  This was mirrored by Reeve et al (2013), especially with regard to 
medicines for cognitive impairment such as Alzheimer’s disease.  These medicines were 
believed to be beneficial, even if the patient was not showing signs of improvement (Reeve et 
al, 2013).  Relatives of those with cognitive impairment were fearful of a medicine for cognitive 
impairment being stopped in case the patient would fail to benefit from the medicine in the future 
(Reeve et al, 2013).  When it is considered that a large proportion of care home residents in the 
UK live with cognitive impairment, this finding may be applicable a care home setting and 
prevent the deprescribing of medicines for cognitive impairment. 
A finding of the literature review being conducted was that care home residents respect the 
doctor, and as such are unlikely to disagree with them.  They therefore displayed little 
resistance to change.  Bokhof and Junius-Walker (2016) reported similar findings, and 
described that older people often trusted their doctor to make decisions concerning their care.  
This suggests that older people in general are trusting of the decisions made by their doctor.  A 
final similarity between the findings of the literature review described in section 2.6 and the 
findings of Bokhof and Junius Walker (2016) was that older people were perceived by 
healthcare professionals and care home staff to lack knowledge of their medicines.  However, 
this was disputed by residents participating in Kalogianis et al’s (2016) study, and so requires 
further in-depth investigation.   
73 
 
 
The other findings from the literature review being conducted, reported in section 2.6, were not 
reported by Reeve et al (2013) or Bokhof and Junius-Walker (2016).  This suggests that they 
are unique to the care home setting, rather than a more widespread barrier to deprescribing.  
One finding reported by Turner et al (2016) that was unique to the care home setting was that 
new or temporary nursing staff are a barrier to deprescribing, as they do not know a resident’s 
history.  This was clearly unique to the care home setting, because it involves care home staff.  
It was unclear, however, how the final finding was unique to the care home setting, as it may 
also be applicable to the treatment of other patients, particularly older ones, who do not live in 
care homes.  Reeve et al’s (2016) finding that there was a conflict over goals of care, where 
relatives and GPs were found to have different beliefs regarding the role of the care home and 
the goals of the resident’s care.  This was not found in the wider literature, although Lundby et al 
(2019) reported that healthcare professionals found it difficult to discuss end of life issues. 
2.7.4 Deprescribing factors identified by healthcare professionals and care 
home staff 
There were many more healthcare professional and care home staff barriers to deprescribing 
identified than resident and relative ones.  This was because more of the articles included in the 
literature review investigated the views of healthcare professionals than residents and relatives.   
Three deprescribing factors were identified in the findings of the literature review (section 2.6) 
which were not mapped to the TDF.  Only one of these findings was reported in the wider 
literature, as Anderson et al (2014) also reported a difference in the way healthcare 
professionals perceive and enact their behaviour.  Under the theme “awareness”, Anderson et 
al (2014) discuss that prescribers have a poor insight into their prescribing practices, and while 
they understood the benefits of deprescribing they were not practising it for individual patients.  
This finding was only reported in papers where the behaviour of prescribers was observed or 
audited, which means that the prescribers did not report this behaviour themselves.  This 
provides further insight into the lack of awareness prescribers have of their own behaviour.  
These differences in the beliefs that prescribers state they have regarding deprescribing, 
compared with how they conduct deprescribing in practice is suitable for examining using 
behaviour change psychology.  This provides rationale for the use of behaviour change 
psychology in this thesis.   
Two deprescribing factors were identified in the literature review but not the wider literature.  Of 
these, one was clearly unique to care homes as it involves care home staff.  As reported by 
Turner et al (2016) and Mavrodaris et al (2013), GPs and care home staff blamed each other for 
a lack of deprescribing and care home staff feared their opinions were dismissed by GPs.  This 
finding was clearly specific to care homes and would not be found in a more general setting as it 
explicitly involves care home staff.  The final deprescribing factor that appears to be specific to 
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care homes was reported by Turner et al (2016) and Palagyi et al (2016).  This finding was that 
residents taking more medicines were more willing to have medicines deprescribed.  While this 
finding was not reported in the reviews conducted by Anderson et al (2014), Reeve et al (2013), 
Lundby et al (2019) or Bokhof and Junius-Wilson(2016), it could apply to a more general 
population and it was not clear whether it was only applicable to care home residents. 
2.7.4.1 Barriers mapped to the Environmental Context and Resources domain of 
the TDF 
Current prescribing practices were reported to be a barrier to deprescribing both inside and 
outside the care home setting.  These systemic barriers to deprescribing were mapped to the 
Environmental Context and Resources domain.  Alongside the need for regular medicines 
review highlighted in the literature review being conducted, Anderson et al (2014) also reported 
that signing repeat prescriptions on behalf of colleagues  and the absence of treatment plans 
were barriers to the deprescribing process, as prescribers did not know the patient or their 
history well enough to consider deprescribing.  This is also likely to be an issue in the UK, where 
prescribers regularly sign prescriptions on behalf of another prescriber (Cantrill et al, 2000).  
Similarly to Harriman et al (2014), Anderson et al (2014) reported that opportunity to conduct 
medicines review, such as when the patient left hospital or changed primary prescriber, acted 
as a potential facilitator to the process as it prompted the prescriber to conduct a medicines 
review.   
Lack of time was another Environmental Context and Resources barrier identified to 
deprescribing in general as well as in care homes.  Anderson et al (2014) highlighted that the 
most prevalent resource barrier to deprescribing was the lack of time available to prescribers to 
conduct thorough medicine reviews, when the amount of effort that this entails is considered.  
This finding was also reported by Lundby et al (2019) and Bokhof and Junius-Wilson (2016), 
with the latter reporting that patients felt that there was a lack of time in GP consultations.  Other 
resources which were identified as lacking in the current review and by Anderson et al (2014) 
were healthcare professionals, such as mental health workers and pharmacists, and financial 
reimbursement and support.  
2.7.4.2 Barriers mapped to the Knowledge domain of the TDF 
The lack of evidence for deprescribing was cited as a barrier to deprescribing generally, as well 
as in care homes specifically.  This barrier was mapped to both the Environmental Context and 
Resources domain and the Knowledge domain of the TDF.  Like Turner et al (2016), Anderson 
et al (2014), Lundby et al (2019) and Bokhof and Junius-Wilson (2016) reported a lack of 
evidence of the benefits and harms of stopping preventative medicines in older people with 
multiple health conditions.  This lack of evidence acted as a barrier to deprescribing medicines 
in older people. 
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Anderson et al (2014) and Bokhof and Junius-Wilson (2016) presented a different perspective of 
the impact of clinical guidance on deprescribing decision-making.  Unlike Mavrodaris et al 
(2013) and Harriman et al (2014), Anderson et al (2014) and Bokhof and Junius-Wilson (2016) 
reported that prescribers felt obliged to comply with guidelines despite the patients’ co-
morbidities and complexities which may make the patient ineligible for guideline-based 
treatment.  Prescribers following the guidance for a particular condition may, therefore, continue 
prescribing a potentially inappropriate medicine in order to adhere to a guideline.   
A prominent barrier to deprescribing across all settings was knowledge deficiencies of GPs, 
care home staff, residents and relatives, which was mapped to the Knowledge and Skills 
domains.  Like Turner et al (2016), Palagyi et al (2016) and Ailabouni et al (2016), Anderson et 
al (2014) and Lundby et al (2019) described numerous barriers related to a lack of information.  
Prescribers may lack the knowledge required to make a decision, for example they may lack the 
ability to recognise side effects or balance the risks and benefits of stopping a medicine 
(Anderson et al, 2014).   
2.7.4.3 Barriers mapped to the Social Influences domain of the TDF 
Social Influences on the deprescribing process were also acknowledged by Anderson et al’s 
(2014) systematic review.  The findings of the review being conducted states that prescribers 
were unwilling to challenge prescribing decisions made by other prescribers, though there was 
not a clear explanation as to why this was (Turner et al 2016, Harriman et al 2014, Mavrodaris 
et al 2013).  Anderson et al (2014) reported similar findings, and they attribute this unwillingness 
to the respect prescribers have for each other and perceived professional hierarchy.  Hierarchy 
was noted between specialist prescribers and GPs, with GPs perceiving the decisions of 
specialists to take precedence over their own opinions (Anderson et al, 2014).   
Lundby et al (2019) also reported social factors involving relationships between healthcare 
professionals, including specialists, and perceptions of older people of their beliefs about 
medicines.  Bokhof and Junius-Wilson (2016) also described the assumptions that GPs have of 
older people, including that they lack knowledge about their medicines.  Care home residents 
were reported by Palagyi et al (2016) to be “apathetic” with regard to their medicines, a 
perception healthcare professionals had of residents.  While multiple social barriers to 
deprescribing have been described in the literature, there was a lack of depth and 
understanding of these barriers.  Research into the social barriers, and how these could be 
overcome, is required. 
2.7.4.4 Barriers mapped to the consequences domain of the TDF 
Mapped to the consequences domain were two synthesised barriers which were also reported 
by Anderson et al (2014), Lundby et al (2019) and Reeve et al (2013): negative beliefs about 
consequences for the resident, and negative beliefs about consequences for health and social 
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care staff.  The emotions felt towards deprescribing were also linked to the consequences of 
deprescribing, as avoidance of negative consequences was sometimes linked with “fear”.  
Some of these fears were similar for both patients and prescribers, such as a fear of the 
worsening of the patient’s condition, while prescribers were also preoccupied with worries of 
damaging relationships with colleagues and patients and an increase in their workload (Reeve 
et al, 2013; Anderson et al, 2014).  Prescribers were also unsure of the potential legal 
consequences of deprescribing, which suggests they need educating on this aspect (Anderson 
et al, 2014; Palagyi et al, 2016).   
However, some prescribers reported being fearful of the potential negative consequences of 
continuing a medicine as these may be unknown (Anderson et al, 2014; Lundby et al, 2019).  
Whilst this was not reported in the care home setting, this finding may be transferable to older 
people living in care homes as the benefits of continuing medicines in this population have not 
often been determined.  This was supported by Anderson et al’s (2014) finding that prescribers 
struggle to weigh up the benefits and risks of prophylactic medicines in older people (Anderson 
et al, 2014). 
2.7.4.5 Other barriers to deprescribing reported in care homes 
Finally, Anderson et al (2014) included two studies in their review which took place in care 
homes and reported a barrier to deprescribing that was unique to care homes.  Flick et al (2012) 
and Iden et al (2011) discussed that prescribers felt pressured by care home staff to prescribe 
sedative and antidepressant medicines respectively as they assisted the care home staff in 
managing the residents and maintaining order in the care home.  This was similar to care home 
staff participating in Azermai et al (2014), who reported being reluctant to stop antipsychotic 
medicines if it could cause the resident to harm another person or increase the workload of care 
home staff.   
Several synthesised barriers to deprescribing in care homes were not reported in the existing 
systematic reviews of barriers and facilitators to deprescribing in care homes.  This suggests 
that these barriers are specific to the care home setting.  For some of these barriers, it was clear 
that they are specific to care homes because, for example, they refer to care home staff.  An 
example of this was the synthesised barrier “staffing issues”, which refers to the perceived lack 
of skilled care home staff and GPs willing to work in care homes which were identified in this 
review.  Other barriers that had clear links to care homes were: 
- Opposition of others to deprescribing, which referred to the views of relatives and care 
home staff.  The views of relatives are not generally considered in the wider literature 
around deprescribing, but are important in the care home setting. 
- Relatives and GPs having differing opinions concerning the resident’s goals of care and 
the role of the care home  
- Lack of funding to provide deprescribing services to care homes  
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- Systemic barriers to communication were largely due to the care home setting, such as 
dislike of the paperwork involved with care home work and unavailability of people 
whose opinions were desired, such as relatives.  However, it was possible that other 
systemic barriers such as poor coordination between primary and secondary care 
settings could exist outside of care homes. 
2.7.5 Strengths and limitations of the literature review 
The purely qualitative studies conducted by Turner et al (2016), Palagyi et al (2016) and 
Ailabouni et al (2016) were of an enhanced quality than the other studies included in the review.  
This means that only a third of the studies included in the review were judged to be of good 
quality, which has implications for the quality of the findings of the review.  In addition to this, the 
two of the three aforementioned studies had limitations that affected their use in the review.  
The study conducted by Turner et al (2016) lacked the depth required for mapping of the 
findings to the TDF.  This meant that only three of Turner et al’s (2016) findings were mapped to 
the TDF, despite many more findings being reported.  It was not possible to map more of the 
findings to the TDF because there was insufficient information presented by Turner et al (2016) 
to determine exactly what caused the barrier and therefore which domain it should be assigned 
to.  This was likely due to the methodology applied to this study (nominal group technique) 
which generated a list of findings rather than more traditional, in depth qualitative findings. 
Ailabouni et al (2016) was methodologically rigorous with regard to the data collection methods 
employed, and contributed valuable findings to be mapped to the TDF.  However, Ailabouni et al 
(2016) mapped their own findings to the TDF as a part of their study and this was not rigorously 
conducted.  The methods employed by Ailabouni et al (2016) to conduct this stage are lacking; 
and the mapping presented in the study appears to have been done superficially, without 
adequate consideration of the meanings of the domains.  Chapter 5, section 5.4, discusses the 
TDF mapping conducted by Ailabouni et al (2016) in more depth. 
The remaining studies included in the review were of a poorer quality, and had methodological 
issues which limit their application to the study.  Simmons et al (2018) conducted a qualitative 
study, however the methods employed for data collection and analysis were not clearly 
described or justified which limits the credibility and transferability of the findings.  Ellis et al 
(2015) conducted a survey with a large sample size which was appropriately analysed, but the 
data collection methods limited the generalisability of the study.  The surveys conducted by 
Mavrodaris et al (2013) and Harriman et al (2014) lacked power for statistical analysis and 
generalisability, and the survey conducted by Kalogianis had several methodological 
irregularities and the statistical analysis provided indicated uncertain and imprecise results.   
Whilst the quality of the included papers is a limitation of this literature review being conducted, 
there are multiple strengths.  The literature search was conducted rigorously and systematically, 
and the included papers were transparently critically appraised using appropriate critical 
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appraisal tools.  The findings were synthesised transparently and presented with a clear audit 
trail and an accompanying explanatory narrative.  A further strength is that the findings of the 
included papers were mapped to the TDF, a theoretical framework which links barriers to 
behaviours.  This means the findings can be applied throughout the thesis, including during the 
identification of behaviours which could be targeted with a novel deprescribing intervention 
(Chapter 5).   
Not all the findings of the included papers were suitable for mapping to the TDF, which could be 
viewed as a limitation of this review.  However, findings that were not suitable for mapping to the 
TDF were synthesised and presented narratively (section 2.6.1 and 2.6.2).  This means that 
important perceptions and beliefs relating to deprescribing that were not suitable for mapping to 
the TDF, especially those voiced by residents and relatives, were not excluded from the 
findings.  This provides a more complete description of the available evidence in relation to 
deprescribing in care homes, and is a further strength of this literature review. 
2.7.6 Conclusion 
This literature review identified that there is a lack of high quality, qualitative research into 
deprescribing in care homes.  In particular, there is a lack of this research in the UK, highlighting 
a need for the empirical work undertaken in this thesis.  An insufficient quantity of quality 
information was gained regarding the feelings of residents and relatives towards deprescribing, 
though it was noted that the residents did not perceive themselves to be a barrier to the 
process.  The empirical research aimed to investigate the feelings of residents and relatives 
towards deprescribing further.   
With regard to healthcare professionals, multiple barriers to deprescribing in care homes were 
extracted including logistical barriers such as relative unavailability and systemic barriers such 
as lack of resource.  In addition to this, the following domains of the TDF were identified as most 
important when considering deprescribing in care homes: Environmental Context and 
Resources, Knowledge and Social Influences. 
The findings of this literature review will be utilised throughout this study.  The resident and 
relative findings will be used to inform the interview schedules for these groups, in order that the 
existing evidence may be built upon.  The findings will also inform the development of the 
healthcare professional and care home staff interview schedules.  However, the interview 
schedules for this part of the empirical work will primarily be informed by the TDF, which will be 
utilised to inform the components of a deprescribing intervention for use in care home.  The 
findings of this review will then be used to contextualise the findings of the study being 
conducted.  The TDF mapping, conducted in section 2.6.3, will be taken forward to Chapter 5, 
where it will be considered with the findings of the study to inform the development of a 
deprescribing intervention for use in care homes.
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Chapter 3 Methodology and methods 
3.1 Introduction 
There are a range of barriers and facilitators to deprescribing in care homes, as addressed in 
Chapter 2.  It was identified that there is a lack of evidence regarding the feelings of residents 
and relatives towards deprescribing in care homes, and regarding the barriers and facilitators to 
deprescribing in care homes in the UK.  This required exploratory work, and therefore using 
qualitative methods is appropriate.  This chapter will describe the qualitative methodology and 
methods utilised to address the following research objectives: 
- To investigate how the deprescribing process happens in care homes, including the 
roles and responsibilities of those involved 
- To explore how older people living in care homes, and their relatives, perceive their 
medicines (or medicines taken by the resident) and their attitudes to deprescribing 
- To explore the attitudes of healthcare professionals and care home staff towards 
deprescribing in care homes, including identification of perceived barriers and facilitators 
to deprescribing. 
3.2 Methodology 
3.2.1 Qualitative research 
Qualitative research is an umbrella term for multiple techniques and practices utilised to collect 
and analyse data in the form of words rather than numbers (Carter and Little, 2007; Van 
Maanen, 1979).  At the heart of qualitative research is a desire by researchers to gain a depth of 
understanding of how their research participants see, construct and interpret their world 
(Merriam, 2009; Mason, 2002; Carter and Little 2007).  The word “interpret” is key when 
describing qualitative research, as the data generated is about the way the participants interpret 
their experiences.  The data is then further interpreted by the researcher, as they assemble their 
own meanings of the breadth of individual participants’ accounts (Merriam, 2009).   
3.2.2 Approach to the study 
Traditionally, qualitative researchers have structured their research around a philosophical 
framework that informs their research design, data collection and analysis (Ritchie and Lewis, 
2014; Seale 2004).  These approaches aid researchers in exploring a phenomenon with an aim 
of gaining and exploring knowledge (Ritchie and Lewis, 2014; Seale 2004).  However, it has 
been acknowledged that it is not always necessary for a researcher to align themselves with a 
particular philosophical theory, especially where qualitative data is required for practical 
application (Robson, 2011). 
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Multiple philosophical frameworks can be utilised to provide a lens for the qualitative research 
being undertaken. Following a framework or tradition of qualitative research can guide the 
research process and lend rigour to a study (Ritchie and Lewis, 2014).  Underpinning these 
frameworks are debates about epistemology and ontology, the researcher’s beliefs about these 
concepts and how these affect their understanding of the social world (Ritchie and Lewis, 2014).  
Ontology refers to the philosophical beliefs about the nature of social reality, such as whether an 
external reality exists or whether there is no external reality and reality is, therefore, what each 
individual interprets it to be (Hesse-Biber and Levy, 2011; Ritchie and Lewis, 2014).  
Epistemology refers to the theory of knowledge, and concerns concepts such as what an 
individual believes can be known, and how they might learn more about the world and reality 
(Ritchie and Lewis, 2014).  Differing beliefs about these concepts have given rise to multiple 
philosophical frameworks and schools of thought which can be used to guide qualitative 
research. 
A pragmatic approach is more flexible, and allows the researcher to use methods most 
appropriate to address the research question.  Seale (2004) argues that this is not a less 
rigorous approach, but rather encourages researchers to exercise caution and select the 
methods most appropriate for their research question.  The aim of this study is to address a 
practical problem; to explore the barriers and facilitators to deprescribing in care homes with a 
view to identify potential components for a behaviour change intervention.  The barriers and 
facilitators, and associated attitudes and feelings about medicines, are most appropriately 
explored qualitatively in order to gain a depth of understanding of the phenomena in the 
participants’ own words.  Therefore, a pragmatic approach was employed for this study rather 
than a philosophical framework. 
3.2.3 Theoretical underpinnings 
The research was informed by the Theoretical Domains Framework (TDF), which provided a 
lens for this study.  The TDF is a composite framework of behaviour change theories (Cane et 
al, 2012; Francis et al, 2012), and it was applied to the findings of the literature review, to frame 
the GP, pharmacist and care home staff interviews and applied to the overall findings to inform 
intervention development.  There are a vast number of models and theories which seek to 
predict and explain human behaviour, and it can be difficult for those who do not have a 
background in psychology to choose a model to apply to their study (Francis et al, 2012).  
Choice of a less suitable model could result in the inclusion of irrelevant concepts and the 
exclusion of relevant ones (Cane et al, 2012).   
An example of the discounted models was the theory of planned behaviour, an extension of the 
theory of reasoned action (Sniehotta et al, 2014; Glanz et al, 2015).  The theory of planned 
behaviour was first published in 1985, and it was a commonly utilised theory for investigating 
health behaviours.  However, it has been superseded by more sophisticated models, such as 
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the TDF.  It has also been criticised because it lacks validation and some of the predictions 
within the theory have been proven false (Sniehotta et al. 2014, Glanz et al, 2015).  The 
transtheoretical model of behaviour change is similar to the theories of planned behaviour and 
reasoned action, in that intention to perform behaviour is at the centre of all three theories.  
These theories are more useful for situations where behaviour change relies on a subject’s 
willpower, or desire to change their behaviour (Glanz et al, 2015).  The literature review 
revealed that there were many potential barriers to deprescribing, including motivation, but also 
social and systemic barriers which required further understanding.  In addition to these issues, 
the three theories are not linked to a process to inform intervention development.  Therefore, 
their use in informing the development of a behaviour change intervention in the context of this 
thesis were limited.   
The TDF was initially proposed by Michie et al (2005) to enhance the accessibility and utility of 
behaviour change theory for a wider range of researchers and to promote applicability to 
intervention development and evaluation.  A group of behaviour scientists and implementation 
researchers synthesised 128 theoretical constructs from 33 theories to produce the TDF (Michie 
et al, 2005; Cane et al, 2012; Francis et al, 2012).  The TDF can also be used in conjunction 
with other methods and frameworks such as the Behaviour Change Wheel to aid researchers in 
designing behaviour change interventions (Michie et al, 2011).   
The first TDF published by Michie et al (2005) consisted of 12 domains, factors believed to 
influence how an individual behaves.  This TDF then underwent a validation exercise seven 
years later, where a further group of behavioural experts aimed to optimise the framework.  This 
involved adjusting the wording and domains of the TDF to ensure that its structure and content 
was optimised, and that the domains represented the key determinants of behaviours.  This 
validated version of the TDF (Appendix C) was used in this study, to ensure that the most 
methodologically robust framework available was used (Cane et al, 2012).  The validated 
version of the TDF was also utilised to create a table showing the TDF domains specified to 
deprescribing in care homes which was used to guide the mapping work.  This can also be 
found in Appendix C. 
Despite first being developed to aid researchers in investigating and optimising intervention 
implementation, it is in this study being used to investigate deprescribing as a behaviour.  It will 
then be utilised to identify candidate intervention components for an intervention aimed at 
increasing deprescribing in care homes.  As described in Chapter 1.4, prescribing is widely 
regarded as a behaviour and deprescribing can also be characterised in this way (Anderson et 
al, 2014).  Deprescribing was considered a behaviour as it fit the definition of behaviour as 
defined by Michie and Johnson, 2013:  
“Anything a person does in response to internal or external events. Actions may be 
overt (motor or verbal) and directly measurable, or covert (activities not viewable 
e.g., physiological responses) and indirectly measurable; behaviours are physical 
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events that occur in the body and are controlled by the brain” (Michie and Jonson, 
2013)  
Deprescribing has been considered a behaviour, and the TDF has been utilised to investigate 
behaviour change as a method of addressing inappropriate polypharmacy in primary care and 
hospitals in the UK (Cadogan et al, 2015, Scott et al, 2019; Ailabouni et al, 2016).  The TDF has 
also been used in several contexts and methodologies as described by Atkins et al (2017) 
including to explore influences on behaviour, to investigate barriers and facilitators to 
intervention development, to aid in intervention design and to identify behaviour change 
techniques.   
Its use is often closely aligned with qualitative techniques such as semi-structured interviews 
and it has also been used to develop questionnaires, design interventions, and as part of 
randomised controlled trials and systematic reviews (Brotherton et al, 2010; McCluskey and 
Middleton, 2010; Jacobs et al, 2011; Godin et al., 2008).  In this study, it was applied to develop 
semi-structured interview schedules and to inform the components of a future behaviour change 
intervention.  If its strengths and limitations are taken into consideration, it can be flexibly 
applied to multiple study types.   
The limitations of the TDF should be noted.  The TDF has been criticised for being too shallow 
(Francis et al, 2012).  This is because it appears straightforward and easy to use, but it requires 
a degree of in-depth knowledge of the domains and their meanings to be utilised appropriately 
(Francis et al, 2012).  Therefore, it is at risk of being used incorrectly by novice researchers 
(Francis et al, 2012).  Francis et al (2012) suggest that in order to overcome this, the research 
team should include a health psychologist, or someone who has experience of using the TDF 
that can assist with its incorporation into the study.  One of the supervisors of this study has 
such experience and expertise in the field, and has used the TDF extensively in collaboration 
with health psychologists (Easthall et al, 2019).   
Another limitation to be considered is that, as a framework not a theory, it does not generate a 
testable hypothesis.  However, this study was designed to explore behaviour rather than 
generate a hypothesis.  There is also no description of the relationship between domains and 
how these interact together to influence behaviour.  This would be a useful addition to the 
framework, as this aspect currently relies on each researcher’s interpretation of the framework.  
Prestwich et al (2015) warned that the TDF can be used superficially, and that casual or 
inappropriate references to it were a limitation in its utilisation.  In order to overcome this, the 
TDF was applied to each stage of the study; to ensure that it was embedded in the study; the 
literature review, data collection and analysis methods and intervention development all feature 
elements of the TDF.   
A final limitation of the TDF in relation to this study is that it was designed for application to 
studies into the behaviour of healthcare professionals, and not patients (Cane et al, 2012).  For 
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this reason, it was not applied to the resident and relative interview schedules as the domains 
were not felt to be relevant to the type of data being sought.  This is because the TDF was being 
used to investigate the current behaviour of healthcare professionals, building upon the findings 
of the literature review, in order to determine how it may be changed.  The aim of the resident 
and relative interview schedules was to explore the feelings and beliefs of residents and 
relatives, as there were insufficient findings regarding this in the literature.  It was, however, 
used to develop the healthcare professional and care home staff interview schedules and was 
applied throughout the study as shown in Table 4 below.   
3.2.3.1 Benefits of using the TDF: the behaviour change wheel and  
The strengths of the TDF in relation to this study are that it provides an accessible, 
methodologically robust framework which combines the most relevant parts of a number of 
behaviour change theories for application to studies such as this: a qualitative interview study 
designed to investigate the behaviour of healthcare professionals with an aim of identifying 
components of a useable change intervention (Atkins et al, 2017).  The TDF has been widely 
applied to research similar in design to this study and therefore there is a wealth of literature to 
inform study design.   
A key benefit of the TDF in relation to this study is that it can be used to inform intervention 
development.  This is described in detail in Chapter 5, section 5.2.  In order to assist 
researchers in applying the TDF to their study, Atkins et al (2017) published a guide to using the 
TDF to design research studies.  Whilst Atkins et al (2017) focus on implementation problems, 
they provide detailed and useful guidance about how the TDF can inform all stages of the study 
from study design to reporting of findings.  The steps recommended by Atkins et al (2017) to 
utilise the TDF to inform study design are presented in Table 4 with a description of how, 
retrospectively, the study fit the steps.  
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Table 4: How the recommendations made by Atkins et al (2017) for designing a study 
incorporating the TDF were reflected in the study design 
Stage of research as advised by 
Atkins et al (2017) 
How the stage was incorporated into 
the study design 
Select and specify the target behaviour Deprescribing is the behaviour, and 
healthcare professionals/care home staff 
were selected as the groups to be 
targeted with the TDF elements of the 
study. 
Select the study design Semi structured interviews, a method 
suggested by Atkins et al (2017) 
Develop study materials Interview schedules were developed 
iteratively, informed by literature and 
theory, and tailored to be appropriate for 
each group, similar to Atkins et al’s 
(2017) recommendations.  
Decide the sampling strategy The sampling strategies undertaken in 
this research (purposive homogenous 
stratified sampling, with elements of 
snowball and convenience sampling) will 
gain a diverse range of views 
Collect the data Completed using audio-recorders to 
record the interviews, as recommended 
by Atkins et al (2017) 
Analyse the data No specific recommendations are made 
with regard to analysis methods that 
could be applied to this study. 
Report the findings To be reported on completion of the 
thesis. 
Whilst the guidance was published after this study was designed, it was found that the steps 
outlined by Atkins et al (2017) had been incorporated into the study design.  The fact that this 
study incorporated the recommendations of Atkins et al (2017) suggests that the TDF has been 
suitably incorporated into the study design.   
The next section discusses reflexivity, which is an important consideration in qualitative 
research. 
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3.2.4 Reflexivity 
It is important that a researcher conducting a qualitative study examines their own place in the 
research to aid the quality appraisal of the research (Berger, 2013)  Each researcher will bring 
their own attitudes, beliefs and opinions to the study which will affect why they selected the 
topic, the way they view the topic, the approach the study and how the data is analysed and 
interpreted.  Reflexivity also increases the dependability (see section 3.7 for a description of this 
term) of the research, by increasing the transparency of the processes taken by the researcher.  
Below is a reflexive account which describes the author’s pre-existing beliefs and attitudes to 
deprescribing and care home residents.  This will aid the reader in understanding the 
researcher’s standpoint and enable them to consider this when they are reading and 
understanding the study. 
I, the researcher, am a pharmacist with experience working in community pharmacy and 
hospital settings with older people and care home residents.  In my professional life, I have 
worked to ensure the safe and effective use of medicines and have been involved in the 
deprescribing process.  I believe that many older people are taking potentially inappropriate 
medicines and, especially whilst working on the care of the elderly wards, I took time to review 
patients’ medicines and identify and recommend medicines that may need to be stopped.  I 
have preconceptions about why older people and care home residents might be taking 
inappropriate medicines, having experienced difficulties in gaining the information required to 
deprescribe and viewed how disjointed healthcare systems in the UK appear to be.  Upon 
viewing information about the PhD before applying, I felt very strongly that this research had to 
be conducted in this population as I felt care home residents were “forgotten” – under prioritised, 
with no-one taking overall responsibility for their care. 
In addition to this, I have always been a pragmatic person, hence the approach to this study.  It 
felt natural to follow a clear, practical approach.  It was important to me to conduct qualitative 
research, as the main question to be addressed appeared to be “why is deprescribing not 
happening in care homes?” and I felt that this question could not be sufficiently answered with 
quantitative methods.  An in-depth approach was required, in order that I could interrogate the 
issue and to gain an understanding of the topic and associated issues for deprescribing in this 
context and for this population.  I also wanted to explore the potential for designing an 
intervention to support (and potentially influence) deprescribing practice in this area. 
Finally, experiences in my personal and professional life made me aware of both the downsides 
of old age, and the problems raised when a person can no longer consent to their treatment.  It 
appeared to me that too often, the patient’s wishes were unknown or not honoured and it was 
unclear whether decisions were being made in the best interests of the patient.  I believe that 
deprescribing decisions with older people are often linked with their limited life expectancy, and 
that improved planning and open conversations about life expectancy, goals of care and the 
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benefit of medicines are key to normalising deprescribing. In providing this account I aim to offer 
transparency and acknowledge the importance of my personal attitudes and beliefs in relation to 
a topic that is the subject of my study.  Acknowledging this is important to promote quality in the 
conduct and reporting of my work and I have explained elsewhere (sections 3.7 and 5.2.2.2) the 
ways in which this has been addressed in my work. 
Several reflective accounts were also written during the research, please see Appendix D for an 
example of these. 
3.3 Sampling methodology 
3.3.1 Sampling strategy 
There are different approaches to sampling for qualitative studies.  A qualitative sample aims to 
investigate the views of the chosen population, so participants are recruited to provide insight 
into the phenomenon being explored (Ritchie and Lewis, 2014).  Unlike a sample for a 
quantitative study it does not seek to be statistically representative of a larger group (Ritchie and 
Lewis, 2014). There are three common approaches to qualitative data sampling (Ritchie and 
Lewis 2014, Merriam 2009): purposive sampling, convenience sampling and theoretical 
sampling.    
Stratified purposive sampling was employed for this study – this takes a largely homogenous 
approach, in that participants shared similar traits such as their job, but participants are also 
selected to show variation in cases (Palinkas et al, 2015; Ritchie and Lewis, 2014).  This was 
demonstrated by seeking residents, relatives and care home staff from different types of care 
homes, and from different GP surgeries and pharmacy services to explore the variation in their 
experiences.  This allowed for the general experience of deprescribing in care homes to be 
investigated, from a range of different participants relevant for the study.  Purposive sampling is 
the most common type of sampling employed to conduct qualitative research and its aim is to 
sample from the population most likely to provide rich data and provide the most meaningful 
insight into the phenomena being investigated (Merriam, 2009; Ritchie and Lewis, 2014).  A 
broad sampling strategy such as this also increases transferability. 
Snowball sampling, another type of purposive sampling, was employed as a secondary 
sampling technique for the recruitment of GPs and pharmacists to this study (Merriam, 2009).  
GPs and pharmacists were asked if they had any colleagues that they thought would be 
interested in taking part, and were asked to contact them about the study.  This allowed the 
researcher to collect data from participants in similar settings with similar roles (Merriam, 2009; 
Palinkas et al 2015).  It can be a useful way to recruit participants, but it can limit the breadth of 
the sample to an individual’s network.  People who network together might work in the same or 
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similar settings, thus leading to a lack of diversity of views and unintentionally excluding 
potential participants (Browne, 2005).   
While the aim was for the sample to be purposive, elements of convenience sampling were also 
present.  The sample gained was convenient in that recruitment of GPs and pharmacists was 
limited to West Yorkshire, and the recruitment of care home residents was limited to care homes 
within a reasonable travelling distance for the lone researcher.  It was also limited by the 
availability of participants at the time the study was conducted.  Convenience sampling is 
defined by Ritchie and Lewis (2014) as a sample based on who is available to take part.  If 
convenience is the only factor considered when sampling, the sample is unlikely to be robust 
and it would limit the transferability and credibility of the study (Merriam, 2009; Ritchie and 
Lewis, 2014). However, Merriam argued that there is likely some element of convenience in all 
qualitative samples, as it is based on who is available and consents to take part within the time 
frame and confines of the study.  The risks of incorporating convenience sampling into the study 
design were minimised by aiming for a purposive sample first and not choosing participants 
solely for their convenience. 
3.3.2 Sample size 
It is difficult to pre-determine a sample size for qualitative research.  The aim of a qualitative 
sample should be to generate a reasonable quantity of data rich in words and meanings to be 
analysed (Fusch, 2015; Dibley 2011), which will be different for each study.  Therefore, 
researchers should be guided by the quality of the data they are generating, and should be 
aiming to ensure that all views on the topic have been represented.  It can therefore be difficult 
to determine a sample size before embarking on data collection and analysis. 
Guest (2006) suggested that a sample size of 6-12 is usually suitable for in-depth interviews 
where the researcher is aiming to understand common experiences in a group.  Guest (2006) 
found during data analysis that 88% of the codes generated had been discovered after twelve 
interviews, and that the majority of the most common ones had been created after six 
interviews.   
It is also important to consider the concept of data saturation, a term associated with sampling 
in qualitative research.  It is preferable to be transparent about what saturation means in the 
context of the study being conducted, as there are various definitions (Bowen, 2008; O’Reilly 
and Parker, 2012).  One definition of data saturation states is that it is achieved when no new 
themes are being generated and every view on the topic has been represented (Fusch, 2015; 
Bowen, 2008).  There is no pre-determined sample size which can guarantee this – one study 
may achieve this with a small sample size, while another may need a much larger sample size 
(Fusch, 2015).  Saturation is a concept most closely related to grounded theory, a methodology 
where the researcher continues to collect data guided by the analysis process, which aims to 
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fully describe and account for all similarities and differences in the themes identified (O’Reilly 
and Parker, 2012; Green and Thorogood, 2014).  Saturation is well defined in grounded theory 
and is a central part of the methodology (O’Reilly and Parker, 2012).  This definition of 
saturation may not be appropriate for all qualitative study designs and is distinct from alternative 
definitions such as that used by Guest (2006), who aimed to ensure that any new data collected 
was not generating new themes. 
While aiming to reach saturation can improve the rigour of qualitative research, conducting a 
transparent and well-defined study is an essential element of improving the rigour of a study.  
With this in mind, data collection for this study was iterative and guided by the familiarisation of 
the researcher with the data.  Data collection, transcription of the data and early analysis stages 
were to be undertaken simultaneously, and more data was sought where it was deemed 
necessary until the researcher felt that themes were well accounted for and the same points 
were being repeated by different participants.  In this sense, data saturation was aimed for. 
Considering the number of groups which were being sampled and the pragmatic considerations 
of this study, the initial aim of this study was to interview 10-15 care home residents and 
relatives, and 15-20 care home staff, GPs and pharmacists.  It was reasoned that this would 
generate a workable amount of data that would provide a sufficiently in-depth understanding of 
the phenomena of deprescribing in care homes.  However, the approach to the sample size was 
flexible and subject to change depending on the data being collected and analysed, plus the 
feasibility and ongoing analysis of the study.  Indeed, as will be discussed, the sample size for 
residents and relatives was increased during the study to 15-20.  Details of the final samples 
can be found in section 3.4. 
3.4 Sampling methods 
3.4.1 Sampling care homes 
As described in Chapter 1.3, there are several different types of care homes in the UK.  These 
include purely residential homes, which provide personal care, and nursing homes, which 
provide 24-hour care from registered nurses.  In order to achieve a purposive sample it was 
important not to recruit too many participants from too few types of care home.  The sample 
frame below (Table 5) outlines how the type of care home and gender of participants was 
considered when sampling for the study.  Aiming to fulfil the sample frame ensured a diverse 
range of participants, likely to cover a wide range of views and attitudes to deprescribing.  
89 
 
 
Table 5: Sample frame for sampling of care homes 
 Residents Relatives 
Local authority owned care homes 2-3 2-3 
Privately/charitably owned care 
homes 
2-3 2-3 
Large chains of care homes 2-3 2-3 
Homes providing nursing care 3-4 3-4 
Homes providing residential care 3-4 3-4 
Gender A 50/50 gender split may 
not have been possible, as 
there are a greater 
proportion of women living 
in care homes than there 
are men.  The aim was to 
interview a minimum of 3 
male residents, but 1 
A more even 
gender split 
should be 
possible with 
the relatives, 
so a 50/50 
gender split 
was aimed for 
and achieved. 
 
In addition to the sampling frame, inclusion and exclusion criteria were created to guide the 
sampling of care homes (Table 6).  Care homes were excluded if they were rated inadequate by 
the CQC, as they may be under further investigation due to poor practice and it may not be 
appropriate to visit these homes.  In addition to this, relatively few care homes are rated 
inadequate and so including these may have limited the transferability of the study.  The CQC 
lists 10,793 care homes providing care for adults aged 65 years and older, of which 182 (1.69%) 
are rated inadequate.  Within the search area, 25 of 1141 care homes (2.37%) were rated 
inadequate.   
It is a requirement of the CQC that care homes must have a named responsible person in order 
to register with the CQC to provide care.  It is not always necessary to name a registered 
manager when registering a care home with the CQC.  However, it was decided that to remove 
ambiguity, only care homes with a named registered manager were considered suitable for 
inclusion in this study (Care Quality Commission, 2019).  
 
1
 
https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/agei
ng/articles/changesintheolderresidentcarehomepopulationbetween2001and2011/2014-
08-01 
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Table 6: Inclusion and exclusion criteria for care homes included in the study 
Inclusion criteria Exclusion criteria 
Provide care to adults aged 65 and over 
 
Care homes rated “inadequate” by the 
CQC 
 
Care homes located in West Yorkshire.  
This was expanded after seeking advice 
from the ethical committee, and care 
homes were eventually included from 
West, North and South Yorkshire 
 
Must have a registered manager and 
responsible person named on the CQC 
website 
 
3.4.1.1 Care home recruitment methods 
In order to recruit 10-15 care home residents and relatives in total, the aim was to recruit 3-5 
care homes.  The Care Quality Commission’s (CQC) website was used to identify care homes 
with the potential to participate.  All care homes in the UK must be registered with the CQC, and 
are listed on this website (http://www.cqc.co.uk), along with contact details and details about the 
care they provide (Care Quality Commission, 2017). 
The CQC website was first searched for care homes within a 15-mile radius of a city in West 
Yorkshire.  The results were then filtered using the CQC’s search tools to care homes catering 
for those over 65 years old as per the inclusion criteria.  This yielded a list of 310 providers who 
provide a care service in Leeds, and each one was checked to determine their eligibility for the 
study against the inclusion and exclusion criteria.  This often involved accessing the care 
provider’s website.  If the care provider did not have a website, or the website did not provide 
the details required, www.carehomes.co.uk  was utilised.  This is a website containing basic 
details for care homes in the UK, such as type of care provided and number of beds alongside 
contact details.  
To ensure that all types of homes were considered (including local authority owned, owned by a 
charitable organisation or privately owned, large chains, residential and nursing homes) were 
represented at this stage, the homes eligible to participate were split into two lists: homes 
providing nursing care, and homes providing residential care only.  Homes that provided both 
were placed on the nursing home list, with an indication that they also provided residential care.  
The two lists also contained details about the ownership of the home and the home’s CQC 
rating.  Twenty homes, ten from each list, were then taken from the list.  The twenty homes 
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chosen represented a geographical spread of the area, and the mix of homes rated “good “and 
“requires improvement” by the CQC reflected the area.  There were no homes rated 
“outstanding” within the sample area.   
The twenty homes were then sent a letter by post (Appendix G), as well as the participant 
information sheet for residents, relatives and care home staff (Appendix F).  The letter was 
printed on University of Leeds headed yellow paper, to aid identification of the letter when 
communicating with the home.  The care home manager was telephoned two weeks after the 
letter was sent to discuss the project and determine whether they were interested in 
participating.  Homes were called up to five times over a period of two weeks, if the researcher 
was unable to speak to the manager after this time the home was not contacted again.   
Due to a lack of engagement from the initial homes approached, a further five homes were 
selected from the list and contacted.  Another approach included contacting local pharmacists 
known to the supervisory team who work in care homes for recommendations of care home 
managers to approach.  Members of the supervisory team also recommended care homes to 
contact.  While this provided care homes for inclusion in the study, there are implications to 
recruiting care homes in this way.  It could bias the sample towards care homes active in 
research or those felt likely to take part by the supervisory team, and care home managers may 
also feel obliged to take part depending on their relationship with the member of the supervisory 
team.  The recommended care homes were approached in the same way, by letter and then 
with a telephone call.  Some care home managers were initially approached via email, if the 
local contact provided an email address for a care home manager.  The email contained the 
same content as the letter, and the participant information sheets were attached. 
The local contacts for NIHR Enabling Research in Care Home network (ENRICH) were also 
approached.  ENRICH is a clinical research network set up by the National Institute for Health 
Research (NIHR) to enable research in care homes (ENRICH, 2017).  This includes a list of 
care homes deemed “research ready”, and a network of research nurses and staff across the 
country who aim to facilitate care home research (ENRICH, 2017).  Research ready homes in 
the study area were contacted, and the local contacts for ENRICH recommended care homes 
which might be interested in taking part.  Nurses working for ENRICH also gave information 
about the study at events they attended.  While this increased awareness of the study, only care 
homes taking part in the events attended by ENRICH were exposed to information about the 
study.  Figure  9 below illustrates how care homes were recruited to the study. 
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Figure 9: Flowchart demonstrating how care homes were recruited to the study 
3.4.1.2 Care homes recruited for inclusion the study 
Table 7 shows details of the care homes which were recruited.  Residents, relatives and care 
home staff were recruited from nine care homes, of which three provided residential care only, 
four provided nursing care only and three provided both residential and nursing care.  Six 
homes were privately owned, with one of those being part of a privately-owned chain; a further 
home was owned by a local authority and another by a charitable trust.  Five homes included in 
the study had a CQC rating of good; two required improvement and one had not been rated at 
the time of the visit.  The ownership details and CQC status of the final home, CH7, is not 
known.  This is because only one relative of a resident living in that home was interviewed by 
telephone, and they were recruited through contact with the ENRICH network and referred to 
the researcher directly without involving the care home.  The relative did not know these details 
about the care home, only that the home provided nursing care.
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Table 7: Care homes recruited for inclusion in the study 
Care home Nursing or 
residential care 
provided 
Care home 
ownership 
CQC rating 
CH1 Residential Privately owned Requires 
improvement 
CH2 Residential Council owned Good 
CH3 Nursing Privately owned, 
part of a chain 
Requires 
improvement 
CH4 Nursing Privately owned Good 
CH5 Nursing Privately owned Good 
CH6 Both Charitable trust Good 
CH7  Nursing Unknown  Unknown 
CH8  Residential Privately owned Good 
CH9 Both Privately owned Unrated at the time of 
visit 
3.4.2 Sampling residents and relatives 
Residents, relatives and later care home staff were recruited from the care homes shown in 
Table 8.  Inclusion and exclusion criteria were developed to guide the recruitment of residents 
and relatives.  If participants met any of the exclusion criteria, they were not eligible to contribute 
to the study.  The inclusion and exclusion criteria applied to residents and relatives is detailed 
below in Tables 8 and 9.  Participants of different genders or ethnic backgrounds were included, 
where possible.   
Table 8: Inclusion and exclusion criteria for care home residents 
Inclusion criteria Exclusion criteria 
Aged 65 years old or over Residents of care homes who have been 
diagnosed with a terminal illness 
Have capacity to consent to be 
interviewed to take part in the study 
Residents of care homes who do not 
take any medicines 
Able to converse in English 
 
Residents who lack capacity to consent 
to partake. 
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Table 9: Inclusion and exclusion criteria for relatives of care home residents included in 
the study 
Inclusion criteria Exclusion criteria 
Relatives of care home residents 
whereby the care home resident is aged 
65 years old or over but lacks capacity to 
consent to interview 
Relatives of care home residents 
whereby the residents have been 
diagnosed with a terminal illness 
Have capacity to consent to be 
interviewed to take part in the study 
Relatives of care home residents who do 
not take any medicines 
Aged 18 years old or over Relatives who lack capacity to consent to 
partake. 
Able to converse in English 
 
 
Care home residents who were diagnosed with a terminal illness, and their relatives, were 
excluded from the study.  There are different definitions of terminally ill, and Hui et al (2014) 
sought to define the term via a systematic review.  The definition Hui et al (2014) described for 
terminally ill was:  
“life limiting disease with irreversible decline and expected survival in terms of months or less” 
(Hui et al, 2014, pp1) 
Residents diagnosed as being terminally ill were excluded from the study, as were their 
relatives, as the awareness of limited life expectancy might impact how they feel about the 
medicines taken by the care home resident.  Their views may differ to the general care home 
population as a terminal diagnosis often prompts a review of medicines, and people may 
change their views on medicines when a terminal illness is diagnosed (Harriman et al, 2014).  
Deprescribing in this context is therefore different to deprescribing in the general care home 
population.  Asking terminally ill residents and/or their relatives to partake in the study was also 
considered to be an unnecessary burden for them at a distressing time.  When speaking with 
the care home manager about residents and relatives to approach, the lead researcher 
requested that residents, and relatives of residents with a life expectancy of months or less were 
not included. 
Relatives of care home residents whereby the resident would have capacity to be interviewed 
themselves were excluded as the aim was to interview only relatives of residents who would be 
unable to partake themselves.  This approach allowed the relatives to provide insight into how 
the resident may feel about the topic if they were able to take part; however, it also importantly 
allowed exploration of the views and influence of relatives of care home residents on the 
decision-making process.  Interviewing relatives of care home residents unable to take part 
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themselves also facilitated some representation of the large proportion of care home residents 
who live with dementia or other cognitive impairment that would not be able to take part 
themselves. 
3.4.2.1 Resident and relative recruitment methods 
Once a manager had agreed for their care home to take part in the study, the researcher met 
face-to-face with the manager to discuss the optimal way to recruit residents and their relatives.  
The manager also signed a letter stating they were aware of the research activities being 
conducted on the premises (see Appendix H), and a copy of this was supplied to the University 
sponsor. 
To recruit residents, care home staff identified residents with capacity to provide informed 
consent and provided a verbal summary of the study to these residents before the lead 
researcher spoke with them.  The care home manager also provided residents eligible to take 
part with a participant information sheet (Appendix F).  If the resident was content to proceed, 
the researcher spoke with the resident in a quiet place at the care home, either in their room or 
other appropriate area, at a convenient time to explain the study, answer questions and obtain 
written, informed consent.  They were also reminded before and during the interview about how 
they could withdraw from the study.  All residents were offered 48 hours to decide whether to 
partake, however if the resident was content to go ahead with the interview straight away this 
was permitted.  Some residents had also received a participant information sheet via the care 
home manager in advance of the interview and had decided in advance of the researcher’s visit 
that they wanted to participate.   
Relatives of residents were recruited with the assistance of the care home manager.  Posters 
were put up in the care home advertising the project, and participant information sheets were 
also provided for care home managers to give to relatives eligible to take part.  Proactive care 
home managers (see Appendix D for a reflective account of the recruitment process) were also 
asked if a member of administration staff could call relatives and introduce the project to them, 
but this was declined.  This was because all relatives of care home residents with cognitive 
impairment had been approached, and those who were interested had already been 
interviewed.  The lead researcher also requested attendance at resident and relative meetings 
to speak with relatives and hand out participant information sheets, however only one home 
invited the researcher to such a meeting, and no relatives were recruited in this way.   
After six residents had been interviewed, the sample size was increased to include 15-20 
residents and relatives.  The pragmatic, flexible approach taken allowed the sample size to be 
adjusted as data were collected, to ensure the aims and objectives of the study were met.  The 
residents were providing rich and varied data, but interviews were relatively short and some had 
not been as in depth as was hoped (see Appendix D for a reflective account of the first 
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interviews conducted).  Increasing the sample size allowed for more data regarding the 
resident’s perspectives to be gathered, without impacting upon the number of relatives who 
could be interviewed.   
To increase the sample size, a substantial amendment to the ethics committee was submitted.  
The substantial amendment also requested changes to the consent process for relatives, GPs 
and pharmacists, with approval granted to gain verbal consent from telephone interviewees, as 
well as changes to the recruitment of relatives.  Once granted, recruitment of relatives was 
permitted through Twitter and the following groups, as well as through methods already 
identified and utilised: 
- The Relative and Resident association: http://www.relres.org/ 
- My Home Life organisation: http://myhomelife.org.uk/ 
- Memory cafes: http://www.memorycafes.org.uk/#!/search 
Contacts from these groups were identified and emailed to see if they were able to assist, 
however no relatives were recruited through these groups.  Multiple tweets were posted which 
generated interest, however again no relatives were recruited in this way.  For details of the 
substantial amendment submitted to the ethics committee, see section 3.6.2.3 
3.4.2.2 Residents and relatives recruited for inclusion in the study 
The following Tables 10 and 11 display the demographic details of residents and relatives 
collected during the interview process, either from the residents themselves or, with their 
permission, from a member of care home staff.  As care home staff were not informed of relative 
participation, they could not be approached to provide to the researcher the number of 
medicines taken by the resident.  The display of these demographic details increases the 
transferability of the research, as readers of the research will be able to determine whether the 
population interviewed, and therefore the data collected, is transferable to their setting.
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Table 10: Demographic information of residents included in the study 
Identifier Gender Age Residential 
or nursing 
care 
Number of 
medicines 
prescribed 
daily 
Care 
home 
identifier  
Res1 Male 80 Residential 15 CH1 
Res2 Male 86 Residential 12 CH1 
Res3 Female 91 Residential 15 CH2 
Res4 Female 83 Residential 8 CH2 
Res5 Male 79 Nursing 6 CH3 
Res6 Male 74 Nursing 7 CH4 
Res7 Female 84 Nursing 9 CH5 
Res8 Female 82 Nursing 7 CH5 
Res9 Female 90 Residential 2 CH6 
Res10 Female 96 Nursing 15 CH6 
Res11 Female 98 Nursing 10 CH6 
Table 11: Demographic information of relatives recruited to the study 
Identifier Gender Resident: 
residential or 
nursing care 
Care home 
recruited from 
Rel1 Male Nursing CH7 
Rel2 Male Nursing CH6 
Rel3 Female Nursing CH6 
Rel4 Female Residential CH8 
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3.4.3 Sampling of GPs, pharmacists and care home staff 
Two sampling frames were developed to guide the sampling of GPs, pharmacists and care 
home staff, demonstrated in Tables 12 and 13 below.  The sampling frames were designed to 
provide a purposive sample and to encourage recruitment of a diverse range of people likely to 
provide a wide range of views about the topic.   
Table 12: Sample frame for the recruitment of GPs and pharmacists 
 Number of GPs sought Number of pharmacists 
sought 
<10 years of experience in 
their current role 
2-4 2-4 
>10 years of experience in 
their current role 
2-4 2-4 
Providing a service for 
CCGs 
N/A 3-4 
Employed by a GP practice N/A 2-3 
Independent prescriber N/A 2-4 
Not an independent 
prescriber 
N/A 2-4 
Gender A 50/50 gender split may 
not be possible, as there 
are more female GPs than 
there are male GPs.   
A 50/50 gender split may 
not be possible, as there 
are more female 
pharmacists than there are 
male pharmacists.   
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Table 13:Sample frame for the recruitment of care home staff 
 Number of care home staff sought 
Registered nurses 2-4 
Carers – not registered nurses 2-4 
Council owned care homes 1-2 
Privately owned care homes 3-4 
Large chain care homes 2-3 
<10 years of experience working in care 
homes 
2-3 
>10 years of experience working in care 
homes 
3-4 
Gender A 50/50 gender split may not be 
possible, as there are a greater 
proportion of women working in care 
homes than there are men.  Men are 
not excluded from being interviewed 
and will be interviewed if they are 
available and fit the inclusion criteria. 
In addition to the sampling frame, inclusion criteria were created to guide the sampling of GPs, 
pharmacists and care home staff.  Whilst there were no specific exclusion criteria, care home 
staff, GPs and pharmacists were only included if they met all the inclusion criteria (Table 14). 
Table 14: Inclusion criteria for GPs, pharmacists and care homes staff included in the 
study 
Inclusion criteria 
GPs must routinely care for care home 
residents 
Pharmacists must routinely care for care 
home residents 
Care home staff must be involved with 
medicines activities in a care home (this 
may include the administration of 
medicines, as well as ordering and 
managing medicines in the home) 
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3.4.3.1 GP and pharmacist recruitment methods 
Pharmacists and GPs could only be recruited from West Yorkshire.  This was decided following 
advice from the local research governance team.  The involvement of the local research 
governance team is required for each area from which the researcher wishes to recruit 
healthcare professionals.  It was felt that there were sufficient GPs and pharmacists to approach 
in West Yorkshire without needing to co-ordinate with other research governance teams, and if 
recruitment was difficult this could be re-visited and expanded as required.   
Local networks were initially used to recruit pharmacists.  This is because there is no register of 
pharmacists working in care homes, and primary care pharmacists work in a number of different 
locations, such as GP surgeries, CCG offices and for private companies, and therefore are not 
as easy to locate and identify as other groups involved in the study.  In the first instance, a 
member of the supervisory team emailed several contacts, introducing them to the study and 
inviting them to contact the researcher.  The head of medicines management at a local CCG 
was also contacted.  Further participants were recruited via snowball sampling: any pharmacists 
recruited were asked if they had any colleagues in West Yorkshire who may be interested in 
taking part, and were encouraged to ask them to contact the researcher.  Finally, pharmacists 
that had assisted with the identification of care homes were contacted again and asked if they 
would like to be interviewed.  All pharmacists were recruited through email conversations and 
were sent copies of the participant information sheet (Appendix F) and consent form (Appendix 
E).   
To recruit GPs, the Royal College of General Practitioners’ list of research ready GP surgeries 
was utilised (Royal College of General Practitioners, 2020).  48 research ready GP surgeries 
were identified in West Yorkshire, and all were sent a participant information sheet and a letter 
on yellow University of Leeds headed paper (Appendix G), to aid identification when speaking to 
the surgery.  GP surgeries that did not reply were then called two weeks later to see if they were 
willing to participate.  Surgeries were called up to five times over the following two weeks; if the 
researcher could not contact the appropriate person after that then the surgery was not called 
again.  Further participants were recruited via snowball sampling: any GPs or pharmacists 
recruited were asked if they had any colleagues in West Yorkshire who may be interested in 
taking part, and were encouraged to ask them to contact the researcher.  The supervisory team 
also contacted eligible colleagues and asked them to contact the researcher if they were 
interested in taking part.  GPs who were recruited via email were sent copies of the consent 
form and participant information sheet (Appendices E and F). 
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3.4.3.2 GPs and pharmacists recruited for inclusion in the study 
Six GPs were recruited from six different GP practices, and six primary care pharmacists were 
recruited from five employers.  The sample of GPs and pharmacists was overwhelmingly 
female, and five of the GPs interviewed were very experienced in the role.  The pharmacists 
sampled had been working as pharmacists for many years but had varying degrees of 
experience in the role as primary care pharmacists.  Only two of the pharmacists interviewed 
were independent prescribers.  Two pharmacists interviewed were directly employed by CCGs, 
and the remainder were employed by private companies contracted by CCGs to provide 
medicines management services.  Tables 15 and 16 summarise the demographic information of 
the GPs and pharmacists recruited to partake in the study. 
Table 15: Demographic information of GPs included in the study 
Identifier Gender Years of experience  
(as a GP) 
GP1 Female 29 
GP2 Female 29 
GP3 Female 21 
GP4 Female 28 
GP5 Female 13 
GP6 Male 3 
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Table 16: Demographic information of pharmacists included in the study 
Identifier Gender Years of 
experience 
Independent 
prescriber 
status 
Role 
Pharm1 Male 31 as a 
pharmacist, 20 in 
this role 
Independent 
prescriber 
Employed by a 
company to 
provide a 
service to 
CCGs 
Pharm2 Female 2 in this role Non-prescriber Employed by a 
CCG 
Pharm3 Female 16 as a 
pharmacist, 11 in 
this role 
Non-prescriber Employed by a 
CCG 
Pharm4 Female 22 as a 
pharmacist, 1 in 
this role 
Non-prescriber Employed by a 
company to 
provide a 
service to 
CCGs 
Pharm5 Female 18 as a 
pharmacist, 5 in 
this role 
Independent 
prescriber 
Employed by a 
company to 
provide a 
service to 
CCGs 
Pharm6 Female 21 as a 
pharmacist, 8 in 
this role 
Non-prescriber Employed by a 
company to 
provide a 
service to 
CCGs 
3.4.3.3 Care home staff recruitment methods 
Care home staff were recruited from the same care homes as the residents and relatives, four 
months after the residents were recruited and while recruitment of relatives, GPs and 
pharmacists was ongoing.  Care home managers were approached and asked if the researcher 
could visit and interview a member of staff that dealt with medicines.  The manager then 
approached staff to ask if they were interested in taking part and gave out participant 
information sheets.  The researcher then met with the staff member in a quiet place in the care 
home to explain the study to them, provide a participant information sheet if necessary and 
consent them to take part in the study.  Only staff involved in the administration or ordering of 
medicines were eligible to participate which limited the staff able to take part, hence the 
involvement of the manager in identifying eligible staff.
103 
 
 
3.4.3.4 Care home staff recruited for inclusion in the study 
Seven care home staff were recruited from a total of five care homes.  All care homes which 
took part in the resident and relative interviews were approached to take part in the care home 
staff interviews, however only four of the homes facilitated the interviewing of staff members.  
The additional participant was recruited from CH9, which was not previously involved in the 
study, via the supervisory team.  All care home staff recruited were female, and all had 
significant experience of working in care homes.  Table 17 summarises the demographic 
information of the care home staff recruited to partake in the study. 
Table 17: Demographic information of care home staff included in the study 
Identifier Gender Job 
title 
Role in 
the care 
home 
Years of 
experience 
Care 
home 
recruited 
from 
Nursing or 
residential 
care 
provided 
CHS1 Female Carer Deputy 
manager 
28 CH2  Residential 
CHS2 Female Carer Team 
Leader 
20 CH2  Residential 
CHS3 Female Nurse Team 
Leader 
14 in care 
homes, 
more as a 
nurse 
CH6  Both 
CHS4 Female Nurse Team 
Leader 
14 in care 
homes, 
more as a 
nurse 
CH6 Both 
CHS5 Female Carer Senior 
carer 
20 CH1 Residential 
CHS6 Female Nurse Senior 
nurse 
23 CH4 Nursing 
CHS7 Female Nurse General 
manager 
23 CH7 Both 
3.5 Data collection  
Face-to-face interviews were offered to all participants, and telephone interviews were offered to 
all relatives, care home staff, GPs and pharmacists who wished to participate.  Telephone 
interviews were not offered to care home residents, as they may not have had access to a 
private telephone or had the stamina to complete an interview over the telephone.  Telephone 
interviews were offered for the convenience of respondents, for example relatives who may not 
be able to travel to the care home or the University to be interviewed, or for healthcare 
professionals who did not have the time to participate during working hours. 
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3.5.1 Developing the interview schedules 
Semi-structured interviews were conducted with each participant.  Interview schedules were 
used for all interviews in order to ensure that the same topics were explored in each interview.  
Semi-structured interviews are a popular method of data collection, especially in healthcare 
research, as it allows a flexible discussion of set topics (Kallio et al, 2016).  Ritchie and Lewis 
(2014) warn that interview schedules consisting of a series of questions can be restrictive, and 
prevent the researcher from partaking in a responsive and flexible conversation.  However, the 
schedule was not used as a script and instead the semi-structured interviews were conducted 
as described below, as Knox and Burkard (2009) and Kallio et al (2016) recommend.   
Interesting points raised by the participants were explored by the researcher even if they did not 
appear on the schedule, and especially as the researcher gained experience and confidence in 
interviewing it became a more general guide to the interview process (Knox and Burkard, 2009).  
The prompts beneath each question on the schedule were a mix of open and closed prompts, 
presented as bullet points rather than further questions.  These acted as a more general 
memory aid for the researcher, reminding them of topics they could ask about or directions in 
which the conversation could be steered.  In this way the interview schedule was a useful tool, 
especially for a novice researcher. 
No interview schedule was piloted, but all were developed iteratively.  After each interview, the 
researcher reflected on which parts of the interview had been successful and which parts had 
not been so successful.  Reflective pieces were written to help the researcher understand how 
their interviewing technique and schedules could be improved.  These reflections were 
discussed with the supervisory team and colleagues, and suggestions to improve the interview 
schedules were made and implemented.  See Appendix D for an example of a reflective 
account. 
Interview schedules (Appendix I) for the resident and relative interviews were developed from 
the literature described in Chapter 2, as recommended by Kallio et al (2016).  A semi-structured 
interview is based upon the available knowledge, and therefore other methods of data collection 
would be more suitable to employ if there is no previous knowledge on the topic (Kallio et al, 
2016).  The evidence base suggested areas the interview schedules should explore, such as 
resident and relative knowledge about medicines, how decisions are made about their 
medicines and attitudes to deprescribing.  The interview schedule was therefore designed to 
explore themes and ideas from the literature.   
The TDF was used to create the healthcare professional and care home staff interviews 
(Appendix I).  This is a use of the TDF that was suggested by Cane et al (2012) when they 
validated the TDF, and the interview questions suggested by Cane et al (2012) were used as 
inspiration for the first iteration of the interview schedule.  Furthermore, the TDF is proven to be 
useful for developing interview schedules for qualitative healthcare research (Duncan et al, 
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2012; Lawton et al, 2016).  This ensured that the interview schedule was rooted in the 
theoretical determinants of deprescribing behaviours and the questions reflected the domains of 
the framework.  This allowed for exploration of the participants’ deprescribing behaviours in 
relation to the TDF, in order that any intervention developed could be tailored to the domains 
which presented the most significant barrier(s).  All domains were included in the interview 
schedules apart from Goals, as it was not felt a relevant question could be written around this 
domain.  Cane et al (2012) define the domain Goals as: 
“Mental representations of outcomes or end states that an individual wants to 
achieve” (Cane et al, 2012, pp114). 
This includes factors such as goal setting and intention of implementation.  It was unclear how 
deprescribing goals may be set by healthcare professionals and whether these could be 
relevant.  With hindsight and experience of utilising the TDF, this may have formed an interview 
question.  However, it did not hinder exploration of goals as a domain as during the mapping 
process data regarding goals of care was mapped to this domain.  The interview schedule 
covered attitudes to deprescribing and medicines taken by care home residents, as well as 
barriers and facilitators encountered to the process. 
Francis et al (2012) disputed claims that interview schedules based on the TDF may be too 
restrictive or shallow for semi-structured interviews.  It has been shown that interview schedules 
based on the TDF have generated data about more beliefs than schedules not based on the 
TDF, especially in relation to the “emotion” domain which may be forgotten by researchers not 
using the TDF (Francis et al, 2012).  In addition to this, the researcher was not restricted by the 
interview schedule and was able to follow interesting leads provided by the interviewee.  This 
often produced discussion of barriers that could be mapped to the TDF despite the fact that, at 
face value, they may seem unconnected to the framework.   
The TDF was not incorporated into the resident and relative interviews for multiple reasons.  
Firstly, the TDF was designed as a tool to investigate and understand the behaviour of 
healthcare professionals.  In addition, any behaviour change intervention developed as a result 
of this work would be designed to change the behaviour of healthcare professionals, and while it 
is anticipated that residents and relatives would be involved in this process, it is the healthcare 
professionals who do the deprescribing who would be using the intervention. 
The literature shed light on why healthcare professionals were not deprescribing in care homes, 
and that a behaviour change intervention may help them to deprescribing.  However, there was 
not enough literature to determine how residents and relatives could be involved in this process.  
This lack of literature about resident and relative attitudes to deprescribing meant that before 
investigating how their behaviour may be changed or how they may use an intervention it was 
necessary to explore more basic concepts.  These more basic concepts include their knowledge 
about medicines, how they experience deprescribing now and their attitudes towards those 
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involved.  Though they would undoubtedly be involved in the implementation of an intervention, 
and in its design, they would not be the people using the intervention to deprescribe. 
Future work may look at how residents and relatives may be involved in intervention design and 
implementation, and this study provides the groundwork for such future research.  Collecting the 
views of residents and relatives was also necessary to investigate whether the perceptions of 
residents and relatives held by healthcare professionals, as explored in the literature review 
(Chapter 2), were accurate.  Therefore, this study focuses on understanding how residents and 
relatives feel about deprescribing and their involvement in the care of the resident, and 
investigating the behaviours displayed by healthcare professionals with regard to deprescribing 
to consider how these could be improved. 
3.5.1.1 Telephone interviews 
Telephone interviews were offered to all study participants except residents who may not have 
access to a private phone or have the stamina to complete a telephone interview.  Telephone 
interviews have been criticised for lacking the depth of face to face interviews, with speculation 
that participants may be withholding of information when speaking over the phone (Novick, 
2008; Trier-Bienick, 2012).  There is also a fear that the lack of body language interaction 
between the interviewer and interviewee could be harmful to establishing rapport and a smooth 
conversation (Novick, 2008; Trier-Bienick, 2012).  However, it has also been reported that 
telephone interviews provide the interviewee with a greater degree of anonymity than face to 
face interviews, which empowers them to discuss sensitive topics more freely (Novick, 2008; 
Sturges and Hanrahan 2004).  In addition to this, telephone interviews do not appear to result in 
harm to the quality or quantity of data being collected (Sturges and Hanrahan, 2004).  
Telephone interviews are also often more convenient than face-to-face interviews, for both 
interviewer and interviewee, and may be safer for the researcher to undertake as they do not 
involve travel to unsafe environments (Sturges and Hanrahan, 2004).  While the potential 
downsides of telephone interviews were considered, it was not believed that their use would be 
detrimental to the study and would be more acceptable to busy practitioners.  
Residents and relatives interviewed were not informed that I was a pharmacist, though it was 
not denied if questioned.  This was to avoid any confusion around the resident thinking that I 
might change their medicines, and I hoped it would facilitate them to speak freely and not 
withhold information as they may do if they knew they were speaking with a healthcare 
professional.  I also did not want to potentially invite them to ask for help or advice about their 
medicines and health, as I was not visiting in that capacity.   
Healthcare professionals and care home staff were not explicitly informed that I was a 
pharmacist.  It was possible, however, that those contacted via the supervisory team assumed 
my background.  I did not feel it was as important that healthcare professionals did not know my 
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background, as my insight into the issues likely came across in the interviews and it facilitated 
an easy, in-depth discussion based on shared understanding. 
3.5.2 Interview transcription 
Transcription of all resident interviews and two of the relative interviews were undertaken by the 
author.  A member of the supervisory team transcribed the remaining two relative interviews.  
The transcription of all GP, pharmacist and care home staff interviews was completed by a 
transcription company the supervisory team had experience of using.  The interviews were 
uploaded to a secure area, accessible by only the researcher and the transcription company.  
Once the interviews had been transcribed, the transcripts were uploaded to the same secure 
area and the audio deleted.  The company employed to transcribe the interviews abided by 
General Data Protection Regulations (GDPR), were subscribed to the Data Protection Act and 
ensured their staff signed confidentiality agreements.   
All transcripts were checked against the audio recording twice by the author, and any potentially 
identifying information (for example, place or people’s names) were deleted to anonymise the 
transcripts 
3.6 Ethical and research governance approval 
Ethical approval was required for this study, as it involved the participation of older people who 
live in care homes.  These people are classed as vulnerable, as they are cared for by others 
and may live with health conditions which increase their vulnerability.  This raised issues around 
ensuring that participants were able to provide informed consent and that they were sufficiently 
resilient to partake.  Safeguarding processes also had to be developed in case any participant 
raised safeguarding concerns that required escalating, and participants also needed to be 
aware of how to withdraw from the study and how their data would be managed. 
3.6.1 Summary of main ethical issues 
Below is a summary of the main ethical issues of the project, which were identified during study 
design and considered by the ethics committee during the ethical approval process.  The study 
was reviewed by the NHS HRA Social Care Research Ethics Committee, who review studies in 
England that are set in the social care setting such as care homes.  The documents that were 
submitted to the ethics committee are in Appendices D-H. 
3.6.1.1 Inclusion of vulnerable adults 
Inclusion of vulnerable adults, such as those who live in care homes, was an ethical issue as 
they may have a degree of cognitive impairment which would impact on their ability to consent 
to take part.   To address this, care home staff that knew the residents were asked to use their 
knowledge of the residents to suggest those who would be able to take part in the study.   
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Residents were then only included if they had capacity to provide their informed consent to be 
included.  All residents who participated were judged to have capacity and were able to make 
an informed choice to participate in the study, and there were no issues around participants’ 
capacity to consent.   
In the event of care home residents becoming fatigued, and unable to complete the interview, 
the following was planned.  The interview would have been stopped and support offered.  The 
resident’s carer may have been invited in to comfort them, if the resident wished.  They did not 
have to continue with the interview if they did not want to, or the interview may have continued 
at a later date.  This did not occur during the interviews. 
3.6.1.1.1 Emotional support 
Plans were also put in place to help residents or relatives if they became upset when talking 
about medicines or health conditions, or found the concept of stopping medicines distressing. If 
this happened, the interview would have been stopped and verbal support offered.   If the 
resident wished, their carer would have been invited in to comfort them.   They did not have to 
continue with the interview if they did not want to, or the interview may have continued at a later 
date. If support was required after the interview, the resident was asked for consent for the 
researcher to speak with care home staff on their behalf to provide support and refer them to the 
GP if necessary. 
If a relative became upset, the interview would have been stopped and verbal support offered.  
They would have been informed that speaking to care home staff or the GP would be the best 
way to receive further advice. 
There were no issues which required such escalation during the interviews. 
3.6.1.1.2 Informed consent 
Once a participant had been recruited, they were asked to sign a consent form (Appendix E).  
Participants involved in face-to-face interviews signed the consent form in the presence of the 
lead researcher.  Participants taking part in a telephone interview were sent a participant 
information sheet and consent form either by post or email, and could either return the signed 
consent form to the lead researcher or provide verbal consent which was recorded at the start of 
the interview.  Consent forms were returned via email, or a stamped, addressed envelope 
provided by the researcher.  If verbal consent was gained, the lead researcher filled in the 
consent form on behalf of the participant, noting the time that verbal consent was given for the 
interview.  The consent from was referred to whilst gaining verbal consent to ensure that all 
participants were consenting to the same conditions.  
Participants unable to give informed consent to participate were excluded from the study.   Care 
home residents with the capacity to consent to participate were identified by care home staff.  
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The researcher also assessed capacity as per training received according to the Mental 
Capacity Act (MCA) 2005, which involved assessing the interviewee’s ability to understand, 
retain and use information to make a decision and communicate their decision.  
This was done using the two-stage functional capacity test, as outlined by the MCA 2005 and 
presented below in Figure 10 (Social Care Institute for Excellence, 2020): 
 
As care home residents who participated must have been able to communicate verbally in order 
to partake in an interview, capacity was assessed through conversation with the resident.  They 
were asked to explain what they were being asked to participate in, what the benefits and risks 
were and demonstrate an understanding of what they were being asked to do.  If the researcher 
felt a resident passed the two-stage functional capacity test, they were able to participate in the 
study 
Despite the opinion of the care home staff, the interview only took place if the researcher was 
confident the interviewee was able to provide informed consent.  In order to ensure participants 
understood the study and their role in it, participant information sheets (participant information 
sheets) were provided to potential participants (Appendix F).  Participants were given at least 48 
hours to read the information and contact the researcher to discuss the study and ask 
questions.   However, if the participant wished to partake in the interview immediately, this was 
permitted.  In order to take part, participants were required to sign a consent form (Appendix E) 
and then verbally consented to take part before the interview took place.  The study did not 
include residents with dementia or other cognitive impairment, or anyone who was unable to 
give informed consent to take part.  There were no issues regarding the ability to consent of any 
participant who took part.
Stage 1. Is there an impairment of or disturbance in the functioning of a person’s mind 
or brain? If so, 
Stage 2. Is the impairment or disturbance sufficient that the person lacks the capacity to 
make a particular decision? 
The MCA says that a person is unable to make their own decision if they cannot do one 
or more of the following four things: 
1. understand information given to them 
2. retain that information long enough to be able to make the decision 
3. weigh up the information available to make the decision 
4. communicate their decision – this could be by talking, using sign language or 
even simple muscle movements such as blinking an eye or squeezing a hand. 
 
Figure 10: The two-stage mental capacity test, as defined by the Social Care Institute 
for Excellence (2020) 
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3.6.1.1.3 Safeguarding concerns 
In the event of a participant raising a safeguarding concern, the interviewer would have 
discussed this with the participant and then consulted with the supervisory team.  Participants 
were informed of this process in writing, on the participant information sheet and consent form, 
and verbally before the interview started.  No safeguarding concerns were raised during the 
interview process. 
3.6.1.2 Withdrawal from the study 
Participants were able to withdraw from the study at any point from receiving the participant 
information sheet up until two weeks after the interview.  If they withdrew after the interview, any 
data collected was destroyed.  They could also withdraw during the interview, if they wished, 
and again collected data was destroyed. Participants were also able to use the two weeks after 
the interview to consider their responses and contact the interviewer to change or withdraw 
individual responses.  No participants withdrew from the study, although one participant 
contacted the researcher to review one of their responses but did not change their response. 
3.6.2 Data protection considerations 
3.6.2.1 Confidentiality 
In order to take part, participants were required to sign a consent form (Appendix E) which gave 
permission for anonymous quotes from the interview to be used in publications.  It was 
acknowledged that instances may have arisen which required information to be shared with a 
third party such as the local safeguarding team.   If this was deemed necessary, it would be 
discussed with the participant first and no action would be taken until this had been done.  It 
was not necessary to break the confidentiality of any participant for any reason during the study. 
3.6.2.2 Anonymity 
All interviewees were assigned an ID number, which was securely stored with their real names 
on a master document.   Only the lead researcher had access to the master document, which 
was stored on a password protected Excel spreadsheet on the secure University of Leeds 
server.  The participant’s ID number was used on all subsequent paperwork.  
Table 18 highlights the varying data protection issues for different aspects of the study, and how 
data was handled throughout the study.
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Table 18: Summary of data protection issues accounted for during the study design 
Consent forms Signed consent forms were scanned onto the secure, 
password protected, University of Leeds drive accessible only 
by the lead researcher and the physical copies were 
destroyed.  Participants were assigned an identifier, which 
was used on all subsequent paperwork and documentation. 
Demographic data 
collection forms 
The forms were anonymised, and the data from them 
transferred to the master spreadsheet detailed below.  They 
were then destroyed. 
Master spreadsheet The master spreadsheet, containing details of the participants 
and their identifiers, were kept on a password protected 
Microsoft Excel spreadsheet on a secure University of Leeds 
drive accessible only by the lead researcher.  This will be 
destroyed after the PhD has been awarded. 
Interview recordings The interview recordings were transferred from the recorder 
to a secure, password protected University of Leeds drive 
accessible only by the lead researcher, and then they were 
deleted off the recorder.   The recordings will be kept until the 
PhD has been awarded. 
Interview transcripts Transcripts were anonymised, and were then kept securely at 
the University of Leeds, either electronically on a secure, 
password protected University of Leeds drive accessible only 
by the lead researcher or in a locked filing cabinet.  
Transcripts will be kept for two years after the results have 
been published, and then they will be destroyed.   
The storage of the all the above complied with the Data Protection Act 1998, the Human Rights 
Act and the University of Leeds Code of Practice on Data Protection.    
3.6.2.3 Details of ethical approval gained 
The research team were first advised that ethical approval from the University of Leeds School 
of Healthcare Ethics Committee (SHREC) would suffice, and this was granted.  However, the 
advice the research team was given was updated and it was determined that alongside Health 
Research Authority (HRA) approval that ethical approval was required from the NHS.  Ethical 
Approval from the NHS HRA Social Care Ethics Committee and HRA approval was granted on 
the 2nd May 2017, reference number 17/IEC08/0017 and IRAS Project ID 215674. 
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A substantial amendment was submitted to the NHS HRA Social Care Ethics Committee and 
the HRA to allow recruitment of more residents and relatives to the study, and to recruit relatives 
through different methods (detailed in section 3.4.2.1).  This was granted on the 3rd October 
2017 
3.7 Ensuring quality 
Qualitative research is undoubtedly useful for generating and analysing the words, thoughts and 
feelings of its participants, and it can also be utilised to help researchers and practitioners 
understand why interventions are not used by the target audience and why patients behave the 
way they do.  This is relevant to this thesis, which aims to understand why healthcare 
professionals are not partaking in deprescribing and how residents and relatives feel about 
deprescribing. 
In order to make a valuable contribution to the field being investigated, qualitative research must 
be rigorously conducted and its methods explained transparently.  Triangulation is a method 
which may be employed to achieve this.  There are different methods of triangulation, a 
common one being the utilisation of different methods to investigate the topic (Flick et al, 2004).  
Whilst this was not a method employed during the empirical research, the involvement of the 
supervisory team throughout the entire research process but especially during the analysis and 
TDF work is a form of investigator triangulation (Flick et al, 2004).  The concepts of credibility, 
transferability dependability and conformability can aid in guiding the researcher to produce high 
quality research, and in the assessment of the quality of qualitative research articles (Hannes et 
al, 2011).  Table 19 shows a description of these terms, alongside how they were addressed in 
this thesis.
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Table 19: How quality of the study was ensured using the concepts of credibility, 
transferability, dependability and confirmability 
Quality 
assessment 
criteria (Hannes 
et al, 2011) 
Definition of the criteria (Hannes et al, 2011) How the quality assessment criteria were fulfilled 
Credibility The findings should reflect the data generated.  
Methods by which to achieve this include involving 
multiple researchers in the analysis process, the use 
of verbatim quotes and the reporting of contradictory 
cases 
Multiple people were involved in the analysis process.  
Inclusion of the supervisory team in this process helped to 
ensure that the findings were credible, as the thoughts of the 
researcher were verified by those external to the main 
analysis process.   
The researcher’s work was regularly discussed and checked, 
both by the supervisory team and with other colleagues.  The 
transfer report process at the end of the first year of the 
research involved two independent assessors who ensured 
that the research was appropriate and achievable, and each 
year an independent assessor ensured the research was 
progressing and that it was being conducted properly.  
Supervision meetings took place every month, with further 
meetings with supervisors and colleagues taking place as 
required. 
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Quality 
assessment 
criteria (Hannes 
et al, 2011) 
Definition of the criteria (Hannes et al, 2011) How the quality assessment criteria were fulfilled 
The research was presented multiple times during the PhD 
process, both internally to colleagues in the department and 
externally at other universities and conferences.  This allowed 
for the researcher to be questioned, and for any potential 
issues with the research to be noticed and rectified or 
defended.  Further details of these presentations can be found 
in Chapter 6, section 6.12. 
 Verbatim quotes are presented in the findings chapter 
(Chapter 4), and contradictory cases are also highlighted and 
presented. 
Transferability To help the reader assess the transferability of the 
findings of a qualitative study to a similar setting, the 
author of a qualitative study should be transparent 
about participants and provide as much detail as 
possible about them.  The author should also provide 
detailed background on the setting of the study. 
A broad sample from different areas was aimed for, and 
largely achieved.  While there were constraints to the sample, 
as discussed in Chapter 6 section 6.7, the sample aimed to be 
inclusive of a large range of people whose views on the topic 
of deprescribing in care homes are important. 
 
 Demographic details of the participants and background 
details of the care homes recruited from were recorded and 
presented. 
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Quality 
assessment 
criteria (Hannes 
et al, 2011) 
Definition of the criteria (Hannes et al, 2011) How the quality assessment criteria were fulfilled 
Dependability Dependability refers to the transparency of reporting.  
The author should provide a clear audit trail to allow 
the reader to understand how the conclusions were 
met 
In addition to the factors listed under credibility, which also 
ensure dependability, framework analysis was employed 
which is a transparent methodology and a clear audit trail of 
the analysis process was produced.  As a result, as the final 
themes and subthemes can clearly be traced back to the data 
through a series of tables, coding and annotations. 
 Research journals and reflective pieces were written 
throughout the research process which allowed the researcher 
to keep a critical account of the processes undertaken. 
 In addition to the study, the researcher undertook a number or 
training courses to enhance their research skills.  Details of 
courses taken can be found in the training plan in Appendix 
K.. 
Confirmability The confirmability refers to how accurate the findings 
are likely to be.  This can be assessed through 
reflexivity and the author being transparent about their 
views and history that may have affected the findings 
In addition to the research journals and reflective pieces 
written and the audit trails detailed, the researcher’s 
background and core beliefs in relation to the topic were 
presented so the reader understands how the researchers 
background may affect the findings described. 
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3.8 Data analysis  
There are many approaches to analysing qualitative data, and the most appropriate method 
depends on factors such as the theoretical frameworks applied and whether language and 
social factors are important to the study (Smith and Firth, 2011).   
Framework analysis, as described by Ritchie and Lewis (2014) and Smith and Firth (2011), was 
employed to analyse the data in this study.  Framework analysis has a strong foundation in 
applied health research, and there are numerous examples of it being used in this discipline.  
This provided a strong foundation for its use in this study (Gale et al, 2013; Smith and Firth, 
2011; Thórarinsdóttir and Kristjánsson, 2013).  Framework analysis is a form of thematic 
analysis, whereby the data is systematically coded into themes in order to uncover patterns and 
meaning in the data.  It has been argued that thematic analysis is a generic method, as 
systematically coding data to discover themes is part of other qualitative analysis techniques 
such as qualitative content analysis, but framework analysis introduces structure to aid with the 
organisation of the data (Ritchie and Lewis, 2014).  The structure comes from the matrix the 
analyser produces which contains the “cases” in rows and the “thematic framework” in columns 
(Gale et al, 2013; Pope and Mays, 2006).  In this study, each participant was presented as a 
case in the matrix.  The thematic framework presented in columns was formed of the 
subthemes defined during the analysis stage.  Below, Table 20, is an example of a framework 
matrix, see Figure 11 for an image of the framework developed during the data analysis 
process. 
Table 20: Example of a framework matrix 
 Subtheme 1 (thematic 
framework) 
Subtheme 2 (thematic 
framework) 
Participant 1 (case) Summary of participant 1’s 
views coded to subtheme 
1 
Summary of participant 1’s 
views coded to subtheme 
2 
Participant 2 (case) Summary of participant 2’s 
views coded to subtheme 
1 
Not discussed 
For this study, framework analysis offered numerous advantages over other analytic methods.  
The strengths of this method in relation to this study were that it was useful for managing and 
organising large datasets, and it allowed clear identification of patterns, differences and 
similarities in the data (Ritchie and Lewis, 2014; Gale et al, 2013).  In addition to this, qualitative 
data analysis techniques can be criticised for being unclear and difficult to follow for readers of 
qualitative studies (Gale et al, 2013).  Framework analysis is a clear and transparent way to 
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manage data and provides an audit trail which demonstrates the researcher’s thought 
processes.  This increases the dependability of the research, and addresses some of the 
concerns that have been raised about the rigour of qualitative data analysis (Ward et al, 2013). 
While framework analysis appears to be a straightforward way of managing the data, it has 
been criticised for reducing data analysis to a sorting exercise, whereby the researcher sorts 
data into a table without properly analysing it.  Gale et al (2013) state that the researcher still 
needs good data analysis techniques and must be able to interpret and draw explanations from 
the data.  It is recommended that the researcher takes notes of thoughts and interpretations that 
occur to them throughout the analysis stage to ensure that the researcher is always actively 
analysing and not simply sorting data (Gale et al, 2013).  Whilst filling the framework with data 
summaries is a form of data interpretation, it is important that the data is also fully interrogated 
and interpreted after this stage (Ritchie and Lewis, 2014; Bazeley, 2013)  
Analysis can be conducted inductively or deductively.  This study adopted an inductive 
approach, as no pre-determined framework was imposed on the data.  The frameworks were 
composed of the subthemes, which were in turn developed from the data.  A deductive 
approach would impose a pre-determined framework upon the data, and the data would be 
categorised into this framework. 
Deductive analysis was considered for the healthcare professional and care home staff 
interviews, as the TDF could have been used as a framework in which to categorise the data.  
However, after completing the interviews, which provided a good quantity of rich data, it was felt 
that inductive analysis was preferable as it allowed the words of the participants to be properly 
represented.  The risk with using deductive analysis would be that the data would be forced to fit 
into pre-determined themes, and valuable meanings and insights could be lost in favour of 
making the data fit the framework.  The TDF was instead applied when contextualising the 
findings and moving from description to interpretation. 
Data analysis was conducted using Ritchie and Lewis’ (2014) five steps of framework analysis, 
outlined above, and was further informed by Smith and Firth (2011).  NVivo® 10, and later 11, 
was used to manage the data and construct the frameworks.  The familiarisation process 
described was conducted on Microsoft Word®.  In addition to this, to aid visualisation of the data 
exercises were undertaken on paper with Post-it® notes used to sort initial categories themes 
and subthemes and notes made in a research journal throughout the process.  The use of a 
research journal improves the dependability of the research.  Ritchie and Lewis recommend the 
use of Post-it® notes, and this recommendation was followed as it was found to be easier to 
move, group and amend Post-it® notes than it was themes in NVivo®.  
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Framework analysis, as described by Ritchie and Lewis (2014), involves five stages: 
Stage 1. Familiarisation 
Stage 2. Constructing an initial framework 
Stage 3. Indexing and sorting 
Stage 4. Reviewing data extracts 
Stage 5. Data display and summary, using the framework 
The first four stages are the same as the stages in thematic analysis, but the fifth stage, 
displaying data summaries in a framework, is what distinguishes framework from general 
thematic analysis.  The data were analysed in two sets:  resident and relative transcripts were 
analysed together, followed by analysis of the GP, pharmacist and care home staff transcripts.  
This was because the interviews had different aims, and so there were differences in the data 
being collected.  Therefore, important nuances in the data could be lost if the five groups were 
analysed together.  
3.8.1 Stage one: Familiarisation 
The first stage which was conducted was familiarisation.  This involved immersion in the data 
and generation of a list of initial categories (Ritchie and Lewis, 2014).  To analyse the resident 
and relative transcripts, the researcher transcribed and read all the transcripts to gain an 
overview of the data.  Four transcripts were selected for the next stage of familiarisation.  
Ritchie and Lewis (2014) suggest that, depending on the amount of data, the familiarisation 
process may involve all the data, or a portion of it.  Due to the large amount of data that had 
been generated by the resident and relative interviews, two resident interviews and two relative 
interviews were selected for initial categorisation.  The interviews which generated the most 
data were selected, as these covered a wide range of views and it was felt that an initial 
framework produced from the categorisation of the four selected interviews would be applicable 
to the remaining data. 
The four interviews were categorised using a method described by Smith and Firth (2011).  This 
method for categorisation was selected as it is a transparent method of categorising data – each 
initial category can be traced back to a quote from the interview, and there is space for the 
researcher to explain how the category was determined.  This stage was completed using 
Microsoft Word®.  Table 21 below is an excerpt of the initial categorisation table for Relative 2, 
designed using Smith’s method (Smith and Firth, 2011).  Data was copied verbatim from the 
transcript into the transcription column and key quotes were extracted in the description column.  
The researcher’s initial thoughts were noted next, with interpretative thoughts separated by 
brackets to be revisited later.  Finally, an initial category was assigned to the piece.  
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Table 21: An excerpt from relative two's initial categorisation table 
Transcript Description (in-vivo 
codes) 
Preliminary 
thoughts (what is 
this about?) 
Initial 
categories 
What I have heard 
subsequently from 
my father’s GP is 
that he doesn’t 
think that 
donepezil is 
making a 
difference, 
“…My father’s 
GP…doesn’t think that 
donepezil is making a 
difference”   
 
Relative perceives 
GP to also doubt 
the efficacy of the 
medicine (but GP 
is not willing to 
stop it – why?) 
 
Doubts about 
medicines 
 
He expressed 
concern, excuse 
me, the GP 
expressed 
concern that my 
father was 
discharged from 
the memory loss 
clinic and he’s on 
donepezil 
indefinitely.   
“…the GP expressed 
concern that my father 
was discharged from 
the memory loss clinic 
and he’s on donepezil 
indefinitely” 
Perceived lack of 
communication 
between primary 
and secondary 
care leading to a 
potentially 
inappropriate 
medicine being 
continued 
unnecessarily. 
Primary and 
secondary care 
 
Tables were created for each of the four care home resident and relative transcripts selected for 
inclusion in this stage.  The transcripts were copied and pasted into the transcript column in full, 
with a separate row for each question or new idea.  The initial categories were then collected 
from each table, which resulted in the generation of over 70 initial categories for the resident 
and relative interviews to be utilised in stage two of the process.   
A similar method was used for the care home staff, GP and pharmacist interviews.  These 
interviews were transcribed externally (as described in section 3.5.2), rather than by the 
researcher, which meant there was a risk that the researcher would not be as familiar with the 
data as they would be had they transcribed it themselves.  However, familiarisation and 
immersion in the data still took place as the researcher listened to each interview and checked 
the transcripts at least twice to ensure they were familiar with the data.  Two interviews from 
each group were selected to undergo the categorisation method described by Smith and Firth 
(2011), again those interviews which generated large amounts of data and represented diverse 
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views were selected for this stage.  This ensured a broad range of categories and made it more 
likely that the initial framework was relevant to the rest of the interviews. 
3.8.2 Stage two: Constructing an initial thematic framework  
Two initial frameworks were constructed: one for the resident and relative interviews, and 
another for the GP, pharmacist and care home staff interviews.  The same process was 
followed to create both frameworks.   
Firstly, the initial categories defined in the first stage were revisited and some were combined, 
reworded or deleted.  Any changes made were only executed after revisiting the transcript and 
making sure that the changes reflected the content of the transcript.  It was important that this 
was also undertaken transparently, and the changes made to the initial categories could be 
traced through a series of documents.  A series of preliminary themes were decided based upon 
the initial categories.  This process is summarised in table 22 below, which is an excerpt of a 
table detailing how initial categories generated by the resident and relative interviews changed 
and where the themes originated from. 
Table 22: An excerpt from a table detailing how initial categories and themes developed 
Initial category Description New category Preliminary theme 
Doubt about 
medicines 
Any doubt or 
question about 
medicines 
Doubt about 
medicines 
Beliefs about 
medicines or illness 
perceptions and 
health beliefs 
Primary and 
secondary care 
Any reference to 
differences or issues 
with primary and 
secondary care. 
Primary and 
secondary care 
Perceptions of 
healthcare systems 
A member of the supervisory team also checked the initial categories and offered insight and 
suggested changes, thus enhancing credibility.  Each of the new categories was written on a 
Post-It® note, all of which were then sorted into the new preliminary themes.  Preliminary 
themes were amended as necessary, and subthemes were also created.  This process yielded 
an initial framework.  An example of an initial framework can be seen below in table 23, which is 
an excerpt of the initial framework generated for the GP, pharmacist and care home staff 
interviews.
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Table 23: An excerpt of the initial framework generated for the GP, pharmacist and care 
home staff interviews 
Preliminary themes Preliminary subthemes 
Environmental consequences and 
resources 
Training 
 Tools and resources (training fit into 
this?) 
 Care home factors 
 Financial implications 
 Healthcare systems 
 Gathering views and information 
Social professional role and identity Skills 
 Professional judgement 
 Personal practice 
In summary, the initial frameworks were comprised of the initial categories defined in stage one, 
reorganised and redefined to create two workable frameworks, each for use on the data on 
which it was based. 
3.8.3 Stage three: Indexing and sorting 
The remaining data was then indexed according to the initial framework.  Each transcript was 
read, and data assigned a subtheme from the initial framework.  Any data which did not fit into 
the framework were set aside.  The data coded to each subtheme was then re-read, and 
checked that it had been indexed appropriately and that the name of each subtheme was 
reflective of its content.  This stage was conducted using NVivo®. 
3.8.4 Stage four: Reviewing data extracts 
The initial framework was adjusted at this stage, with some subthemes re-worded, combined or 
otherwise amended to make sure the themes reflected the data contained within them.  The 
data which had not been indexed in stage three was also sorted, being assigned to newly 
created or amended subthemes.  This was again done carefully, with careful consideration 
given to each change and notes made in a research journal to monitor the process.  The 
finalised themes and subthemes were then displayed in two frameworks for use in stage five.
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3.8.5 Stage five: Data summary and display, using the framework 
Once the frameworks had been finalised, the data was summarised in the matrix.  The 
subthemes formed the columns of the matrix, with the participants forming the rows of the 
matrix.  The matrix was completed by subtheme, i.e. each column was filled in turn.  This 
provided an overview of each subtheme and its relevance and meaning.  The matrix was also 
read across the rows as a part of the analysis process, which helped to build the story of each 
participant.  An example of the final framework constructed in NVivo for the resident and relative 
interviews is shown below in Figure 11.  The frameworks into which the data were sorted are 
displayed in Appendix J. 
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Figure 11: Excerpt of a framework matrix produced while analysing the resident and relative interviews.  The theme is 
the name of the framework.  The subthemes are presented as columns and the rows are filled with a description of each 
participant’s data.  See Appendix J for the frameworks constructed during framework analysis. 
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3.8.6 Data abstraction and interpretation 
After the framework had been constructed, the final stage was to interpret the data (Ritchie and 
Lewis, 2014).  Producing the framework starts the interpretation process, as the researcher 
becomes fully immersed in the data and, through the process of organising the themes and 
subthemes and summarising, starts to interpret the data.  However, the framework is primarily 
an organisation tool, which makes the data manageable and useable.  The interpretation phase 
comes next, and is used to mould the findings into a cohesive story and useable findings.   
Resident and relative interviews were analysed together using the same frameworks, and GP, 
pharmacist and care home staff interviews were analysed together using separate frameworks 
(displayed in Appendix J).  This was because the groups were deemed to be too diverse and 
different to be analysed together, and doing so could have meant losing important detail and 
nuances.   
All the frameworks produced for both groups (see Appendix J) were then viewed together to 
produce a narrative of the barriers and facilitators to deprescribing in care homes.  The 
transcripts and summaries contained within the frameworks were revisited and the barriers and 
facilitators to deprescribing in care homes were identified and listed.  Through a process of 
writing and sorting concepts, three themes were identified: one which described barriers and 
facilitators related to the individual’s beliefs about deprescribing and medicines, another which 
explored the interaction of the individual with other people and a final which described the 
interaction between key stakeholders and health and social care systems.  This gave rise to the 
themes presented in Table 24, which form the findings chapter (Chapter 4).
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Table 24: Themes and subthemes identified and presented as the findings of this study 
Theme Subthemes 
“There’s more stakeholders than 
you might have with a regular, 
average patient”: the roles, 
knowledge and beliefs of the 
individuals involved in 
deprescribing in care homes. 
“The GP has ultimate responsibility ’cause we’re the 
ones who sign that prescription”: Perceived roles and 
responsibilities in the deprescribing process 
“Well, it’s for my own benefit love”: Knowledge of 
medicines taken by care home residents 
“If the doctor stops them, I’m not worried about it really, 
I’m in his hands”: Beliefs about consequences 
Perceptions of others and difficult 
conversations: social barriers and 
facilitators to deprescribing in 
care homes 
“I’d probably feel secretly, well there must be some 
reason, but I respect him so I would take what he 
said”: Care home residents and their relationships with 
those caring for them “This is a, sort of, awkward one, 
but I haven’t actually spoken to [the relatives]: 
Involving the relatives: a complex relationship 
“I find, if I’m very complimentary of the doctor when he 
comes in, that seems to change the doctor’s mood, 
they can be happier”: Attitudes towards pharmacists 
and  
“They feel that I’m giving up on their relative because 
I’m stopping meds”: Talking about the future benefit of 
medicines 
Working together, navigating 
systems: Logistical barriers and 
facilitators to deprescribing in care 
homes 
“If that funding goes, then, I [GP] won’t be going in on a 
regular basis and I think that will be a shame”: Healthcare 
systems: a barrier to deprescribing? 
“There just aren’t enough hours in the day, really”: Access 
to deprescribing resources 
4.4.3 “Most of the care homes that I do, they all have 
quite a lot of dementia, so they’re not really able to discuss 
the medication as such with me”: Physical barriers and 
facilitators to communication 
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3.9 Summary 
This chapter has outlined the methodology and methods applied to the design of this study.  
Firstly, the methodologies employed were explained, including details of the qualitative, 
pragmatic approach which was selected to conduct the research.  A qualitative, pragmatic 
approach allowed for exploration of a practical problem, deprescribing in care homes, in the 
participants’ own words.  The theoretical underpinning of the study through use of the TDF was 
then described, followed by pertinent information about the researcher’s background which may 
influence the findings of the study.  This included information about the researcher’s 
professional background as a pharmacist, and preconceptions that were bought to the study as 
a result of this. 
The second part of the chapter addressed the methods utilised to conduct the study, as well as 
relevant methodological information relating to these methods.  Considerations about sample, 
including size, were discussed, and the specific details utilised to recruit care homes, residents, 
relatives, GPs, pharmacists and care home staff were then outlined.  This section also included 
demographic details of the care homes, residents, relatives, GPs, pharmacists and care home 
staff who were recruited to participate in the study. 
The chapter continued to detail the methods.  The data protection and ethical considerations 
were also reported, as well as the steps taken to safeguard participants’ data.  Finally, the 
methodology behind the chosen data analysis technique, framework analysis, was described, 
followed by a detailed explanation of the analysis process.  This led to development of the 
themes which were developed as a part of the analysis process:  
- “There’s more stakeholders than you might have with a regular, average patient”: the 
roles, knowledge and beliefs of the individuals involved in deprescribing in care homes. 
- Perceptions of others and difficult conversations: social barriers and facilitators to 
deprescribing in care homes 
- Working together, navigating systems: Logistical barriers and facilitators to deprescribing 
in care homes 
These themes will be discussed in detail in the next chapter, and then applied to the TDF to 
inform the development of components of an intervention to facilitate deprescribing in care 
homes.
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Chapter 4 Findings 
4.1 Introduction 
The qualitative methods undertaken for this study were described in the last chapter, and this 
chapter presents the findings of the empirical research.   
Eleven residents and four residents from a total of eight care homes were interviewed over a 
nine-month period.  The care home residents sampled ranged in age from 74 to 98 years old, 
and were prescribed a mean of 9.7 medicines each (range 2-15).  Six GPs, six pharmacists and 
seven care home staff were interviewed over an overlapping six-month period.  The healthcare 
professionals and care home staff had varying experience of care home work, and varying job 
titles.  Tables 25-30 show a summary of the participants and the identifiers that will be utilised 
throughout this chapter.  Further details of the sample are described in Chapter 3, sections 3.3 
and 3.4. 
Table 25: Care homes recruited for inclusion in the study 
Care home Nursing or 
residential care 
provided 
Care home 
ownership 
CQC rating 
CH1 Residential Privately owned Requires 
improvement 
CH2 Residential Council owned Good 
CH3 Nursing Privately owned, 
part of a chain 
Requires 
improvement 
CH4 Nursing Privately owned Good 
CH5 Nursing Privately owned Good 
CH6 Both Charitable trust Good 
CH7  Nursing Unknown  Unknown 
CH8  Residential Privately owned Good 
CH9 Both Privately owned Unrated at the time of 
visit 
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Table 26: Demographic information of residents included in the study 
Identifier Gender Age Residential 
or nursing 
care 
Number of 
medicines 
prescribed 
daily 
Care 
home 
identifier  
Res1 Male 80 Residential 15 CH1 
Res2 Male 86 Residential 12 CH1 
Res3 Female 91 Residential 15 CH2 
Res4 Female 83 Residential 8 CH2 
Res5 Male 79 Nursing 6 CH3 
Res6 Male 74 Nursing 7 CH4 
Res7 Female 84 Nursing 9 CH5 
Res8 Female 82 Nursing 7 CH5 
Res9 Female 90 Residential 2 CH6 
Res10 Female 96 Nursing 15 CH6 
Res11 Female 98 Nursing 10 CH6 
Table 27: Demographic information of relatives recruited to the study 
Identifier Gender Resident: 
residential or 
nursing care 
Care home 
recruited from 
Rel1 Male Nursing CH7 
Rel2 Male Nursing CH6 
Rel3 Female Nursing CH6 
Rel4 Female Residential CH8 
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Table 28: Demographic information of GPs included in the study 
Identifier Gender Years of experience  
(as a GP) 
GP1 Female 29 
GP2 Female 29 
GP3 Female 21 
GP4 Female 28 
GP5 Female 13 
GP6 Male 3 
 
Table 29: Demographic information of pharmacists included in the study 
Identifier Gender Years of 
experience 
Independent 
prescriber 
status 
Role 
Pharm1 Male 31 as a 
pharmacist, 20 in 
this role 
Independent 
prescriber 
Employed by a 
company to 
provide a 
service to 
CCGs 
Pharm2 Female 2 in this role Non-prescriber Employed by a 
CCG 
Pharm3 Female 16 as a 
pharmacist, 11 in 
this role 
Non-prescriber Employed by a 
CCG 
Pharm4 Female 22 as a 
pharmacist, 1 in 
this role 
Non-prescriber Employed by a 
company to 
provide a 
service to 
CCGs 
Pharm5 Female 18 as a 
pharmacist, 5 in 
this role 
Independent 
prescriber 
Employed by a 
company to 
provide a 
service to 
CCGs 
Pharm6 Female 21 as a 
pharmacist, 8 in 
this role 
Non-prescriber Employed by a 
company to 
provide a 
service to 
CCGs 
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Table 30: Demographic information of care home staff included in the study 
Identifier Gender Job 
title 
Role in 
the care 
home 
Years of 
experience 
Care 
home 
recruited 
from 
Nursing or 
residential 
care 
provided 
CHS1 Female Carer Deputy 
manager 
28 CH2  Residential 
CHS2 Female Carer Team 
Leader 
20 CH2  Residential 
CHS3 Female Nurse Team 
Leader 
14 in care 
homes, 
more as a 
nurse 
CH6  Both 
CHS4 Female Nurse Team 
Leader 
14 in care 
homes, 
more as a 
nurse 
CH6 Both 
CHS5 Female Carer Senior 
carer 
20 CH1 Residential 
CHS6 Female Nurse Senior 
nurse 
23 CH4 Nursing 
CHS7 Female Nurse General 
manager 
23 CH7 Both 
The findings are presented in this chapter, addressing the following objectives of the 
research: 
• To investigate how the deprescribing process happens in care homes, including the 
roles and responsibilities of those involved 
• To explore how older people living in care homes, and their relatives, perceive their 
medicines (or medicines taken by the resident) and their attitudes to deprescribing 
• To explore the attitudes of healthcare professionals towards deprescribing in care 
homes, including identification of perceived barriers and facilitators to deprescribing. 
Three main themes were identified which explore the complexity of deprescribing in care 
homes.  There are several people involved in the deprescribing process in care homes, 
including health care professionals, care home staff, residents and their relatives and 
friends.  The complex interplay of interactions between these stakeholders magnifies the 
challenge of deprescribing in care homes.  
The complexities involved in deprescribing in care homes are outlined below.  As detailed in 
Chapter 1, an older person residing in their own home may make an appointment with their 
GP, attend and discuss their medicines and come to a decision about deprescribing.  The 
process for a care home resident is different.  Firstly, residents were (in the main) unable to 
make their own GP appointments: care home staff advocate to liaise with the GP surgery 
and to arrange consultations for residents.  The GP may wish to speak to the resident, their 
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family and care home staff before making a decision.  In addition to this, other healthcare 
professionals, mainly pharmacists but sometimes nurses, are being employed to conduct 
medicine reviews in care homes and they may also need to liaise with GPs, care home staff, 
residents and relatives before a decision is made.  Each new person involved presents 
another logistical challenge, as they must be contacted and consulted, and each individual 
will bring their beliefs, attitudes and perceptions to the deprescribing process.  GPs and 
pharmacists interviewed reported that this made the deprescribing of medicines for care 
home residents comparatively more challenging than stopping the medicines of someone 
who does not live in a care home.  
The first theme exploring the complexities of deprescribing in care homes examines the 
individuals involved in the deprescribing process, and is entitled: “There’s more stakeholders 
than you might have with a regular, average patient” the roles, beliefs and knowledge of the 
individuals involved in deprescribing in care homes.  This theme demonstrates that there are 
multiple individuals are involved in deprescribing in care homes, each of whom have their 
own beliefs, knowledge and attitudes about deprescribing that they bring to the process.   
The second and third themes explore the complex social context in which deprescribing 
takes place: the care home.  Individual stakeholders must work together and within health 
and care systems to implement deprescribing in care homes.  Broadly, system barriers and 
facilitators for involving people in deprescribing can be considered in two areas: social 
barriers and logistical barriers.  These two areas are explored in the final themes: 
- Perceptions of others and difficult conversations: social barriers and facilitators to 
deprescribing in care homes. 
-  Working together, navigating systems: Logistical barriers and facilitators to 
deprescribing in care homes 
The names of the themes and subthemes include quotes from the interviews, where 
appropriate.  These quotes encapsulate the theme or subtheme and reflect its contents.  To 
begin with, the first theme will be explored.  This examines the individuals involved in 
deprescribing and how their own knowledge and beliefs influence deprescribing behaviour.  
Figure 12 below is a flowchart of the themes and subthemes which comprise the findings.
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Figure 12: Diagram of the themes and subthemes which comprise the findings 
chapter (Chapter 4) 
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4.2  “There’s more stakeholders than you might have with a 
regular, average patient”: the roles, knowledge and beliefs of 
the individuals involved in deprescribing in care homes. 
This theme examines the individuals, including residents, relatives, GPs, pharmacists and 
care home staff, involved in deprescribing in care homes.  These are explored over three 
subthemes: 
- “The GP has ultimate responsibility ’cause we’re the ones who sign that prescription”: 
Perceived roles and responsibilities in the deprescribing process 
- “Well, it’s for my own benefit love”: Knowledge of medicines taken by care home 
residents 
- “If the doctor stops them I’m not worried about it really, I’m in his hands”: Beliefs 
about consequences 
4.2.1  “The GP has ultimate responsibility ’cause we’re the ones who 
sign that prescription”: Perceived roles and responsibilities in the 
deprescribing process 
The perceived roles and responsibilities of those involved in deprescribing (including GPs, 
pharmacists, care homes staff, residents and their relatives) are outlined in this subtheme.  
This provides an understanding of the approaches and perspectives of the different 
stakeholders involved in deprescribing, and also enables the later exploration of the 
relationships and interactions between these groups and the systems in which they operate. 
The perception that the GP assumed ultimate responsibility for the resident’s medicines was 
reported ubiquitously across all groups interviewed.  When prompted, GPs, pharmacists and 
care home staff named others such as pharmacists, care home staff and mental health 
professionals to also have a role in deprescribing, referring to it as a team activity or 
something that “everyone” was responsible for.  Relatives and residents were only 
occasionally referred to as having a role in the deprescribing process, as demonstrated by 
GP5 below.    
Interviewer: Who do you think is responsible for de-prescribing in care homes? 
GP5: I think…well, the GP has ultimate responsibility ’cause we’re the ones who 
sign that prescription.  But I think everyone has a role to identify these things and 
so, you know, care home staff, the patient, relatives, they all have a role, but I 
think the ultimate responsibility lies with the person doing the prescription. 
The potential role that pharmacists can perform in the care of the resident was not well 
understood by residents and relatives.  Half of the relatives interviewed were in favour of 
increasing the role of the pharmacist in care homes, as they believed the workload of GPs 
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was too high and they required assistance to provide healthcare services.  The other 
relatives and some residents were unsure of the role of the pharmacists in deprescribing in 
care homes.  The reasons for this are discussed in section 4.3.3. 
Interviewer: And how would you feel if it was a pharmacist or a nurse that had 
reviewed the medicines and they suggested stopping some that weren’t 
appropriate anymore? 
Relative 2: Fine.  Yeah, no these are very highly professional…I’m very happy, in 
my personal life I go to a pharmacist and I say: “I need something for that” and 
he says: “no you don’t, actually, just do this”.  I’m very comfortable with 
pharmacists and nurses.  They need a bigger role in this, doctors can’t do it all. 
GPs and care home staff reported appreciation of pharmacists who often relied on their 
knowledge and skills to stop medicines.  There were, however, differences of opinion about 
how being trained as an independent prescriber impacted on the pharmacist’s role in 
deprescribing.  GPs generally believed that it would be beneficial if the pharmacist were able 
to deprescribe and enact their recommendations without involving the GP, as it would save 
the GP time and could increase number of medicines appropriately deprescribed.  Three of 
the pharmacists interviewed also believed it would be beneficial to the deprescribing process 
if they were prescribers, and were in the process of gaining the qualification.  From the point 
of view of these healthcare professionals, pharmacists becoming independent prescribers 
could relieve the GP burden of deprescribing.  However, this assumes that pharmacists are 
effective deprescribers, and that they can carry out deprescribing knowledgeably and 
confidently. 
Interviewer:  Does it help if they're [pharmacist] a prescriber and they're able to 
do the actual physical de-prescribing themselves or would you still prefer to do 
that? 
GP6:  Yeah, no I think it's really useful to have pharmacists as prescribers.  
Because clearly they'll do whatever they're doing within their competence and if 
there's any particular issues that then they can be discussed with the individual 
GP.  Otherwise every query then needs to come back to the GP, whereas if 
they're a prescriber that can be done without that contact, which helps and so it 
saves a bit of time really. 
However, pharmacists did not unilaterally agree that becoming prescribers was key to 
improving deprescribing in care homes, and one GP expressed a wish to be involved in 
deprescribing even if the pharmacist making the recommendations was a prescriber.  While 
it was acknowledged that it would be more efficient for pharmacists to be prescribers, the 
two pharmacist prescribers interviewed did not use their qualification routinely, and did not 
feel the qualification was essential to their role.  One explained that they preferred 
deprescribing to be a team activity, while the other worked within a service designed for non-
prescribers and so did not need to use it.  One pharmacist interviewed (Pharm6) did not 
believe the prescribing qualification would be beneficial to their practice as it would remove 
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the teamwork aspect of deprescribing and eliminate people and their knowledge from the 
process, for example the GP’s knowledge of the resident would not be considered.   
Interviewer:  Do you think, how do you find doing the de-prescribing without 
being a prescriber or do you think it would help you if you were a prescriber? 
Pharm6:  I think that de-prescribing is a form of prescribing and I think we do well 
to remember that.  So if I come up with some recommendations in terms of 
changing medication or stopping something I would communicate that to the GP 
so that the decision to actually stop is made by a prescriber and I think that's 
really important.  If I was a prescriber I would not involve the GP.  So, from an 
NHS productivity or smoothing the system it would make more sense.  My 
personal opinion is, who am I to stop this medication in some ways?  I like the 
fact that I involve the GP.   
The role of care home staff in deprescribing was less clearly defined than that of the 
pharmacist.  Care home staff believed they did not have a role in deciding which medicines 
were stopped, as they believed that they lacked the knowledge for this role.  While some 
care home staff expressed an interest in being involved in deprescribing, most believed that 
such involvement with medicines was beyond the scope of their role and was instead the 
responsibility of the GP.  Instead, their role in the deprescribing process was identified by 
themselves and others as messengers, relaying information about the resident to healthcare 
professionals and relatives, and vice versa.  They were also advocates for the resident, who 
may be unable to take part in discussions or be overlooked by healthcare professionals.  
Care home staff were not acknowledged as having a clinical role by healthcare 
professionals, although some acknowledged the role that care home staff do currently play 
as demonstrated by Pharmacist 1 below. 
Interviewer: And do you think that care home staff have a role to play in de-
prescribing? 
Pharm1: They have a role in giving us information and a view on whether it’s 
appropriate to continue a medicine.  So they do give valuable advice on how that 
patient’s getting on.  So they’re the ones who’ll tell us,  that medicine’s making 
them drowsy…or they’re very constipated on that.  They’re not really highly 
involved in making clinical decisions or advising us on stopping stuff.   
The role of relatives and residents in the deprescribing process were the least well defined.  
Relatives that did wish to be involved in the deprescribing process perceived their role as 
being challenging to perform, both morally and logistically.  These participants were relatives 
of residents with cognitive impairment, and so they were making decisions in the best 
interest of their relative living in a care home.  This involved considering their own views, the 
resident’s wishes and the views of those around them, such as healthcare professionals, 
care home staff and other family members.  They had to co-ordinate the information 
received from others, seek views and opinions and come to a decision that they felt 
represented these varied views and what was best for the resident.  This process and the 
responsibility were described as burdensome by relatives, who spent time gathering views 
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and deliberating how to best progress with treatment decisions.  The complications 
experienced by relatives undertaking this role was not acknowledged by the other 
participants. 
Interviewer: And how do you find being the main decision maker since your dad’s 
not able to make these decisions anymore? 
Relative 2: Y’know, I am comfortable, I never take a decision alone, I’ve got two 
brothers and our health and wellbeing local [sic] power of attorney requires us to 
be of one mind.  So, although I’m here on the ground, y’know it’s me who 
delivers the decision to [manager], or the nurse or the GP, it’s triangulated, so 
y’know the brothers are of different minds so we argue it.  I find the GP 
knowledgeable and we can— I feel confident to disagree with him.   
Interviewer:  But you’re having to liaise between the doctor and the staff here 
and your brothers as well, and trying to bring that all together into what’s in the 
best interests for your dad? 
Relative 2: Yeah, and a close family friend of my father who has medical training 
so y’know I go round all of them to make sure we come up with a decision that’s 
not partial to any one of us but is in his best interests.  But I accept the 
healthcare professional’s lead.   
In contrast, despite it being the resident and their medicines at the centre of deprescribing 
decisions, the resident was generally perceived as having little involvement and unclear, if 
any, roles and responsibilities in the deprescribing process, by a range of stakeholders.  
Even though many participants acknowledged that residents should be involved in 
deprescribing, their role was not defined.  It was recognised by most participants that, in 
reality, residents had very little involvement in the process.  Residents themselves were 
unsure of their role in deprescribing, either actual or desired.  While most residents stated 
they would like to be involved, they were unable to expand on this and explain how they may 
be involved. 
Interviewer: Would you want to be involved in that decision if they wanted to stop 
some of your medicines?   
Resident 6: Oh yes, yes, oh yes.  It’s me, y’know what I mean, whether it’ll do me 
any good or not I don’t know. 
As demonstrated by this subtheme, according to participants GPs have the clearest role in 
deprescribing in care homes and the roles of other key stakeholders are poorly defined.  The 
next subtheme examines the knowledge and beliefs about medicines of those involved in 
deprescribing.  
4.2.2 “Well, it’s for my own benefit love”: Knowledge of medicines taken 
by care home residents 
Residents generally lacked knowledge of the medicines they were taking, and were largely 
unaware of the concept of inappropriate medicines.  Relatives were usually more 
knowledgeable, and more challenging about the use and necessity of medicines.  GPs and 
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pharmacists believed themselves to be knowledgeable about medicines, although they 
identified some gaps in their knowledge.  However, they did not always believe that they 
would benefit from deprescribing training.  Finally, care home staff usually gained their 
knowledge from experience, though some registered nurses acknowledged that their nursing 
training had provided them with some knowledge that carers may not have.  Care home staff 
were generally willing to learn more about medicines, though some carers believed this to be 
beyond the scope of their role. These perceptions of self-reported knowledge of medicines 
are explored further below. 
The majority of residents lacked knowledge of the medicines they were taking.  Residents 
generally knew the amount of medicines they took during each medicines round, but only 
knew the names of some of their medicines and often had partial understanding of why they 
were taking medicines.  Relatives generally displayed more knowledge of the resident’s 
medicines, and all but one relative were able to provide information about the resident’s 
diagnoses and medicines.  Few relatives were able to name all the medicines taken by the 
resident.  Resident 2, below, provides an example of the knowledge held by residents about 
their medicines: 
Interviewer: So firstly, don’t worry if you don’t, but do you know how many 
medicines you take in a day? 
Resident 2: Oh let’s see — I take two on a morning, and two at teatime, and one 
when I’m in bed at night…the warfarin. 
Interviewer: So do you know why you taking them? 
Resident 2: Well I think it’s something to do with blood. 
Interviewer: And what about your other tablets, do you know why you’re taking 
those? 
Resident 2: I think one’s for my heart. 
The number of medicines that residents reported they took often differed from the number of 
medicines listed on their medicine administration record (MAR) chart, which further supports 
the finding that residents lacked knowledge of their medicines.  Despite this lack of 
knowledge, residents, generally believed that the resident’s medicines were beneficial.  Most 
residents did not demonstrate an understanding of the concept of inappropriate medicines 
as something which may affect them, believing instead that their medicines were beneficial, 
appropriate and necessary. They were, however, supportive of the idea of deprescribing if 
this were suggested by a healthcare professional.   
Interviewer:  Do you know why you’re taking them? 
Resident 3: Well, it’s for my own benefit love [laughs]. 
Interviewer: I just wondered whether you knew what they were treating, whether 
they were for—? 
Resident 3: No.  They help me love, so I know that like y’know 
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However, some residents and most relatives were well informed and opinionated about 
medicines.  These participants also had more doubts about medicines than other 
respondents, and were aware of the concept of inappropriate medicines and how it might 
affect them.  However, raising doubts about medicines did not seem to be a priority for 
residents and relatives, unless the resident was experiencing harm from their medicines.   
Interviewer:  Do you feel happy about the number of medicines that you take? 
Resident 11: Well, I’ve got to the point where, although I’m not really keen on 
seeing him, of saying to the doctor “do I really need to take this one that’s 
supposed to prevent me from having urine problems, because it doesn’t?” and 
“can I try without bothering about the other one at teatime, and see if my acid 
stomach comes back, I’ll go back on it but at the moment, I’ll come off both of 
them.”  But I haven’t got round to it yet, have I?  Just think about it! 
Whilst residents generally believed their medicines to be appropriate and beneficial, 
pharmacists and GPs believed otherwise.  GPs and pharmacists all believed that there were 
care home residents in their care who were taking inappropriate medicines:  
Interviewer:  Do you think all the medicines taken by care home residents in your 
care are useful to them? 
GP1: No, I’m ashamed to say they’re probably not. 
 
Interviewer:  And how do you feel about the medicines taken by care home 
residents?  
Pharm5: It’s a load of crap that they’re on, aren’t they?  A load of sedatives, a 
load of horrible stuff. 
This demonstrates a difference in beliefs about medicines between residents and GPs and 
pharmacists.  Deprescribing was considered a useful method by both GPs and pharmacists 
to reduce the number of inappropriate medicines taken by residents. Various explanations 
were provided to as to why GPs and pharmacists believe residents were taking inappropriate 
medicines, and these will be explored throughout this chapter. 
Pharmacists and GPs reported a good knowledge of medicines, and all felt that there were 
few areas where their knowledge of deprescribing could be improved.  However, medicines 
for mental health conditions, such as dementia and depression, were identified as medicines 
which present a challenge when deprescribing.  Pharmacists felt deprescribing these 
medicines fell outside their competence, and admitted that they would not deprescribe them 
if they were in doubt.  Lacking knowledge of a medicine appeared to affect the healthcare 
professional’s confidence to deprescribe that medicine, and in turn lead to medicines that 
may be deprescribed being continued.  GPs were more comfortable with these medicines, 
though GP4 did report that a lack of knowledge about medicines for dementia was a barrier 
to them stopping such medicines.   
GP4: With all the donepezil and the dementia meds, I don’t know how long we 
should be even…if we should be stopping them if it’s appropriate. I really don’t 
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know what the guidelines are or what the evidence is for these medications. In 
severely demented, unwell, frail people, I don’t know whether we should be 
carrying on or not. So, it’s just the knowledge really, I don’t have the knowledge 
as to whether they should keep going. The easiest thing is just to keep them on 
it.  
Care home staff were reported by some participants in all groups (GPs, care home staff, 
pharmacists, residents and relatives) to have insufficient knowledge to advise on medicines.  
This included answering the questions of residents and relatives about medicines, and 
suggesting medicine changes to healthcare professionals.  Care home staff interact with the 
resident the most out of any group interviewed and, as reported by healthcare professionals, 
relatives and care home staff, are relied upon to notice and report changes in the resident’s 
condition and behaviour which may be due to their medicines.  A few care home staff 
suggested they would be interested in receiving training about medicines to enable them to 
assist with the deprescribing process. 
Interviewer:  Is there anything that you feel that you would need to help you 
suggest medicines would be stopped? 
CHS1:  I am all for stopping medication.  So, I’d probably want more knowledge 
about side-effects and things and I suppose it would be good then, because 
they’re probably more likely to speak to us about how they feel than a doctor 
because a doctor doesn’t see them every day. 
Some healthcare professionals expressed frustration that care home staff were not more 
knowledgeable about medicines, speculating that if they were, they would be able to 
facilitate deprescribing.  GPs reported the impact of the high turnover of care home staff, and 
that this prevented training being conducted and disseminated.   
Interviewer: Do you feel you have any other barriers that we haven't spoken 
about? 
GP2:I do think the ongoing support and training on a whole host of matters to the 
care staff is hugely helpful, because they have quite a high…they often have a 
high turnover and education is supplied, doesn't always get disseminated as 
widely as it can do, and that's a shame.   
Despite acknowledging their knowledge deficits, GPs and pharmacists did not always feel 
they would benefit from training.  Whilst GPs and pharmacists commented variations of 
“there are always areas where knowledge can be improved”, it was not always felt that 
training would be the best way to meet these knowledge deficits.  Those GPs and 
pharmacists who discussed training fell into three groups which are summarised in Table 31.  
The first group did not express a strong view about how training may assist them to 
deprescribe.  They may have identified some training needs, but would prefer to work with 
others to complement their skills rather than attend training to improve their own skills.  The 
second group identified training needs and stated that training in these areas would help 
them, while the final group explicitly stated that they did not think they would benefit from 
training even if they identified knowledge or skill deficiencies.
140 
 
 
 
Table 31: GPs’ and pharmacists’ beliefs about their training needs and the benefits of 
training 
Opinion on training  How this was demonstrated 
Neutral about training  These participants spoke about where their 
training lacked, but did not explicitly state that they 
would benefit from training in the identified area.  
They stated that instead, they would work within 
their competencies and involve others to 
complement their skills. 
Identified training  Training needs identified were training around 
risks and benefits of medicines (GP5), 
therapeutics, medicines that are safe to stop and 
consultation skills (Pharm1), mental health and 
dementia (Pharm2)  
Did not think they would benefit from 
training 
Some GPs and pharmacists stated explicitly that 
they would not benefit from training.  Reasons 
provided for this include that it would not be a good 
use of their time (GP3), that they are the trainer at 
deprescribing sessions rather than the trainee 
(Pharm5) and that they did not learn anything new 
at training sessions (Pharm6). 
Time and staffing were barriers to training highlighted by GPs and pharmacists.  Care home 
staff, GPs and pharmacists reported that their knowledge about medicines and deprescribing 
came from experience, rather than from dedicated education or training.  Some care home 
staff, such as those who were registered nurses or those who had many years of 
experience, reported being more knowledgeable about medicines, and more able to assist 
with medicine queries.   
Interviewer:  You are comfortable answering their questions with the knowledge 
of the drugs and stuff and things they want to know? 
CHS3:  Yeah, yes.  To be fair, if I haven’t got that knowledge after forty years I 
shouldn’t be here. 
Interviewer:  And do you feel that you need anything to help you with the process 
of stopping medicines in care homes?  So, I don’t know, any extra skills or 
knowledge or anything that would help you out? 
CHS3:  I don’t think so.  I think a lot of it is knowledge that you have got over the 
years and, you know, if like we are here, giving drugs all the time, it’s, you know, 
you know what they are for, you know why you are giving them and you can see 
why your patient may or may not need to continue with them all the time. 
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GPs and pharmacists identified difficulties and knowledge deficits when stopping medicines 
and understanding the consequences of this.  Healthcare professionals were clear that more 
guidance and evidence for deprescribing in complex, multi-morbid older people would 
support them in this area of practice.  As demonstrated by the quote below, the lack of this 
guidance can lead to difficulties when deprescribing.  Healthcare professionals reported that 
it is not clear what medicines can be deprescribed or how deprescribing should occur, for 
example whether medicines need withdrawing slowly or can be stopped abruptly.  However, 
this was not identified as a personal knowledge deficit, but rather a systematic problem 
related to a lack of available information which was outside the control of the healthcare 
professional. 
Interviewer: Would it help if there was more research?  
GP5: I think if there was more guidelines for GPs to follow, that would be useful.  
’Cause at the moment…that’s not very common.  Most guidelines seem to be 
very single disease.  Or individual rather than combinations of disease which a 
lot of care home residents have, so knowing which [medicines] are likely to be 
causing harm and getting less benefit from becomes a little more complicated, I 
think in those situations. 
In addition to the lack of guidance, participants also reported a lack of evidence about the 
benefit of medicines in this population.  This was especially evident with preventative 
medicines, for example statins which lower cholesterol. The evidence base required to assist 
healthcare professionals with deprescribing decision-making in this population often does 
not exist.  Participants described having to weigh up multiple unclear factors when stopping 
a medicine, such as the resident’s life expectancy, the goals of treatment, the resident’s 
beliefs and the limited evidence for continuing the medicines.  This lack of evidence 
impacted on a prescriber’s confidence to deprescribe.   
Interviewer: Are there any other concerns that people have when you suggest 
stopping some medicines? 
GP6: If you take sort of preventative medicine for example, there's concerns…if I 
stop a statin does this mean [the patient is] going to have a stroke.  It's in some 
ways trying to explain [to residents and relatives] that even people on statins 
have strokes and it's weighing up those benefits of being on it long-term with the 
potential side effects or adverse effects versus the benefits in the longer term.  
When you've got patients who are much older, then there's not so much 
evidence about the effects and benefits in those patients.   
There were also several beliefs reported about the consequences of stopping medicines, 
both positive and negative.  These were beliefs held by participants and which were 
considered to affect deprescribing decisions. This is explored further below. 
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4.2.3 “If the doctor stops them I’m not worried about it really, I’m in his 
hands”: Beliefs about consequences 
GPs, pharmacists and care home staff were aware of positive and negative consequences 
of deprescribing. Though GPs and pharmacists expressed fear about some of these 
consequences, they often believed that they were potentially less harmful than continuing 
the medicine.  Positive consequences of deprescribing were described by GPs and 
pharmacists as the resident becoming “brighter”, in part due to the reduction of medicines 
with a sedative effect.  In this way, deprescribing may improve the quality of life of the 
resident.  The reduced medicines burden was also noted to benefit care home staff, who 
manage the resident’s medicines. 
Interviewer:   
Is there any sort of positive consequences that you could…? 
Pharm1:  Yeah, people wake up sometimes when you stop all that stuff.  They 
have a better quality of life, if you can reduce the sedatives, reduce the drugs 
that are constipating them et cetera, then you do see people perk up.    But 
there’s definite positive benefits of stopping stuff, in terms of quality of life for 
some of these individuals. 
The most common negative consequences raised amongst participants (GPs, pharmacists, 
care home staff, relatives and residents) were concern of the resident deteriorating, 
experiencing withdrawal effects or recurrence of the condition the medicine was prescribed 
for. For some healthcare professionals, a fear of litigation resulting from a deprescribing 
decision was raised.  Concern about the negative consequences of deprescribing could be 
mitigated for some, by involving multiple people in the decision to stop a medicine. 
Interviewer:  What do you think  the potential consequences of deprescribing for 
a care home resident might be? 
Pharm1:  Well, harm, I guess.  That they could end up having an event that 
might have not happened if they’d stayed on the medicine.  So some of those 
could be serious, couldn’t they.  So you stop the statin and they have a stroke, 
which probably would be a coincidence but would be attributed to you stopping 
the statin.  That’s why I would definitely want to involve as many people as 
possible in the decision. 
On the other hand, residents were unconcerned about the potential consequences of 
stopping medicines, even when prompted to consider what those consequences might be, 
for example side effects.  While some wished to avoid negative consequences, fear of them 
did not make residents resistant to the idea of deprescribing.  Indeed, residents relied on 
those caring for them to make decisions in their best interest.  
Interviewer: If your doctor suggested stopping some medicines, is there anything 
you’d be worried about?  
Resident 1: No not really. If the doctor stops them I’m not worried about it really 
I’m in his hands, if he stops them he stops them.  I’m not worried about it. 
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Relatives, however, reported more concerns about stopping medicines, including 
consequences for the resident and for themselves.  This meant relatives were more 
challenging of the prescriber’s suggestions than residents were, and they may act as more 
of a barrier to deprescribing than residents.  Relative 1 rationalised that, because 
deprescribing decisions can impact the relative as well as the resident, the relative should be 
involved in making these decisions.  
Interviewer: Would you need any support if it was suggested that your mum 
stopped taking a medicine? 
Relative 1: As she has stopped some medication recently, the amitriptyline, she 
now requires more intensive support in the home.  She’s got care staff that are 
watching her more closely ‘cause she’s saying things like she wishes she was 
dead and she’s tried on occasions, she’s quite disabled, and she’s tried on 
occasions to get out of her chair recently.  The effect that has on me is obviously 
distressing for me too. 
Generally, however, relatives were supportive of stopping inappropriate medicines if they 
were consulted, and they were satisfied with the prescriber’s reasoning and approach.   
Interviewer: OK, so if the Dr suggested stopping some of her medicines that they 
felt weren’t useful to her anymore, how would that make you feel?   
Relative 3: Well I suppose I’d want to talk about it and make sure, you know that 
I knew what the risks were but, you know I tend to think that, as I say I have a 
good relationship with the GP that she sees. Provided I’d had a conversation and 
I was confident that he was recommending things with the right kind of 
motivation, I’d be fine with that. 
4.2.4 Theme summary 
In summary, this theme examines the roles and responsibilities, knowledge and beliefs of 
the individuals involved in the deprescribing process. The GP was acknowledged as the 
person who is responsible for deprescribing, with pharmacists having an emerging role that 
is not always understood by residents and relatives.  Residents have the least clearly 
defined role in deprescribing, and often the least involvement into the cessation of their own 
medicines.  Residents generally lacked knowledge of their medicines but believed that all 
their medicines were necessary. However, pharmacists and GPs acknowledged that this 
was not always the case and that some medicines were inappropriate.  GPs and 
pharmacists did not place great emphasis on their knowledge deficits being a barrier to 
deprescribing, which suggests that they believe other factors act as larger barriers to the 
process.  Finally, beliefs about negative consequences held by all individuals involved in the 
process can act as a barrier to deprescribing. 
These findings provide an important foundation for the second theme, which will bring these 
individuals together and examine how they work together when deprescribing.   
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4.3 Perceptions of others and difficult conversations: social 
barriers and facilitators to deprescribing in care homes 
Many of the reported barriers to deprescribing were social in their nature.  These social 
barriers were based on perceptions and attitudes held by and towards those involved, which 
affected their relationships and ultimately impacted their prescribing and deprescribing 
behaviours.  Relationships exist between each individual involved in deprescribing and are 
influenced by experiences, perceptions and attitudes that people have about each other.  
This theme explores these barriers and facilitators under four subthemes:   
1. “I’d probably feel secretly, well there must be some reason, but I respect him so I 
would take what he said”: Care home residents and their relationships with those 
caring for them 
2. “This is a, sort of, awkward one, but I haven’t actually spoken to [the relatives]: 
Involving the relatives: a complex relationship 
3. “I find, if I’m very complimentary of the doctor when he comes in, that seems to 
change the doctor’s mood, they can be happier”: Attitudes towards pharmacists and 
GPs  
4. “They feel that I’m giving up on their relative because I’m stopping meds”: Talking 
about the future benefit of medicines 
Relationships between key stakeholders in deprescribing are crucial when trying to 
understand this process.  The first social barrier to deprescribing to be explored will be the 
relationships that residents form with those caring for them, including GPs and care home 
staff.   
4.3.1 “I’d probably feel secretly, well there must be some reason, but I 
respect him so I would take what he said”: Care home residents 
and their relationships with those caring for them 
Residents and, to a lesser extent, relatives displayed a large amount of faith in the actions of 
the GP and trusted them to manage the resident’s medicines, often with little involvement of 
the residents and relatives. 
The amount of trust placed in GPs by residents, and by some relatives, with regard to 
medicines and the review of these is important.  While relatives had more concerns about 
the medicines taken by the resident and were more willing to challenge the prescriber about 
their decisions, they still trusted the GP to act in the best interests of the resident.  With 
residents, their trust of the GP ran deeper as they did not tend to challenge healthcare 
professionals, nor did they have a good knowledge of their medicines.  They believed that 
the GP knew the medicines they took, and that the GP had ensured they were all 
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appropriate and suitable for the resident to take.  However, as identified in section 4.2.2, 
GPs and pharmacists acknowledged an awareness that many medicines prescribed for Care 
Home residents are inappropriate.  It was generally acknowledged that residents believed 
that healthcare professionals were acting in their best interests, and would therefore agree 
with their suggestions. 
Interviewer: So if the doctor suggested it would you be worried about your 
condition getting worse? 
Resident 4: I’d have faith in my doctor. 
 
Interviewer: how do you think your mum would feel if one of the doctors 
suggested stopping one of her medicines?  
Relative 3: I think she’d be completely fine with that, so I think she assumes that 
they’re doing their best.  Though she thinks a lot of it is a bit pointless because 
she thinks that she’s 87 and she’s not really, by her way of thinking, having a 
useful life.  So I think she would just go along with whatever anybody suggested  
This trust could be a facilitator to deprescribing, as residents and relatives were likely to 
accept whatever the GP suggested without question, allowing for changes to their medicines 
to be made.  However, healthcare professionals viewed this level of trust by residents and 
relatives as lacking interest in medicines, which in turn meant they may not be interested in 
the deprescribing process.   
Interviewer: Do you feel that the residents themselves or their relatives have a 
part in deprescribing? 
GP3: Yes, I think that would be great, if they did show interest.  I'm not sure that 
there is…the cohort that we look after, I'm not sure that there is enough 
awareness within that group and our population aren't hugely self-empowered. 
Another factor in the relationship between residents and their GP was that the GP was often 
viewed as an authority figure to be obeyed, rather than someone with whom to engage in 
decision-making.  Residents also perceived the same relationship with care home staff.  This 
may be a reason why residents took their medicine without questioning it, as it was 
prescribed and provided for them by people they viewed as authority figures that they were 
unwilling to challenge.  It also may explain why some residents were unlikely to challenge 
deprescribing decisions even if they did not agree with them.  For example, Resident 9 
spoke knowledgably and confidently about her medicines, but she was uncomfortable with 
criticising GPs and would not challenge their decisions, even if she disagreed with them.  
While this lack of resistance may be a facilitator to deprescribing, residents may be unsure 
or disappointed by a deprescribing decision, despite reporting otherwise. 
Interviewer: Would you feel anything about stopping a medicine?  Would you feel 
happy, or sad or anything? 
Resident 9: I would feel resigned. 
Interviewer: OK, that’s a good word. 
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Resident 9: I mean these Fultium [vitamin D supplement] they— if my sister had 
been on this sort of thing she wouldn’t be as bad as— I think I’ve been kept on 
the edge of bone problems so I would feel resigned, but- and I’d probably feel 
secretly, well there must be some reason, but I respect him so I would take what 
he said. 
However, not all residents displayed this trust in their GPs decisions or in their medicines. 
Resident 11 disagreed with some decisions made by her doctor, and therefore did not 
readily trust their opinion.  She had also lost some trust in him due to an incident she 
experienced while living in the care home.  Resident 11 had seen some information about 
blood tests for depression on the television, and mentioned it to a nurse who in turn told the 
doctor who came to talk to her about it.  This quote highlights the importance of good 
relationships between the GP and the resident - where the resident trusts that the GP is 
acting in their best interests and is comfortable to raise concerns and challenge decisions - 
as key to the deprescribing process. 
Resident 11: I’m not very happy with the doctor that comes here every [week]. 
Interviewer: Oh, are you not?  Why is that?  
Resident 11: [The doctor came] and he stood in the doorway, he let me in and I 
hadn’t even sat down, he said [imitates a man’s voice]: “there’s no such thing as 
a blood test for depression”.  And then he sits over there and I said: “well, I saw it 
on the television”.  And he said: “well I’m a busy doctor, I haven’t got time to 
watch the television.” 
Interviewer: So have you ever talked to the doctor about your medicines? 
Resident 11:  Not this doctor.  I say, I’ve mentioned it when it’s been on the telly 
and he pooh-poohs it so…I haven’t been bothered with him. 
A further barrier to deprescribing was that residents were perceived by one GP as unwilling 
to change, and one relative thought that change was unsuitable for the resident.  This 
deterred some relatives and healthcare professionals from embarking upon the 
deprescribing process.  While some residents did indeed display a degree of resistance to 
change, all residents portrayed a willingness to agree with the doctor if medicine changes 
were suggested.  This demonstrates an incongruity in the perceptions held of residents, and 
how the residents feel in reality. 
Interviewer: So just thinking maybe about her antidepressant, in the future [if] 
you thought she could maybe do without it, what would you do about that? 
Relative 3: I don’t really know. I mean, given her age I don’t know if I’d want to 
interfere at this stage because as I say, she’s 87, so I think in some ways, having 
routine is better for her than having a lot of changes to manage.  
This perception of a resident being unwilling to change was the only perception of residents 
discussed by relatives, with regard to deprescribing.  Relatives were otherwise largely keen 
for the resident and themselves to be consulted as part of the deprescribing process.  The 
next subtheme examines the complex relationship between relatives and those caring for the 
resident, including GPs, pharmacists and care home staff.
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4.3.2 “This is a, sort of, awkward one, but I haven’t actually spoken to 
[the relatives]: Involving the relatives: a complex relationship 
When considering the relationship between the relative and healthcare professionals and 
care home staff, it is necessary to understand how some relatives were perceived by these 
stakeholders.  The complicated relationship between relatives and the GPs, pharmacists and 
care home staff caring for the resident meant that relatives were not routinely involved in 
deprescribing decisions.  The involvement of relatives was often viewed as a barrier to 
deprescribing by GPs, pharmacists and care home staff, and not just for logistical reasons 
such as their relative lack of unavailability.  GPs, pharmacists and care home staff preferred 
relatives to be supportive of deprescribing, and content to let staff act in the best interests of 
the resident.  Relatives who question decisions or request more information were described 
as “actively involved” which was a negative description of a relative’s involvement.   
“Actively involved” relatives were described as unreceptive to the idea of deprescribing, 
instead perhaps being challenging of the prescriber’s decisions or wanting full, active care 
for the resident, which may not be appropriate given the resident’s condition and stage of 
life.  It is not clear whether the label of “actively involved” would extend to the other relatives 
interviewed for this study, who understood the limits of the care that was appropriate for the 
resident but were not afraid to challenge the GP’s prescribing decisions and wanted active 
involvement in the resident’s care.  It was perceived that “actively involved” relatives led to 
difficult discussions for the healthcare professionals, and meant that they sometimes 
avoided speaking to the relatives, or deprescribing for the resident at all.  This suggests that 
healthcare professionals wish for relatives to be compliant with their decisions, which is not 
demonstrative of a balanced relationship. 
Interviewer: Is it the same with the relatives [that they agree with deprescribing], 
if you do get a chance to speak to those, do you think? 
Pharm2: Again, I’ve been…this is a, sort of, awkward one, but I haven’t actually 
spoken to [them]…just feedback from the care home staff with particular patients 
where they would really, benefit from de-prescribing, some of the relatives are 
really actively involved that they want the patient to have this, and they think the 
patient should be on that, when it’s probably not particularly right for the patient.  
But because they cause that much of a fuss that the care home…and again with 
the GPs, as well, you know; so sometimes they tend to…we tend to, maybe, just 
back off a bit when maybe we should just get involved. 
Healthcare professionals had differing opinions on whether relatives acted as a facilitator to 
deprescribing.  Some indicated that they could facilitate the process and described being 
approached by relatives asking for medicines to be deprescribed.  However, some GPs and 
pharmacists were cautious of deprescribing requests from relatives as they were suspicious 
of the relative’s motives, sometimes suspecting the potential for sinister intent.  This turns a 
potential facilitator to deprescribing into a barrier, depending on the people involved and the 
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healthcare professional’s perceptions, and adds a layer of complexity to the 
relative/healthcare professional relationship. 
Interviewer:  Are there any scenarios where you might decide not to proceed with 
de-prescribing for a resident? 
GP5:  I’ve had conversations with some relatives who – for a patient who wasn’t 
able to have that conversation themselves, where the relatives just want 
everything stopping – and I’ve been a little bit uncertain about the motive to just 
stop everything.  I mean, I would certainly review things and see if there was 
anything not needed, but I’ve had a couple where I’ve been rather concerned, 
and quite often that concern comes from the care home staff…’cause they often 
see what’s happening to resident and relatives coming to visit and things.   
Conversely, other GPs stated that relatives were barriers, as they had experienced more 
resistance from relatives about deprescribing than they had requests to deprescribe.  For 
example, they may have to dispel accusations of deprescribing being a cost saving exercise 
or that they were “giving up” on the resident.  Indeed, relative 2 explained that he was initially 
sceptical of deprescribing, but the ongoing investment of the GP into his father’s care had 
reassured him that this was not the case.  
Interviewer: how would you feel if the doctor suggested stopping some 
medicines that they felt weren’t useful to them anymore? 
Relative 2: I was nervous when he wanted to stop the Madopar.  ‘Cause I 
thought: “this guy just wants to save his drug budget”.  I thought that this must be 
some CCG campaign and nursing homes are an easy target.  So I didn’t say no, 
but I was wary.  But I don’t believe that was the case.  I believe my GP had the 
best interests of my dad.   
The relationship between GPs and relatives could also be damaged by perceptions such as 
those held by Relative 1, who perceived that care home residents were not often a priority 
for GPs, due to their advanced age and living situation.  Relative 1 praised the resident’s 
new GP as they appeared to be making more of an effort to treat the resident than past GPs 
had.  This view may arise as a result of not being involved in decision-making by the GP, or 
be due to the way that GPs act towards residents and relatives.  It could cause further rifts in 
the relationship and deepen the barriers to deprescribing that already exist.   
Interviewer: Yeah, and it would have been good for you to [voice your opinion 
about stopping a medicine] for her as well.   
Relative 1: The problem is that, in the care setting, on an elderly ward and a 70 
year old [the age of his mother] goes into a care home, and a lot of people 
around her are, say, the average age of 90, then people all get treated the same 
and doctors and nurses and specialists sometimes just make decisions for 
people rather than involving them. 
The perceptions and relationships explored under this subtheme demonstrate that the 
relationship between relatives and healthcare professionals is multifaceted, and complicated 
by the attitudes and perceptions that each group held of each other.  These attitudes and 
perceptions were based upon the actions and behaviours of a small subset of each group, 
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which were then generalised to the rest of the population.  As a result, relatives are prone to 
being excluded from deprescribing decisions by healthcare professionals.  Whilst it must be 
stated that relatives were not always excluded, and their views were considered by 
healthcare professionals, they were not often involved by healthcare professionals.   
4.3.3  “I find, if I’m very complimentary of the doctor when he comes in, 
that seems to change the doctor’s mood, they can be happier”: 
Attitudes towards pharmacists and GPs 
The attitudes held by some residents and relatives towards pharmacists require exploration, 
especially if pharmacists are to become more involved in the deprescribing process.  Some 
residents and one relative believed that pharmacists lacked the knowledge and skills to be 
involved in deprescribing, perhaps because they were not familiar with the abilities and roles 
of pharmacists outside of a community pharmacy.  For some interviewed, this extended to a 
belief that pharmacists would lack the knowledge needed about the resident to make 
deprescribing recommendations.  This could be a barrier to pharmacists being involved in 
deprescribing, as some residents may not wish to work with the pharmacist and the 
pharmacist may need time to earn the resident’s trust. 
Interviewer: So we have different people working in nursing homes now with the 
medicines, so pharmacists and nurses are often reviewing medicines and things 
as well now, so how would you feel if they suggested stopping a medicine that 
they felt weren’t useful to you anymore? 
Resident 9: No, I don’t think with the medicines I take, I don’t think the 
pharmacist would really have the authority, or the knowledge, the information 
about me to suggest not taking them.  Unless there was something he thought 
was better.  
Some pharmacists interviewed described experiencing such attitudes, but stated that once 
they had explained their role to the resident or relative and reassured them that the 
medicines review was being done in partnership with the doctor that they were usually happy 
to proceed.  
Interviewer:  have you ever had any issues, particularly with the resident or the 
relative sort of because you're a pharmacist and not a doctor? 
Pharm6: I think that you do get people saying the doctor has told me I've got to 
be on this forever.  The doctor reviews my medicines.  So, there’s definitely 
some conversations sometimes needed around that in terms of doctor so and so 
asked me to come and I'm working with them and anything I talk about will be 
discussed with them.   
However, pharmacists instead often did background work, conducting medicine reviews and 
making recommendations to the GP.  They did not routinely interact with residents and 
relatives, and so did not have an opportunity to explain their role.  This is also problematic 
because residents and relatives wish to at least be informed of deprescribing decisions, and 
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pharmacists do not appear to be doing this routinely.  This could further distance 
pharmacists from residents and relatives, and contribute to poor understanding of their role.   
A final relationship to be examined is the relationship between GPs and care home staff.  
Some care home staff described problems with the attitude of the GP, in addition to logistical 
challenges with accessing them.  While it was clear that the majority of GPs were helpful and 
respected, some GPs were reported by care home staff to be difficult to work with.  The 
tactics employed by CHS1, described below, may be surprising, as it seems illogical to have 
to go to such lengths in order to engage the GP in the care of their own patient.  Such GPs 
and experiences with GPs may act as a barrier to deprescribing, because care home staff 
might be reluctant to contact a GP who is perceived as difficult.  The GP may also be 
dismissive of care home staff and unwilling to engage in the deprescribing process, further 
affecting the relationship between the two groups. 
Interviewer: Yes, I think that’s something I’m finding, is that care home residents, 
they want to be involved in these decisions but they’re not being involved. 
CHS1:  So, while [residents are living at the home], we can use three GP 
services round here.  So, when they come, one doctor can be really nice and be 
involved with the client and chat to them, other doctors are not as involved.  I 
encourage them to be involved because that’s the patient, it’s not me. 
I always ask the client if I can go in with them, but I would encourage the doctor 
to talk to them and often you have to do that.  Some you’ve got to direct them, 
they might say to me, “how’s she sleeping?”  I’ll say, “shall we ask her?  She’s 
sat here.  Are you sleeping well?”  Or I find, if I’m very complimentary of the 
doctor when he comes in, if I say to the client, this is Doctor so and so, he’s a 
really nice doctor and he’ll do all he can for you, that seems to change the 
doctor’s mood, they can be happier.  Or Doctor, you’re looking very nice today, 
this is so and so, looking forward to seeing you and then he probably thinks, oh 
god, they’re saying I’m right nice, so I best be nice.  It does work. 
Interviewer: You’re really having to…? 
CHS1: Yes, but all I want is for that person to think, oh I’ve seen the doctor, I feel 
reassured, I feel better, because that’s what I want if I ever go.   
The final subtheme examines the future of the resident’s medicines.  The future benefit of a 
resident’s medicines is linked with the resident’s life expectancy, which is a difficult topic for 
residents, relatives and those involved in their care to discuss. 
4.3.4 “They feel that I’m giving up on their relative because I’m stopping 
meds”: Talking about the future benefit of medicines 
A reason that participants in all groups found it difficult to discuss stopping medicines for 
care home residents was that it involves discussion of the future, and acknowledgment of 
the fact that, due to the resident’s advanced age, they were entering the last stage of their 
life.  This may last for months or years, and could include declining health and further 
difficulties that the resident and their family would have to face.  While healthcare 
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professionals believed that consideration of the resident’s limited life expectancy was 
entwined in deprescribing decision-making, residents and relatives were reluctant to 
consider this.  This demonstrates a further social factor in addition to the already layered and 
complex relationships that exist, and lead to difficult discussions that both parties wished to 
avoid. 
Healthcare professionals perceived residents to be in the later stages of their lives, and 
understood that this meant that some medicines may be of limited benefit and suitable for 
deprescribing.  This does not mean that healthcare professionals thought that residents’ 
medicines should be stopped because they have a limited life expectancy, but rather that life 
expectancy and quality versus quantity of life were factors when considering the future risk 
and benefit of medicines in these patients.   This means that healthcare professionals and 
residents and relatives may have different goals of care, and the reluctance to discuss this 
may lead to misunderstandings between the GP and residents/relatives and reinforce the 
perceptions that each group has of each other.   The quote below from a GP interview 
highlights this: 
Interviewer: What makes the decision [to deprescribe] hard to make? 
GP4: Other things that may stop me, or make me think about it…oh, not fear of 
litigation, but you know…[I] think will the families complain or will there be some 
problem if I stop this? In the past I’ve had discussions with families about 
stopping medication and it can be quite difficult if they don’t really understand the 
reasons why I’m stopping the medication. They feel that I’m giving up on their 
relative because I’m stopping meds, so it can be quite a long discussion to 
explain why I’m stopping them. So, sometimes that actually is a barrier to me 
stopping the medication.  
While healthcare professionals spoke of life expectancy without prompt when discussing 
deprescribing in care homes, residents did not acknowledge or understand the link between 
the two.  When prompted, all residents but one were unable or unwilling to consider a future 
where they might be more unwell and how this may affect their views about their medicines.  
Relatives generally had a pragmatic approach, understanding that the resident was elderly 
and frail and that this may affect prescribing decisions, but only one, Relative 3, had 
considered how this may impact the resident’s treatment in the future.  Relative 3 spoke of 
the living will that the resident had made a number of years ago, which guided the relative’s 
decision-making at difficult times. 
Interviewer: And is it difficult having to make those decisions [about stopping 
medicines] and considering her wishes and your wishes and things like that? 
Relative 3:  One if the things that happened when she was taken ill was that we 
discovered she’d made a living will…but I think we’re both very committed to 
make sure that she is comfortable as she can be and we certainly don’t want her 
to suffer any kind of discomfort if she doesn’t have to suffer…I think the 
medication is part of that. 
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However, many healthcare professionals and some care home staff felt discussing life 
expectancy was an intrinsic part of the deprescribing process in care homes.  Of these, 
some participants believed that improved end of life planning and more confident 
communication about goals of care would facilitate the deprescribing process.   
Interviewer:  Do you feel it [your nursing training] gives you anymore of an edge 
over people who might not have that qualification? 
CHS3:  Possibly, but I think also it’s a confidence thing.  Some people find it 
difficult to have conversations about things that are a little bit difficult, end of life 
type decisions, do not resuscitate decisions.  [But] my take is the more 
everybody knows, the better treatment people get.  If things are hidden and you 
can’t talk about them, then, you know, you don’t always get the best treatment. 
4.3.5 Theme summary 
In summary, this theme brings together the individuals whose roles, knowledge and beliefs 
were explored in the first theme.  This allows for exploration of the social barriers to 
deprescribing, which exist due to interactions between individuals.  There are numerous 
social barriers and facilitators to deprescribing which are built on perceptions, beliefs and 
unspoken thoughts about other individuals involved in the process.  The avoidance of 
difficult conversations, the negative perception of relatives who wish to be involved in the 
resident’s care and the trust that residents in particular place in their GP are examples of 
these social barriers. 
The final theme, presented below, provides the setting for these interactions and examines 
the barriers and facilitators presented by the health and social care systems in which care 
homes operate. 
4.4 Working together, navigating systems: Logistical barriers and 
facilitators to deprescribing in care homes 
This theme examines the logistical barriers to deprescribing.  These are barriers to 
deprescribing attributed to challenges navigating healthcare systems, lack of resources and 
physical barriers to communication such as the resident being unable to communicate.  
These are explored under the following three subthemes: 
1. “If that funding goes, then, I [GP] won’t be going in on a regular basis and I think that 
will be a shame”: Healthcare systems: a barrier to deprescribing? 
2. “There just aren’t enough hours in the day, really”: Access to deprescribing resources 
3. “Most of the care homes that I do, they all have quite a lot of dementia, so they’re not 
really able to discuss the medication as such with me”: Physical barriers and 
facilitators to communication  
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4.4.1 “If that funding goes, then, I [GP] won’t be going in on a regular 
basis and I think that will be a shame”: Healthcare systems: a 
barrier to deprescribing? 
The organisational structure and systems of health and social care can present barriers to 
deprescribing for care home residents.  To understand this further a consideration of how 
GP services are provided to care homes is required.  This includes the fulfilment of QOF 
(which contributes to the payments made to GP practices) and the impact of the CQC, a 
regulatory inspection body, as described in section 1.3.2.1 of the introductory chapter to this 
thesis.  QOF, (Quality and Outcomes Framework) is utilised when remunerating GP 
practices for the services they provide.  The CQC, or Care Quality Commission, is the 
regulator of health and social care providers in England. 
QOF was highlighted by GPs, as unhelpful in this population as it was believed to encourage 
treating to target and prescribing, rather than deprescribing, of medicines.  Many frail, elderly 
people with multiple co-morbidities, such as those who live in care homes, were identified by 
healthcare professionals as unsuitable for treating to the targets stipulated in QOF. In 
addition to irrelevance, the administration work involved with QOF as also considered time 
consuming by healthcare professionals.  Therefore, it was suggested by GPs that this 
particular population (care home residents) should be exempt from QOF.  There was clear 
frustration among GPs of the way QOF works in this population and queries about whether it 
was appropriate.   
Interviewer:  Do things like that [incentivised prescribing] open up a barrier then 
for deprescribing as well?  
GP5: I think because it just means that you automatically think about prescribing 
rather than de-prescribing, there’s nothing on the QOF that says, “do they still 
need this medication?”  “Are they going to get any benefit from it?”  It’s, “are they 
prescribed this?”  But it never prompts you to think about whether or not 
someone’s getting benefit there, it’s always to prescribe more of various things or 
to record a reason why not.  Which actually is more work in some ways.  I don’t 
think they help. 
The CQC was also identified by GPs as making deprescribing in care homes more difficult.  
The inspectors for this regulatory body were criticised for asking care homes to record 
paperwork, such as written confirmation of a medicine being stopped in addition to updated 
prescriptions, which was identified by GPs as an unnecessary increase to their workload.  
GPs understood where the requests originated, and therefore directed frustration at the CQC 
rather than the care homes.   
Interviewer: And how do you find dealing with care home staff about that?  Do 
you find that they facilitate this process or do they have any issues with it? 
GP2: I think there's a lot of process and I think it's important that we are mindful 
of…in the way that we have guidance and regulations and things that we have to 
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follow, so the care homes do, and sometimes that can be challenging over them 
wanting new prescriptions and handwritten letters over things, but it's having an 
understanding that this is what their perception of what they're being asked to do 
by CQC or by their regulating authorities and so that can be a little bit 
challenging.  But I think if you turn it round and recognise the challenges that 
they're facing then we have to do our best to be respectful of their concerns. 
 
A major barrier, perceived by a range of stakeholders including GPs, pharmacists and care 
home staff, was the organisation and provision of GP services to care home residents.  
Multiple GPs often provided care to each care home, rather than one GP covering all 
residents in a single care home. Participants described three approaches of primary care 
provision to care homes, as summarised in Table 32 (below).  Most care homes did not have 
a consistent GP presence.  Instead, residents within the same care home received care from 
different GPs and this was then considered to complicate the communications between care 
home staff, pharmacists and GPs.  This was then reported to limit opportunities for 
deprescribing.   
Table 32: Description of approaches to providing GP/pharmacist care to care homes 
Approach to providing GP/pharmacist 
care to care homes 
Description of approaches to providing 
GP/pharmacist care to care homes 
1. Care home residents keep the GP 
they had before they moved into the 
home 
This was a common, but unpopular way 
amongst care home staff and pharmacists of 
providing GP services to care homes because 
it involves care home staff and pharmacists 
liaising with multiple GP surgeries and GPs in 
order to ensure the resident is seen by a GP 
or that deprescribing recommendations are 
implemented.  This created barriers, as it was 
difficult to identify, contact and involve the 
appropriate person to ensure the resident 
received the best care. 
2. The care home may be serviced by 
more than one GP surgery, but a named 
GP from each surgery took responsibility 
for several residents in the care home 
This was preferred to the system described 
above as it made it easier to contact the 
correct person and provide GP services to the 
resident. 
3. One GP per care home This model sees all residents registered to the 
same GP surgery, where a named GP takes 
responsibility for the care home provision.   
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The first model shown in Table 32 was considered by participants to be the most common 
way that GP services were provided to care homes.  However, it was criticised by those who 
worked within this system, and especially by care home staff.  Dealing with multiple GP 
surgeries was perceived as time consuming, and different surgeries had different methods 
for tasks such as making appointments and requesting medicines.  Therefore, care home 
staff found it difficult and frustrating to locate and speak with the relevant health care 
professional to provide timely and responsive care for residents.  This is summarised by 
Care Home Staff member 7, who liaised with five GP surgeries providing care for the 
residents in their home.  Logistical issues with the resident attending a GP appointment, 
such as those caused by the practice not being able to offer a home visit, also affected the 
residents’ ability to access and consult with a GP. 
Interviewer: So, does everybody here have different GPs? 
CHS7:  We’ve got five surgeries.  
Interviewer: Is it quite difficult getting them here in the first place?  
CHS7:  It can be. Again it’s dependent on the practice: how many GPs are doing 
visits that day. They won’t let us pre-book appointments so if we’ve got 
somebody who has requested a GP we can’t ring and book an appointment like 
you would if you were at home. We’ve got to ring on the day and put them on the 
list to do the acute visits.  Something else that’s started is if we ring, they’re 
asking if they can go to the surgery but logistically for us to have somebody to 
escort somebody to a surgery to sit and wait in an appointment queue isn’t 
possible.  
The third model (Table 32) was reported to be the most desirable way for GP services to be 
provided to a care home, by several health and social care staff   This model saw the same 
GP visit the care home regularly.  Those who worked, or had worked, under similar models 
reported that it made seeking medical advice easier, and improved relationships between 
care home staff, residents, relatives, pharmacists and the GP.  However, it also appeared to 
be unavailable to most participants.  GP4, who provided a weekly service to a single care 
home, explained that it was funded, and should the funding be lost then the service would 
not continue.  Therefore, lack of funding for such services was also a barrier to improving 
provision of GP services, including deprescribing, to care homes. 
Interviewer:  Do you have the resources available to help you reduce the number 
of medicines that care home residents take?  
GP4:  think so. I think it’s quite good.  We’re funded on the care home scheme 
for one session a week with a GP or a nurse, but I’m doing it, because the 
nurses can’t make these medication changes. So, at the moment we’re well 
resourced. How long that funding is going to carry on, I don’t know. The risk is, if 
that funding goes, then that…you know, I won’t be going in on a regular basis 
and I think that will be a shame.  
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4.4.2  “There just aren’t enough hours in the day, really”: Access to 
deprescribing resources 
Understanding how individuals can access resources for deprescribing, including time and 
staff, is essential to the process and the deprescribing behaviours of individuals.  In general, 
pharmacists and GPs believed that deprescribing was not occurring due to factors outside 
their control.  In their opinion, the main barrier to deprescribing was not, for example, a skill 
deficiency but rather the size of their workload and lack of resource, including time and staff.  
Time and staffing resource were the most frequently cited barriers to deprescribing cited by 
GPs and pharmacists. 
GPs often stated that they would be more effective deprescribers if they had more or 
dedicated time to do this work, support from appropriate colleagues and other resources 
such as evidence-based guidance.  They believed that the daily running of their GP practice, 
including holding consultations with patients in person and over the phone and completing 
necessary paperwork, took the majority of their time leaving little or no time for deprescribing 
in care homes.   
Interviewer: What sort of things do you prioritise above going to do the reviews?   
GP1: Well most GP’s have two surgeries a day to do, which can take five to six 
hours.  We then have acute visits, like for instance today, our practice has five 
acute visits to do.  We have lab results, other tasks fly in, out of hours stuff to 
look at, other admin referrals, there just aren’t enough hours in the day, really.  
The process of undertaking medicine reviews alongside the other tasks associated with 
deprescribing, such as liaising with other stakeholders, was described by GPs and 
pharmacists as time consuming.  This meant that GPs simply felt they did not have time to 
conduct medicine reviews, and pharmacists did not have the time to review the medicines of 
all the care home residents in their care. 
Interviewer: Are there any other barriers that we haven’t covered that you can 
think of or...? 
Pharm4: I think the number of people doing it. There’s no way I can do the 
amount of reviews I’m meant to get done in a year, and that almost feels like a 
pressure sometimes that ideally every resident must have a medication review 
every six months.  And there’s no way I’m going to get round every resident in 
[region].  
Rather than being identified as ‘proactive’ or ‘routine’ activity, healthcare professionals 
identified that deprescribing often took place at specific times in a resident’s care.  These 
“deprescribing moments” were examples of reactive deprescribing, where changes in the 
resident’s life prompted a review of their medicines.  Prescribers generally prioritised this 
type of deprescribing over proactive deprescribing, which can be defined as the prescriber 
reviewing medicines and deprescribing without being prompted to by a change in the 
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resident’s condition.  The following table (Table 33) details the deprescribing moments 
identified by GPs and pharmacists. 
Table 33: Deprescribing moments identified by participants in this study 
Deprescribing moment Participants who identified 
the deprescribing moment 
Resident receives a terminal diagnosis Pharm6 
Change in the resident’s condition, for example newly 
identified swallowing difficulties 
GP4, GP5, Pharm2, Pharm6 
Resident is discharged from hospital GP4 
Resident is refusing medicines GP5 
Annual review of the resident’s medicines GP4, GP5 
 
To facilitate deprescribing in care homes, pharmacists and GPs reported that more human 
resource was required, for example appropriately skilled pharmacists and pharmacy 
technicians. These staff would relieve the burden of the current workload and increase the 
amount of care home residents being reviewed.  However, there was perceived to be a lack 
of funding for this and healthcare professionals felt that deprescribing would not improve 
without a fundamental change to healthcare systems, including more staff and a 
redistribution of roles. 
Interviewer: Do you have the resources available to you, to help reduce the 
number of medicines that care home residents take? 
GP1: Well yes, we do because we’ve got [pharmacist].  Without [pharmacist] we 
wouldn’t be doing it. 
Interviewer: Do you think you wouldn’t be doing it as much or at all without 
[pharmacist]’s help? 
GP1: It really wouldn’t happen, no.  It might happen to a certain extent but not to 
the systematic way that it happens now. 
GPs and pharmacists also expressed a desire for more continuity in care home staff, as this 
would facilitate monitoring of residents increase awareness of deprescribing.  A high 
turnover of care home staff was viewed as a barrier to deprescribing as it hindered long term 
efforts to monitor residents whose medicines had been stopped or who required a structured 
approach to deprescribing multiple medicines.  It also diminished the effects of educational 
efforts and awareness of deprescribing.  
Interviewer: Is there anything that interferes with the process for you that we 
haven’t already covered?  
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GP3: I think sometimes it’s the lack of continuity in the care home staff 
themselves, that can be an issue. So, I guess if there was somebody perhaps 
within the care homes who was dedicated as well for it so that they understood it 
better and they could have some training maybe then that would make some 
sense I think. Because if they understood the principles of it within the care home 
so then they could be thinking about it themselves, and I don’t think that they do.  
Healthcare professionals also struggled to access the physical resources they needed to 
undertake a medicine review, such as the resident’s medical records.  The resident’s 
medical records were described as essential for the deprescribing process, however 
participants experienced difficulties in accessing the records, especially if the resident joined 
the GP surgery as a new patient when they moved into the care home.  With residents 
viewed as poor historians the information required to deprescribe, such as indications for 
medicines, may only be present in the records.   
Interviewer: Is that [the resident’s medical history] something that’s quite hard to 
find out then? 
GP4: Yes, very hard.  Because you don’t actually get the patient’s records for 
several months after they’ve been at the home. One time I emailed the past 
practice to find out how long they’d been on this and why were they on various 
things, but I never got anything back. With the way that different computer 
systems are, patients can be in the home for several months with [no] past 
history.  Then they’re just on the medications and they just stay on them.  
Some participants could not access the records while in the care home either, with 
resources such as Wi-Fi internet connections being unreliable or non-existent.  This led to 
difficulties deprescribing while in the home, leading to a duplication of work and a reduction 
in the opportunity for residents to be involved.  It was believed that improved access to such 
vital resources was necessary to increase the probability of deprescribing occurring. 
Interviewer:  Is there anything else you’d like to add? 
Pharm5:  The Wi-Fi in care homes is horrendous, and so is the 3G.  But I really 
do think it’s essential to have access to the records, so you need to be 
documenting it there and then, because it’s just not efficient to do it any other 
way.  But the problem is, when you’ve got a really, really slow or non-existent 
connection, and you, kind of, then have to work around it.  
While access to time, staff and other resources were barriers to deprescribing identified by 
GPs and pharmacists, participants from all groups (GPs, care home staff, pharmacists, 
residents and relatives) identified communication barriers which impacted upon 
deprescribing behaviour.  Communication barriers fell into two groups: social barriers to 
communication, which were discussed in the last theme, and physical barriers, which will be 
discussed in the next theme.
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4.4.3 “Most of the care homes that I do, they all have quite a lot of 
dementia, so they’re not really able to discuss the medication as 
such with me”: Physical barriers and facilitators to communication  
Residents and relatives expressed, to some degree, a desire to be involved in the 
deprescribing process. However, this opportunity was not always provided by healthcare 
professionals and communication difficulties led to delays in the deprescribing process.  The 
physical barriers and facilitators to communication with care home residents and relatives 
are described in this subtheme below. 
It was perceived by GPs and pharmacists that most residents lived with cognitive impairment 
or other communication difficulties which affected their ability to be involved in decision-
making.  For this reason, residents were often not approached when deprescribing was 
occurring, especially by pharmacists.  GPs believed they attempted to involve residents, and 
that it was important to do so even if it was unlikely the resident would be able to be 
involved.  Pharmacists, on the other hand, did not prioritise involving residents as they 
generalised residents as being unable to be involved.   
Interviewer: Do you ever talk to the care home residents or their relatives about 
their medicines? 
Pharm3: Most of the care homes that I do, they all have quite a lot of dementia, 
so they’re not really able to discuss the medication as such with me. So I don’t 
really have much to do with the residents themselves.  
However, residents and relatives expressed a wish for residents to at least be informed of 
prescribing decisions, even if the resident may not be able to take part in the conversation.  
Despite Relative 1 wishing for his mother to be involved in deprescribing decisions, he 
acknowledged that this would be difficult due to her health conditions.   
Interviewer: How do you think your mum would feel about that [stopping a 
medicine], do you think she’d want to be involved in those decision if she could 
be? 
Relative 1: I do, I don’t think she would input a great deal into the conversation, 
but I think she would listen, and she certainly would understand to a point. 
Conversely, care home residents were described by some GPs as a “captive audience”, and 
in this way the care home environment was a facilitator to deprescribing.  Residents were 
perceived to be almost always in the home and therefore available to potentially partake in 
discussions about deprescribing.  In theory, this means it would be easier to involve them in 
deprescribing decisions.  This suggests that the communication barriers described to 
involving residents in deprescribing were not being overcome by the availability of the 
resident, and that other strategies are needed if residents are to be involved in 
deprescribing. 
Interviewer:  So, how do you usually go about reviewing the patients?  
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GP3: And for care homes that’s a lot easier because they’re there; they’re a 
captive audience. For the housebound patients that can be a little bit more 
awkward because although in theory they ought to be housebound they can be 
at the hospital or even [somewhere else].  
Unlike residents, relatives were seldom at the care home at the same time as the person 
reviewing the medicines and may not be easily contactable by telephone.  This was a barrier 
to their involvement in deprescribing decisions.  A GP interviewed also noted that relatives 
could make appointments to discuss the resident, although it is not known whether relatives 
were aware or took advantage of this.  GPs and pharmacists often prioritised the decisions 
that they would involve the relatives in as well, for example they would always involve the 
relative in end of life care decisions but not necessarily in more routine deprescribing 
decisions. 
Interviewer: …would you ever go to them [the relatives] before you were going to 
stop anything…  
GP4: I think if it was just stopping something like maybe a statin or something 
along those lines, probably not, however if I was making the decision to stop 
most of the medications ’cause this is someone reaching end of life, then I would 
be speaking to the family anyway to let them know the change in circumstances.  
So it really depends if it’s something fairly straightforward like a statin in a 99-
year-old or a [inaudible] a bit more stopping everything. 
Similarly, the lack of availability of hospital prescribers, including specialists, and GPs also 
hindered communications necessary to facilitate deprescribing A member of care home staff 
interviewed believed that it was necessary to be assertive to communicate with GPs, as they 
were frequently unavailable.  For GPs, the barrier to deprescribing specialist medicines was 
difficulty communicating with the prescriber, rather than their own lack of knowledge of the 
medicine.  GPs reported that they had difficulty gaining advice from hospital prescribers 
because their communications were unanswered.  One GP noted that the prescriber may 
have to be contacted multiple times to receive an answer, and felt that you had to be 
“bolshie” to receive answers to the questions being asked.   
Interviewer: How do you find accessing specialists, if a medicine's been 
started in the hospital or by a specialist? 
GP2: If we were particularly concerned about something or other, we would 
write to the specialist and say, you've put this on, what was your plan, if it wasn't 
clear in the letters.  That's usually the most effective way of doing it, is to write to 
them. 
Interviewer: And do you tend to get the results that you need by doing that? 
GP2: Most of the time, and if we don't we write back again.  We're a bit 
bolshie.   
4.4.4 Theme summary 
This theme examined the logistical barriers faced by those involved in deprescribing in care 
homes.  The fact that there is no simplified, standard model of providing primary care 
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services to care homes meant that care home staff in particular experienced challenges 
when coordinating the medical care of the resident.  GPs then faced barriers posed by the 
CQC, a regulatory body, and QOF, an incentive-based system involved in the payment of 
GP practices, for the services they provide.  The requirements of these organisations were 
perceived to be time consuming and inappropriate for the care home population.  The most 
frequently cited barrier to deprescribing in care homes was, however, time and staffing 
deficiencies.  GPs required more dedicated care home time, or more pharmacists to manage 
the care home workload.  Pharmacists acknowledged they had the dedicated time to do the 
work, but that their workloads were too large for them to effectively manage; they could not 
review everyone that they needed to review.  Finally, the physical barriers to communication 
between groups involved in deprescribing in care homes were explored, including the mental 
capacity of residents and the unavailability of people whose opinions were required. 
4.5 Summary 
The aim of this chapter was to explain the findings of this study, which were displayed in 
three themes: 
• “There’s more stakeholders than you might have with a regular, average patient”: the 
roles, knowledge and beliefs of the individuals involved in deprescribing in care 
homes 
• Working together, navigating systems: Logistical barriers and facilitators to 
deprescribing in care homes 
• Perceptions of others and difficult conversations: Social barriers and facilitators to 
deprescribing in care homes. 
The first theme first explained that roles and responsibilities of those involved in 
deprescribing, as defined by participants.  It then examined the barriers and facilitators 
attributed to issues at an individual level, such as knowledge deficiencies and how they 
might be overcome and beliefs about the consequences of deprescribing.  However, GPs 
and pharmacists in particular perceived these barriers to be less important than the systemic 
barriers which were discussed in the third theme. 
The second theme bought together the individuals whose roles, knowledge and beliefs were 
explored in the first theme and described how they interact with each other and healthcare 
systems.  A higher priority was assigned by healthcare professionals and care home staff to 
systemic barriers to deprescribing, such as a lack of time and resources and those posed by 
the method of the provision of GP care.  However, perhaps more difficult to overcome will be 
the barriers resulting from the complicated relationships between the individuals involved.  
These relationships, often based on perceptions and assumptions disputed by other 
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interviewees, layer further complications onto a background of accounts of disjointed and 
under-resourced care.   
At the centre of care and treatment decision-making is the care home resident, who is 
unsure about the concept of deprescribing, trusts those caring for them and does not have 
much knowledge about their medicines.  They seem unaware of the issues faced by their 
relatives, GPs, pharmacists and care home staff who are striving to ensure that all their 
medicines are safe and effective. 
The next chapter takes these findings and maps them to the Theoretical Domains 
Framework (TDF) and Behaviour Change Wheel (BCW) in order to identify potential 
components of a deprescribing behaviour intervention for use in care homes. 
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Chapter 5 Identifying behaviour change techniques to inform 
components of a deprescribing intervention 
5.1 Introduction 
A narrative of the qualitative findings was presented in Chapter 4, and in this chapter the 
findings are taken and mapped to the Theoretical Domains Framework (TDF) and Behaviour 
Change Wheel (BCW) (Cane et al, 2012; Michie et al, 2011).  This allowed identification of 
behaviour change techniques which may comprise a future behaviour change intervention 
for use in care homes.  Firstly, the methods employed are described, including the rationale 
for the mapping process.  This is followed by the mapping, which follows the steps outlined 
by Michie et al (2014).  The barriers extracted from the empirical work were firstly mapped to 
the Theoretical Domains Framework, as were the findings of the literature review were in 
Chapter 2.6.3.  These mapped barriers, from both the findings of the empirical interview data 
and the empirical literature review, were then mapped to the Behaviour Change Wheel to 
identify intervention functions, policy categories and behaviour change techniques which 
could be employed as part of a novel intervention to facilitate deprescribing in care homes.   
5.2 Methodology and methods 
Before embarking on the study, it may have seemed self-evident what would facilitate 
deprescribing in care homes: more time, training, more resources, more staff.  This raises 
the question: why was it necessary to conduct this study, and to investigate behaviour 
change techniques? 
Whilst it is true that these findings were reflected in both the findings of the empirical 
interview data and the literature review, a key strength of this study was that more barriers to 
deprescribing, plus more unique barriers to the care home context were also identified.  An 
example of these were the social influences, such as the perceptions participants held of 
each other, which were found to have a strong influence on deprescribing behaviour.  These 
social influences would still be present and would influence deprescribing behaviour even if 
prescribers had more funding and staff.  Training may also seem an obvious potential 
solution to deprescribing in care homes, but the findings of the empirical study revealed that 
not all healthcare professionals believed this to be true.   
Without the insight and detail described in the findings of this study (Chapter 4), any 
intervention based upon initial preconceptions of the barriers to deprescribing in care homes 
may be less likely to succeed.  This is because deprescribing is a complex behaviour, which 
will not be changed with a simple intervention.  The findings of the empirical work provided 
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the depth required to design a meaningful, useful deprescribing intervention, and the use of 
the TDF, COM-B and BCW will ensure that the intervention is rooted in theory. 
Behaviour change interventions rooted in theory which are systematically designed have 
been found to be likely to be successful (Medical Research Council, 2006).  Interrogating the 
aspects of a behaviour to determine what needs to change, and how this may be achieved, 
produces interventions which directly target the behaviour (Michie et al, 2014).  There are 
many frameworks available to guide intervention development (for example, the theory of 
planned behaviour, described in Chapter 3 section 3.2.3), but the TDF, COM-B and BCW 
were selected because they are the product of the synthesis of multiple frameworks.  While 
individual frameworks may be selective about the behaviour change techniques they 
incorporate, the TDF, COM-B and BCW include multiple potential behaviour change 
techniques (BCTs).  This ensures that the use of these intervention development tools 
comprehensively incorporates behaviour change techniques into complex intervention 
design.  There is also extensive experience of the use of the TDF in investigating 
deprescribing and other healthcare associated behaviours (Scott et al, 2019; Ailabouni et al, 
2016; Cadogan et al; 2015; Atkins et al, 2017).  This provides support for the use of the TDF, 
COM-B and BCW to investigate deprescribing. 
5.2.1 The COM-B model, Theoretical Domains Framework, Behaviour 
Change Wheel and the APEASE criteria 
Four models or frameworks were utilised to deepen understanding of deprescribing 
behaviour.  These are summarised, and their relationships described, below. 
5.2.1.1 COM-B 
The COM-B (Capability, Opportunity, Motivation, Behaviour) model of behaviour change was 
developed by Michie et al (2011) as a method of defining the three components which are 
essential for any behaviour to be undertaken.  If any of the three is missing, a behaviour is 
unlikely to occur (Michie et al, 2011).  In turn, this provides insight into how a behaviour may 
be changed by targeting one of the three components.  These components are presented 
below in Figure 13 and Table 34, which also presents the components in the context of 
deprescribing (Michie et al, 2011).
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Table 34: COM-B components, their definition and how they are applied to 
deprescribing 
COM-B component Definition (Michie et al, 
2011) 
The COM-B component in the 
context of deprescribing 
Capability 
(Psychological and 
physical) 
The capability to change 
behaviour.  This refers to a 
person’s mental and physical 
capacity to change their 
behaviour. 
A prescriber having the 
knowledge and/or skills 
necessary to identify 
inappropriate medicines to stop 
and be able to safely and 
effectively stop them.  
Opportunity (social 
and physical) 
The opportunity to change 
behaviour.  This refers to 
factors outside the 
individual’s control that affect 
their ability to change their 
behaviour 
A prescriber having the 
resources, such as the staffing, 
time, and other tools, to conduct 
deprescribing 
Motivation (Automatic 
and reflective) 
The motivation to change 
behaviour.   
A prescriber having the desire to 
change their behaviour and/or a 
desire to stop inappropriate 
medicines, which can be 
supported by goal setting and 
decision making tools. 
 
 
Figure 13: The COM-B model of behaviour change (Michie et al, 2011) 
The COM-B is the most broad and basic model utilised to understand behaviour in this 
thesis.  It is, however, an important component of the behaviour change wheel and it is also 
linked to the Theoretical Domains Framework (TDF), which is described below. 
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5.2.1.2 The Theoretical Domains Framework (TDF) 
The TDF provides further detail and insight into behaviours, and the reasons the TDF was 
selected for application to this thesis are outlined in Chapter 3 (section 3.2.3).  As described 
in section 3.2.3, the Theoretical Domains Framework (TDF) is a composite framework of 
factors which influence behaviour.  128 theoretical constructs from 33 theories were 
synthesised to produce the 12 domains of the original TDF, which underwent a validation 
exercise seven years later (Michie et al, 2005; Cane et al, 2012).  This validated version of 
the TDF, consisting of 14 optimised domains was utilised in this thesis (Appendix C, Cane et 
al, 2012).  Whilst mapping a behaviour to the COM-B would assign each behaviour 
component to one of three categories, mapping a behaviour to the 14 domains of the TDF 
allows the behaviour component to be mapped more specifically.  This provides more insight 
about the behaviour.  However, the 14 domains in the validated TDF can also be mapped to 
the COM-B model, which demonstrates that the COM-B model and TDF are linked.  Table 
35 below shows how the TDF can be mapped to the COM-B model.  See Appendix C for a 
presentation of the COM-B and TDF respectively in the context of deprescribing.   
Table 35: How the domains of the TDF are mapped to the COM-B model as defined by 
Michie et al (2014) 
COM-B component TDF domains  
Capability Psychological Memory, attention and decision processes 
Knowledge 
Behavioural regulation 
Physical (Physical) skills 
Opportunity Social Social influences 
Physical Environmental context and resources 
Motivation Reflective Social/professional role and identity 
Beliefs about capabilities 
Optimism 
Intentions 
Goals 
Beliefs about consequences 
Automatic Reinforcement 
Emotions 
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5.2.1.3 The Behaviour Change Wheel (BCW) 
The Behaviour Change Wheel (BCW) guides intervention development by linking behaviour 
components, which have been mapped to the COM-B or TDF, to intervention functions.  
Intervention functions are the “building blocks” of an intervention, and identify what the basis 
of a successful intervention may be.   
The BCW is built around the COM-B model, which in turn provides the link to the TDF.  See 
Table 35 above which shows how the TDF is mapped to the COM-B.  The BCW is a 
framework developed following a systematic review of 19 behaviour change intervention 
frameworks (Michie et al, 2011).  It consists of nine intervention functions, which are 
potential bases of a behaviour change intervention.  For example, identification of education 
as an intervention function means that an educational intervention, such as a training 
package, may be appropriate to produce the desired behaviour change.  The BCW also 
contains seven policy functions which would support the implementation of an intervention.  
For example, an educational intervention would be supported by the development of 
guidelines, communication/marketing, regulation, legislation or service provision (Michie at 
al, 2011).  It aims to aid with the design of behaviour change interventions by linking analysis 
of behaviour to intervention design (Michie et al, 2011).  The Behaviour Change Wheel is 
presented below in Figure 14: 
 
Figure 14: The Behaviour Change Wheel (Michie et al, 2011) 
5.2.1.4 The APEASE criteria 
The APEASE criteria were applied throughout this chapter to aid the selection of appropriate 
intervention functions, behaviour change techniques, policy categories and modes of 
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delivery.  The application of the APEASE criteria in this way is suggested in the guidance by 
Michie et al (2014).  
The APEASE acronym represents: 
- Affordability 
- Practicability 
- Effectiveness and cost-effectiveness 
- Acceptability 
- Side-effects/safety 
- Equity 
In order for an intervention to be successful, its components should meet these criteria.  
Efficacy is often focused upon; however, the other factors are also important and contribute 
to the uptake and usability of an intervention.  For example, an intervention that is effective 
but prohibitively expensive is unlikely to be utilised widely, and an effective intervention that 
is time consuming and impractical to use is also unlikely to be utilised.  Application of the 
APEASE criteria enhanced the likelihood that any intervention developed as a result of this 
work would be successfully adopted.  See Table X (was 43) for an example of the 
application of the APEASE criteria to the data collected in this thesis. 
5.2.2 Methods 
Firstly, the barriers to deprescribing identified in the empirical work were mapped to the TDF.  
Mapping barriers to the TDF is the first step in eight steps described by Michie et al (2014) 
which aim to identify behaviour change intervention functions from the barriers identified in 
the study being conducted.  Once the eight steps have been completed, the following will 
have been identified: 
- The target behaviour to be targeted by a behaviour change intervention 
- The domains of the TDF (and the components of the COM-B) which would be the 
most appropriate to target with a behaviour change intervention 
- Candidate intervention functions, which are broad indications of which components 
might be appropriate to incorporate into a targeted behaviour change intervention 
- Behaviour change techniques, which are defined by Michie et al (2014) as “an active 
component of an intervention designed to change behaviour”  
- Policy categories, which are policies which may be developed to support the delivery 
of a targeted behaviour change intervention 
- The delivery mechanisms which may be utilised to deliver a targeted behaviour 
change intervention 
Once these have been identified, they can be utilised to inform the development of a 
targeted behaviour change intervention.  Following the eight steps does not create a 
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Figure 15: The stages and steps of defining an intervention as defined by Michie et al 
(2014) pp25 
behaviour change intervention.  Instead, it informs what a behaviour change intervention 
may be comprised of, how it may be delivered and the policies which could support its 
delivery (Michie et al, 2014).  The steps were as follows (Figure 15):Stage one: Understand 
the behaviour 
Step 1. Define the problem in behavioural terms 
Step 2. Select target behaviour 
Step 3. Specify the target behaviour 
Step 4. Identify what needs to change 
Stage two: Identify intervention options 
Step 5. Identify intervention functions 
Step 6. Identify policy categories 
Stage three: identify content and implementation options 
Step 7. Identify behaviour change techniques 
Step 8. Identify mode of delivery 
 
 
Whilst figure 15 (above) is how Michie et al (2014) presented the stages of intervention 
development, the steps were presented slightly differently throughout this chapter.  The 
structure presented in figure 16 below, with stages six and seven swapped, provided a 
logical narrative structure that was easier to follow: 
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Figure 16: The process of identifying potential components of a deprescribing 
behaviour change intervention that was undertaken in this thesis, informed by Michie 
et al (2014)
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5.2.2.1 Application of the steps outlined by Michie et al (2014) to inform the 
development of a deprescribing behaviour change intervention 
Steps 1-2, definition and selection of the target behaviour were carried out after due 
consideration of the phenomenon of interest, deprescribing.  This involved consideration of 
the literature and discussion with the supervisory team.  Deprescribing was identified as the 
target behaviour at the very start of the research.  Step three, specification of the behaviour, 
was completed as an exercise suggested by Michie et al (2014) and can be found in section 
5.3.1.   
Step four was more involved than steps 1-3 and involved identifying exactly which part of the 
behaviour would be the most appropriate to target with an intervention.  This step introduced 
the COM-B and the TDF.  Michie et al (2014) recommend that the COM-B is mapped to first, 
and then the TDF can be introduced in order to provide further depth and detail.  However, 
as the TDF had already been incorporated into the literature review and the interview 
schedules the barriers were mapped to the TDF first and then to COM-B for completeness.  
Information about the COM-B and the TDF can be found in section 5.2.1.   
Firstly, the barriers to deprescribing in care homes identified in the empirical research were 
extracted from the findings and mapped to the TDF.  The barriers identified in the literature 
review were then mapped to the COM-B components, and the domains of the TDF which 
should be targeted by a deprescribing intervention were identified.  The flowchart below 
shows how the barriers from the literature review and empirical research were synthesised 
and combined.  This is demonstrated in Figure 17, 
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Figure 17: Step 4: The process of synthesising and mapping the barriers identified in 
the literature review and the empirical findings 
Step five was the first step towards identifying the behaviour change techniques that would 
comprise a useful intervention.  In step five, the domains of the TDF were mapped to 
intervention functions provided by Michie et al (2014).  Intervention functions are broad 
indications of which components might be appropriate to incorporate into a behaviour 
change intervention to improve the target behaviour.  For example, the intervention function 
“education” simply identifies that an educational intervention may be effective.  Behaviour 
Change Techniques, as described below, provide the specific components which may 
comprise an effective intervention.  The APEASE criteria were used to identify the 
intervention functions which were likely to be effective.  The effective intervention functions 
identified were utilised in steps six and seven. 
Step six takes the intervention functions identified in step five and maps them to Behaviour 
Change Techniques.  Michie et al (2014) have identified 93 BCTs, which are defined as “an 
active component of an intervention designed to change behaviour”.  An intervention may 
consist of one, or multiple, BCTs.  In order to identify the BCTs which are likely to be 
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effective, Michie et al (2014) provide a table which demonstrates the links between 
candidate intervention functions and BCTs.  Each intervention function has multiple BCTs 
associated with it, and these are separated into two groups: most frequently used BCTs, and 
less frequently used BCTs.  Michie et al (2014) recommend using the most frequently 
identified BCTs, alongside the APEASE criteria, to determine which BCTs are likely to be 
effective. 
Once the BCTs had been identified, it was necessary to investigate how an intervention may 
be delivered.  Step seven takes the intervention functions identified in step five and maps 
them to policy categories identified by Michie et al (2014).  Policy categories are the types of 
policies which would support an intervention in its delivery, for example communication and 
marketing, guidelines and environmental planning.  The final step, step 8, examines how an 
intervention may be delivered.  Michie et al (2014) stated that interventions were usually 
identified in one of two ways: face-to-face, or distantly.  Each of these are then further 
categorised into ways that an intervention may be delivered, for example individual training 
or by posters, phone apps or television.  The APEASE criteria were applied throughout steps 
seven and eight to identify the policy categories and modes of delivery most likely to be 
effective. 
5.2.2.2 Ensuring rigor through the mapping processes 
Throughout the processes undertaken to map the barriers to the TDF, and the subsequent 
mapping of the identified TDF domains to the BCW, steps were taken to ensure rigor.  The 
mapping work was carried out in collaboration with a member of the supervisory team (CE), 
who has extensive experience in utilising the TDF and behaviour change psychology 
(Easthall et al, 2019).  Each stage of the mapping process was discussed by the author and 
CE before the mapping was undertaken.  Both the author and CE independently mapped the 
barriers identified in the literature review and the empirical research to the TDF, and then 
compared their findings.  A high level of agreement was found between the mapping 
decisions, and any disagreement was resolved through discussion.  The subsequent 
mapping processes were undertaken by the author, and then discussed with CE to ensure 
their accuracy.  Furthermore, the methods for intervention development presented by Michie 
et al (2014) were followed and each stage of the process is presented clearly, and all 
mapping decisions and processes are presented for transparency (Chapter 2, section 
2.6.3.1; Chapter 5 section 5.4).   
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5.3 Findings 
5.3.1 Step 3: Specify the target behaviour 
In order to specify the behaviour, Michie et al (2014) recommended that the researcher 
should identify the following factors, as displayed in table 36 below.  This stage allowed 
consolidation of key information about the deprescribing behaviour, for example, that it is 
performed by HCPs such as GPs and primary care pharmacists and that is most commonly 
undertaken during medication reviews.  This allowed for an improved assessment of the 
behaviour and a more targeted, intervention. 
Table 36: Step 3: specifying the target behaviour 
Factor of the behaviour (taken from 
Michie et al, 2014, pp48) 
The behaviour factor described with 
regard to deprescribing 
Who needs to perform the behaviour? Healthcare professionals, particularly GPs 
and pharmacists working in primary care 
What does the person need to do differently 
to achieve the desired change? 
Review the medicines of older people in 
care homes to ensure they are all 
appropriate, stop any that are not 
When will they do it? During reviews of medicines or when the 
resident is experiencing an acute issue 
which requires treatment 
Where will they do it? Preferably while visiting the resident in the 
home, although remote reviews may be 
possible if the resident/relative is 
appropriately involved 
How often will they do it? Routinely – at least annually, when a 
resident’s condition changes and when a 
review is requested by a resident, relative 
or care home staff member 
With whom will they do it? Residents, relatives, care home staff and 
other healthcare professionals 
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5.3.2 Step 4: Identifying what needs to change: mapping of the barriers 
identified in the empirical interview data to the TDF 
The first part of step four was the synthesis and mapping of barriers identified in the 
empirical interview data study.  The barriers were extracted from the findings, grouped and 
synthesised, and mapped to the TDF as shown in table 37 below.  This is the same process 
as was undertaken in the literature review (described in Chapter 2, section 2.4.6.1).  The 
rationale for the mapping is then provided in section 5.3.2.2 
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Table 37: How barriers extracted from the findings of the empirical work were synthesised and mapped to the TDF 
Barriers extracted from 
findings 
Synthesised barrier Description TDF domain  
- Logistical challenges presented 
when a resident requires a GP 
appointment. 
- The organisation and provision 
of GP services to care homes. 
- Care homes have to deal with 
multiple GP surgeries. 
Navigating primary care 
systems 
Incorporates the difficulties care 
home staff experience when 
arranging GP care for residents. 
Environmental context and 
resources 
- Residents perceived as 
unwilling to change. 
- Healthcare professionals 
perceive residents to lack interest 
in their medicines. 
- Relatives perceived to be 
challenging of deprescribing 
decisions. 
- Healthcare professionals are 
suspicious of the motives of 
relatives for deprescribing. 
Healthcare professionals’ 
perceptions of residents and 
relatives 
Perceptions held by healthcare 
professionals of residents and 
relatives which may affect a 
healthcare professional’s 
willingness to deprescribe. 
Social influences 
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Barriers extracted from 
findings 
Synthesised barrier Description TDF domain  
- Relatives or residents resist 
deprescribing 
Opposition of others to 
deprescribing 
This barrier incorporated instances 
in which healthcare professionals 
described experiencing resistance 
to deprescribing from residents 
and relatives. 
Social influences 
- Difficulty accessing specialist 
opinion. 
- Logistical barriers to 
communicating with relatives. 
Logistical barriers to 
communication 
Includes logistical barriers to 
communication such as the 
unavailability of the person with 
whom communication is sought. 
Environmental context and 
resources 
- Healthcare professionals less 
comfortable deprescribing 
medicines of which they lack 
knowledge. 
Confidence to deprescribe Incorporates lack of knowledge, 
which was reported to affect a 
healthcare professional’s 
confidence to deprescribe. 
Knowledge 
- Lack of evidence to assist with 
deprescribing. 
- Lack of guidance 
 to assist with deprescribing. 
Lack of evidence and guidance Healthcare professionals believed 
a lack of deprescribing evidence 
and guidance, especially for this 
population, was a barrier to 
deprescribing. 
Knowledge 
Environmental context and 
resources 
- Barriers posed by regulatory 
and payment systems. 
Barriers posed by regulatory 
and payment systems 
Incorporates how the requirements 
of the CQC, a regulatory system, 
Environmental context and 
resources 
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Barriers extracted from 
findings 
Synthesised barrier Description TDF domain  
and QOF, a payment system, 
affect the deprescribing process. 
Reinforcement 
- Residents and relatives believe 
pharmacists lack knowledge to 
deprescribe. 
- Role of the pharmacist not 
understood by residents and 
relatives. 
Perceptions of pharmacists Includes how the perceptions that 
residents and relatives had of the 
potential role that pharmacists 
could have in deprescribing in care 
homes impacts the deprescribing 
process. 
Social influences 
- Care home staff were perceived 
by themselves and others to lack 
knowledge about medicines. 
- Lack of medicines training 
available to care home staff. 
Knowledge deficiencies of 
care home staff 
Some care home staff and 
healthcare professionals perceived 
care home staff to lack knowledge 
about medicines, and believed that 
this impacted upon their ability to 
be involved in deprescribing. 
Knowledge 
- Perceived high workload of GPs 
means it is difficult to prioritise 
deprescribing above other tasks  
Prioritising deprescribing GPs believed their high workload, 
of both deprescribing and other 
routine tasks, prevented them from 
undertaking as much deprescribing 
work as they would like to do.  
Intentions 
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Barriers extracted from 
findings 
Synthesised barrier Description TDF domain  
- Lack of skilled pharmacy staff. 
- High turnover of care home 
staff. 
Staffing issues How a lack of regular, skilled staff 
affects deprescribing. 
Environmental context and 
resources 
- Goals of care are poorly 
planned. 
Setting goals of care Incorporates the beliefs around 
setting goals of care and how 
these impact the deprescribing 
process.   
Goals 
 
- GPs who are difficult for care 
home staff to work with. 
The attitude of the GP towards 
care home work 
Care home staff reported that 
some GPs displayed a poor 
attitude towards care home 
residents which may affect their 
attitude to deprescribing for this 
population. 
Social influences 
- Uncertainties related to the 
resident’s condition. 
- High number of residents 
perceived by healthcare 
professionals as being unable to 
communicate.  
Influence of the resident’s 
health 
Includes how the aspects of the 
resident’s health impacts on 
deprescribing decisions and the 
deprescribing process. 
Environmental context and 
resources 
- Difficulty balancing both known 
and unknown risks/benefits of a 
Skill deficiencies  This barrier incorporates instances 
of healthcare professionals 
describing the difficulties of 
Skills 
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Barriers extracted from 
findings 
Synthesised barrier Description TDF domain  
medicines with the resident’s 
condition 
reconciling the properties of a 
medicine with the resident’s 
presenting condition.  
- Unwillingness of some 
healthcare professionals to 
discuss life expectancy with 
residents and relatives when 
considering deprescribing in care 
homes. 
- Poor communication about 
goals of care 
Avoidance of difficult 
discussions 
Includes how communication about 
goals of care and end of life affect 
the deprescribing process.  
Social influences 
- Lack of Wi-Fi in care homes. 
- Lack of timely access to a 
resident’s medical records. 
- Perceived lack of time available 
to healthcare professionals to 
deprescribe. 
Lack of resources This barrier includes the issues 
caused by restricted access to 
resources which facilitate the 
deprescribing process. 
Environmental context and 
resources 
- Beliefs about negative 
consequences of deprescribing, 
for example the resident’s 
condition worsening or litigation. 
Negative beliefs about 
consequences 
The potential negative 
consequences of deprescribing 
faced by residents, relatives and 
healthcare professionals which 
were discussed without emotive 
language. 
Beliefs about consequences 
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Barriers extracted from 
findings 
Synthesised barrier Description TDF domain  
- Concern about litigation arising 
from a deprescribing decision. 
- Fear of negative consequences. 
Emotions felt towards 
deprescribing 
This barrier is linked with the 
beliefs about consequences 
barrier, but emotions such as fear 
and concern were attached by 
some healthcare professionals to 
the potential consequences of 
deprescribing.   
Emotions 
- Role of residents and relatives 
is not clearly defined. 
- Role of care home staff is not 
clearly defined. 
Disagreement about the role and 
skillset required of the 
pharmacist. 
 
Uncertainty of roles How a lack of clarity about the 
roles of residents, relatives and 
care home staff in the 
deprescribing process affected the 
involvement of these groups in the 
decision-making process. 
Social and professional role 
and identity 
- Lack of funding for dedicated 
services providing primary care 
to care homes. 
- Lack of funding for more skilled 
staff to undertake deprescribing. 
Lack of funding Healthcare professionals believed 
that more funding was required to 
enable deprescribing in care 
homes. 
Environmental context and 
resources 
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5.3.2.1 Rationale for the mapping of the barriers identified in the empirical 
interview data to the TDF 
Firstly, the barriers were mapped to domains of the TDF as displayed in Table 37.  This was 
then discussed with a member of the supervisory team who is experienced in the utilisation 
of the TDF (Easthall et al, 2019).  Disagreements were resolved through discussion.  The 
mapping was then compared to the synthesis and mapping of barriers identified in the 
literature review (Chapter 2, section 2.6.3) to ensure consistency.  Table 38 presents the 
synthesised barriers that were identified in both the findings and the literature review that 
were then mapped to the same TDF domain.  The rationale for mapping these barriers to 
their respective domains can be found in Chapter 2, section 2.6.3. 
Table 38: Synthesised barriers identified in both the literature review findings and in 
the findings of the study being conducted 
Synthesised barrier TDF mapping of the synthesised barrier 
Influence of the resident’s health Environmental context and resources 
Staffing issues Environmental context and resources 
Lack of funding Environmental context and resources 
Lack of evidence and guidance Environmental context and resources 
Knowledge 
Emotions felt towards deprescribing Emotions 
Opposition of others to deprescribing Social influences 
Skill deficiencies Skills 
Uncertainty of roles Social/professional role and identity 
Negative beliefs about consequences Beliefs about consequences 
The following sections outline the rationale for mapping decisions made where there was a 
divergence from the decisions made in the literature review, or where the barrier was not 
identified in the literature review 
5.3.2.1.1  Points of divergence: barriers that were also identified in the literature 
review (Chapter 2) 
Tables 39 and 40 (below) present points of divergence in the synthesis or mapping process.  
Table 39 shows synthesised barriers and mapping decisions made during the literature 
review.  Table 40 shows the similar barriers found in the empirical research, and the 
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mapping decisions that were made for those.  The rationale for the mapping decisions are 
discussed below the table. 
Table 39:  Barriers synthesised and mapped in the literature review (Chapter 2, 
section 2.6.3) 
Synthesised barrier identified from 
the literature review 
TDF mapping of synthesised barrier from the 
literature review  
Systemic barriers to communication Environmental context and resources 
Confidence to deprescribe  Beliefs about capabilities 
Goals of care Social influences 
Knowledge deficiencies of GPs, care 
home staff, residents and relatives 
Knowledge 
Lack of time Environmental context and resources 
 
Table 40: Barriers synthesised and mapped in the empirical research that are similar 
to those displayed in table 39 
Synthesised barrier identified from the 
empirical interview data 
TDF mapping of the synthesised barrier from 
the empirical interview data 
Logistical barriers to communication Environmental context and resources 
Navigating primary care systems Environmental context and resources  
Barriers posed by regulatory and payment 
systems 
Environmental context and resources 
Reinforcement  
Confidence to deprescribe Knowledge 
Setting goals of care Goals 
Avoidance of difficult discussions Social influences 
Knowledge deficiencies of care home staff Knowledge 
Lack of resources Environmental context and resources 
 
In the literature review, the barrier “systemic barriers to communication” was identified and 
mapped to the Environmental Context and Resources domain (Chapter 2, section 2.6.3).  
This barrier incorporated barriers to communication caused by healthcare systems, for 
example the administrative work required of prescribers.  It also included the barrier created 
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when healthcare professionals were unable to contact relatives to involve them in decision-
making.  The findings of the empirical interview data provided in-depth insight of the 
systemic barriers to deprescribing, which allowed the barriers to be separated to provide a 
more comprehensive and detailed reflection of the issues.  Barriers relating to unavailability 
of people whose input was sought, for example specialist prescribers or relatives, were 
synthesised to the barrier “logistical barriers to deprescribing” which was then mapped to the 
Environmental Context and Resources domain.  The only systemic barriers identified in the 
literature review were the burden of paperwork.  However, multiple systemic barriers to 
deprescribing were identified in the empirical interview data, and it was deemed that these 
did not fit in the same synthesised barrier as the logistical barriers to communication. 
The main systemic barriers to deprescribing explored in the findings of the empirical 
interview data were the issues care home staff experienced navigating primary care systems 
on behalf of the resident.  These barriers were synthesised to the barrier “navigating primary 
care systems”, which was mapped to the Environmental Context and Resources domain.  
There was a burden of paperwork identified in the empirical interview data, but this was 
described as a problem with the regulatory and payment systems (the CQC and QOF) that 
care homes and GP practices must adhere to.  Therefore, it was mapped to the 
Environmental Context and Resources domain but also to the Reinforcement domain.  
Cane et al (2012) defined reinforcement as: 
“increasing the probability of a response by arranging a dependent relationship, 
or contingency, between the response and a given stimulus”.  Cane et al, 2012 
While the paperwork generated by the CQC and QOF did not act as a deterrent to 
deprescribing, it did not act as a reinforcement or reward either.  Cane et al’s (2012) 
definition of the domain only refers to factors which reinforce a behaviour, and not those 
which may discourage behaviour such as CQC or QOF requirements.  However, it was 
mapped to this domain because it was decided that this domain best reflected how CQC or 
QOF could reinforce deprescribing behaviours but were instead reported to discourage 
them.   
The barrier “confidence to deprescribe” was synthesised from the findings of both the 
literature review and the empirical interview data, however it was mapped to different 
domains of the TDF in each case.  There was a lack of detail in the studies included in the 
literature review to determine what affected a prescriber’s confidence to deprescribe, and 
therefore it was mapped to the Beliefs about Capabilities domain.  However, the data 
analysis from the empirical interview data allowed an improved understanding of the factors 
that influenced a healthcare professional’s confidence to deprescribe.  It was determined 
that a lack of confidence to deprescribe certain medicines stemmed from a lack of 
knowledge about them, and so consequently it was mapped to the Knowledge domain.  
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Improving knowledge via an intervention would also improve confidence to deprescribe, and 
would thus change behaviour.  This finding was particularly prominent in the pharmacist 
interviews, as pharmacists often reported a lack of confidence deprescribing medicines they 
were less knowledgeable of, such as medicines for mental health issues or cognitive decline.   
Knowledge deficiencies were synthesised and mapped differently from the findings of the 
empirical interview data.  In the literature review, there was a lack of depth about knowledge 
deficiencies and therefore one barrier, “lack of knowledge” was created and was applicable 
to all stakeholders.  In the empirical interview data, it was clear that some care home staff 
and healthcare professionals felt that if care home staff had more knowledge of medicines, 
they could be more involved in the deprescribing process.  Therefore, the barrier “knowledge 
deficiencies of care home staff” was synthesised and mapped to the Knowledge domain.  
Healthcare professionals partaking in the empirical interviews did not report that care home 
residents lacking knowledge about their medicines was a barrier to deprescribing, but did 
report that they perceived care home residents to lack interest in their medicines.  Therefore, 
no barrier was synthesised referring to the knowledge of care home residents and the 
perceived disinterest in medicines displayed by residents was synthesised to “healthcare 
professionals’ perceptions of residents and relatives” and mapped to the Social Influences 
domain. 
Another barrier that was evident in both the literature review and the empirical interview data 
was the issues around the resident’s goals of care.  The barrier synthesised from the 
literature review, simply called “goals of care”, was mapped to the Social Influences domain 
as it represented the finding that healthcare professionals and relatives disagreed about the 
resident’s care.  Again, the analysis and interpretation from the qualitative interviews in this 
thesis provided more in-depth insight about these issues and so the findings were 
synthesised to two barriers.  “Setting goals of care” referred to the finding that goals of care 
for the resident were not often set.  As it described the process of setting goals, it was 
mapped to the Goals domain.  The second barrier identified around this topic was more 
influenced by social factors, and referred to the finding that difficult discussions about the 
resident’s life expectancy were sometimes avoided by healthcare professionals.  Healthcare 
professionals explained that it was sometimes difficult to talk about topics such as life 
expectancy of the resident with the resident or their relatives.  There was, however, 
insufficient depth to the data in this area to determine the reasons that these discussions 
were sometimes avoided and so it was mapped to the Social Influences domain. 
The barrier “lack of time” was identified as the only resource barrier in the literature review, 
other than the resources synthesised and mapped elsewhere such as staffing issues and the 
lack of evidence and guidance.  Therefore, it was defined as a barrier alone, and mapped to 
the Environmental Context and Resources domain.  In the empirical interview data, lack of 
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time was one of three resource barriers, with the others being the lack of internet access in 
care homes and difficulty accessing the resident’s medical notes.  These resource issues 
were synthesised to the barrier “lack of resources”, which was also mapped to the 
Environmental Context and Resources domain. 
5.3.2.1.2 Rationale for the mapping of the barriers identified in the empirical interview 
data to the TDF: barriers that were unique to the empirical findings 
The remaining barriers identified from the empirical interview data were not directly 
comparable to the barriers identified in the literature review.  They are displayed in Table 41 
below, followed by the rationale for the mapping decisions and discussion of the overall 
mapping process. 
Table 41: Barriers unique to the empirical findings mapped to the TDF 
Synthesised barrier from the empirical 
interview 
TDF mapping of the synthesised barrier 
Healthcare professionals’ perceptions of 
residents and relatives 
Social influences 
Perceptions of pharmacists Social influences 
The attitude of the GP towards care home 
work 
Social influences 
Prioritising deprescribing Intentions 
Three of the four barriers which were not comparable to the barriers synthesised from the 
literature review were mapped to the Social Influences domain.  This demonstrates the 
importance of perceptions of people and relationships to the deprescribing process, and how 
the empirical interview data allowed for exploration of these issues.   
It was determined that, in some instances, it was the perceptions that healthcare 
professionals held of residents and relatives that was the barrier to deprescribing, rather 
than the resident or relative themselves.  While there were some instances of residents or 
relatives resisting deprescribing (instances which were synthesised to the “opposition to 
deprescribing” domain), most residents and relatives reported being content to agree with 
the decision of the healthcare professional.  They also reported being willing to learn about 
their medicines.  However, healthcare professionals believed that residents were 
uninterested in their medicines and relatives were challenging of their decisions and 
described occasions where such issues had prevented them from deprescribing    
The final two barriers, “perceptions of pharmacists” and “the attitude of the GP towards care 
home work” also reflect how perceptions can affect the deprescribing process.  Some 
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residents and relatives were reported as perceiving pharmacists to lack the knowledge and 
skills to deprescribe medicines, which could create a barrier for pharmacists working in care 
homes.  GPs perceived as having a poor attitude towards care home work, such as those 
who required prompting to communicate with residents, were reported to be more difficult to 
work with.  This may have deterred others from engaging with them to deprescribe.   
The final barrier, “prioritising deprescribing”, was mapped to the Intentions domain.  This 
barrier addressed the finding that GPs reported their workload was too high to be involved in 
deprescribing.  The findings revealed that their high workload was a result of holding 
surgeries, completing home visits and completing paperwork.  These were tasks which were 
took priority over deprescribing.  The “intentions” domain was defined by Cane et al (2012) 
as: 
“a conscious decision to perform a behaviour or a resolve to act in a certain 
way”.  Cane et al (2012) 
GPs were therefore not making a conscious decision to deprescribe, unless they were given 
the time to complete care home work, and they did not intend to deprescribe as part of their 
routine.  Therefore, this barrier was mapped to the Intentions domain. 
Finally, two barriers were identified in the literature review which were not identified in the 
findings of the empirical interview data.  These were “lack of education and training” and 
“influence of other prescribers”.  Healthcare professionals partaking in the empirical interview 
data did not generally feel that there was a lack of education and training preventing them 
from deprescribing.  They did not report feeling influenced by other prescribers, only that 
other prescribers may be difficult to contact for their input.  GPs in particular, were confident 
to make deprescribing decisions that they believed were in the best interest of the resident, 
regardless of who initially started the medicine.  Pharmacists worked with the resident’s GP 
to make deprescribing decisions, and did not report being influenced by the initial prescriber. 
5.3.2.1.3 Summary of the synthesis and mapping processes 
Similarly to the literature review, most of the synthesised barriers from the findings of the 
empirical interview data were mapped to the Environmental Context and Resources domain.  
This suggested that the environment in which healthcare professionals were working, and 
the resources available to help them, were a major barrier to deprescribing.  The empirical 
interview data and literature review also identified Social Influences and Knowledge as the 
next domains with the most barriers mapped to them.  Social influences were more prevalent 
in the empirical interview data, while Knowledge was the most prevalent in the literature 
review.  This suggested that these three domains may be the most appropriate to target with 
an intervention. 
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While there were multiple similarities between the barriers identified in the literature review 
and the empirical interview data, there were several important differences as well.  These 
differences demonstrated the benefit of conducting the empirical research, as the extra 
depth and richness of the data collected, analysed and interpreted allowed for clearer 
synthesised barriers which provided a more comprehensive reflection of the findings.  This 
means that the barriers could be confidently mapped to the TDF, which provides a stronger 
basis for intervention development than if the literature review findings had been utilised 
alone. 
5.3.2.2 Mapping of the synthesised barriers to the COM-B system 
Once the synthesised barriers from the empirical interview data had been identified and 
mapped to the TDF, they were mapped to the COM-B system with the barriers identified 
during the literature review (Chapter 2).  The COM-B system is described in detail in section 
5.2.1.  In summary, the abbreviation COM stand for capability, opportunity and motivation 
which are three factors which influence how a person behaves.  The B stands for behaviour. 
Mapping the barriers to the COM-B system was not strictly necessary in this situation.  
Michie et al (2014) recommend mapping identified barriers to the COM-B first for an 
overarching view, and then to the TDF for a more in-depth analysis.  However, as the TDF 
had already been utilised in the literature review (Chapter 2) and in the design of the 
interview schedules, the barriers identified in the empirical findings were mapped to the TDF 
first and then to the COM-B for completeness, and to provide further insight. 
Table 42, below, combines the synthesised barriers identified in both the literature review 
and in the findings of the empirical interview data.  The components of the COM-B system 
are stated, followed by the TDF domain to which they were mapped. 
Key: (L) synthesised barrier identified in the literature review,  
        (E) synthesised barrier identified in the findings of the empirical interview data 
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Table 42: Barriers identified in the literature review and empirical findings and the TDF domains and COM-B components they are 
mapped to 
 COM-B component TDF Domain  Barriers to deprescribing mapped to this domain  
C
A
P
A
B
IL
IT
Y
 
Physical capability Skills (physical) No barriers mapped to this domain. 
Psychological 
capability 
Knowledge Lack of evidence and guidance (L) (E) 
Confidence to deprescribe (E) 
Knowledge deficiencies of GPs, care home staff, residents and relatives (L) 
Knowledge deficiencies of care home staff (E) 
Lack of education and training (L) 
Skills (cognitive & 
interpersonal) 
Skill deficiencies (L) (E) 
Memory, attention & 
decision processes 
No barriers mapped to this domain. 
Behavioural regulation No barriers mapped to this domain. 
O
P
P
O
R
T
U
N
IT
Y
 Physical opportunity Environmental context 
& resources 
Influence of the resident’s health (L) (E) 
Staffing issues (L) (E) 
Lack of funding (L) (E) 
Lack of evidence and guidance (L) (E) 
Systemic barriers to communication (L) 
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 COM-B component TDF Domain  Barriers to deprescribing mapped to this domain  
Logistical barriers to communication (E) 
Navigating primary care systems (E) 
Barriers posed by regulatory and payment systems (E) 
Lack of time (L) 
Lack of resources (E) 
Social opportunity Social influences Opposition of others to deprescribing (L) (E) 
Goals of care (L) 
Influence of other prescribers (L) 
Avoidance of difficult discussions (E) 
Healthcare professionals’ perceptions of residents and relatives (E) 
Perceptions of pharmacists (E) 
The attitude of the GP towards care home work (E) 
M
O
T
IV
A
T
IO
N
 Reflective motivation Professional/ social 
role & identity 
Uncertainty of roles (L) (E) 
Beliefs about 
capabilities 
Confidence to deprescribe (L) 
Optimism No barriers mapped to this domain. 
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 COM-B component TDF Domain  Barriers to deprescribing mapped to this domain  
Beliefs about 
consequences 
Negative beliefs about consequences (L) (E)  
Intentions Prioritising deprescribing (E) 
Goals Setting goals of care (E) 
Automatic motivation Reinforcement Barriers posed by regulatory and payment systems (E) 
Emotion Emotions felt towards deprescribing (L) (E) 
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5.3.2.3 Selection of the TDF domains and COM-B components to target with a 
behaviour change intervention 
All components of the COM-B model were identified as potential areas for change except for 
physical capability.  Physical capability is defined by Michie et al (2014) as “physical skill, 
strength or stamina”.  No such physical skill, strength or stamina was identified as necessary 
for deprescribing.  The majority of the barriers fell into the opportunity component, especially 
physical opportunity but also social opportunity.  The domain of the TDF which is matched 
with physical opportunity is Environmental Context and Resources.  The domain of the TDF 
which is matched with social opportunity is Social Influences.  These domains, 
Environmental Context and Resources, and Social Influences, were prioritised for 
intervention development.  Key findings of the empirical research identified that healthcare 
professionals believed that external factors, such as lack of resource, were the major barrier 
to deprescribing in care homes.  Several social factors which influenced their behaviour were 
also identified as important.   
The Knowledge domain of the TDF, mapped to the psychological capability component of 
the COM-B, was the next domain prioritised for intervention development.  This domain also 
had multiple barriers mapped to it, more than the other domains, which was the reason it 
was prioritised.  Healthcare professionals identified multiple areas in which improved 
knowledge, through evidence, guidance and the education of those around them could 
facilitate deprescribing. 
Whilst the other domains had fewer barriers mapped to them and were not prioritised for 
intervention development at this stage, it does not mean that they were not important.  For 
example, setting goals of care and negative beliefs about consequences, which fall in 
reflective motivation, were of particular importance in this study.  However, as a starting 
point the three domains identified above were selected for initial investigation.  The other 
barriers should be considered during intervention development, for example an intervention 
could still proved information about consequences. 
In summary, the TDF domains and their corresponding COM-B components selected for the 
next stages of the process were: 
- Knowledge (TDF domain), psychological capability (COM-B component) 
- Environmental Context and Resources (TDF domain), physical opportunity (COM-B 
component) 
- Social Influences (TDF domain), social opportunity (COM-B component)
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5.3.3 Step 5: Identify candidate intervention functions using the BCW 
utilising the TDF domains identified in step 4 
The prioritised domains of the TDF (Knowledge, Environmental Context and Resources, 
Social Influences) were matched with potentially useful intervention functions as detailed in 
the guiding literature (Michie et al, 2014).  Intervention functions are broad categories which 
indicate a wide area in which an intervention may be developed.  Table 43 details the 
candidate intervention functions for each of the prioritised TDF domains and whether each 
function fits the APEASE (affordability, practicability, effectiveness and cost-effectiveness, 
acceptability, side-effects/safety and equity) criteria, and thus it’s likely utility in further 
exploration for this study.  The shaded cells indicate that the candidate intervention function 
will not be carried forward to the further stages of this process.   
Table 43 shows that multiple intervention functions were eliminated from consideration at 
this stage, either because they did not fit the APEASE criteria or they were not applicable to 
the behaviour or setting.  Use of the APEASE criteria highlighted, for example, that whilst 
large scale environmental changes were likely to be effective and acceptable to healthcare 
professionals, they were not deemed to be affordable or practical.  On the other hand, whist 
training was likely to be affordable and practical with no likely side effects or equity concerns, 
additional training may not be acceptable to all healthcare professionals and the 
effectiveness of this approach is also unclear.  It was determined that, through co-design, 
improving the acceptability of a training intervention was likely to be more feasible than 
overcoming the large cost and practical difficulties of large-scale changes to the health and 
social care system. 
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Table 43: TDF domains prioritised in step 4. their candidate intervention functions and detail of whether the intervention function fits 
the APEASE criteria 
TDF Domain 
prioritised in step 4 
Candidate 
intervention 
functions (taken 
from Michie et al, 
2014, pp 111-112) 
The intervention function in 
the context of the domain 
and deprescribing in care 
homes 
Does the intervention 
function fit the APEASE 
criteria with regard to 
deprescribing in care 
homes? 
Comments 
Environmental context 
and resources 
Training  Train healthcare 
professionals in deprescribing 
to reduce competing time 
demands for deprescribing 
Yes Likely to be affordable and 
practical with no side effects 
or equity concerns.  May not 
be acceptable to some 
healthcare professionals, 
and the effectiveness would 
need to be determined. 
 Restriction  Restricting undesired 
behaviours, such as not 
conducting annual reviews 
with a view to deprescribing.  
No Likely to be impractical, 
ineffective and unacceptable 
to healthcare professionals. 
Environmental 
restructuring 
Large scale: improving 
access to primary care for 
care home residents, 
improving access to medical 
records. 
Small scale interventions: 
yes 
Large scale interventions: 
no 
Small scale interventions: 
likely to be effective, 
affordable, practical and 
acceptable.  Large scale 
changes likely to be effective 
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TDF Domain 
prioritised in step 4 
Candidate 
intervention 
functions (taken 
from Michie et al, 
2014, pp 111-112) 
The intervention function in 
the context of the domain 
and deprescribing in care 
homes 
Does the intervention 
function fit the APEASE 
criteria with regard to 
deprescribing in care 
homes? 
Comments 
Small scale: create 
deprescribing prompts, 
improve access to resources 
such as Wi-Fi in care homes. 
and acceptable, but 
impractical and unaffordable. 
Social influences Enablement  Increasing means/reducing 
barriers to increase 
opportunity beyond education 
or environmental 
restructuring (Michie et al, 
2014).  None identified in this 
setting. 
Not applicable in this 
context. 
 
 Modelling  Provision of an example for 
people to aspire to or imitate 
(Michie et al, 2014).  None 
identified in this setting. 
Not applicable in this 
context. 
 
Restriction  Restricting undesired 
behaviours, such as not 
No Likely to be impractical, 
ineffective and unacceptable 
to healthcare professionals. 
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TDF Domain 
prioritised in step 4 
Candidate 
intervention 
functions (taken 
from Michie et al, 
2014, pp 111-112) 
The intervention function in 
the context of the domain 
and deprescribing in care 
homes 
Does the intervention 
function fit the APEASE 
criteria with regard to 
deprescribing in care 
homes? 
Comments 
conducting annual reviews 
with a view to deprescribing.  
Environmental 
restructuring  
Changes to the approach to 
the resident’s medicines, for 
example a named healthcare 
professional to conduct 
reviews, increased 
awareness of the concept of 
deprescribing, improved 
planning for the future of 
medicines incorporated into 
consultations 
Yes Likely to be effective and 
acceptable, but there may be 
practical and affordability 
barriers to overcome. 
 Enablement  A cultural change towards 
deprescribing; changing 
attitudes to medicines 
No 
 
Likely to be effective, but 
impractical to implement in 
the context of this thesis. 
Knowledge Education Provision of educational 
materials to stakeholders in 
deprescribing in care homes 
Yes Likely to be affordable and 
practical with no side effects 
or equity concerns.  May not 
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TDF Domain 
prioritised in step 4 
Candidate 
intervention 
functions (taken 
from Michie et al, 
2014, pp 111-112) 
The intervention function in 
the context of the domain 
and deprescribing in care 
homes 
Does the intervention 
function fit the APEASE 
criteria with regard to 
deprescribing in care 
homes? 
Comments 
be acceptable to some 
healthcare professionals, 
and the effectiveness would 
need to be determined. 
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Table 43 shows that the following candidate intervention functions were identified as the 
functions most likely to provide the foundation of a successful deprescribing intervention in 
care homes: 
- Environmental restructuring (with smaller scale changes to health and social care 
systems) 
- Training 
- Education  
In step six, the candidate intervention functions identified in Table 43 were used to identify 
the Behaviour Change Techniques (BCTs) that are most likely to be effective to engender 
behaviour change and thus increase deprescribing in care homes.  BCTs are more specific 
than intervention functions, and are “active components” of a behaviour change intervention 
(Michie et al, 2014) 
5.3.4 Step 6: Behaviour change techniques: identified utilising the 
intervention functions defined in step 5 
Table 44 details the most frequently used BCTs associated with the candidate intervention 
functions training, environmental restructuring and education, as reported in guiding 
literature (Michie et al, 2014).  The APEASE criteria was also applied to the candidate BCTs, 
as it was in step 5.    
Table 44 shows that many of the BCTs identified as potential intervention components were 
identified as likely to be successful.  Many more BCTs are identified for each intervention 
function by Michie et al (2014), but it is recommended to begin with the most frequently 
successfully used BCTs.  Therefore, the most frequently used BCTs for each intervention 
function are displayed in the table, and during future intervention development the less 
frequently utilised BCTs could be considered if necessary. 
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Table 44:  Identification of potentially useful BCTs from candidate intervention functions 
Candidate 
intervention 
function 
COM-B 
components 
Frequently used BCTs Whether or not 
the BCT fits the 
APEASE criteria 
Comments 
Training Psychological 
capability 
Physical 
opportunity 
Demonstration of the behaviour Yes For example, role play of a consultation or a 
demonstration of how to conduct a medicine 
review with a view to deprescribing. 
Instruction on how to perform the 
behaviour 
Yes  
Feedback on the behaviour No Monitoring evaluative feedback on 
behaviour was considered to be impractical. 
Feedback on outcomes of the 
behaviour 
Yes Healthcare professionals wished for input on 
outcomes of deprescribing from care home 
staff.  This could also help to improve 
perceptions of consequences of 
deprescribing, and communication between 
care home staff and healthcare 
professionals. 
 Self-monitoring of behaviour No Designing a method for a person to monitor 
their own behaviour was not felt to be 
applicable to this process. 
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Candidate 
intervention 
function 
COM-B 
components 
Frequently used BCTs Whether or not 
the BCT fits the 
APEASE criteria 
Comments 
Behavioural practice/rehearsal No Practicing deprescribing was not felt to be 
applicable to this process. 
Environmental 
restructuring 
Physical 
opportunity 
Social 
opportunity 
Adding objects to the environment No The definition of this BCT states that this 
does not include the provision of written 
materials such as guidance, and so it was 
not felt to be applicable in this context. 
Prompts/cues Yes This could include computer prompts or 
prompts provided to be used whilst 
conducting a medicine review for a care 
home resident  
Restructuring the physical 
environment 
No Changing the physical environment was not 
felt to be applicable to this context. 
 
Education Psychological 
capability 
Information about social and 
environmental consequences  
Yes Providing information about the potential 
benefits of deprescribing for residents, the 
NHS and care home staff could facilitate 
deprescribing in care homes. 
Information about health 
consequences 
Yes Providing information about the potential 
positive consequences of deprescribing, and 
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Candidate 
intervention 
function 
COM-B 
components 
Frequently used BCTs Whether or not 
the BCT fits the 
APEASE criteria 
Comments 
how to mitigate potential negative 
consequences of deprescribing, could 
facilitate the process. 
 Feedback on behaviour No As above. 
 Feedback on outcomes of the 
behaviour 
Yes As above. 
 Prompts/cues Yes As above. 
 Self-monitoring of behaviour No As above. 
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Table 44 shows that the BCTs likely to be the most appropriate to target with an intervention 
to improve the deprescribing behaviour of healthcare professionals in care homes are: 
- Demonstration of the behaviour 
- Instruction on how to perform the behaviour 
- Feedback on outcomes of the behaviour 
- Prompts/cues 
- Information about social and environmental consequences 
- Information about health consequences 
Steps seven and eight focus on how an intervention may be delivered through policy 
categories and delivery mechanisms.   
5.3.5 Step 7: Identification of policy categories: utilising the behaviour 
change functions identified in step 5 
In step seven, the intervention functions identified in step five (training, environmental 
restructuring and education) were utilised to identify the policy categories which may be 
used to support and deliver the intervention.  Policy categories are  
“decisions made by authorities that help to support and enact the interventions” 
(Michie et al, 2014 pp 134) 
Table 45 summarises the candidate intervention functions (education, training and 
environmental restructuring, obtained in step 5), the candidate policy categories aligned to 
these, as per guiding literature, an explanation of what this policy category could mean in the 
context of deprescribing in care homes and then a summary of how the APEASE criteria 
could apply to this policy category.  It highlights that several the policy categories were 
identified multiple times for different intervention functions, and that legislation and fiscal 
measures were discounted for being unacceptable and impractical in this setting.  It also 
identified that environmental restructuring and service provision were likely to be effective 
and acceptable, but beyond the scope of this thesis.  However, environmental restructuring 
and service provision are being implemented as part of the enhanced health in care homes 
Direct Enhanced Service (DES), as outlined in Chapter 1 section 1.3.4.  This suggests that 
the process of identifying policy categories was successful, as categories identified as likely 
successful but beyond the scope of this thesis are being implemented at a higher level.
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Table 45: Identification of the policy categories which could support a deprescribing behaviour change intervention in care homes 
Intervention function Candidate policy 
categories (taken from 
Michie et al, 2014, pp 135) 
The policy category in the 
context of the domain and 
deprescribing in care 
homes 
Does the policy 
category fit the 
APEASE criteria with 
regard to deprescribing 
in care homes? 
Comments, including 
how the APEASE 
criteria 
Training Guidelines (creating 
documents that recommend 
or mandate practice.  This 
includes all changes to 
service provision) 
The production of 
deprescribing guidelines to 
aid with deprescribing 
decisions 
Yes Likely to be affordable, 
practical, acceptable 
with no equity 
concerns or side 
effects.  Effectiveness 
would need assessing. 
Fiscal measures (using the 
tax system to reduce or 
increase the financial cost) 
Amendment to the GP 
contract to include fiscal 
measures related to 
deprescribing in care homes 
No Likely to be effective, 
but may be impractical 
and unacceptable 
depending on the 
methods used.  Side 
effects and equity 
would need to be 
determined 
Regulation (establishing 
rules or principles of 
behaviour or practice) 
Establishing deprescribing 
good practice principles as 
Yes Likely to be affordable, 
practical, acceptable 
with no equity 
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Intervention function Candidate policy 
categories (taken from 
Michie et al, 2014, pp 135) 
The policy category in the 
context of the domain and 
deprescribing in care 
homes 
Does the policy 
category fit the 
APEASE criteria with 
regard to deprescribing 
in care homes? 
Comments, including 
how the APEASE 
criteria 
part of deprescribing 
guidance. 
concerns or side 
effects.  Effectiveness 
would need assessing. 
Legislation (making or 
changing laws) 
Not applicable in this context. Not applicable in this 
context. 
 
Service provision (delivering 
a service) 
Delivering a funded, 
specialised 
deprescribing/medicine 
review service 
No Likely to be effective 
and acceptable, but 
unaffordable and 
beyond the scope of 
this thesis. 
Environmental 
restructuring 
Guidelines  As above As above  
Fiscal measures  As above As above  
Regulation  As above As above  
Legislation  Not applicable in this context. Not applicable in this 
context. 
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Intervention function Candidate policy 
categories (taken from 
Michie et al, 2014, pp 135) 
The policy category in the 
context of the domain and 
deprescribing in care 
homes 
Does the policy 
category fit the 
APEASE criteria with 
regard to deprescribing 
in care homes? 
Comments, including 
how the APEASE 
criteria 
Environmental/social 
planning (designing and/or 
controlling the physical or 
social environment) 
Changing the health and 
social care structure to 
improve the primary care 
provision to care homes 
No Likely to be effective 
and acceptable, but 
unaffordable and 
beyond the scope of 
this thesis. 
Education Communication/marketing 
(using print, electronic, 
telephonic or broadcast 
media) 
The production of materials 
promoting deprescribing 
Yes Likely to be affordable, 
practical, acceptable 
with no equity 
concerns or side 
effects.  Effectiveness 
would need assessing. 
Guidelines As above As above  
Regulation As above As above  
Legislation  As above As above  
Service provision  As above As above  
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Table 45 shows that the following policy categories were identified as the policies most likely 
to support the delivery of a successful deprescribing intervention in care homes: 
- Guidelines (including regulation) 
- Communication/marketing 
In the final step, step 8, the ways in which an intervention may be delivered were identified.  
These were identified by Michie et al (2014), and the APEASE criteria was applied to these 
to determine those which would be most appropriate.  These are displayed below in table 
46. 
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5.3.6 Step 8: Mode of delivery 
Table 46: Modes of delivery for interventions as described by Michie et al (2014) and whether they fit the APEASE criteria in the 
context of deprescribing in care homes 
Mode of delivery Does the mode of delivery meet the 
APEASE criteria in the context of 
deprescribing in care homes? 
Comments 
Face to 
face 
Individual Yes Likely to practical and acceptable with no 
equity or side effect concerns. May be 
designed to be affordable, effectiveness 
would need to be assessed. 
Group Yes Likely to practical and acceptable with no 
equity or side effect concerns. May be 
designed to be affordable, effectiveness 
would need to be assessed. 
Distance Population 
level 
Broadcast 
media 
TV No Not applicable in this context. 
Film No Not applicable in this context. 
Outdoor 
media 
Billboard No Not applicable in this context. 
Poster Yes2 Likely to affordable, practical and acceptable 
with no equity or side effect concerns. 
Effectiveness would need to be assessed. 
 
2 If placed in an appropriate location, for example a GP practice, a care home 
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Mode of delivery Does the mode of delivery meet the 
APEASE criteria in the context of 
deprescribing in care homes? 
Comments 
Print 
media 
Newspaper No Not applicable in this context. 
Leaflet Yes1 Likely to affordable, practical and acceptable 
with no equity or side effect concerns. 
Effectiveness would need to be assessed. 
Digital 
media 
Internet Yes, if on an appropriate website Likely to affordable, practical and acceptable 
with no equity or side effect concerns. 
Effectiveness would need to be assessed. 
Phone app Yes Likely to affordable, practical and acceptable 
with no equity or side effect concerns. 
Effectiveness would need to be assessed. 
Individual 
level 
Phone Phone 
helpline 
No Not applicable in this context. 
Mobile 
phone text 
No Not applicable in this context. 
Individually accessed 
computer program 
Yes Likely to affordable, practical and acceptable 
with no equity or side effect concerns. 
Effectiveness would need to be assessed. 
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5.3.7 Summary of the results 
This process has identified the following: 
- The COM-B components which were prioritised for the development of a 
deprescribing intervention were physical and social opportunity and psychological 
capability. 
- The TDF components which were prioritised for the development of a deprescribing 
intervention were; Environmental Context and Resource; Social Influences and 
Knowledge. 
- The intervention functions that were prioritised for the development of a 
deprescribing intervention were: 
▪ Training 
▪ Environmental restructure 
▪ Education 
- The behaviour change techniques which were identified as potential components of a 
behaviour change intervention were:  
▪ Demonstration of the behaviour 
▪ Instruction on how to perform the behaviour 
▪ Feedback on outcomes of the behaviour 
▪ Prompts/cues 
▪ Information about social and environmental consequences 
▪ Information about health consequences 
- The policies which would potentially support the development of an intervention were 
identified to be: 
▪ Guidance, including regulation 
▪ Communication/marketing 
- The intervention may be best delivered: 
▪ Face to face, either individually or in a group 
▪ Appropriately situated posters or leaflets  
▪ Appropriate websites 
▪ A phone app 
▪ An individually accessed computer programme
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5.4 Discussion of the process of identifying potential intervention 
components for a deprescribing intervention for use in care 
homes 
This section discusses the above findings and provides context for the mapping decisions 
made throughout this thesis.   
Environmental Context and Resources was the domain of the TDF which had the most 
barriers mapped to it.  This suggests that healthcare professionals believe that 
environmental and resource deficiencies are a major barrier to deprescribing in care homes.  
However, the scope of a large-scale behaviour change intervention to change the wider 
health and social care environment in the UK to facilitate communication and resident care is 
limited.  Nevertheless, there are some smaller scale changes to the environment that could 
be made to improve deprescribing behaviour.  This could include computer prompts to assist 
those reviewing the medicines of care home residents, and/or a worksheet to assist with the 
review process to prompt change.  At least one healthcare professional identified the utility 
of computer prompts. 
Changes could be made to influence social change, for example discussing when a 
medicine should be stopped at the prescribing and review stages.  Plans for the resident’s 
medicines could also be discussed on admission to the care home.  Finally, allowing 
healthcare professionals to access Wi-Fi in care homes could facilitate the review process 
and allow them to access the resources they require. 
Most of the behaviour change techniques which were identified as potential intervention 
components related to education and training, which suggests that this is the area in which 
to develop an intervention.  Education and training interventions were a more appropriate fit 
for the APEASE criteria than large scale environmental restructuring, as they are more 
affordable and practical.  Education or training interventions could include workshops or 
distance learning programmes, and incorporate the BCTs demonstration of the behaviour, 
instruction on how to perform the behaviour and information about social, environmental and 
health consequences.   
However, healthcare professionals partaking in the empirical research indicated that they did 
not always believe that training was necessary.  Therefore, any training or education 
problem would have to be developed with healthcare professionals to ensure its 
acceptability.  To improve acceptability, the training could incorporate areas in which 
healthcare professionals indicated that their knowledge could be lacking, for example 
medicines for dementia or mental health.  They could also be employed to increase 
confidence with regard to the consequences of deprescribing or the future benefit of 
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medicines.  Healthcare professionals also indicated that they preferred to learn from 
colleagues, so a mentoring or “buddy” programme could provide healthcare professionals 
with acceptable learning, and feedback on their behaviour.  Any intervention designed as a 
result of this would be co-designed with healthcare professionals, care home staff and 
residents and relatives in order to increase acceptability.  This is discussed further in 
Chapter 6, section 6.6.2. 
It was identified in step seven that the policies that could be developed to support the 
delivery of a deprescribing behaviour change intervention in care homes were guidance and 
communications.  This was reflected by the healthcare professionals who partook in the 
empirical research, who stated that they wanted more deprescribing guidance and evidence.  
Communications and marketing about deprescribing. addressing its consequences and 
opening the dialogue between the key stakeholders in deprescribing, may also facilitate 
deprescribing.  A behaviour change technique that was identified as an intervention 
component was “feedback on outcomes”.  This could be facilitated by communication 
between care home staff and GPs, including ensuing that GPs and care home staff maintain 
a positive relationship with each other.  Communicating the social influences on 
deprescribing could also raise awareness of how perceptions affect deprescribing behaviour, 
and encourage self-reflection and improvement of behaviour.  Finally, residents and relatives 
should also be involved in intervention development to ensure that their views are included 
and respected.  This is discussed further in Chapter 6.6.2. 
5.4.1 Comparison of TDF mapping with other deprescribing studies 
which incorporated the TDF 
The mapping exercises completed in this thesis were compared to the mapping decisions 
made in two articles which mapped barriers to deprescribing to the TDF.  This was 
undertaken in order to ensure consistency in mapping decisions and to validate the mapping 
decisions made in this thesis.   
Ailabouni et al (2016) investigated the challenges and enablers of deprescribing as 
perceived by GPs in New Zealand.  Semi-structured interviews were conducted with ten 
GPs, and the findings were analysed using the TDF and constant comparison techniques.  
Their reasons for mapping the barriers to the TDF are not evident, for example there is no 
mention of how these findings may be used or why it was important to utilise the TDF.  The 
deprescribing beliefs that were mapped to the TDF lacked detail, and were ambiguous in 
their meaning.  Ailabouni et al (2016) also used the original version of the TDF (Michie et al, 
2005) rather than the later, validated version by Cane et al (2012).  There is no rationale 
provided for the decision to use the original TDF.  When these methodological inadequacies 
are considered, the TDF appears to have been superficially applied to this study.   
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The TDF was more rigorously and transparently incorporated into the study by Scott et al 
(2019).  Scott et al (2019) conducted eight focus groups with 54 doctors specialising in 
medicine for older people and pharmacists to provide understanding of their perceived 
barriers and facilitators to deprescribing in a hospital setting in the UK.  Content analysis was 
utilised to analyse the qualitative findings.  The TDF was considered throughout the study, 
and the reasons for the use of the TDF were justified.  The TDF domains identified were 
then prioritised, in order to demonstrate which domains the researchers believed were to be 
targeted by future interventions aiming to change deprescribing behaviours.  While there is a 
lack of justification provided to explain why the themes and subthemes were mapped to the 
domains of the TDF that they were mapped to, the findings are presented clearly with 
relevant quotes provided to support the analysis.  Justification is provided to rationalise the 
prioritisation of the TDF domains.  However, mapping the themes and subthemes to the TDF 
rather than the specific barriers considered within the subthemes means that the mapping 
may be too general and lack accuracy. 
5.4.2 Comparison of TDF mapping for the literature review and similar 
studies  
Firstly, the instances in which there was agreement about which domains barriers to 
deprescribing should be mapped to will be discussed.  Barriers to deprescribing centred 
around the concept of an influential person (be it a healthcare provider, patient, or relative) 
being opposed deprescribing, were mapped to the Social Influences domain of the TDF in all 
four studies.  The findings of the literature review identified a lack of education and training 
as a knowledge barrier, as did Scott et al (2019).  Ailabouni et al (2016) mapped “difficulty 
determining medicines to deprescribe” to the Skills domain, which is similar to the factors 
covered by the “skill deficiencies” barrier in this review; also mapped to the Skills domain.   
The literature review, empirical findings, Scott et al (2020) and Ailabouni et al (2016) 
identified the lack of several resources as barriers to deprescribing, including time, access to 
medical records and decision support systems.  All these were mapped to the environmental 
domain3.  The findings of the empirical interviews and Ailabouni et al (2016) identified 
logistical barriers to communication, such as the accessibility of residents and relatives.  In 
both cases, these barriers were mapped to the environmental domain3.  Ailabouni et al 
(2016) mapped the influence of the beliefs, ideas or concerns of patients to the Social 
Influences domain.  As Ailabouni et al (2016) interviewed GPs to obtain this finding, this 
barrier refers to the GP’s perceptions of patients.  This is similar to the barrier identified by 
 
3 Ailabouni et al, 2016, utilised the original version of the TDF which included the domain 
environmental constraints.  In the validated version used in the other cases, the domain 
is called Environmental Context and Resources 
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the empirical interview data, “healthcare professionals’ perceptions of residents and 
relatives” which was also mapped to the Social Influences domain. 
Finally, the Knowledge domain was utilised in the empirical literature review and findings, 
and by Ailabouni et al (2016) when referring to the knowledge that study participants had 
about deprescribing.  These findings suggest that some barriers are easily mapped to the 
TDF, especially where the barrier explicitly mirrors the definitions of the TDF domains 
provided by Cane et al (2012).  An example of this is “knowledge” being identified as a 
barrier, which is also a domain of the TDF.  It is possible to map these barriers with little 
context. 
There were several barriers which were identified through the collection, analysis and 
interpretation of the empirical interview data that were not identified in the empirical literature 
review, or by Scott et al (2020) or Ailabouni et al (2016).  This highlights the necessity for 
this research, and the in-depth details captured by the empirical research which have not 
previously been described. 
Some barriers were more difficult to map, and as a result there were disagreements between 
the four sources in how to map the barriers.  In the empirical literature review and the 
empirical findings, factors about the resident which affected deprescribing (such as their 
health affecting their ability to communicate) were mapped to the Environmental Context and 
Resources domain, as such patients are a part of the environment of working in care homes.  
Scott et al (2019) had a similar barrier which was mapped to the same domain.  However, 
Ailabouni et al (2016) mapped their barrier about the resident’s lack of ability to 
communicate to the Social Influences domain.  This was considered when mapping barriers 
in this literature review, but it was decided that because the resident was not influencing the 
prescriber through interpersonal processes that the Social Influences domain was not 
appropriate.  This was an example of a barrier that is more difficult to map, and mapping 
such a barrier requires careful consideration of the definitions of the domains as provided by 
Cane et al (2012) and discussion with people experienced in using the TDF.  
Ailabouni et al (2016) also mapped other barriers to the Social Influences domain, where 
Environmental Context and Resources were deemed more appropriate when mapping the 
findings from the empirical literature review and interviews.  The Environmental Context and 
Resources domain refers to “any circumstance of a person’s situation or environment” that 
affects their behaviour, while the Social Influences domain refers to interpersonal factors 
which affect behaviour (Cane et al, 2012).  Ailabouni et al (2016) mapped their barrier “lack 
of adequate reimbursement, communication at points of healthcare transfer” to the Social 
Influences domain.  These two factors, lack of reimbursement and communication at points 
of healthcare transfer, may be more suited to being separated.  If separated, consideration 
should be given to whether reimbursement is a resource barrier, and therefore it would be 
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more appropriate to map it to the Environmental Constraints barrier.  Reimbursement may 
refer simply to funding to provide a service, or recognition and reward for providing a service 
which may be more of a social barrier than a resource barrier.  Communication at points of 
healthcare transfer may be a social influence, but there is insufficient context to justify it 
being mapped to this domain.  In empirical research, such logistical barriers were included in 
the synthesised barrier “systemic barriers to communication” and mapped to the 
Environmental Context and Resources domain as the barrier was a result of the 
environment. 
Beliefs about Consequences was an example of a domain which can be ambiguous in the 
context of deprescribing.  For example, it is clear that a belief that deprescribing will result in 
adverse consequences is linked to the beliefs about Consequences domain.  However, the 
word “fear” was often assigned to Beliefs about Consequences, which means the barrier 
would fit more suitably into the Emotions domain.  In the empirical research, both domains 
were utilised – the Emotions domain for barriers which explicitly mentioned fear, and the 
Beliefs about Consequences domain for ones which did not.  This was reflected by Scott et 
al (2019), who also utilised both domains in the same way.  Ailabouni et al (2016) 
characterised all beliefs about negative consequences as a fear, and mapped this barrier to 
the Emotions domain.  However, it is not clear whether prescribers were actually fearful of 
the consequences or whether this descriptor was attached by Ailabouni et al (2016).  In 
addition to this, the original version of the TDF employed by Ailabouni et al (2016) does not 
include a Beliefs about Consequences domain which may have influenced their choice of 
words and mapping decisions. 
Confidence is another barrier which can be ambiguous in the context of deprescribing.  In 
the empirical literature review, confidence was mapped to Beliefs about Capabilities.  Beliefs 
about Capabilities is referred to by Cane et al (2012) as 
“acceptance of the truth, reality or validity about an ability, talent or facility that a 
person can put to constructive use”. (Cane et al, 2012) 
This reflects a prescribers confidence and belief in their ability to deprescribe.  This decision 
was also made by Scott et al (2020) and Ailabouni et al (2016).  However, the depth of the 
findings provided by the empirical interviews showed that, in the empirical research, lack of 
confidence stemmed from a lack of knowledge.  For this reason, the confidence barrier was 
mapped to the Knowledge domain. 
Lack of evidence and guidance as a barrier to deprescribing was also treated differently.  In 
the empirical research, both the literature review and findings, it was mapped to both the 
Knowledge and Environmental Context and Resources domain.  This was because the 
availability of such evidence impacts upon the knowledge the healthcare professionals have 
of deprescribing, but its lack of availability is a systemic barrier rather than an individual 
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issue.  This is because individuals are not responsible for producing systemic guidance.  
Ailabouni et al (2016) mapped the barrier to the Knowledge domain, whilst Scott et al (2019) 
mapped their barrier “treatment guidelines” to the social influence domain.  There is a lack of 
context to explain why this barrier was mapped to the Social Influences domain which is 
defined by Cane et al (2012) as regarding interpersonal processes.  It is unclear whether it is 
the most appropriate domain for this barrier. 
The final barrier to be discussed is the influence of other prescribers, which in the empirical 
literature review was mapped to the Social Influences domain.  This is because the influence 
of other prescribers was perceived to be due to the interpersonal factors that exist between 
prescribers.   Ailabouni et al (2016) characterised “the reluctance to change medicines 
prescribed by a specialist” as an emotion and mapped it to the Emotions domain.  Again, 
there is a lack of detail provided to determine whether this was an appropriate choice, as 
while reluctance could be classified as an emotion it would be useful to know why 
participants were reluctant to stop medicines started by a specialist.  This may provide more 
insight into why GPs participating in Ailabouni et al’s (2016) study were not willing to 
deprescribe medicines started by a specialist. 
Table 47 is summarises the similarities and differences in how Scott et al (2019) and 
Ailabouni et al (2016) mapped barriers similar to those found in the empirical research and 
the literature review to the TDF.   
Key: (L) synthesised barrier identified in the literature review 
        (E) synthesised barrier identified in the findings of the empirical interview data 
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Table 47: Comparison of TDF mapping for literature review and similar studies 
Synthesised barrier identified in this 
thesis and the domain it was mapped to 
Comparable Barrier identified by Scott et 
al (2019) and the domain it was mapped 
to 
Comparable Barrier identified by Ailabouni 
et al (2016) and the domain it was mapped 
to 
L+E Influence of the resident’s health: 
Environmental Context and Resources 
Artificial patient status (factors such as the 
patient having set mealtimes and their 
medicines managed by staff): 
Environmental Context and Resources 
Patient’s ability to communicate: Social 
Influences 
L+E Opposition of others to deprescribing: 
Social Influences 
Patient and carer attachment to medicines: 
Social Influences 
Patient beliefs, ideas, concerns or preferences 
Involving family members or relatives 
Influence of nurses’ suggestions: all mapped to 
Social Influences 
L+E Negative beliefs about consequences: 
Beliefs about Consequences 
Adverse outcomes for patients, practitioners 
and hospitals: Beliefs about Consequences 
Fear of potential negative consequences of 
deprescribing: Emotions 
L+E Emotions felt towards deprescribing: 
Emotions 
Fear of consequences and assuming 
responsibility: Emotion 
Fear of potential negative consequences of 
deprescribing: Emotions 
L+E Lack of funding: Environmental Context 
and Resources 
Not covered Lack of adequate reimbursement, 
communication at points of health care 
transfer: Social Influences 
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L+E Skill deficiencies: Skills Not covered Difficulty determining medicines to 
deprescribing, and appropriate timing of 
deprescribing: Skills 
L+E Lack of evidence and guidance: 
knowledge, Environmental Context and 
Resources 
Treatment guidelines: social influence Uncertainty about the relevance of evidence-
based guidelines to older people with 
multimorbidity 
Lack of guidelines relevant to deprescribing in 
older people with multimorbidity: both mapped 
to knowledge 
L Confidence to deprescribe: Beliefs about 
Capabilities 
E Confidence to deprescribe: knowledge 
Pharmacists lack confidence to make 
decisions: Beliefs about Capabilities 
Not covered 
L Lack of education and training: knowledge Deprescribing education is poor: knowledge Not covered 
L Systemic barriers to communication: 
Environmental Context and Resources 
Not covered Lack of adequate reimbursement, 
communication at points of health care 
transfer: Social Influences 
L Knowledge deficiencies of GPs, care 
home staff, residents and relatives: 
Knowledge 
Not covered GPs’ knowledge about deprescribing: 
Knowledge 
L Influence of other prescribers: Social 
Influences 
Not covered Reluctance to change medicines prescribed by 
a specialist: Emotions 
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4 Environmental Constraints and Motivation and Goals were domains in the original version of the TDF (Michie et al, 2005) and were replaced 
in the validated version (Cane et a, 2012) 
E Healthcare professionals’ perceptions of 
residents and relatives: Social Influences 
Not covered Patient beliefs, ideas, concerns or preferences: 
Social Influences 
E Logistical barriers to communication: 
Environmental Context and Resources 
Not covered Accessibility of the residents or patients: 
Environmental Constraints4 
E Prioritising deprescribing: intentions Hospital’s primary role is acute care: 
Social/Professional Role and Identity 
Deprescribing is not a hospital’s priority: 
Goals 
Competing factors and (time, rest home 
practices, other prescribers) decrease 
motivation to deprescribe: Motivation and goals 
Multiple competing demands of professional 
role: Environmental Constraints 
E Lack of resources: Environmental Context 
and Resources 
Incomplete medication history: 
Environmental Context and Resources 
Access to clinical notes: Environmental 
Constraints 
Lack of decision support systems: 
Environmental Constraints 
E Staffing issues: Environmental Context 
and Resources 
Not covered Not covered 
E Setting goals of care: Goals Not covered Not covered 
E The attitude of the GP towards care home 
work: Social Influences 
Not covered Not covered 
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E Avoidance of difficult discussions: Social 
Influences 
Not covered Not covered 
E Uncertainty of roles: Social/Professional 
Role and Identity 
Not covered Not covered 
E Navigating primary care systems: 
Environmental Context and Resources 
Not covered Not covered 
E Barriers posed by regulatory and payment 
systems: Environmental Context and 
Resources 
Not covered Not covered 
E Perceptions of pharmacists: Social 
Influences 
Not covered Not covered 
E Knowledge deficiencies of care home 
staff: Knowledge 
Not covered Not covered 
220 
 
 
A further study which investigated behaviour change techniques and improving appropriate 
polypharmacy must be noted.  Cadogan et al (2015) interviewed GPs and community 
pharmacists in the UK, utilising interview schedules informed by the TDF, regarding their 
perceptions of barriers and facilitators to prescribing and dispensing appropriate 
polypharmacy for older people in the UK (Michie et al, 2005; Cadogan et al, 2015).  The 
qualitative findings were analysed deductively using the TDF, and then domains of the TDF 
were prioritised and mapped to Behaviour Change Techniques (Cadogan et al, 2015). 
Whilst elements of Cadogan et al’s (2015) study seem similar to the empirical work 
undertaken in this thesis, the findings are incomparable to the empirical findings.  Firstly, 
Cadogan et al (2015) were investigating improving appropriate polypharmacy.  This is not 
defined by the authors, but it is likely that improving appropriate polypharmacy may also 
include starting appropriate medicines, increasing and decreasing doses and monitoring 
medicines.  Unlike Scott et al (2019) and Ailabouni et al (2016), whose findings were 
compared to the findings of the empirical research, Cadogan et al (2015) did not analyse 
their findings inductively and then map them to the TDF.  The findings were analysed 
deductively using the TDF, and the findings were presented as domains of the TDF with a 
brief description of the factors assigned to that domain during the analysis.  It was not 
appropriate to relate all these factors to deprescribing, as the study did not explicitly address 
this.  Furthermore, there were some methodological inaccuracies.  The original version of 
the TDF was utilised, and whilst justification was provided for this it was not compatible with 
the BCT mapping process.  This is because the source utilised for mapping the TDF 
domains to BCTs was based on the validated version of the TDF.  This means the results 
lack validity and are unsuitable for direct comparison with the findings of the empirical 
research.   
5.4.3 Advantages and disadvantages of applying the TDF to this 
research 
Mapping the findings of the empirical study to the TDF, and subsequent mapping exercises, 
was completed successfully.  There were a few disagreements between the author and the 
member of the supervisory team that reviewed the work that required resolving through 
discussion.  As the author was immersed in the data, the context required to make mapping 
decisions was present and all mapping decisions could be supported by reference to the 
empirical data.  As such, it was easier to map the empirical findings to the TDF and 
subsequent frameworks than it was to map the findings of the literature review.  This is 
because the depth and detail of the empirical findings allowed for the nuances of the data to 
be understood and accurately mapped. 
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There are multiple strengths associated with this method for identifying components of a 
behaviour change intervention.  Utilising the systematic methodology described by Michie et 
al (2014) ensured that the behaviour was considered holistically, and that as many aspects 
of the behaviour possible were included.  Any intervention developed as a result of this work 
will also be targeted at the barriers, and therefore behaviours, identified as future users of 
the intervention as key barriers to deprescribing in care homes. This has provided a 
complete, strong foundation for a behaviour change intervention, rooted in theory, which 
means that it is more likely to be successful (Medical Research Council, 2006; Michie et al, 
2014).   
However, whilst a behaviour change intervention may assist individual healthcare 
professionals to improve their deprescribing behaviour in care homes, it may not improve the 
communication difficulties which participants in the empirical interviews reported.  The 
intervention functions which were identified using the prioritised domains of the TDF and 
which also fit the APEASE criteria – education, training and environmental restructuring - 
may not improve the social barriers to deprescribing as much as they may affect the 
knowledge related barriers to deprescribing.  These intervention functions could be tailored 
to the social influences, for example through educating and training healthcare professionals 
about the needs and expectations of residents and relatives.  Some healthcare professionals 
partaking in the empirical interviews also indicated that they did not believe they would 
benefit from education or training, and so they may not benefit from such an intervention.  
Whilst the APEASE criteria, applied throughout this chapter, accounted for the acceptability 
of the intervention, the intervention would need to be co-designed with residents, relatives, 
GPs, care home staff and pharmacists in order to ensure it was acceptable to all groups. 
A further limitation is that this method of intervention development has focused on healthcare 
professionals, as the users of any potential intervention.  However, it is important that 
residents, relatives and care home staff are also considered throughout the intervention 
development process.  They would be involved in the design of any intervention, and they 
were involved in the preliminary work for this chapter by being interviewed for the empirical 
research.  Perceptions healthcare professionals held of residents and relatives, and the 
validation or rejection of these perceptions by the residents and relatives interviewed, would 
also be considered during intervention design.  The co-design of the intervention with 
residents, relatives and care home staff as well as healthcare professionals would be 
imperative to the intervention development process.  The potential involvement of these 
groups is described in Chapter 6, section 6.6.2. 
There are also criticisms of this method for designing an intervention.  It is possible that 
Michie et al’s (2014) design is incomplete, and did not include all relevant behaviour change 
frameworks.  However, they describe a robust methodology and conducted a rigorous 
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systematic review in order to minimise the possibility of this (Michie et al 2014).  Michie et al 
(2013) described the behaviour change technique taxonomy, the list of 93 behaviour change 
techniques utilised in step six (section 5.3.4), as a basic list which it was intended would be 
improved over time.  However, no such improvement has been published.  They also noted 
the lack of diversity in the Delphi group (Michie et al, 2013).  This may mean that the 
behaviour change taxonomy utilised lacks depth and is not sufficiently sophisticated to 
inform the development of a behaviour change intervention.  However, the process 
undertaken in this thesis represents only the beginning of the development of a behaviour 
change intervention, and any intervention would be developed in the wider context of the 
setting, in conjunction with the people who would be using it and the people who would be 
affected by it. 
5.4.4 Summary 
This chapter utilised the BCW, TDF and COM-B models to identify candidate components of 
a behaviour change intervention to facilitate deprescribing in care homes.  It was identified 
that a behaviour change intervention should target training, education and smaller scale 
physical and social environment changes.  The BCTs which would comprise the intervention 
should include demonstration and instruction on how to perform the behaviour, feedback on 
outcomes of the behaviour, prompts and information about social, environmental and health 
consequences.  The intervention could be delivered face-to-face or by distance, and would 
be supported by guidance, communication and marketing. 
The final chapter is the discussion, which brings all aspects of the thesis together and 
describes its findings, impact and importance. 
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Chapter 6 Discussion and Conclusions 
6.1 Introduction 
This final chapter, discussion and conclusions, brings together the previous chapters to 
contextualise the findings in the literature, policy and current practice.  The chapter includes 
a summary of the thesis, followed by contextualisation of the findings of the empirical work 
undertaken.  These are presented under four headings: 
- Disjointed structures and systems of working across health and care contexts  
- The unique context of care homes 
- Ensuring shared decision-making  
- Promoting medicine optimisation by addressing behaviour change  
Finally, the strengths and limitations of the work undertaken, implications for policy and 
practice, how the research adds to the body of knowledge and a reflective account of the 
personal impact of the work are presented. 
This thesis was undertaken to address the following aim and objectives: 
Aim 
To investigate the barriers and facilitators to deprescribing for older people living in care 
homes. 
Objectives 
- To examine the existing evidence of barriers and facilitators to deprescribing 
unnecessary medicines for older people living in care homes 
- To investigate how the deprescribing process happens in care homes, including the 
roles and responsibilities of those involved 
- To explore how older people living in care homes, and their relatives, perceive their 
medicines (or medicines taken by the resident) and their attitudes to deprescribing 
- To explore the attitudes of healthcare professionals and care home staff towards 
deprescribing in care homes, including identification of perceived barriers and 
facilitators to deprescribing. 
- To use the evidence and findings to identify behaviour change techniques that may 
inform the development of a novel intervention.  
6.1.1 Overview of the thesis 
There is evidence that older people in care homes are prescribed inappropriate medicines 
(Shah et al, 2013; Stafford et al, 2011).  Taking inappropriate medicines can lead to an 
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increased risk of a care home resident experiencing side effects, falls, hospital admissions 
and drug interactions, all of which can negatively affect a resident’s quality of life (Masnoon 
et al, 2017).  This thesis sought to address this important problem, investigate why older 
people in care homes are prescribed inappropriate medicines, and what the barriers are to 
stopping these medicines.  This is important, as reducing the inappropriate medicines 
prescribed for care home residents may improve their care, outcomes and quality of life and 
potentially save the NHS millions of pounds (Royal Pharmaceutical Society, 2016). 
Firstly, it was necessary to understand the work already undertaken in this area, which was 
addressed by the literature review (Chapter 2).  The literature review revealed nine studies 
had been conducted investigating deprescribing in care homes, and four systematic reviews 
which were relevant to the topic (Ailabouni et al, 2016; Turner et al, 2016; Azermai et al, 
2013; Ellis et al, 2014; Mavrodaris et al, 2013; Harriman et al, 2014; Kalogianis et al, 2015; 
Palagyi et al, 2016; Simmons et al, 2017; Reeve et al, 2013; Anderson et al, 2014; Lundby et 
al, 2019; Bokhof and Junius-Walker, 2016).  The systematic reviews were utilised to 
contextualise the findings, but none were specific to the care home setting and instead 
focussed on patients, prescribers and older people.  The literature review revealed 
numerous barriers to deprescribing in care homes, for example lack of evidence and 
guidance, knowledge deficiencies and lack of resources such as staff and time.  However, 
the findings of the literature review lacked the depth and detail for truly accurate mapping to 
the TDF, and only one study was conducted in the UK.  These deficiencies provided the 
focus for the work conducted for this thesis, which sought to gain an in depth understanding 
of the barriers and facilitators to deprescribing in care homes in the UK.  This understanding 
would be utilised define the components, such as behaviour change techniques and delivery 
mechanisms, that could be incorporated into a novel behaviour change intervention to 
facilitate deprescribing in the care home setting. 
The theoretical underpinning for the thesis was the TDF, which provided a “lens” for the 
study.  The TDF was utilised because it is a composite framework of factors which influence 
behaviour (Cane et al, 2012; Francis et al, 2012).  It can be utilised in combination with other 
frameworks and mapping devices, such as the COM-B and Behaviour Change Wheel, to 
identify behaviours that require change and ways in which they may be changed.   There is 
also extensive experience with using the TDF to investigate behaviours in healthcare, 
including prescribing and deprescribing.  This provided a foundation of support for using the 
TDF in the work conducted for this thesis. 
To conduct the study, a range of stakeholders were interviewed.  Care home residents and 
their relatives were interviewed, alongside GPs, care home staff and primary care 
pharmacists.  The findings were analysed using framework analysis and interpreted through 
three themes:  
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- “There’s more stakeholders than you might have with a regular, average patient” the 
roles, beliefs and knowledge of the individuals involved in deprescribing in care 
homes.   
- Perceptions of others and difficult conversations: social barriers and facilitators to 
deprescribing in care homes. 
-  Working together, navigating systems: logistical barriers and facilitators to 
deprescribing in care homes 
These themes reflect those factors related to the individuals involved in deprescribing, and 
those related to the interaction between these individuals and the individuals and their 
environment.  This included barriers such as knowledge deficiencies, beliefs about 
consequences, navigating healthcare systems and social barriers.  The findings of this thesis 
provided an in-depth understanding of the barriers present in the UK, such as those 
presented by navigating primary care systems.  It also provided more insight of the social 
influences which affect deprescribing behaviour, such as perceptions that healthcare 
professionals have of residents and relatives and their avoidance of conversations they 
perceive to be difficult.    
The findings were then used to identify the potential components of a deprescribing 
behaviour change intervention for use in care homes.  This identified that, broadly, 
education, training and environmental restructuring are key areas for intervention 
development in this field.  Furthermore, it identified that Behaviour Change Techniques such 
as demonstrating the behaviour, the provision of prompts and feedback may be successful, 
as would supporting these Techniques through guidance.  This final chapter summarises the 
work presented in this thesis, comparing the findings with existing literature and placing it in 
the current contexts of policy and practice. 
6.1.2 Key findings from the empirical work 
When investigating the roles of the key stakeholders interviewed for the empirical interviews, 
it was clear that GPs had the most clearly defined and well understood role as the prescriber 
with responsibility for the resident’s medicines.  There was uncertainty about what the role of 
pharmacists was and whether they needed to be in independent prescribers, and some 
residents and relatives were unsure that pharmacists had the knowledge to perform a role in 
deprescribing.  The role of care home staff in deprescribing was limited to being a 
messenger, as some they were perceived by themselves and others to lack the clinical 
knowledge to have more responsibility in the deprescribing process.  Relatives understood 
their role as the resident’s advocate and perceived it as difficult to enact; difficulties which 
were not appreciated by other participants.  Residents were not acknowledged by 
themselves or others to have a clear role in the deprescribing process, despite it being their 
medicines at the centre of the deprescribing conversation. 
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When discussing the barriers to deprescribing, GPs and pharmacists did not perceive their 
own lack of knowledge to be a major barrier. Instead, any knowledge deficiency was 
believed to be due to the lack of evidence and guidance available to assist and support 
deprescribing decision-making.  This was perceived as a systemic barrier to deprescribing 
rather than an individual barrier arising from a personal lack of knowledge.  Emphasis was 
also placed on systemic barriers such as a lack of time, staff and their high workload.  The 
current provision of GP and primary care services to the majority of care homes was not 
believed to be conducive to deprescribing.  Instead, health and social care systems were 
perceived as difficult to navigate, with GPs, pharmacists and pharmacists reporting 
difficulties in locating and communicating with the person they wished to speak to.  This 
extended further to hospital specialists and relatives. 
Care home residents and their relatives generally lacked knowledge about medicines and 
were content to agree with the healthcare professional when deprescribing decisions were 
being made.  Those with more knowledge of their medicines were more challenging of 
deprescribing decisions.  A major difference between GPs and pharmacists and residents 
were that residents generally believed all their medicines were beneficial.   GPs and 
pharmacists, however, acknowledged that the opposite was true and that there were 
residents in their care taking inappropriate medicines. 
It was important for all stakeholders to maintain effective working relationships between each 
other.  However, the relationships between the resident and the healthcare professional and 
the relative and healthcare professional were of particular importance.  The resident often 
displayed a great deal of trust in the GP and relied on them to make the correct decisions 
about their medicines.  GPs and care home staff were often viewed as an authority figure to 
be obeyed, rather than someone with whom to engage in decision-making.  Meanwhile, 
relatives who wished to be involved in the resident’s care and were challenging of 
prescribing decisions were viewed negatively by healthcare professionals.   
There was evidence that beliefs about the potential negative consequences of deprescribing 
may deter participants from deprescribing.  However, healthcare professionals often noted 
positive consequences of deprescribing which led them to believe that deprescribing can be 
beneficial for residents.  Residents and relatives were, on the other hand, generally unaware 
of the potential positive consequences of deprescribing, and many residents were 
unconcerned about any consequences of deprescribing at all. 
Healthcare professionals acknowledged the importance of discussing life expectancy and 
quality versus quantity of life when deprescribing for older people, such as those living in 
care homes.  However, this link was not apparent to residents and relatives and most were 
unwilling to think about a future where the resident may be unwell and need changes to their 
medicines.  This gave rise to conversations perceived by healthcare professionals as 
227 
 
 
“difficult” which were consequently avoided; however, these conversations are potentially 
important facilitators of deprescribing. 
The following sections (6.2-6.6) contextualise the findings with existing literature, policies 
and practices in the UK. 
6.2 Disjointed structures and systems of working across health 
and care contexts 
A predominance of barriers to deprescribing in care homes identified in both the empirical 
research and the literature review were focussed on the structure of health and social care 
systems.  The findings of the literature review described how health and social care systems 
in other countries such as Australia acted as a barrier to deprescribing, for example GPs in 
Australia perceive care home work to be inadequately reimbursed to be desirable (Palagyi et 
al, 2016).  The empirical work identified that the way that health and social care systems are 
structured in the UK affects the ability of GPs and pharmacists to deprescribe in care homes.  
This also complicated communication between care homes, GPs and other healthcare 
professionals.  Few GPs reported protected time to visit or review care home residents, 
meaning that they believed they were unable to prioritise deprescribing for residents.   
6.2.1 Reactive vs proactive care 
Many of the barriers to deprescribing identified in Chapter 4 related to the structure of the 
health and social care system in the UK.  Despite there being more beds in care homes than 
there are in the NHS (Age UK, 2019, Anandaciva et al, 2020), care homes are currently on 
the periphery of the health and social care system.  Many of the 400,000 people who live in 
care homes in the UK have complex medical histories, and yet there is no structured way to 
provide routine GP care to the residents who live there (Gordon et al, 2014; Barber et al, 
2009).  This empirical research and the literature review identified that GP care is often 
provided to residents on a reactive, rather than proactive, basis (Harriman et al, 2014).  This 
was also identified in the Care home staff and GPs partaking in this study reported that they 
mainly saw care home residents when the resident was experiencing an acute issue.  Once 
the issue had been dealt with, it was unlikely the GP would consult with the resident again 
unless they were to experience another problem.  This is an example of reactive care, which 
is a barrier to proactive deprescribing (Wright et al, 2015).  Proactive deprescribing would 
involve the healthcare professional reviewing a resident’s medicine before any problems 
occurred and stopping any potentially inappropriate medicines before they cause the 
resident harm (Wright et al, 2015).   
Providing care reactively rather than proactively can be problematic, as dealing with 
problems as they arise rather than preventing them through proactive care can cause harm 
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to the patient and be more costly (Royal Pharmaceutical Society, 2016).  The medical 
intervention required when a resident experiences a fall or adverse drug reaction is also 
potentially more costly to the NHS than a medicines review; the RPS estimated that £75 
million could be saved through reduced hospital admissions as a result of medicines 
optimisation (Royal Pharmaceutical Society, 2016).  Over recent years, one of the goals of 
the NHS has been to focus on prevention of illness through, for example, supporting people 
to live healthier lifestyles and screening programmes aimed at identifying at risk groups 
(NHS 2019).  Proactive deprescribing is an example of preventative care, as stopping 
unnecessary medicines can reduce the risk of future harm to a resident (Royal 
Pharmaceutical Society, 2016).   
There is evidence that it is not only in care homes in the UK where deprescribing occurs 
reactively instead of proactively.  Scott et al (2018) showed that 16 % of deprescribing 
conducted in a UK hospital was proactive, and 84% was reactive.  While there are no similar 
statistics for care homes, Scott et al’s findings are evidence of a larger problem and one 
faced by healthcare professionals across settings.  A possible reason for this is that GPs and 
hospital doctors do not prioritise deprescribing.  This could be due to perceived limited 
opportunity to deprescribe, or a lack of motivation to deprescribe; the evidence suggests that 
the former is the primary reason for a lack of deprescribing (Palagyi et al, 2016; Scott et al; 
2018, Turner et al, 2016). 
Whilst there have been multiple resources produced outlining the risks of polypharmacy and 
the benefits of medicines optimisation, the findings from the empirical work provided 
evidence that GPs believed they were not currently able to proactively deprescribe and that 
medicines reviews were lacking (Scottish Government Polypharmacy Model of Care Group, 
2018; Royal Pharmaceutical Society, 2020).  Steps have been taken to address this 
recently, with pharmacists being employed by GP practices and CCGs to undertake 
medicine reviews and recommend how medicines may be optimised.  However, healthcare 
professionals who participated in this study believed that there were still many care home 
residents whose medicines were not reviewed, and who may be taking inappropriate 
medicines.   
The findings of the empirical work presented in Chapter 4 suggested that routine, proactive 
deprescribing was not a priority for GPs who did not have protected time to conduct this 
activity.  The literature review did not identify prioritisation specifically as a barrier to 
deprescribing, but time was a frequently identified barrier to deprescribing.  Indeed, the 
participants interviewed for this thesis did not explicitly state that they did not prioritise 
deprescribing.  Instead, this was identified from data where GPs described their high 
workload and lack of time.  In this way, GPs identified that other tasks were more important 
or urgent than proactive deprescribing for care home residents.  Time was a barrier to 
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deprescribing that was referred to by every healthcare professional who participated in the 
empirical work, and it was identified by healthcare professionals in the literature review 
(Ailabouni et al, 2016; Ellis et al, 2014; Palagyi et al, 2016).  
It is hard to determine what the barrier “lack of time” means in reality.  It has been identified 
that people often believe that external factors affect their behaviour more than intrinsic 
factors (Duncan et al, 2012).  In this way, stating that a lack of time is influencing behaviour 
is convenient, socially acceptable and supported by the description of other tasks which 
require completing.  However, an internal factor that may explain why lack of time is a barrier 
is that prescribers may not feel comfortable admitting that they do not prioritise 
deprescribing.  This may be because they believe they should be deprescribing to reduce 
the prevalence of inappropriate prescribing, but they are not enacting this behaviour.  The 
empirical research demonstrated that all healthcare professionals believed there were 
residents in their care taking unnecessary medicines and attached feelings such as shame 
to this fact.  They also acknowledged that deprescribing was a useful way to reduce the 
inappropriate medicines taken by care home residents.  However, it was the perception of 
healthcare professionals that this was due to external factors influencing their behaviour, 
rather than anything they could change themselves. 
6.2.2 The provision of GP services to care homes 
A common, shared issue for care home staff, GPs and pharmacists was that the GP care 
provided to care homes was uncoordinated and complex.  One member of care home staff 
described having to deal with five GP surgeries to provide care to her residents, each of 
which had different systems to navigate.  This was a problem for care home staff who found 
it difficult to communicate with the GP they wanted to, and it was also a problem for 
pharmacists employed by the CCG to provide medicine services to care homes.  CCG-
employed pharmacists reported visiting care homes to review the medicines of all residents, 
and then having to liaise with multiple GP practices to implement their deprescribing 
recommendations.  Both pharmacists and care home staff found this time consuming, and 
reported that it prevented them from building relationships with GPs which they believed 
would facilitate deprescribing. 
GPs who did not have the protected, and/or funded, time to provide this service were unable 
to prioritise the routine review of care home residents, instead reporting that this was most 
likely to happen annually.  In this way, they felt they were only able to offer reactive care to 
care homes rather than the potentially more beneficial proactive care.  Given the limited life 
expectancy of care home residents and the complexity of their medical history, annual 
reviews may not be sufficiently frequent.  It is possible that the change in primary care 
provision to care homes, facilitated by PCNs and outlined above, could facilitate 
deprescribing in care homes. 
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In contrast, care home staff, pharmacists and GPs who had worked in care homes where a 
single, named GP took responsibility for all care home residents reported satisfaction with 
this system.  The GP visited on a set day each week, and non-urgent tasks were saved by 
care home staff for the GP’s visit.  The GP knew the care home residents and staff well and 
had the opportunity to review medicines regularly.  Both care home residents and staff 
believed that this facilitated consultations with the GP,  and there was a lot of praise for the 
system.  However, this care home was in the minority because residents currently choose 
their care home and their GP.  This system will be introduced in 2020 as part of the 
enhanced health in care homes Direct Enhanced Service by Primary Care Networks across 
England, as described in Chapter 1 section 1.3.4 (Primary Care Strategy and NHS Contracts 
Team, 2019).   
There are also potential disadvantages to this system.  In order for the system to work, 
residents would have to move from their current GP practice to a new one.  However, 
healthcare professionals participating in the interviews reported in Chapter 4 stated that 
medical records could be inaccessible for the new care team when a resident moved to a 
new practice, and that this was a barrier to deprescribing.  Residents may not want to move 
to a different GP practice, as moving to a new care home may also end long-standing 
doctor-resident/relative relationships, and require residents and relatives to build new 
relationships with healthcare professionals.  New relationships may take time to establish, 
and successful relationships between the resident, relative and healthcare professionals 
were identified as key to the deprescribing process by the empirical research.  The time 
taken to build a new relationship could act as a further barrier to deprescribing. 
Pharmacists employed by CCGs to provide medicine reviews to care homes had more time 
than GPs to conduct reviews, as reviewing care home residents was the main part of their 
workload.  However, they felt they did not have the resources to review the required number 
of residents due to their large workload and reported only being able to review a small 
proportion of care home residents.  Pharmacists called for more resource, such as pharmacy 
technicians and additional pharmacists, to assist them.  This was, in part, addressed by the 
NHS England Medicines Optimisation in Care Homes initiative that provided funding for 350 
new pharmacy roles in care homes, to relieve the burden on current staff and potentially aid 
the deprescribing process in care homes (Baqir and Joshua, 2018/).  It will also be 
addressed by the multi-disciplinary team allocated by the PCN who will be providing care to 
care homes. 
6.2.3 1.1.1   A standard approach to deprescribing 
In addition to there being no standard approach to the provision of GP care to care homes, 
there was reported to be no standard approach to deprescribing.  Each pharmacist and GP 
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interviewed described how they would review the medicines of care home residents with a 
view to deprescribing.  However, they rarely reported using a specific framework, guidance 
or evidence to deprescribe and the approach described was variable across the participants. 
This may risk important parts of the process being omitted or not considered by some 
practitioners. 
One GP described how doctors are taught how to prescribe, and there were significant 
resources available to support prescribing.  However, there was not the same support 
available to assist with deprescribing decisions and deprescribing was reported not to be a 
skill that was taught in the same way as prescribing.  Several interventions aimed at 
optimising medicines, including deprescribing, in care homes have been developed and 
tested (Kua et al, 2018).  Whilst deprescribing is most often enacted through medicine 
review, there is no standardised way of providing medicine reviews to care homes.  This 
finding was reported by the empirical findings, which also supports the fact that none of the 
tools or interventions developed have experienced systemic uptake into practice supported 
by frequent and widespread use by healthcare professionals.  
The STOPP criteria has experienced some uptake into practice, as it has been incorporated 
into the GP Electronic Health Record as reported by a pharmacist participant in the 
interviews.  However, knowledge of it was not widespread and some participants claimed it 
was too time consuming to use.  Therefore, participants preferred to utilise their experience 
and knowledge of medicines to deprescribe, rather than assistive tools such as 
STOPP/START.  The STOPP criteria is an explicit tool consisting of a list of medicines that 
may be inappropriate for older people, and that can therefore assist healthcare professionals 
to deprescribe for this cohort (Curtin et al, 2019; O'Mahony et al, 2014).  It is accompanied 
by the START tool, which is a list of medicines which it may be appropriate to start in older 
people.  Multiple studies have applied the STOPP criteria to the medicines of care home 
residents, and all of them reported that it resulted in a reduction in the number of medicines 
deemed inappropriate by the criteria medicines prescribed in this setting. (Curtin et al, 2019, 
original paper 2015).  Other tools were rarely mentioned by participants in the empirical 
research. 
The Beers criteria is a similar tool to STOPP/START, in that it is a list of medicines that 
healthcare professionals may consider deprescribing in older people (Poudel et al, 2013).  
However, it has been criticised for being less applicable in the UK than it is in the US, where 
the tool originated, as it features multiple medicines which are not licensed for use in the UK.  
This may be why it was not reported as a widely used tool by participants in the empirical 
research.  Several deprescribing frameworks have also been developed that aim to guide 
healthcare professionals through the deprescribing process (Woodward, 2003, Scott et al, 
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2015; Todd et al, 2018).  Whilst none of these are specific to care homes, many facets of the 
process are the same and Todd et al’s (2018) focuses on older people. 
The first deprescribing framework was published by Woodward in 2003 (Woodward, 2003; 
Alldred 2014) and proposed deprescribing as a process that could improve the poor 
outcomes related to polypharmacy in older people, such as adverse events and hospital 
admissions.  It was suggested deprescribing was a five part process, and that the patient 
and their relatives/carers should be consulted throughout (Woodward et al 2003): 
1. Review all current medicines 
2. Identify medicines to be targeted for deprescribing 
3. Plan a deprescribing regimen 
4. Plan in partnership with patient and carers 
5. Frequent review and support 
As evidence for deprescribing has increased in volume and quality since 2003, further 
deprescribing guidelines have been developed and published such as that published by 
Scott et al (2015).  Their five step process is more comprehensive than the one proposed by 
Woodward (2003), although its focus is not older people or the care home population.  The 
five step process included by Scott et al (2015) included: 
1. Ascertain all medicines the patient is taking, and the indications for each one 
2. Consider factors such as number of medicines, number of high risk medicines, the 
patient’s age co-morbidities and adherence to medicines 
3. Assess each medicine for its eligibility to be discontinued, considering multiple 
medicine and patient factors some of which are present in flow chart in Figure 18 below. 
4. Prioritise medicines for discontinuation, also using the flow chart in Figure 18 below. 
5. Implement and monitor deprescribing regimen. 
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Figure 18: The deprescribing framework proposed by Scott et al (2015) 
Scott et al (2015) highlighted the importance of considering both the medicine and the 
patient at each stage in the deprescribing process.   
A further framework designed to ensure that the deprescribing process is patient-centred 
was published by Todd et al (2018), and this framework focuses on older people.  The 
“deprescribing rainbow” highlights five key points that healthcare professionals should 
consider during the deprescribing process to ensure that the older patient’s beliefs, values 
and concerns are accounted for.   
Todd et al (2018) indicated a range of aspects that fall under each of the factors present in 
the rainbow with consideration of these factors ensuring a holistic approach to deprescribing, 
and that the patient is involved to the extent that they wish to be involved.  The deprescribing 
rainbow reflects many of the factors of deprescribing considered important by the 
participants of the empirical research, for example: the impact of social influence on 
deprescribing behaviour, the importance of considering the patient’s health beliefs and 
attitudes and the necessity for consideration of the benefits and harms of medicines.  Some 
examples of the factors identified by Todd et al (2018) are presented in Table 48 below:
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Table 48: Examples of factors to be considered by utilising the deprescribing rainbow 
(Todd et al, 2018) 
Factors identified as important by the 
deprescribing rainbow (Todd et al, 
2018) 
Examples of aspects to be 
considered within these factors 
(Todd et al, 2018) 
Clinical Benefits and harms of medicines, 
available evidence, knowledge of the 
healthcare professional 
Psychological Health beliefs and attitudes, personal 
preferences for health outcomes and 
level of involvement, health literacy 
Social Influence of family and friends, medicine 
burden 
Financial Cost of medicines/health insurance 
Physical Management of medicines, swallowing 
difficulties, overall health 
 
Many of the aspects present in these frameworks were referred to by participants, who each 
described their own deprescribing process.  A standardised process of deprescribing for 
care home residents, followed by healthcare professionals when considering deprescribing 
in care homes, would help to ensure that all important patient and medicine factors involved 
in deprescribing had been considered.  This could perhaps be developed as part of an 
intervention, and/or issued as guidance to healthcare professionals.  This would ensure a 
consistent approach to deprescribing, that the resident and relative were appropriately 
involved in the process, and that no important factors were omitted.   
6.3 The unique context of care homes 
The fact that provision of GP care to care homes is inconsistent is problematic because care 
home residents are complex and vulnerable due to their age, medical conditions and 
medicines (Barber et al, 2009).  Caring for residents involves balancing multiple health 
conditions and their treatments with the advanced age of the resident, as well as the wishes 
of the resident and their relatives.  With respect to deprescribing, care home staff are also 
often involved as a messenger and patient advocate creating a complex and unique context 
to the deprescribing process compared with community dwelling patients.  Therefore, there 
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are additional barriers to deprescribing in care homes that are not present for patients who 
live in their own homes.  The barriers that will be explored in this section are: 
- Care home residents are generally complex, multimorbid patients, who are 
prescribed multiple medicines (polypharmacy) 
- Discussing deprescribing and the future of medicines use involves confronting the 
resident’s relatively limited life span, which residents, their relatives and healthcare 
professionals may be reluctant to do.  
- Deprescribing in care homes requires effective communication between multiple 
people, including relatives and care home staff, which adds extra layers of 
communication that complicates the process.  The involvement of multiple people in 
the deprescribing process is not only complicated by the logistics of communicating 
with so many people, but by the feelings and attitudes of those involved   
6.3.1 Complex patients  
Care home residents in the UK are prescribed an average of 8-10 medicines daily, usually 
for multiple health conditions (Barber et al, 2009).  In the empirical research, residents 
participating were prescribed a mean of 9.7 medicines daily (range 2-15).  They are also 
generally very elderly, with participants in Barber et al’s (2009) study and the study in this 
thesis having a mean age of 85 years old (the empirical work: a mean of 85 years old, range 
74-98 years old, SD 7).  As noted earlier, this means that they are more prone to 
experiencing adverse effects from their medicines, including adverse drug reactions, effects 
from drug interactions, falls and hospitalisation (Barber et al 2009, Fried et al 2011).  It was 
reported by Shah et al (2013) that the number of medicine classes a resident was prescribed 
impacted their mortality with an adjusted hazard ratio of one year mortality for residents 
prescribed 11 or more medicines compared to 0-2 medicines of 1.59 (95%CI 1.26-2.00), 
indicating that mortality may be improved by reducing the number of medicines prescribed.  
However, this is confounded by the fact that people who take more medicines are more ill, 
and care home residents are in the last years of their life and may have died regardless of 
the intervention. 
As described in Chapter 1, these patients provide a unique challenge for prescribers, as in 
addition to their multimorbidities there are age-related changes which affect the medicines 
they are prescribed (Klotz, 2009).  For example, declines in renal function may affect the 
elimination of medicines and changes in hepatic function may affect the way medicines are 
metabolised (Koltz, 2009).  However, there is a lack of evidence about medicine use in older 
people, as older people are usually excluded from clinical trials, and guidelines do not 
generally cater for multimorbid patients (Mooijart et al, 2015).  Therefore, as reported in the 
literature review, prescribers can find it challenging to determine the merit of a medicine 
which may dissuade them from deprescribing it (Anderson et al 2014).  This finding was also 
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described in the interviews conducted in Chapter 4, as uncertainties about the clinical 
consequences of stopping or continuing medicines contributed to reluctance to deprescribe 
for some GPs and pharmacists.  Many GPs and pharmacists also wished for more evidence 
and guidance to assist with deprescribing in older people, which was a feature in the 
empirical research and in the wider literature. 
In the UK, patients are treated using disease-specific clinical guidance, and the more 
diseases they have, the more guidance-based treatments they may be prescribed (Okeowo 
et al, 2018).  Some prescribers feel compelled to continue to follow this guidance, even 
when the patient may not be suitable for guideline-based treatment (Okeowo et al, 2018).  
Okeowo et al (2018) suggested that prescribers may follow potentially inappropriate 
guidance due to a fear of litigation, or to ensure that guideline-related payment targets were 
met.  This can lead to patients accumulating medicines which may no longer be appropriate 
for them, and there is evidence that prescribers have difficulty in identifying which medicines 
are inappropriate (Ramaswamy et al, 2011, Anderson et al, 2014).  There is little guidance 
for multimorbid patients, and guidance does not include how to optimise medicines when the 
patient is older and approaching end of life (Fried et al, 2011, Todd and Holmes 2016).  
These issues were also identified in this thesis, as it was found that prescribers were 
uncertain about which medicines were appropriate to stop.  This reluctance to stop 
medicines with an uncertain risk-benefit profile was coined by Harriman et al (2014) as “if it 
ain’t broke, don’t fix it”.   
The lack of evidence and guidance as a barrier to deprescribing in care homes was also 
identified in the literature review (Chapter 2).  This suggested that it was a prominent barrier 
to deprescribing in care homes, experienced by healthcare professionals across the world.  
It was felt by participants in the interviews conducted that deficiencies in their knowledge 
was a systematic problem due to a lack of evidence and guidance, and not a personal 
deficiency.  This was reflected in the finding that some healthcare participants who 
participated in the empirical research did not think that they would benefit from deprescribing 
training.  In order to investigate this, an in-depth investigation into the knowledge and skills 
required to deprescribe and how they are gained would need to be undertaken. 
In the literature review, Palagyi et al (2016) also identified that healthcare professional’s 
confidence was a factor for deprescribing in care homes, although there was little detail 
provided about how healthcare professionals gained confidence to deprescribe.  Anderson 
et al (2014) identified confidence was a factor in deprescribing generally, reporting that 
prescribers required confidence to deviate from guidance and to identify medicines to stop.  
The findings from the empirical work in this thesis demonstrated that lack of confidence to 
deprescribe a medicine was caused by a lack of knowledge of the medicine in question.  
When mapping this to the TDF, a lack of confidence at first appeared to be a belief about a 
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prescriber’s capability.  However, this empirical work showed it was in fact an issue around 
knowledge, and a lack of knowledge was at the root of a lack of confidence.  This was an 
example of the value of the empirical work in this thesis, and the extra insight it provided. 
Improving the knowledge or access to knowledge of healthcare professionals about 
medicines could therefore increase their confidence to deprescribe.  Healthcare 
professionals interviewed for the empirical research indicated that their knowledge of the 
risks and benefits of medicines, or how and when to stop some medicines such as those for 
dementia, would facilitate deprescribing in care homes.  The alternative to the systemic 
production of evidence and guidance is improving the skills and knowledge of healthcare 
professionals, thus enabling them to make improved use of the available information.  
Improving the knowledge of healthcare professionals about the potential consequences of 
deprescribing, both positive and negative, and how to minimise the negative consequences 
may facilitate deprescribing.  However, it may also dissuade them from deprescribing if it 
confirms their fears about negative consequences.  Similarly, training healthcare 
professionals to consider the indication and impact of each medicine taken by a resident and 
increasing awareness of the potential benefits of deprescribing may also help. Healthcare 
professionals also reported that they preferred to learn through conversation with 
colleagues.  Facilitating the sharing of information and experience between healthcare 
professionals may also increase confidence to deprescribe. 
Residents were reported in the empirical findings and in the literature review to lack 
knowledge of their medicines; however, the empirical findings also identified that residents 
were willing to learn about their medicines.  This was not perceived by healthcare 
professionals, who believed that residents were not interested in their medicines, a finding 
corroborated by the literature (Palagyi et al, 2016).  Engaging residents in their medicines 
may encourage them to engage in conversations about deprescribing with healthcare 
professionals and care home staff, and also reverse the perceptions of healthcare 
professionals.  This could be achieved through the training of care home staff to enable them 
to provide some information to residents about their medicines, or through healthcare 
professionals visiting the home to talk about medicines 
6.3.2 The implications of a limited life expectancy 
A further complexity with care home residents is that they have a limited life expectancy, as 
they are entering the last stage of their life (Davies and Nolan, 2005).  In 2011, it was 
reported that care home residents live an average of 26 months in a care home before dying 
(Forder and Fernandez, 2011).  This stage may last years – care home residents are not 
necessarily living with a life limiting disease, but their advanced age means that they have a 
limited life expectancy.  This must be taken account of by prescribers who are considering 
deprescribing and assessing the risks and benefits of medicines, particularly medicines 
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prescribed to prevent future illnesses.  However, there is evidence that although prescribers 
acknowledge that care home residents are entering the last stage of their life, they are 
reluctant to approach this topic with care home residents and their relatives (Travis et al 
2002, Schuling et al 2012).  The poor planning of end of life care, as well as difficulties 
associated with discussing a resident’s limited life expectancy with the resident and their 
relatives with regard to medicines was identified as a barrier to deprescribing in care homes 
in the empirical research (Chapter 4).   
The findings of the empirical study presented in Chapter 4 demonstrated that healthcare 
professionals believed considering the remaining length and quality of a resident’s life was 
part of considering the risks and benefits of continuing a medicine.  However, healthcare 
professionals perceived this as a difficult conversation to have with residents and relatives.  
This is because residents and relatives were not perceived to understand that medicines 
may have a limited benefit in older people and would instead consider the healthcare 
professional to be “giving up” on the resident.  This would make a conversation about 
deprescribing time consuming, due to a need to address the topic sensitively, explain the 
risks and benefits of medicines in older people and provide adequate reassurance.  The 
healthcare professional also risks upsetting the resident or relative, and they may wish to 
avoid this.  Some healthcare professionals partaking in the empirical research also spoke of 
a concern of complaints and litigation resulting from deprescribing decisions and discussion. 
Indeed, residents and relatives who participated in the interviews had rarely considered how 
they might feel about medicines as the resident got older, and some were reluctant to 
consider this at all.  It was perhaps unsurprising that residents and relatives did not want to 
think about a time when the resident was more unwell or had died.  However, the reluctance 
to discuss this was perceived by healthcare professionals to make deprescribing in this 
setting more difficult than with other patients.  Palagyi et al (2016) et al discovered similar 
findings to this study, with their finding that relatives and GPs had different goals of care and 
ideas about the care home setting (Chapter 2, section 2.7). 
Schuling et al (2012) provided more insight into the views of Dutch GPs on discussing life 
expectancy with older people and their relatives, reporting that some GPs avoided 
discussing life expectancy with older patients.  They avoided such conversations, although 
they considered that this was a part of the deprescribing process (Schuling et al, 2012).  
Some of the GPs interviewed by Schuling et al (2012) even went as far as describing 
discussing life expectancy “unethical”, although it was acknowledged that some patients 
were aware of their relatively limited life expectancy and were comfortable discussing it.  
Despite the fact that it was described as a sensitive topic to approach, some GPs noted that 
speaking about life expectancy strengthened their relationship with the patient (Schuling et 
al, 2012). Travis et al (2002) noted similar communication problems, suggesting that doctors 
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may not want to deliver bad news, especially over the telephone which is how many doctors 
and relatives of care home residents communicate.  Unwillingness to discuss this sensitive 
topic acts as a barrier to the deprescribing process. 
Despite a limited life expectancy being described as a barrier to deprescribing, it can also be 
a facilitator to the process.  In the literature review, Anderson et al (2014) mirrored the 
findings of the empirical work presented in Chapter 4 and reported that a diagnosis of a 
terminal illness made the goals of a patient’s care clearer, and thus meant that it was easier 
to make deprescribing decisions.  For example, a diagnosis of a terminal illness meant that 
medicines prescribed to prevent disease in the future are more likely to be identified as 
inappropriate, while medicines which provide symptom relief to the patient are likely to be 
continued.  This is an example of reactive deprescribing, already discussed in section 6.2.1.  
The fact that healthcare professionals are more comfortable with reactive deprescribing in 
response to a terminal diagnosis suggests that it is a lack of certainty about the resident’s 
future quality and quantity of life that is a barrier to deprescribing.  Once a terminal diagnosis 
is received the deprescribing process is more approachable (Todd and Holmes, 2016).   
In order to overcome this barrier, a culture change is needed.  As a society, there is a 
perception that we are generally not comfortable with speaking about death or our remaining 
life expectancy (Kirshbaum et al, 2011).  This was reflected in the findings of the empirical 
work, as participants were reluctant to discuss this topic.  However, in order to have a good 
remaining quality of life, a degree of planning is required.  Some care home staff and 
healthcare professionals expressed frustration that this was not often considered and there 
are few plans in place for if a resident becomes more unwell.  Only one of the residents and 
relatives interviewed spoke about plans made for a resident’s future through the form of a 
living will, which they found helpful.  If this barrier is to be overcome, sensitive planning for 
end of life and the use of medicines in those with a limited life expectancy would need to 
become more commonplace, and healthcare professionals and care home staff would need 
to be comfortable in discussing this sensitively and professionally. 
6.3.3 Involving relatives in deprescribing 
While relatives generally wanted to be involved in decisions about the resident’s care, this 
study provided evidence that they were sometimes excluded from this by care home staff, 
and therefore by GPs as well.  Despite wishing to be involved in the deprescribing process, 
relatives of older people reported finding it challenging to make decisions for others, and 
found being involved in the deprescribing process on behalf of the resident to be a burden – 
a finding which was corroborated by Reeve et al (2016).  These difficulties involved the 
logistics involved in collating the views of multiple people and the weight of responsibility in 
making the best decision for the resident.  In order to facilitate a more open dialogue and to 
improve relationships between healthcare staff, improved planning of the resident’s care 
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would be required.  For example, a meeting between the resident, relatives, care home staff 
and healthcare professionals to discuss goals of care, how residents wanted to be involved, 
how relatives wanted to be involved and contacted and discussion of the resident’s 
medicines could facilitate this process.   
Similar findings were also reported by Davies and Nolan (2006) in their study of the role of 
family caregivers in the life of a care home resident Davies and Nolan (2006) explored how 
relatives of care home residents perceived their role in the resident’s care, and reported that 
the role that relatives played in the resident’s care was not often negotiated between care 
home staff and the relative which left the relative unsure of their role.  One of the themes 
reported by Davies and Nolan (2006) was entitled “keeping an eye”, which referred to the 
role of the relative once the resident was settled in the care home.  Relatives saw their role 
as monitoring care, which extended to noticing problems with medicines and reporting them 
to care home staff.  This finding was also reflected by empirical research undertaken 
(Chapter 4).  The role of the relatives interviewed could also be described as keeping an eye 
as they described holding healthcare professionals accountable to their decisions and 
ensuring they were content with the care received by the resident.  This role could be 
affected if the resident moved to a new GP practice, where the relative did not know the GP.  
Furthermore, in findings similar to those presented as a result of the empirical work 
undertaken (Chapter 4), Davies and Nolan (2006) reported that the relative’s input was not 
always welcomed by care home staff. 
There is also evidence that relatives were have found doctors inaccessible and care home 
staff withholding of information, especially when the resident was receiving end of life care 
(Shield et al, 2005).  While in theory this could make it even harder for relatives to attain 
information they need, the opposite was found by the empirical research.  Where it was 
mentioned, healthcare professionals reported that an instance in which they would always 
speak to the relatives about deprescribing was end of life care.    
Residents and relatives may benefit from relatives being more routinely involved in 
deprescribing decisions by healthcare professionals and care home staff.  However, whilst 
some relatives were keen, and took steps, to be involved in the resident’s care, others were 
reported in the empirical findings as being more difficult to engage.  There were logistical 
issues to involving the relatives in deprescribing, for example they were unlikely to be in the 
care home when a healthcare professional visited unless it was a planned, well 
communicated visit which were not common.  Relatives were likely to be of working age, and 
so may work similar hours to healthcare professionals which would leave them unable to 
visit the care home at the same time as a healthcare professional.  Logistical issues may be 
overcome by relatives being made aware of scheduled healthcare professional visits and 
being invited to attend, or improved communication between the two groups.  This could be 
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facilitated through telephone conversations or videocall consultations.  A GP who 
participated in the empirical study stated that relatives could make GP appointments to 
discuss the relative, and so ensuring that relatives were aware of this could also ease 
communication.  
Poor communication between relatives and care home staff was also reported by Edge 
(2007) who described how relatives wished for more forthcoming communication from care 
home staff after the resident had been admitted to the home.  Whilst this finding was 
reflected by three of the relatives interviewed, it did not account for the relatives who care 
home staff described as more passive.  It appears relatives, similar to residents, fall into two 
groups: those who are keen to be involved in the resident’s care, and those who are content 
to follow the advice of healthcare professionals.  While most of the available literature 
included the former, little is known about the latter group (Davies and Nolan, 2006; Barry and 
Davies, 2006; Edge, 2007).  Due to the difficulties experienced in recruiting relatives to the 
empirical study conducted (Appendix D), the latter group may comprise the majority of care 
home relatives and their views are not well documented.  Further work needs to be 
undertaken to investigate the views of all relatives, and understand the beliefs of this under-
represented group if relatives are to be more involved in deprescribing (where appropriate 
and desired by the resident). 
Involving residents and relatives in medicines optimisation in care homes was an approach 
that was investigated by the SHINE project, which evaluated models of providing multi-
disciplinary medicine reviews for care home residents (The Health Foundation, 2014). The 
reviews improved quality, measured by the number of interventions, the number of the 
medicines stopped and cost-savings gained from changing, stopping and starting medicines.  
The project was a success, in that it 1346 interventions for 422 residents were made and 
9.5% of the medicines prescribed for these residents were deprescribed.  £184 was saved 
per person reviewed, assuming the resident would have taken a deprescribed medicine for 
at least a further year.  It was also estimated that for every one pound invested in the project, 
£2.38 was released from the medicines budget.  It was also demonstrated that medicine 
reviews that did not involve the GP were the most cost-effective, which provides an 
argument for upskilling pharmacists to become prescribers to work in this setting.  This 
project was successful in identifying that the most efficient way to run medicine reviews in 
care homes in the UK, and also in attempting to engage the resident and/or relative in 
medicine reviews.  However, clinical outcomes were not measured so the impact of the 
medicine changes on the resident are not known.
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6.3.4 Implications of involving care home staff in the deprescribing 
process 
Issues relating to care home staff and knowledge about medicines could also be a barrier to 
deprescribing, as discussed in the literature review.  There was evidence that staff required 
more training to manage medicines in care homes, which suggested they may not be 
confident in dealing with issues associated with medicines (Barber et al, 2009).  However, it 
has been reported that it is challenging to provide training to care home staff, in part due to 
the high turnover of staff in this sector (Castle and Enberg 2005 and 2007, Donoghue 2010) 
as it is expensive to train staff when they are regularly leaving and joining the workforce 
(Castle and Enberg 2005 and 2007, Donoghue 2010).  These concerns were mirrored by 
GPs participating in the empirical work.  In addition, there may be funding constraints that 
affect the ability of care home managers to provide training to their staff contributing to a 
deficit in knowledge and skills about medicines. 
Care home staff also described problems communicating with doctors, reporting them to be 
unprofessional and to appear uncaring or disinterested in the resident’s or the nurse’s 
opinion (Tija et al, 2009).  This attitude was also alluded to by some care home staff and 
relatives who participated in the interviews in Chapter 4 whereby care home staff described 
having to encourage GPs to involve the resident in their consultation.  Care home staff were 
also reluctant to communicate with GPs who had a reputation of being difficult to work with.  
Such social barriers to communication are not easily solved, as it requires open 
communication between the two groups, GPs to be engaged in their role and the resolution 
of the negative perceptions of care home staff. 
Care home staff partaking in the empirical research reported that it was challenging to 
contact the resident’s GP and arrange care for them.  Logistical barriers to communication 
included issues such as GPs being unable to visit the care home and having to contact 
multiple GP surgeries to arrange care for different residents.  This was also reported by Tija 
et al (2009), who also found that care home staff have also reported that it can be 
challenging for them to contact the doctor and vice versa, with staff additionally lacking the 
quiet space and time needed to telephone the doctor (Tija et al 2009).  Such communication 
problems could deter staff from contacting the doctor to discuss deprescribing, and thus lead 
to the resident continuing to take inappropriate medicines.  These logistical barriers to 
communication may be addressed by the changes to the provision of primary care to care 
homes proposed by the Enhanced Health in Care Homes Direct Enhanced Service that will 
be implemented by Primary Care Networks as described in Chapter 1.3.4.
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6.4 Ensuring shared decision-making 
Patients, with their families and carers, where appropriate, will be involved in and 
consulted on all decisions about their care and treatment.  (The NHS 
Constitution, Department of Health, 2015. pp4) 
It was identified by the empirical work conducted (Chapter 4) that the ability of care home 
residents to be involved in shared decision-making was impaired.  This was due to multiple 
factors, including the perceptions healthcare professionals had of residents, the attitude of 
residents towards their medicines and the fact that many residents lived with cognitive 
impairment.  These issues will be explored below. 
6.4.1 A “passive” attitude to medicines 
In the literature review, Palagyi et al (2016) and Turner et al (2016) suggested care home 
residents were generally “passive” in the deprescribing process.  This was because 
residents were found to lack the knowledge about their medicines that they would need to 
partake in deprescribing, and were content to defer to the doctor’s judgement (Palagyi et al, 
2016).  This finding resonated with the findings of Reeve et al (2013) who alluded to apathy 
outside of the care home setting when they discussed that some patients were reluctant to 
partake in deprescribing because their medicines were a “habit” and because “I am old so 
why change things”.  This was also reported by Hughes et al (2009) in their study of 
adherence and resident involvement in medicines decision making.  Anderson et al (2014) 
described this apathy as problematic, stating that prescribers would find deprescribing would 
be facilitated by patients being more willing to be involved in shared decision-making, more 
receptive to change and were more knowledgeable about their medicines.   
This “passivity” displayed by residents towards deprescribing was also described in the 
empirical research whereby residents generally reported a lack of knowledge about their 
medicines, and a preference towards healthcare professionals making decisions about their 
medicines.  In the empirical work, residents rarely questioned their medicines unless they 
were experiencing side effects, which suggested that they were are unaware that medicines 
may cause future harm.  While they wished to be informed about these decisions, they did 
not appear to understand how they may be involved in the process.   
Healthcare professionals and some relatives perceived this attitude as the resident being 
uninterested in their medicines, or lacking the willingness to change.  However, in the 
findings of the empirical study residents reported that they were willing to change their 
medicines if it was suggested by their doctor, and that they were interested in learning more 
about their medicines.  This was also reported in the literature review (Chapter 2; Kalogianis 
et al, 2016; Palagyi et al, 2016; Reeve et al, 2016, Turner et al) and suggests that while 
residents may not have a great knowledge of their medicines, they are curious about them 
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and are not averse to change despite how others perceive their attitude and behaviour.  In 
this case, there is incongruity between the perceptions of healthcare professionals and how 
residents feel in reality. 
Residents were also unlikely to question their medicines or suggest deprescribing 
themselves, unless they were experiencing harm from their medicines or were querying their 
efficacy.  This could be due to the fact that they lacked knowledge about their medicines, 
including their names, indications or potential side effects, or that they were unaware of the 
concept of inappropriate medicines.  Indeed, nearly all residents who partook in the empirical 
work believed their medicines were beneficial and that their doctor had ensured their 
medicines were appropriate.  However, every healthcare professional interviewed believed 
that there were care home residents in their care who were receiving inappropriate 
medicines.  This dissonance in beliefs provided insight into the trust that residents displayed 
in healthcare professionals.  Residents were generally disconnected from their medicines, as 
they did not manage their medicines themselves and had little knowledge of them.  They 
relied on those caring for them to manage their medicines for them, and believed their 
medicines were correct and appropriate without their input.  Healthcare professionals may 
not be aware of how the residents perceived them, and awareness of this may help them to 
manage the expectations of care home residents.  Through improved communication with 
residents, from the point of prescribing, GPs may be able to explain the concept of 
inappropriate medicines and encourage residents to be more involved in deprescribing 
decisions.  It also highlighted the need for improved communication between healthcare 
professionals and residents, so that residents are aware that medicines may not always be 
beneficial and are encouraged to question the ongoing necessity of their medicines.   
The reasons that a resident may appear uninterested in their medicines are unclear and 
complex.  One reason may be that they are generally no longer responsible for managing 
their own medicines, and so may be detached from them.  As described in Chapter 1,  the 
medicines of care home residents in the UK are generally ordered, managed and provided to 
the resident by care home staff (Barber et al, 2009), removing the resident from the medicine 
management process and reducing their concept of medicines to a number of tablets that 
are provided to be taken daily.  This is an example of institutionalisation, whereby the care 
home resident becomes accustomed to living in a care home and having their daily routines 
managed on their behalf.  Factors of care home living such as following a routine set by 
management and having limited decisions to make result in care home residents being at 
risk of losing aspects of their independence, which can affect their quality of life (Cooney, 
2010).  It is possible to see how this may affect their perception of their medicines, and how 
they may not be provided with the opportunity to be engaged in the medicines they are 
prescribed. 
245 
 
 
In order to overcome institutionalisation and maintain a good quality of life, Wilson et al, 
(2009) identified that residents needed to maintain a sense of individuality, involvement in 
decision-making and being in a partnership with those providing their care.  These factors 
could also help care home residents maintain interest and reduce apathy towards their 
medicines, and empower them to be involved in deprescribing decisions.  However, as 
demonstrated by Cooney’s (2010) research, residents often felt like their views were not 
important when it came to establishing themselves in a care home.  There was evidence this 
spread to their view of medicines in the way they deferred to the doctor’s opinion, as 
demonstrated in the literature review and the empirical research (Palagyi et al, 2016).   
6.4.2 Involving residents in deprescribing 
Shared decision-making has become a central tenet of patient care in the NHS (NHS, 2019), 
Traditionally, patients followed the directions of healthcare professionals in a compliant 
relationship (Dickinson et al, 1999).  However, there has been a move towards a more 
concordant relationship, a relationship that is exemplified by the concept of shared decision-
making.  Shared decision-making in the context of medicines can be defined as:  
“One where the person, their prescriber and those supplying the medicines are 
equal partners in supporting decisions that are agreed upon as acceptable by all 
parties” (Royal Pharmaceutical Society, 2020.  Last accessed 26.03.2020). 
Shared decision-making requires the patient to understand the options for their care and to 
feel comfortable to ask questions of, and disagree with, the healthcare professional.  It also 
requires the healthcare professional to be understanding and sensitive to the patient’s 
priorities and healthcare beliefs.  However, the evidence from the literature review and the 
empirical work undertaken suggested that care home residents were not often given the 
opportunity to be involved in decisions about their care.  In this way, residents were a 
passive receptors of care. 
While GPs who participated in the study reported that they often at least informed the 
resident of the changes being made to their medicines, pharmacists reported that they rarely 
spoke with residents.  This could contribute to the poor understanding that residents and 
relatives had of the pharmacists’ role.  It was possible that the model within which 
pharmacists worked, where they worked remotely or visited a home were required to review 
all residents, did not lend itself to consulting with residents.  In addition to this, and 
pharmacists may lack the time to involve residents as well as conducting the detailed, often 
time consuming, medicine review.  It was also worth noting that this reflected the 
experiences of those pharmacists interviewed who were overwhelmingly employed by CCGs 
and it was possible that pharmacists conducting medicine reviews in care homes employed 
in different capacity, such as directly by a GP practice, may work differently.  Pharmacists 
working remotely, while efficient, can also be problematic. Some residents and relatives 
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interviewed were unsure of the skillset of the pharmacist and did not believe they were 
suitable to be involved in deprescribing.  If pharmacists were more present in the care home 
and took time to consult with residents, this may increase their profile and improve the 
relationship and trust between the two groups.   
A frequently cited reason for not involving the resident in deprescribing decisions in the 
findings of the empirical work (Chapter 4) was that many care home residents were 
perceived to live with cognitive impairment.  While it is true that around 70% of care home 
residents in the UK live with dementia or another form of cognitive impairment, this means 
that the remaining 30% do not (Age UK, 2019).  Therefore, by the reasoning of healthcare 
professionals who participated, these residents would be able to participate in discussions 
about their care but may not be being given the opportunity to.  However, a diagnosis of 
dementia does not mean that the resident would be unable to participate in deprescribing 
decisions.  There are different levels of cognitive impairment and the ability of a resident to 
discuss their medicines with a healthcare professional may change on a day to day basis.  
Therefore, the assumption that care home residents have dementia and therefore are unable 
to partake in deprescribing decisions is not necessarily true.  This suggests that efforts 
should be made to ensure deprescribing is individualised, and that all residents are given a 
fair opportunity to be involved.  Indeed, this was a wish of the relatives interviewed who 
acknowledged that while the resident may not be able to partake in discussions about their 
medicines, they should at least be informed by the healthcare professional and given the 
opportunity to hear about the decisions being made about them.   
In addition to this, residents who participated in the empirical work undertaken generally 
displayed a belief that healthcare professionals and care home staff were authority figures to 
be obeyed.  This harked back to the “paternalism” age of medicine that healthcare 
professionals are being encouraged to move away from (Dickinson et al, 1999(.  Care home 
residents may need to be encouraged more to be involved in decisions about their care than 
other patients by, for example, being prompted during consultations for their input or being 
provided with choices to make.   
6.5 Promoting medicine optimisation by addressing behaviour 
change  
6.6 Existing deprescribing interventions in care homes 
It was identified in Chapter 5 that a deprescribing behaviour change intervention for use by 
healthcare professionals in care homes should broadly consist of training, environmental 
restructuring, and/or education.  A detailed breakdown of the behaviour change techniques, 
policies and delivery methods of a potential behaviour change intervention for deprescribing 
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in care homes is presented in Chapter 5, section 5.3.  This section focusses on existing 
deprescribing interventions that have been trialled in care homes, and considers their use 
and efficacy alongside the findings presented in this thesis. 
6.6.1 Existing deprescribing interventions in care homes 
Although few specific deprescribing interventions in care homes have been trialled, several 
trials have been conducted to test interventions designed to improve prescribing or 
medicines optimisation in care homes (Alldred et al, 2016).  Medicines optimisation is wider 
than deprescribing, as it involves activities such as reducing and increasing the doses of 
medicines, monitoring therapy and starting medicines if necessary, as well as stopping them 
(Scottish Government Polypharmacy Model of Care Group, 2018).  Therefore, the 
interventions trialled to specifically improve deprescribing in care homes were the focus of 
this section. 
Kua et al (2018) conducted a systematic review and meta-analysis to investigate the health 
outcomes of deprescribing interventions amongst older people in nursing homes.  The 
outcomes reported were mortality, number of people experiencing a fall, hospitalisation rate 
and the number of potentially inappropriate medicines prescribed before and after the 
intervention was trialled. The authors defined deprescribing as  
“the discontinuation, reduction or substitution of inappropriate or unnecessary 
medicines” (Kua et al 2018 pp 2) 
This is an expansion on most agreed definitions of deprescribing (discussed in Chapter 1, 
section 1.2) as it includes the reduction or substitution of potentially inappropriate medicines 
as opposed to solely the cessation of such medicines.  This should be considered when 
contextualising the results of this review in the context of this thesis.   
Forty-one randomised controlled trials were included in the review and, and 30 in a meta-
analysis.  Fourteen studies investigated medicine cessation by healthcare professionals 
including doctors, nurses and pharmacists and these studies focussed on specific classes of 
medicines such as antipsychotic, antidepressant and hypnotic medicines.  Eleven studies 
examined the use of medication reviews by pharmacists, doctors and nurses informed by the 
STOPP/START criteria or the Beers criteria, focussing on multiple medicines or 
antipsychotic medicines.  Six studies evaluated the effect of educational interventions 
provided to nursing home staff and doctors.  The remainder of the included studies 
investigated interventions such as case conferences, alternative therapies, technological 
interventions, outreach visits, comprehensive assessment of the resident and profiling of 
adverse drug reactions (Kua et al, 2018). 
The main analysis showed that deprescribing interventions did not have a significant effect 
on the measured outcomes.  Sub-group analyses revealed that medicine review 
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interventions reduced the odds of a resident dying by 26% (OR 0.74, 95% CI 0.65-0.84), and 
reduce the number of residents suffering a fall by 24% (OR 0.76, 95%CI 0.62-0.93) (Kua et 
al, 2018).  Medicine review interventions were also shown to reduce the number of residents 
prescribed a potentially inappropriate medicine, as defined by the author of the primary 
studies (OR 0.41, 95%CI 0.19-0.89).   
This systematic review suggested that deprescribing interventions in care homes, 
particularly interventions centred around a medicine review process, were successful in 
reducing the number of medicines taken by care home residents and may have an effect on 
mortality and falls.  There was limited evidence that other types of intervention were similarly 
efficacious.  Education, a broad intervention function that could form the foundation of a 
deprescribing intervention, was identified in the empirical findings (Chapter 5, section 5.3.3) 
as an intervention function which could improve deprescribing behaviour in care homes, and 
education was investigated by six trials included in Kua et al’s (2018) review.  Of these six 
education trials, two of the educational interventions focussed on nursing home staff only 
(Fossey et al, 2006; Rapp et al, 2013; Pitkälä et al, 2014), one intervention concerned only 
the use of quinolones for the treatment of urinary tract infections (Pettersson et al, 2011), 
one concerned only non-steroidal anti-inflammatory medicines (Stein et al, 2001) and three 
focussed on medicines taken for behavioural issues in dementia patients (Fossey et al, 
2006; Rapp et al, 2013; Pieper et al, 2016).  In addition to this, none of the interventions 
utilised behaviour change theory.  Although the educational interventions were not reported 
to significantly improve the outcomes presented by Kua et al (2018), the interventions 
investigated were not comparable to the type of intervention which may be developed as a 
result of this thesis.  This is because the incorporation of behaviour change psychology in 
this thesis aims to inform a behaviour change intervention to reduce problematic 
polypharmacy in care homes.   
As noted above, medication review was identified as the most effective deprescribing 
intervention from the studies included in Kua et al (2018).  However, medication review is not 
a behaviour change function or technique in itself.  Nevertheless, behaviour change 
functions and techniques could be incorporated into medicine reviews and education and 
training around how to conduct medicine reviews could form the basis of an intervention.  
The findings of Kua et al’s (2018) study combined with the findings of the empirical work 
could be the foundation of a of a novel deprescribing intervention for use in care homes.  
Table 49 shows how a deprescribing medicines review may be incorporated into the 
behaviour change techniques identified as intervention components in Chapter 5.  
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Table 49: How behaviour change techniques, functions, policy and delivery techniques identified in Chapter 5 could be incorporated 
into the medicine review process 
Identified behaviour change functions 
and techniques 
How a deprescribing medicine review may 
be incorporated into the Identified 
behaviour change functions/techniques 
The identified policies and delivery 
techniques which could support the 
intervention 
Training (behaviour change function) Training about how to conduct medicine 
reviews with a view to deprescribing, which 
may involve utilising tools such as STOPP or 
the BEERs criteria 
Delivery mechanisms: face to face, 
appropriate websites, a phone app, an 
individually accessed computer programme 
Policies: guidance, communication/marketing 
Education (behaviour change function) Educating healthcare professionals about how 
to conduct medicines reviews with a view to 
deprescribing, which may involve utilising tools 
such as STOPP or the BEERs criteria 
Delivery mechanisms: Face to face, 
appropriately situated posters or leaflets, 
appropriate websites, a phone app, an 
individually accessed computer programme 
Policies: guidance, communication/marketing 
Demonstration of the behaviour (behaviour 
change technique) 
Demonstration of how to conduct medicine 
reviews with a view to deprescribing, as above 
under training and education 
Delivery mechanisms: face to face, 
appropriate websites, a phone app, an 
individually accessed computer programme 
Policies: guidance, communication/marketing 
Instruction on how to perform the 
behaviour (behaviour change technique) 
Instruction on how to conduct medicine 
reviews with a view to deprescribing, as above 
under training and education 
Delivery mechanisms: face to face, 
appropriately situated posters or leaflets, 
appropriate websites, a phone app, an 
individually accessed computer programme 
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Identified behaviour change functions 
and techniques 
How a deprescribing medicine review may 
be incorporated into the Identified 
behaviour change functions/techniques 
The identified policies and delivery 
techniques which could support the 
intervention 
Policies: guidance, communication/marketing 
Feedback on outcomes of the behaviour 
(behaviour change technique) 
Feedback on outcomes of the deprescribing 
medicine review – positive to reinforce 
deprescribing, and negative to provide 
learning materials for future reviews 
Delivery mechanisms: face to face, an 
individually accessed computer programme 
Policies: guidance 
Prompts/cues (behaviour change 
technique) 
Prompts and cues, either on computer 
systems or as a physical accompaniment to 
deprescribing medicine reviews 
Delivery mechanisms: appropriately situated 
posters or leaflets, appropriate websites, a 
phone app, an individually accessed computer 
programme 
Policies: communication/marketing 
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Hansen et al (2018) conducted a systematic review and meta-analysis to identify the 
behaviour change techniques in deprescribing interventions.  25 randomised controlled trials 
of deprescribing were included in the review, and the Behaviour Change Techniques for 
each intervention were identified and coded by the researchers.  It was reported that 
interventions lowered the number of medicines taken per patient (MD -0.74, 95%CI -1.26-
0.22), which was widely variable across studies and not significantly affected by the type of 
intervention.  However, of interest to this thesis is the clusters (groups of Behaviour Change 
Techniques) that were coded the most frequently in successful interventions.  These can be 
found below in Figure 19: 
- - Goals and planning 
- - Social support 
- - Shaping knowledge  
- - Natural consequences  
- - Comparison of behaviour  
- - Comparison of outcomes  
- - Regulation  
- - Antecedents 
- - Identity 
 
 
There are some similarities between the findings of Hansen et al (2018) and the empirical 
research.  The following BCTs identified as potential intervention components in the 
empirical research fall under the BCT clusters identified by Hansen et al (2018) (Figure 19) 
as likely to be effective: demonstration of the behaviour, instruction on how to perform the 
behaviour, information about health consequences and information about social and 
environmental consequences.  These were covered by three of the BCT clusters in (Figure 
19).  The empirical research also identified two BCTs which were not included in the BCT 
clusters identified by Hansen et al (2018): feedback on outcomes of the behaviour and 
prompts and clues.  Five BCT clusters Hansen et al (2018) identified as components of 
successful deprescribing interventions were not identified in the empirical research as 
potentially beneficial components of a deprescribing intervention for use in care homes.  
However, this is not a concern because the empirical research was focussed on care homes 
and informed through extensive in-depth qualitative study rooted in the TDF.  The 
deprescribing interventions included in Hansen et al’s (2018) study were not set in care 
homes or a similar population such as older people, and therefore could have included 
participants of any age or living situation.  Therefore, they were likely to identify more BCT 
clusters as potentially successful than the empirical research.  The empirical research also 
Figure 19: The clusters of Behaviour Change Techniques which were found to be the 
most frequently identified BCTs in successful deprescribing interventions (Hansen et al, 
2018, pp2722) 
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identified two potential BCTs that Hansen et al (2018) did not, again likely due to the specific 
nature of the empirical work. 
6.6.2 A patient centred approach  
Whilst the intervention components, and any final intervention that is developed as a result 
of this work, will be aimed at and used by healthcare professionals, care home staff, 
residents and relatives must also be involved.  The Theoretical Domains Framework and 
associated models and components, such as the COM-B and Behaviour Change Wheel, 
were designed for use to modify the behaviour of healthcare professionals (Michie et al, 
2014). Therefore, the patient, whose care will be affected by the changed behaviour of 
healthcare professionals, is not considered in these frameworks and models.  In this study, it 
was also important to consider how care home staff may be involved in a deprescribing 
intervention and the resources they might need to enable their involvement. 
Patient/person centred care is now a key cornerstone of the NHS.  Plans to improve the 
relationships between healthcare professionals and their patients were outlined in the Five 
Year Forward view, which produced guidance for staff to encourage person-centred care 
(NHS, 2019).  In addition to this, there are a number of interventions being proposed that are 
described as patient-centred, including deprescribing interventions (Reeve et al, 2014; 
Vasilevskis et al, 2019).  Whilst neither of these interventions were designed for use in care 
homes, they do provide insight into the necessary components of a patient-centred 
deprescribing intervention.  In the context of care homes, resident-centred care is an 
alternative to patient or person-centred care in that care decisions are made with the 
resident and with consideration of their values, beliefs and priorities (Nord, 2018). 
It is important that any intervention designed as a result of this work is resident-centred, as 
the findings of the empirical study (Chapter 4) indicated that residents and their relatives 
were keen to be involved in deprescribing decisions.  The findings of the empirical study also 
showed that this often did not take place, and that healthcare professionals, particularly 
pharmacists, were not routinely involving residents or their relatives in discussions about 
medicines and deprescribing decisions.  Intervention development and implementation 
should include these key stakeholders in order to encourage resident-centred care.  Most 
importantly, this will also ensure that the values, beliefs and concerns of residents and their 
relatives are considered when deprescribing.  The findings of the empirical study highlighted 
numerous beliefs of residents and relatives that should be considered by healthcare 
professionals when deprescribing, such as their concerns about consequences, beliefs that 
medicines were beneficial and uncertainties about the roles and abilities of healthcare 
professionals.  The patient should be involved by healthcare professionals to ascertain their 
beliefs and values at the point of prescribing, at regular interviews while the medicine is 
prescribed and during the deprescribing process. 
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Patient-centred interventions focus on clinically meaningful outcomes that are important to 
the patient, as well as other targets.  Vasilevskis et al’s (2019) study protocol outlined a 
randomised controlled trial designed to test a patient-centred deprescribing intervention for 
older hospitalised patient with polypharmacy.  They aim to ensure their intervention is 
patient-centred by interviewing patients as a part of the deprescribing process in order to 
gain understanding of their priorities, values and beliefs.  This includes the healthcare 
professional conducting the review asking the patient, about each medicine identified as a 
target for deprescribing: adherence, experience of side effects, perceived benefit or harm of 
the medicine, cost and level of interest in deprescribing the medicine (Vasilevskis et al 
2019).  The patient will also be asked if they would like to stop any medicine that the 
healthcare professional has not identified as a target for deprescribing (Vasilevskis et al 
2019). 
The secondary outcomes of the study also focus on patient-centred factors (Vasilevskis et al 
2019).  While the primary outcome for the study will be measured using a calculated Drug 
Burden Index, the secondary outcomes are factors that are likely to be important or 
measurable to the patient.  These include their confusion level, cognitive impairment, 
presence or absence of symptoms of depression, anxiety pain, pressure ulcers, falls or 
incontinence and weight loss or gain (Vasilevskis et al 2019).  Adherence to medicines will 
also be measured, as well as unplanned hospital admissions Vasilevskis et al (2019).   
Reeve et al (2014) suggested a five step deprescribing intervention that focussed on 
discussion of the medicines between the healthcare professional conducting the 
deprescribing and the patient at each stage.  This has not been tested to determine efficacy.  
Figure 20 details the intervention: 
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Figure 20: The five-step patient-centred deprescribing intervention suggested by 
Reeve et al, 2014, pp740. 
This model could be considered alongside the findings of this thesis and patient-centred 
outcomes as suggested by Vasilevskiy et al (2019) when developing a novel behaviour 
change intervention to ensure a resident-centred deprescribing approach. 
The residents and relatives should also be involved in intervention development to ensure it 
is an intervention that they would be satisfied for a healthcare professional to use when 
reviewing the resident’s medicines.  They could also be involved to ensure that they are 
satisfied with the level of resident and relative involvement proposed by the planned 
intervention.  Care home staff are also crucial to the future success of any intervention, and 
their potential role requires further research.  The would also be involved in any intervention 
development. 
6.7 Strengths and limitations 
This thesis has multiple strengths.  It provides in-depth insight into deprescribing in care 
homes in the UK that was obtained through semi-structured interviews with all the key 
stakeholders involved in the process: residents, relatives, GPs, pharmacists and care home 
staff.  This has provided novel data about understanding and knowledge of deprescribing, 
opportunities and challenges for deprescribing in this context, and consideration of how 
these behaviours could be improved.  It is also the only study of deprescribing to have 
employed the TDF to explore deprescribing as a behaviour enacted by GPs, pharmacists 
and care home staff.  As such, it provides a valuable contribution to an emerging evidence 
base in the following ways.  The use of the TDF throughout the study grounds the findings in 
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health behaviour psychology theory, and consequently the findings can be used to 
contribute a solution to the problem of deprescribing in care homes.  The findings 
themselves provide depth of insight into the topic, and may be transferable to other similar 
health and social care settings in the UK, for example other care homes.  The TDF was used 
specifically for the purpose of understanding the interviews with health and care 
professionals, and not the resident and relative interviews. The TDF was designed to 
influence the behaviour of healthcare professionals who would be the recipients of any 
intervention aimed at influencing their deprescribing behaviours.  Whilst residents (as the 
ultimate recipients of the care decisions made by health and care professionals) and 
relatives ought to be involved in the deprescribing process, they would not be using the 
intervention to stop medicines taken by the resident. However, any proposed intervention 
should be co-designed with residents, relatives, care home staff, GPs and pharmacists.   
A further strength of the research is that, despite there being challenges to recruiting in the 
care home setting, strategies were found to undertake the research.  In the first instance, it 
was difficult to engage care homes.  In the first rounds of recruitment, letters were sent to 
multiple care homes, none of which were replied to.  Upon calling the care homes to follow 
up the letter, it was difficult to speak to the manager who was often busy and had not read 
the letter.  Once the manager of the care home had been spoken to, recruiting the care 
home and speaking to residents and staff was relatively straightforward.  Despite these 
difficulties, nine care homes were recruited to partake in the study.  A further strength of the 
study was that the care home staff sample was limited to managers and team leaders.  This 
decision was made because staff members involved in the management and administration 
of medicines were sought and these tasks were allocated to more senior staff. 
There were some methodological limitations of this study which must be considered when 
appraising this work, its quality and relevance for the sector and policy.  Recruiting the 
relatives of care home residents was very challenging.  The relatives were rarely in the care 
home at the time of the researcher’s visit, the researcher was not able to contact them 
directly via telephone or letter, and posters placed in the care home did not generate any 
participants.  Recruitment of relatives relied on the motivation of the care home manager to 
identify and aid in recruitment of relatives, and most care home managers were not 
motivated to assist with relative recruitment.  See Appendix D for a reflective account of the 
recruitment process. 
A further recruitment limitation was that one GP, three pharmacists and two care homes 
were recruited via the supervisory team, which may have affected the characteristics of the 
participants.  Healthcare professionals recruited in this way may be particularly active and 
prominent in their field and therefore, the data collected may not have captured all views and 
working practices of health and care professionals, as those who were less active may not 
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have been represented.  There was a similar issue with those care homes recruited via the 
NIHR ENRICH programme which targets ‘research ready’ care homes. These homes may 
have been approached because they were more likely to participate or that they had a good 
relationship with ENRICH.   
Five of the nine care homes included in the study had a CQC rating of “good”. However, in 
the study area, most homes were rated “requires improvement”. This introduces sampling 
bias, which potentially limits the transferability of the findings.  The transferability of the 
findings was also potentially affected by the gender imbalance of the samples, particularly 
the GP and pharmacist samples which were overwhelmingly female.  The GPs who 
participated had similar amounts of experience, and the pharmacists were generally 
experienced too.  This meant that views of less experienced practitioners were not obtained.  
However, the views of more experienced practitioners such as those obtained were likely to 
provide a broad overview of the topic from people familiar with the work and practice of 
deprescribing.  In addition to this, many participants were asked about the approach of their 
colleagues to deprescribing, including those with less experience, and whether it was felt 
that less experienced colleagues would approach deprescribing in a different way.  However, 
the sample frames GPs and pharmacists were not fulfilled, and so the data may not have 
captured the views of these populations.   
A final point is the background of the author of this thesis.  I am a pharmacist, with 
experience of working in a hospital and community setting.  I had pre-existing thoughts on 
the topic of deprescribing in care homes, which may have influenced my interpretation of the 
findings.  I am also a novice researcher and had not utilised qualitative research techniques 
before or the TDF.  This meant that there was a risk that these techniques were not utilised 
to their full potential.  However, I was supported by several experienced researchers, both 
inside and outside the supervisory team, and I undertook reflective writing throughout the 
research process.  This reflexivity allowed me to identify parts of the research that had been 
conducted well or which could be improved, and informed the development of my research 
techniques.  The reflexivity section, Chapter 3 section 3.2.4, provides more background 
about the researcher for fuller consideration of this issue, as does Appendix D.
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6.8 Contributions of this work to the body of knowledge 
This is one of very few qualitative studies to have been conducted on this subject worldwide.  
Some of the key findings had been found by others, for example that residents lack 
knowledge about their medicines (Turner et al, 2016; Ellis et al, 2015; Palagyi et al, 2016) 
and prescribers believe that a lack of evidence is a barrier to deprescribing (Ailabouni et al, 
2016; Palagyi et al, 2016).  However, the unique barriers provided by the structure of health 
and social care systems in the UK had not been described in such depth in the context of 
deprescribing before.  In addition to this, this thesis provides improved understanding of the 
previously poorly described social influences that affect deprescribing decisions.  
This confirmed that deprescribing is a complex behaviour, influenced by numerous factors 
including social influences, environmental factors and knowledge deficiencies.  Mapping 
these to the Theoretical Domains Framework (TDF) and Behaviour Change Wheel (BCW) to 
inform intervention development was a novel aspect of this study.  Whilst other studies 
(Ailabouni et al 2016; Scott et al, 2019) have incorporated the TDF into their methodologies 
(as discussed in section 5.4.1), this is the first study to also incorporate the Behaviour 
Change Wheel to inform the content of a deprescribing intervention.  This has provided 
information that can be used to develop a targeted deprescribing intervention that has the 
potential to change the deprescribing behaviour of healthcare professionals in care homes.  
The chances of the intervention being successful is improved because the factors most likely 
to affect deprescribing in care homes (environmental and social influences, and knowledge) 
have been identified, as well as how these factors may best be addressed (through 
education, training and environmental restructuring).  This increases the likelihood that any 
intervention developed as a result of this research will be implemented and successful.  The 
likelihood of success would also be increased through co-design of the research with key 
stakeholders. 
6.9 Implications for policy and practice 
This study has significant implications for policy and practice.  There is increasing interest in 
both deprescribing and care homes in the UK from the UK Government and the NHS 
(Department of Health and Social Care, 2018).  In addition to this, bodies such as NICE, the 
RPS, NHS Scotland and the GPhC have produced guidance and reports relating to 
medicines use and optimisation in care homes, including deprescribing as discussed in 
Chapter 1.3.2 (National Institute for Health and Care Excellence, 2014; Royal 
Pharmaceutical Society, 2016; Scottish Government Polypharmacy Model of Care Group, 
2018; Webber, 2015).  This study provides depth of understanding about why deprescribing 
may not be occurring as often or as effectively as it could be within care home contexts, 
despite policy recommendations, and suggests how the behaviour of healthcare 
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professionals could be targeted to address this issue and potentially improve deprescribing 
practices in care homes. 
The study may be utilised to inform the work of the PCNs as they aim to reduce 
inappropriate prescribing in all settings, including care homes, which involves a multi-
disciplinary team working together in care homes.  However, the empirical work found that 
some residents and relatives were unsure of the skillset and ability of pharmacists to be 
involved in deprescribing.  Therefore, work to increase the awareness of pharmacists, their 
knowledge and their skills to care home residents and relatives may be beneficial to improve 
the acceptance of pharmacists by residents and relatives.  This may be done by adjusting 
the workload of working practices of pharmacists so they are able to visit care homes more 
often.  This study found that residents and relatives wanted to be involved or at least 
informed of deprescribing decisions; however, pharmacists did not always involve these 
groups in their decision-making.  These findings may be used to encourage pharmacists to 
involve residents and relatives in deprescribing decisions, and to raise the profile of 
pharmacists working in care homes.  Examples of ways this could be done are through 
alerting pharmacists to these findings, which may encourage them to reflect on their working 
practices and attempt to involve care home residents more in deprescribing decisions.  As a 
result, the understanding of roles between pharmacists, care home residents, and relatives 
would improve.  The findings about the perceptions of GPs towards residents and relatives 
should be shared with GPs, in order to encourage them be more open to involving residents 
and their values, beliefs and priorities.   
The findings about the complexities of providing GP care to care homes may be utilised 
inform improvements to health and social care systems which would enable healthcare 
professionals to be able to assign a higher priority to deprescribing in care homes.  The 
National Overprescribing Review is yet to be published, but this review into problematic 
overprescribing aims to investigate large scale facilitators to minimising inappropriate 
pharmacy (Department of Health and Social Care, 2018).  This includes improving the 
interface between primary and secondary care and investigating how improved technology 
could be used to minimise inappropriate medicines use.  These barriers were described in 
the findings of the empirical work, and so the findings reflect the current barriers to 
deprescribing that are being investigated on a large scale.  This study may, therefore, be 
utilised in this review. 
An example of the technological changes that were required by participants in the empirical 
research was improved communication between care homes and primary care.  These 
improvements are proposed as part of the enhanced health in care homes DES which will be 
provided by each PCN from late 2020, as each care home will have an NHS email address 
to facilitate the sending and receiving of confidential information across settings.  Again, this 
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verifies the findings of this thesis as strategies are already in place to overcome some of the 
barriers to deprescribing in this setting.  The creation of this particular DES also addresses 
some of the environmental factors that were acting as a barrier to deprescribing, for example 
difficulty in contacting a GP and navigating primary care systems.   
The empirical work may also be utilised alongside the work of the enhanced health in care 
homes DES.  A planned increase in the formal provision of primary care to care homes is 
planned through this initiative, and so more practitioners will require training and will be 
considering how to deprescribe in care homes  The knowledge that it is the opportunity and 
psychological capability components of the COM-B which require targeting through 
education, training and environmental restructure can usefully inform the PCNs as they 
increase the primary care provided to care homes.  The findings of this thesis are ideally 
placed to help with the development of an intervention to address the knowledge deficits of 
healthcare professionals in ways that are likely to be successful, such as guidelines or 
computer prompts.  The development of an intervention to be utilised in this setting requires 
further research, in conjunction with residents, relatives, care home staff, GPs and 
pharmacists. 
Finally, key findings were that the residents and relatives interviewed were open to the idea 
of deprescribing, being educated about their medicines and being involved in deprescribing 
decisions.  Healthcare professionals were uncertain of the willingness and ability of residents 
and relatives to be involved in the deprescribing process, and this study suggests that more 
effort should be made to involve them.  Increased presence of healthcare professionals in 
the care home, who attempt to involve the resident and/or their relative in every decision, 
would be a way that this could be achieved.  The initiation of a weekly round of the care 
home, proposed by the enhanced health in care homes DES, is likely to facilitate this.  
Involving residents and their relatives in their care has the potential improve the relationship 
between residents, relatives and healthcare professionals and improve shared decision-
making with regard to deprescribing in care homes. 
6.10 Future research 
The development of a behaviour change intervention to improve deprescribing behaviour in 
care homes is a key area for future research.  Intervention development should be co-
designed with residents, relatives and care homes, as well as the healthcare professionals 
who will be using the intervention.  Further work would focus on the recommendations for 
intervention development laid out in Chapter 5, and investigate the type of intervention that 
healthcare professionals desire and what would be most useful to them.  Based on the 
findings of this thesis, a medicine review process co-designed with key stakeholders that 
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would address the knowledge and skill deficiencies of healthcare professionals is likely to be 
an intervention strategy that should be further developed and tested. 
Healthcare professionals expressed a desire for more deprescribing guidance and evidence, 
but it was unclear what form this may take.  Future research should investigate this, with a 
view to developing relevant evidence and guidance.  Further research is also required into 
the social barriers to deprescribing, such as how much of an influence other people are to 
the deprescribing process and how difficult discussions may be facilitated.  There is also 
more research into the role of residents, relatives and care home staff in deprescribing 
required, in order to gain a deeper understanding of the roles that these groups desire and 
how this may be enabled. 
6.11 Reflective account 
During the process of this PhD, I have learnt a great deal – about deprescribing, care 
homes, qualitative research, behaviour change psychology and myself.  It has been a steep 
learning curve in the art of qualitative research, a discipline I had always been interested and 
felt drawn to.  The skills learnt throughout this study, such as how to conduct a literature 
review, how to conduct qualitative interviews and the analysis of qualitative data will be 
applicable throughout my career as I continue to attempt to find out why people act in the 
way they do.  The numerous training courses attended (Appendix K) have provided a solid 
foundation in research skills.  The skills I have learnt in behaviour change psychology, and 
how to use the TDF, COM-B and Behaviour Change Wheel, will also assist with this mission 
wherever I choose to work. 
Professionally, I have a deeper understanding of the barriers to deprescribing and why it is 
not as straightforward as I may have thought.  I have learnt that GPs and pharmacists are 
keen to learn from my and each other’s experience, and that GPs require evidence and 
confidence in my skills to implement my recommendations which I will strive to provide.  I 
have also been inspired and reminded to always involve my patients in decisions, and if I 
ever work in care homes I will not remain behind a computer but will involve the people who 
matter in my decisions – residents and relatives. 
Finally, the PhD process has had a huge impact on me personally.  I have learnt resilience, 
and how resilient I am, but also when to step back, rest and ask for help.  It has tested me 
mentally and emotionally, and I feel I have changed as a person throughout this process.  I 
am more aware of my limits, more patient, and ultimately surer of myself now than I was at 
the start of the project. 
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6.12 Dissemination of the findings 
Preliminary findings of this thesis have been disseminated via a poster presentation at the 
Prescribing and Research in Medicines Management (PRIMM) annual scientific meeting 
2017, and via oral presentation at the FIP international pharmacy conference in 2018 (Bolton 
et al, 2017).  The abstracts for the FIP conference can be found in Appendix L.  Further 
poster and oral presentations have been presented internally at the University of Leeds and 
regionally at the Great North Pharmacy Conferences 2016 and 2017.  The findings have 
also been presented at Royal Pharmaceutical Society Local Pharmacy Forums to other 
academics conducting research in pharmacy as well as to practising pharmacists.  This in 
particular encouraged practising pharmacists present to reflect upon their practice.  The 
findings will be further disseminated through publication in healthcare and pharmacy journals 
and publicised in order that the findings reach as many people involved in deprescribing in 
care homes as possible. 
6.13 Conclusion 
This thesis provides the findings of a novel qualitative study informed by behaviour change 
psychology into deprescribing in care homes in the UK.  More depth is provided by this 
thesis to previously reported findings, and it has also provided some findings which have not 
been reported before.  A key finding which demonstrates the difference in the views of 
residents and relatives and healthcare professionals is that nearly all residents and relatives 
expressed a belief that the resident’s medicines were beneficial.  In contrast, every 
pharmacist and GP acknowledged that there were residents in their care who were taking 
inappropriate medicines.  This demonstrates that there is a key difference in the way that 
healthcare professionals and residents and relatives perceive medicines, which requires 
intervention from the moment a medicine is prescribed.  This thesis also highlighted the 
social influences on deprescribing, and described them in more detail than has been done 
previously.  This includes the hesitance of residents, relatives and healthcare professionals 
to discuss the limited life expectancy of the resident with regard to deprescribing, as well as 
the negative perceptions held by healthcare professionals of some relatives and residents.  
These social barriers can have an impact on deprescribing, and are not as easy to overcome 
as physical barriers.   
The behaviour change work which runs through this thesis from the literature review to the 
discussion is another unique feature of this PhD.  While previous studies have utilised the 
Theoretical Domains Framework to identify factors likely to influence deprescribing 
behaviour, this is the first study conducted to have applied this theory to the care home 
setting.  (Scott et al, 2019; Ailabouni et al, 2016; Cadogan et al, 2015).  Taking the extra step 
to map these factors to the Behaviour Change Wheel has provided meaningful information 
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about the behaviour change techniques, policies and delivery mechanisms which can 
usefully inform the development of a behaviour change intervention for use in care homes.  
Basing the development of an intervention in theory, including empirical work and the 
findings of a systematic literature review, increases its likelihood of success and 
implementation (Michie et al, 2014; Medical Research Council, 2006). 
As well as the research having impact through publications, the findings have the potential to 
inform practice especially at a time of rapid change in primary care.  The provision of primary 
care to care homes is changing, via the funding of 350 new pharmacy professionals to work 
in care homes and the introduction of PCNs who must deliver a service designed to enhance 
health in care homes.  The findings of this thesis may be utilised to inform the education and 
training of these individuals, and inform the work of the PCNs as they increase the presence 
of healthcare professionals in care homes and improve the provision of primary care to care 
homes.  It may also inform the National Overprescribing Review, a government-led 
nationwide review into why overprescribing is occurring and what the solutions might be. 
This research comes at a critical time, as there are hundreds of thousands of older people 
living in care homes who are prescribed potentially inappropriate medicines.  There is 
significant potential for deprescribing to minimise poor health-related outcomes for these 
residents and to save money for the NHS.  The introduction of PCNs and the work they will 
be doing to enhance health in care homes reflects the importance of this thesis, and the 
necessity of its findings.  The older people who live in care homes rely on healthcare 
professionals to manage their medicines effectively and involve them in decision-making, 
however this thesis provides evidence that this is not always happening.  However, this 
thesis also provides solutions that can ultimately facilitate older people living in care homes 
to be able to live a good quality of remaining life on as few medicines as possible.   
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Appendix A: Literature review search strategy 
Table 50: The search strategy utilised for the literature review undertaken in Chapter 2 
Search 
string 
Search terms 
1 exp nursing home/ or exp nursing home patient/ or exp nursing home personnel/ 
2 ((nursing or "aged care" or "aged nursing" or "aged residential" or care or convalescent 
or residential or "long term" or "long-term") adj (home* or centre or center or 
facilit*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
3 assisted living facilit*.mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] 
4 assisted living facilit* for the elderly.mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
5 (("life care" or "continued care" or "respite care" or "extended care") adj (center or 
centre or facilit*)).mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] 
6 ((geriatric or elderly) adj2 (home* or centre or center or facilit*)).mp. [mp=title, 
abstract, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
7 residential aged care facilit*.mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
8 home for the aged.mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] 
9 home for the elderly.mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] 
10 (deprescribe or deprescribing or deprescribed or "de-prescribe" or "de-prescribing" or 
"de-prescribed").mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword] 
11 ((stop or stopped or stopping) adj2 (medicine* or medication* or drug* or 
prescription* or treatment*)).mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
12 ((withdrawal or withdraw or withdrawn or withdrawing) adj2 (medicine* or 
medication* or drug* or prescription* or treatment*)).mp. [mp=title, abstract, heading 
word, drug trade name, original title, device manufacturer, drug manufacturer, device 
trade name, keyword] 
13 ((cease or ceased or cessation or ceasing) adj2 (medicine* or medication* or drug* or 
prescription* or treatment*)).mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
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Search 
string 
Search terms 
14 ((discontinuation or discontinued or discontinuing or discontinue) adj2 (medicine* or 
medication* or drug* or prescription* or treatment*)).mp. [mp=title, abstract, heading 
word, drug trade name, original title, device manufacturer, drug manufacturer, device 
trade name, keyword] 
15 ((polypharmacy or medication* or medicine* or prescription*) adj2 (reduce or reducing 
or reduction or reduced or minimise or minimising or minimised or minimisation or 
minimize or minimizing or minimized or minimization)).mp. [mp=title, abstract, heading 
word, drug trade name, original title, device manufacturer, drug manufacturer, device 
trade name, keyword] 
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 
17 10 or 11 or 12 or 13 or 14 or 15 
18 16 nd 17 
281 
 
 
Appendix B: Papers not included in the literature review 
Table 51, below, contains the details of papers which were considered for inclusion in the 
literature review, but were ultimately not included.  The reasons for their exclusion are 
described below. 
Table 51: Papers which were not included in the literature review chapter after 
discussion with the supervisory team, with reasons for their exclusion 
Reference Why the article was not included in the 
literature review in Chapter 2 
Bolmsjö, BB; Palagyi, A; Keay, L; Potter, 
J; Lindley, RI (2016) Factors influencing 
deprescribing for residents in advanced 
care facilities: insights from general 
practitioners in Australia and Sweden.  
BMC Fam Practice 17:152 
A review article consisting of two papers.  The two 
primary studies included in the review were read 
and assessed for inclusion into Chapter 2 
separately.  Palagyi et al (2016) was included in 
the review in chapter 2, whilst Bolmsjö et al 
(2015) was excluded for reasons outlined below. 
Bolmsjö, BB; Strandberg, EL; Midlov, P; 
Brorsson, A (2015) “It is meaningful, I 
feel I can make a difference” – A 
qualitative study about GPs’ experiences 
of work at nursing homes in Sweden.  
BMC Family Practice. 16:111 
Bolmsjö et al (2015) was not about deprescribing 
in care homes and was about the general 
experiences GPs had with care home work.  
While many of the barriers and facilitators to care 
home work described by Bolmsjö et al (2015) 
mirrored barriers and facilitators to deprescribing 
in care homes, they were not presented with the 
specific focus and angle of deprescribing.  Palagyi 
et al 2016 was the other paper included in the 
aforementioned two paper review article, and this 
was included in the , which was included in the 
literature review,  
Ailabouni, N; Tordoff, J; Mangin, D; 
Nishtala, PS (2017) Do residents need 
all their medications?  A cross-sectional 
survey of RNs’ views on deprescribing 
and the role of clinical pharmacists. 
Journal of Gerontological Nursing, 43:10 
pages 13-20 
The article contained some consequences to 
deprescribing in care homes, but no barriers and 
facilitators to deprescribing in this setting.  The 
study comprised of a survey which nurses 
working in care homes completed, and covered a 
range of topics about medicine management and 
administration but deprescribing was not a focus 
of this survey or the findings. 
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Reference Why the article was not included in the 
literature review in Chapter 2 
Iden, KR; Hjørleifsson, S; Ruths, S 
(2011) Treatment decisions on 
antidepressants in nursing homes: a 
qualitative study. Scandinavian Journal 
of Primary Health Care, 29:252-256 
While this article appeared in other reviews about 
deprescribing, the article focussed on why 
antidepressant medicines were started and 
continued in care homes.  While these reasons 
mirrored the barriers and facilitators to 
deprescribing in care homes, the focus was not 
specific enough for this review. 
Flick, U; Garms-Homolová, V; Röhnsch, 
G (2012) “And mostly they have a need 
for sleeping pills”: Physicians’ views on 
treatment of sleep disorders with drugs in 
nursing homes. Journal of Ageing 
Studies, 26:484-494 
Despite appearing in other review articles about 
deprescribing, and containing some information 
about stopping medicines for sleep disorders, this 
article did not focus on the barriers and facilitators 
to deprescribing medicines in care homes.  
Instead, it focused on why medicines for sleeping 
disorders were started in the first place and the 
risks and benefits of using these medicines in this 
population.  
Jokanovic, N; Tan, ECK; Dooley, MJ; 
Kirkpatrick, CM; Elliott, RA; Bell, JS 
(2016) Why is polypharmacy increasing 
in aged care facilities?  The views of 
Australian health care professionals. 
Journal of Evaluation in Clinical Practice 
22:677-682 
This paper was about why residents are taking so 
many medicines in care homes, and not why 
those medicines are not being stopped.  There 
were no barriers and facilitators to deprescribing. 
Pruskowski, J; Zarowitz, BJ; Handler, S 
(2018) Perceptions of nursing facility 
providers on the utility of deprescribing. 
The Consultant Pharmacist, 33:7 pages 
386-402 
This study focussed on the desired components 
of a deprescribing intervention in care homes, and 
there was minimal mention of barriers to 
deprescribing.  It was decided that the findings of 
this paper would be useful when writing chapter 2, 
intervention design, but were not useful to the 
literature review. 
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Appendix C: Theoretical Domains Framework utilised in the study 
Table 52 shows the validated TDF as presented by Cane et al (2012).   
Table 52: Validated TDF presented by Cane et al (2012) 
Domain and definition Constructs 
Knowledge 
(An awareness of the existence of something) 
Knowledge (including knowledge of 
condition /scientific rationale) 
Procedural knowledge 
Knowledge of task environment 
Skills 
(An ability or proficiency acquired through 
practice) 
Skills 
Skills development 
Competence 
Ability 
Interpersonal skills 
Practice 
Skill assessment 
Social/Professional Role and Identity 
(A coherent set of behaviours and displayed 
personal qualities of an individual in a social or 
work setting) 
Professional identity 
Professional role 
Social identity 
Identity 
Professional boundaries 
Professional confidence 
Group identity 
Leadership 
Organisational commitment 
Beliefs about Capabilities 
(Acceptance of the truth, reality, or validity about 
an ability, talent, or facility that a person can put 
to constructive use) 
Self-confidence 
(Perceived competence 
Self-efficacy 
Perceived behavioural control 
Beliefs 
Self-esteem 
Empowerment 
Professional confidence 
Optimism 
(The confidence that things will happen for the 
best or that desired goals will be attained) 
Optimism 
Pessimism 
Unrealistic optimism 
Identity 
Beliefs about Consequences 
(Acceptance of the truth, reality, or validity about 
outcomes of a behaviour in a given situation) 
Beliefs 
Outcome expectancies 
Characteristics of outcome expectancies 
Anticipated regret 
Consequents 
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Domain and definition Constructs 
Reinforcement 
(Increasing the probability of a response by 
arranging a dependent relationship, or 
contingency, between the response and a given 
stimulus) 
Rewards (proximal / distal, valued / not 
valued, probable / improbable) 
Incentives 
Punishment 
Consequents 
Reinforcement 
Contingencies 
Sanctions 
Intentions 
(A conscious decision to perform a behaviour or 
a resolve to act in a certain way) 
Stability of intentions 
Stages of change model 
Transtheoretical model and stages of 
change 
Goals 
(Mental representations of outcomes or end 
states that an individual wants to achieve) 
Goals (distal / proximal) 
Goal priority 
Goal / target setting 
Goals (autonomous / controlled) 
Action planning 
Implementation intention 
Memory, Attention and Decision Processes 
(The ability to retain information, focus 
selectively on aspects of the environment and 
choose between two or more alternatives) 
Memory 
Attention 
Attention control 
Decision making 
Cognitive overload / tiredness 
Environmental Context and Resources 
(Any circumstance of a person's situation or 
environment that discourages or encourages the 
development of skills and abilities, 
independence, social competence, and adaptive 
behaviour)  
Environmental stressors 
Resources / material resources 
Organisational culture /climate 
Salient events / critical incidents 
Person x environment interaction 
Barriers and facilitators 
Social Influences 
(Those interpersonal processes that can cause 
individuals to change their thoughts, feelings, or 
behaviours) 
Social pressure 
Social norms 
Group conformity 
Social comparisons 
Group norms 
Social support 
Power 
Intergroup conflict 
Alienation 
Group identity 
Modelling 
Emotion 
Fear 
Anxiety 
Affect 
Stress 
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Domain and definition Constructs 
(A complex reaction pattern, involving 
experiential, behavioural, and physiological 
elements, by which the individual attempts to 
deal with a personally significant matter or 
event) 
Depression 
Positive / negative affect 
Burn-out 
Behavioural Regulation 
(Anything aimed at managing or changing 
objectively observed or measured actions) 
Self-monitoring 
Breaking habit 
 
Table 53, below, was created by the author and the member of the supervisory team to 
guide the mapping process.  Domains of the TDF are in the first column, followed by the 
definition provided by Cane et al (2012) and a definition of the domain with regard to 
deprescribing, which was provided by the author in conjunction with a member of the 
supervisory team 
Table 53:TDF domains and their relationship to barriers to deprescribing in care 
homes 
Domain Definition (according to Cane 
et al, 2012) 
Deprescribing barriers that will 
fit into this domain 
Knowledge An awareness of the existence of 
something 
All aspects of knowing how to 
deprescribing, including knowing 
which medicines to stop and how 
to undertake the process 
Skills An ability of proficiency acquired 
through practice 
Ability to apply deprescribing 
knowledge 
Social/professional 
role and identity 
A coherent set of behaviours and 
displayed personal qualities of an 
individual in a social or work 
setting 
The extent to which a participant 
sees themselves as involved in 
deprescribing and thinks it is part 
of their role, understanding their 
role and the role of others in the 
process 
Beliefs about 
capabilities 
Acceptance of the truth, reality, 
or validity about an ability, talent 
or facility that a person can put to 
constructive use 
The participant’s confidence in 
deprescribing and perceived 
ability to do so effectively.   
Optimism The confidence that things will 
happen for the best or that 
desired goals will be obtained 
General pre-disposition to 
believing that prescribing is best 
left alone/untouched 
Beliefs about 
consequences 
Acceptance of the truth, reality or 
validity about outcomes of a 
behaviour in a given situation 
Prescriber’s beliefs about 
negative consequences, e.g. 
harm, litigation 
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Domain Definition (according to Cane 
et al, 2012) 
Deprescribing barriers that will 
fit into this domain 
Reinforcement Increasing the probability of a 
response by arranging a 
dependent relationship, or 
contingency between the 
response and a given stimulus 
An absence of processes, which 
reward/incentivise deprescribing 
Intentions A conscious decision to perform 
a behaviour or a resolve to act in 
a certain way 
Whether a prescriber sees 
deprescribing as a priority 
Goals Mental representations of 
outcomes or end stages that an 
individual wants to achieve 
Whether a prescriber has set 
goals to deprescribe, difficulties 
in setting deprescribing goals, 
goals which affect the 
deprescribing process 
Memory, attention 
and decision 
processes 
The ability to retain information, 
focus selectively, on aspects of 
the environment and choose 
between two or more alternatives 
All cognitive aspects of 
deprescribing, e.g. remembering 
to deprescribe and the ability to 
make a decision 
Environmental 
context and 
resources 
Any circumstances of a person’s 
situation or environment that 
discourages or encourages the 
development of skills and 
abilities, independences, social 
competence and adaptive 
behaviour 
Contextual, resource and 
material limitations which 
impeded deprescribing including 
time, funding, staffing, 
technology, equipment. 
Social influences Those interpersonal processes 
that can cause individuals to 
change their thoughts, feeling 
and behaviours 
Social factors or how other 
people may influence 
deprescribing behaviours e.g. 
influence of the resident and 
relative, beliefs and perceptions 
about others  
Emotion A complex reaction pattern 
involving experiential, 
behavioural and psychological 
elements, by which the individual 
attempts to deal with a personally 
significant matter or event 
The negative emotional elements 
of deprescribing, e.g. fear, stress 
Behavioural 
regulation 
Anything aimed at managing or 
checking objectively observed or 
measured actions 
The absence of dedicated 
deprescribing programmes and 
specialist services 
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Appendix D: Reflections on the first care home visit 
Two reflective accounts are presented: the first was written after the first two interviews, 
which took place in a care home with care home residents.  The second is a reflection on 
recruitment challenges. 
The home I visited seemed fairly basic, situated on a busy road in (place).  The residents 
were sitting in a couple of living rooms with the TV on, and staff around busy and chatting to 
them.  I was taken to the manager’s office where I spoke with the manager and assistant 
manager, who was sorting out medications.  Both were happy for me to speak to residents, 
and when I explained about the relatives I was hoping to recruit they had some people in 
mind who visit regularly and may be happy to take part.  They were supportive and said 
they’d put up the posters and give information to eligible residents. 
The managers seemed to have a few residents in mind that I could speak to, and when I 
said I was hoping to interview a couple today they immediately agreed on the two I should 
interview and confirmed they would be able to consent to take part.  We went to the lounge 
where I was introduced to the two potential participants, and I gave them both PIS to read.  
The first then came through with me to the dining room. 
I again explained who I am and what I was there to do, and gave him some more time to 
read the PIS.  However, he said he was having trouble reading it so I read it out to him, with 
regular pauses to check his understanding and whether he was happy with it.  I also 
encouraged him to read through the sheet afterwards as well.  He signed the consent form, 
and I went through the introduction on the interview schedule making sure he understood it 
would be confidential and recorded.  He said he was happy to go ahead, and so the 
interview started. 
Up to this point he had been very chatty and referred to himself as a chatterbox on a couple 
of occasions.  He had been chatting about his family, where he lived before the home, his 
daily routine and his friends in the home.  However, once the interview started it became 
more of a question and answer session than a conversation – I felt I wasn’t getting the depth 
I had hoped for, and was flying through the interview schedule.  Even when I tried to probe 
further for answers, I wasn’t getting more, and the interview only took about 20/25 minutes to 
complete.  He did go off on a couple of tangents, but mostly stuck to the questions and didn’t 
give very deep answers. 
I thanked him and accompanied him back to the lounge, where I approached the second 
participant and asked him if he had read through the sheet and whether he was happy to 
take part.  He said he was, so we went to the dining room.  I checked his understanding of 
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the PIS and asked him if he would like to take part, and he agreed and signed the consent 
form.  He wasn’t as chatty as the first participant, but as I didn’t have to spend a lot of time 
going through the PIS with him we didn’t have the same rapport.  However, I went through 
the interview introduction with him and he was happy to take part. 
Once I started the interview though, it very much became a question and answer session 
again rather than a conversation.  I felt more aware of this and really tried to push for depth, 
but I wasn’t getting it.  For example, when I asked how he thought his niece would feel if the 
doctor suggested he stopped taking some of his medicines, the exchange went something 
like: 
Resident: Oh no, she wouldn’t like that! 
Me: why do you think this is? 
R: I don’t know, she just wouldn’t like it 
M: would your niece stop you discussing stopping a medicine with your doctor? 
R:  I’d still talk to the doctor about it, but she wouldn’t like it. 
Again, we flew through the schedule and the interview was done in 15/20 minutes.  I felt 
more conscious of needing depth during this interview, so tried to push and create scenarios 
for him and use the prompts, but was still only getting brief answers. 
After the interview had ended, I accompanied him to the lounge then went to the office to 
collect demographic information.  The first resident I had interviewed was in there again, 
talking to the staff.  I collected the information and had a chat with one of the carers about 
what I was doing, then left.   
Immediately after the interviews, I felt they hadn’t gone badly but hadn’t gone well.  I had 
collected some data, but I was hoping for the interviews to last longer and be more in depth.  
I had invented a few prompts on the spot to try get more information, but found I couldn’t 
think as well on my feet as I’d hoped I’d be able to and I’m not sure why this is – I felt a bit 
like a rabbit in the headlights, even though I hadn’t felt nervous about doing the interviews.  I 
was aware that they weren’t going as I’d hoped, and didn’t know how to retrieve the 
situation.  My first thought was that the interview schedule needed revisiting, and either more 
prompts/questions adding or perhaps re-wording the prompts – the prompts were worded as 
questions, but perhaps if they were reduced to just a few words I might have to think a bit 
more about what I was asking rather than reading them off. 
I also found myself going into “pharmacist” mode – the first question felt a bit like the start of 
a drug history, and I wanted to write down what they were saying before realising I didn’t 
have to as it was being recorded, which as ridiculous as it sounds did throw me a bit!  I 
couldn’t really think past what they were saying, as I’m used to my drug histories/medicines 
289 
 
 
use reviews being quite to the point and straightforward, and it is obvious when things are 
said during them that require further probing and how to go about that.  With this, I knew I 
had to probe more but it wasn’t obvious to me how to go about this. 
I came back to the office and discussed it with a colleague, who noticed that it sounded like 
the mood changed when the interview “officially” started.  I agree with this and will try to 
make this transition from “chat” to “recorded interview” less obvious next time.  We also 
wondered whether the dictaphones may have thrown them off, however the first resident’s 
voice did keep going quiet and there was traffic noise, so they had to be obvious on the 
table. 
Going forward, I do think the interview schedule needs reviewing and there are a couple of 
things mentioned above I can try amending for the next interview.  I am also going to 
transcribe and listen to the interviews, and as I am listening try to think of further prompts 
and probes I could have tried to get more information from them.  We can also discuss it at 
our next supervision meeting, and I can get some tips from the team.  Hopefully, by being 
aware of the issues this time and taking steps to minimise them next time, the interviews will 
go better in the future. 
Reflections on recruitment challenges 
A barrier to recruiting care homes was accessing the registered manager.  A maximum of 
five phone calls were made to care homes which had been sent letters, and on many 
occasions the researcher was unable to speak to the manager to discuss the project.  Many 
reasons were given for the manager being unavailable, but often the manager was busy 
dealing with relatives, in meetings, or on leave.  Once the researcher was able to speak to 
the manager, they generally wanted to take part.  On calling the home, many managers 
requested more information by email – in future, it would be worthwhile calling the care 
homes to ask for an email address and assess initial interest, as email addresses were 
rarely available on the internet.  Sending information via email also creates a paper trail, 
unlike the sending of letters which can be misplaced.  Having said this, emails often went 
unanswered and a follow up phone call is still the best way to speak to a manager. 
Once a manager was happy for their home to be involved in the study, accessing the 
residents and staff at the home was relatively easy.  However, while most residents were 
happy to take part in the study, others were not.   “Suspicion” of the researcher was a barrier 
to recruiting residents to the study in one instance.  One participant refused to take part on 
account of the researcher’s apparent age, believing they were too young to have the 
knowledge to discuss the topic.  Another took part in the interview, and fully understood and 
consented to the interview, but was reluctant to answer many questions as the researcher 
was not their doctor and they did not think they should be discussing such matters with other 
people.   
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The main challenge to recruitment was the recruitment of relatives.  This was because care 
home relatives were not at the care homes when the researcher visited, so recruitment relied 
on care home managers handing out PIS, or the relative seeing a poster and contacting the 
researcher.  When applying for ethical approval, it was not requested that the researcher 
could, with the relative’s permission, gain the contact details of relatives interested in the 
study via the care home manager.  Therefore, the researcher was unable to follow up on 
potential participants and instead had to hope that participants made the first contact.   
It was difficult to gain details of resident and relative meetings, due to the difficulties 
described above with accessing the manager.  Only one visit to a resident and relative 
meeting was arranged, and this was poorly attended by relatives.  One manager remarked 
that they were not surprised that I was having trouble recruiting them, as it was difficult to 
involve them in life at the care home. 
Due to these difficulties, a substantial ethical amendment was submitted to the ethics 
committee.  When approved, this allowed recruitment of relatives via social media on Twitter 
and through various relative groups.  However, these proved unsuccessful as well – the 
tweets generated significant interest, but people who responded were either ineligible to take 
part or did not make further contact with the researcher. 
Overall, the best approach to recruiting relatives was the involvement of a proactive care 
home manager.  They would distribute information, arrange meetings and act as a go-
between for the researcher and participant, encouraging the interview to go ahead.  In 
homes where managers were not as proactive, there was no interest from relatives in taking 
part.  Proactive, interested managers also aided with the recruitment of residents and staff.  
For example, these managers would ensure they had enough staff at the home on the day 
the researcher was visiting so the interview could take place without affecting staffing levels.  
They also had good rapport with the residents which helped when introducing the 
researcher. 
The utilisation of local contacts, via the supervisory team and snowball sampling, was the 
best way to recruit GPs and pharmacists.  While there was some success recruiting GPs 
through the research ready GP surgery list, there was more success through the local 
networks.  GP surgeries were only followed up three times as opposed to the five times that 
care homes were contacted as it was very difficult to speak with the right person when 
calling the surgery, and recruitment through other methods was going well.  Many people – 
academics, researchers and participants – told me that GPs would be the most difficult 
group to recruit, especially as I was unable to offer them compensation for their time.  
However, they were amongst the easiest group to recruit and all were very happy to partake 
in the interview for as long as it took. 
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other written information provided to the participants. A copy of the signed and dated 
consent form should be kept with the project’s main documents which must be kept in a 
secure location. 
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Appendix F: Sample participant information sheets (PIS) 
The first PIS is an example of the consent form provided to care home residents.  The same 
form, with amended pronouns, was provided to relatives of care home residents. 
The second form was provided to healthcare professionals with adjustments made only to 
reflect the occupation of group. 
What do people living in care homes think about their medicines? 
Participant information sheet: Care home residents and relatives 
You are being invited to take part in a research project.  Before you decide whether to take 
part it is important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it with 
others if you wish.  Please use the contact details at the bottom if there is anything that is not 
clear or if you would like more information.  Take your time when deciding whether or not to 
take part. 
What is the purpose of the study? 
While taking lots of medicines can be safe and necessary, it can sometimes be a problem.  
As you get older, the way medicines affect your body changes and some people are affected 
by side effects. 
The purpose of the research is to find out how people who live in care homes feel about 
taking medicines, and how they feel about stopping medicines.  To find this out, interviews 
will be carried out with people who live in care homes. 
The purpose of this project is not for you to get specific advice about your medicines, instead 
we will just talk about medicines use in general.   
Why have I been chosen? 
You have been chosen because you live in a care home and you take medicines. 
What do I have to do? 
If you decide to take part, you will be interviewed by Emma Bolton, a PhD student from the 
University of Leeds.  The interview will be a one-to-one interview and will last 30-60 minutes.  
The interview will take place in a quiet place in your care home. 
You will be asked about how you feel about taking medicines in general.  None of your 
medicines will be changed or stopped because of this interview. 
What are the possible disadvantages and risks of taking part? 
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It is possible that you may become upset when talking about your medicines or health 
conditions.  If this happens, the interview will be stopped and support offered.  You will not 
have to continue with the interview if you do not want to.   
Advice about medicines cannot be given during the interview, and your medicines will not be 
stopped or changed by anybody involved in this research project. If you have concerns 
about your medicines, speak to the staff at your care home. 
What are the possible benefits of taking part? 
Your views will help us learn what is important to people like you about medicines.  We hope 
this will then help us to improve the care of people who live in care homes. 
Do I have to take part? 
You do not have to take part.  It is up to you to decide whether or not to take part.  If you do 
decide to take part, you will be given this information sheet to keep and you will be asked to 
sign a consent form.  After you have signed the consent form, you can withdraw from the 
study at any point until two weeks after the interview.  You do not have to give a reason. 
If you decide not to take part, you do not have to do anything else.  Thank you for taking the 
time to read about the project. 
Will I be recorded, and how will the recording be used? 
The interview will be recorded and then someone will listen to it and write down what you 
said.  The written interview will then be analysed.  Quotes from your interview may be used 
in publications, at conference presentations and lectures, however none of your details will 
be said or published so no-one will know, or be able to work out, that you took part.     
Will my contribution be kept confidential? 
Only you and the interviewer will know what you say in this interview.  However, if you say 
anything that concerns the interviewer about your safety, they might have to tell someone 
who could help.  This might be the supervisors of the project or someone in the care home.  
The interviewer will talk to you about this before they tell anyone else. 
The results of the research may be published in an article or presented at a conference.  
You will not be identified in any publication or presentation. 
The interview recordings will be kept securely at the University of Leeds until the project is 
finished and has been submitted to be marked, then they will be destroyed.  The written 
interviews will be kept securely at the University of Leeds for two years after the results have 
been published, and then they will be destroyed as well.  The storage of the recordings and 
written interviews will comply with the Data Protection Act 1998, the Human Rights Act and 
the University of Leeds’ Code of Practice on Data Protection. 
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What will happen to the results of the research project? 
The results may be published in a scientific journal and presented at conferences and in 
lectures.  Your involvement will be kept anonymous and no-one will know, or be able to work 
out, that you took part. 
Withdrawing from the project 
You can withdraw from the project at any time before or during the interview, and for two 
weeks after the interview.  If you do withdraw, the recording and notes taken during the 
interview will be destroyed and none of your contributions will be used.  Analysis of the 
interview will start two weeks after the interview, and it will no longer be possible to withdraw 
after this point.  You do not have to give a reason for withdrawing.  Your care won’t be 
affected, and you won’t get into trouble if you want to withdraw.  
Who is organising/funding the research? 
The research is being organised and funded by the School of Healthcare at the University of 
Leeds. 
Contact for further information 
Contact Emma Bolton for further information: 
Email: hcevb@leeds.ac.uk 
Telephone: 0113 343 3484 
Alternatively, you can contact Dr David Alldred, Emma’s supervisor: 
Email: D.P.Alldred@leeds.ac.uk 
Telephone: 0113 343 1805 
Ethics approval 
Ethical Approval from the NHS HRA Social Care Ethics Committee and HRA approval was 
granted on the 2nd May 2017, reference number 17/IEC08/0017 and IRAS Project ID 
215674. 
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Exploring barriers and facilitators to reducing inappropriate 
medicines in care homes 
Participant information sheet: Healthcare professionals and care 
home staff 
You are being invited to take part in a research project.  Before you decide whether to take 
part or not it is important for you to understand why the research is being conducted and 
what it will involve.  Please take time to read the following information carefully and discuss it 
with others if you wish.  Please use the contact details at the bottom if there is anything that 
is not clear or if you would like more information.  Take your time when deciding whether or 
not to take part. 
What is the purpose of the study? 
Care home residents often have a number of health conditions, and are prescribed an 
average of 8-10 medicines every day.  As you will be aware, this polypharmacy can 
potentially cause side effects, adverse drug events and reduce care home residents’ quality-
of-life.   
The aim of the research is to explore the barriers and facilitators to stopping inappropriate 
medicines, “deprescribing”, in care homes.  Interviews will be conducted to find out why care 
home residents are sometimes prescribed medicines which are not useful to them anymore, 
and to explore people’s views on stopping these medicines.  
The information collected from the interviews will be used to design an intervention to 
facilitate appropriate deprescribing in care homes as part of a three-year PhD project. 
Why have I been chosen? 
You have been chosen because you are responsible for prescribing medicines for care 
home patients and stopping inappropriate medicines.   
What do I have to do? 
In order to take part, you will be interviewed by Emma Bolton, a PhD student from the 
University of Leeds.  The interview will be a one-to-one interview and will last 30-60 minutes.  
The interview will take place at your place of work, or over the telephone.   
You will be asked questions about your views of stopping unnecessary medicines for care 
home residents, including exploration of any barriers and facilitators to this process that you 
have encountered.  This will include reflection on your own practice as well as your 
understanding of the practice of the GP profession as a whole.  It will also include 
consideration of any tools that you feel could assist you to identify and stop inappropriate 
medicines for care home residents. 
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What are the possible disadvantages and risks of taking part? 
No risks to taking part have been identified.  A disadvantage to taking part is that you would 
have to give up some of your time to participate. 
What are the possible benefits of taking part? 
Taking part in the project will offer you the opportunity to reflect on your working practices.  
Your views will help us to identify the barriers and facilitators to reducing inappropriate 
medicines and therefore contribute to developing a successful intervention to improve the 
care of care home residents. 
Do I have to take part? 
You do not have to take part.  It is up to you to decide whether or not to take part.  If you do 
decide to take part, you will be given this information sheet to keep and you will be asked to 
sign a consent form.  After you have signed the consent form, you can still withdraw from the 
study at any point until two weeks after the interview.  You do not have to give a reason. 
If you decide not to take part, that’s OK.  Thank you for taking the time to consider the study, 
you do not need to do anything else.  
Will I be recorded, and how will the recording be used? 
The interview will be audio recorded and transcribed.  The transcript will then be analysed.  
Quotes from your interview may be used in publications, at conference presentations and 
lectures, however the quotes will be anonymous. 
Will my contribution be kept confidential? 
The interview is confidential and the data will be anonymised, however if you reveal anything 
which raises safeguarding or similar concerns, this may have to be discussed with the 
supervisors of the project or the care home manager.  However, this will be discussed with 
you before anyone else is involved.  Similarly, if you reveal information that suggests you 
have breached your duty of care this will be referred to the practice/care home manager, the 
General Medical Council and/or the Care Quality Commission, as appropriate.   The local 
safeguarding team is aware of this project.   
The results of the research will be published within the next two years.  No identifiable 
information will be revealed in any publication. 
The interview recordings will be kept securely at the University of Leeds until the PhD thesis 
has been submitted, then they will be destroyed.  The written interviews will be kept securely 
at the University of Leeds for two years after the results have been published, and then they 
will be destroyed as well.  The storage of the recordings and written interviews will comply 
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with the Data Protection Act 1998, the Human Rights Act and the University of Leeds’ Code 
of Practice on Data Protection. 
What will happen to the results of the research project? 
The results will be published in an appropriate peer reviewed journal and presented at 
conferences and in lectures.  Your involvement will be kept anonymous and no-one will 
know, or be able to work out, that you took part. 
Withdrawing from the project 
You can withdraw from the project at any time before or during the interview, and for two 
weeks after the interview.  If you do withdraw, the recording and notes taken during the 
interview will be destroyed and none of your contributions will be used.  Analysis of the 
interview will start two weeks after the interview, and it will no longer be possible to withdraw 
after this point.  You do not have to give a reason for wishing to withdraw. 
Who is organising/funding the research? 
The research is being organised and funded by the School of Healthcare at the University of 
Leeds. 
Contact for further information 
Contact Emma Bolton, PhD student and interviewer, for further information: 
Email: hcevb@leeds.ac.uk 
Telephone: 0113 343 3484 
Alternatively, you can contact Dr David Alldred, Emma’s supervisor: 
Email: D.P.Alldred@leeds.ac.uk 
Telephone: 0113 343 1805 
Ethics approval 
Ethical Approval from the NHS HRA Social Care Ethics Committee and HRA approval was 
granted on the 2nd May 2017, reference number 17/IEC08/0017 and IRAS Project ID 
215674. 
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Appendix G: Recruitment letters 
The following is an example of the recruitment letter sent to care homes and GP practices.  
The content of the letter reflected the setting of the destination. 
Emma Bolton 
Room 3.35, Baines Wing 
University of Leeds 
Leeds 
LS2 9JT 
 
0113 3433484 
hcevb@leeds.ac.uk 
 
XX/XX/XXXX 
[Care home/GP practice address, or body of letter could be sent by email] 
 
Dear XXXXX, 
 
I am a PhD student at the University of Leeds, conducting research into the barriers and 
facilitators to stopping inappropriate medicines for care home residents.  As you will be 
aware, care home residents are prescribed many medicines, some of which are probably not 
necessary, and we are seeking to work out why this is and how we can reduce the burden of 
medicines for residents and staff. This project will involve interviewing care home residents, 
their relatives and staff as well as general practitioners and pharmacists who provide a 
service to care homes. I am writing to enquire as to whether you would be happy for your 
residents, their relatives and your staff to be approached to participate in a one-off interview. 
The project has received ethical approval from the School of Healthcare Research Ethics 
Committee and any individuals wishing to participate would be asked to provide informed 
consent. 
The project aims to: 
299 
 
 
• Find out why care home residents are sometimes taking medicines that may not be 
useful anymore,  
• Explore how people feel about stopping medicines which may not be useful anymore 
• Work out how inappropriate medicines can be reduced. 
Participants will be asked to take part in a one-to-one interview with myself.  The interview 
will last 30-60 minutes and will take place in the care home at a mutually convenient time; 
staff and relatives of care home residents will have the option of taking part in a telephone 
interview.   
Please find enclosed/attached example participant information sheets for care home 
residents, their relatives and care home staff. 
Please do not hesitate to contact me for more information.  I will follow up this letter in two 
weeks with a telephone call to discuss the project with you. 
I look forward to hearing from you, 
 
 
 
Emma Bolton 
PhD student 
University of Leeds 
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Appendix H: Confirmation of care home participation in the 
research project: 
The following form was signed by care home managers to indicate they were aware of 
research being conducted on the premises 
Confirmation of care home participation in the research project: 
How do people who live in care homes, their residents and care 
home staff feel about the medicines taken by care home residents? 
 
I can confirm that I,          ,  
 
manager of             
 
             
give permission for the research project to be undertaken and am aware of the research 
activity taking place in the care home. 
 
Signed:           
Care home manager 
 
Date:            
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Appendix I: Sample interview schedules 
This appendix contains two interview schedules.  The first was utilised in interviews with 
residents and relatives (with pronouns reflecting the participant’s role) and the second was 
utilised in interviews with healthcare professionals and care home staff (again, amended 
only to reflect the occupation of the participant). 
Interview schedule: Care home residents and relatives 
Hello, my name is Emma.  I’m a student and I’m doing some research at the University of 
Leeds.  Thank you for letting me come today to talk to you as part of the study.   
Today, I’d like to talk to you about medicines.  I’m trying to find out, in general, how people 
feel about their medicines, how many they take, how they would feel about stopping 
medicines which might not be useful anymore, that sort of thing.  No-one is going to stop any 
of your medicines because of our conversation.  I just want to find out how you feel about the 
amount of medicines you take. 
Please can I confirm that I have your consent to talk to you for this research? 
I’m going to record our conversation on this (show dictaphone/recording equipment).  Is that 
OK? 
After our conversation, I will listen to the interview and write it down.  Is that OK? 
Only you and I will know what you say in this interview, and I won’t tell anyone your name.  
However, if you tell me something that concerns me I might have to speak to someone about 
it that could help.  I will talk to you about this before I do it though. 
You do not have to answer any questions that you don’t want to. If you don’t want to answer 
a question, just let me know.  
We can stop the interview at any time, just let me know.  We can also take a break if you 
need to, again just let me know. 
Is there anything you want to ask me before we start? 
1 Can you tell me about the medicines you take? 
Prompts:  
Do you know why you take them?/What do you understand about your 
medicines?/Why do you think you need them? 
 
302 
 
 
How do you take them? 
Do you have any eye drops, creams, patches, injections etc.? 
3 Do you think all your medicines help you? 
Prompts: 
Which ones do you think help you?  Why? 
Which ones do you find most beneficial? Why? 
Are there any you particularly like taking? Why? 
 
2  
Do you feel happy about the number of medicines that you take? 
Prompts:  
Do you like taking your medicines?  Why/why not? 
 
4  
 Would you like to take more medicines?   
Prompts: 
What for?  If not, why not? 
How would you feel if your doctor wanted to start some more 
medicines? 
Do you feel there is more your medicines can do? 
 
5 Are there any medicines you wish you didn’t have to take? 
Prompts: 
Are there any medicines you don’t like taking? 
Have you ever thought about doing anything about this? 
What could you do?  
Why haven’t you? 
Which ones would you like to stop and why? 
Are there any medicines which make you feel unwell? 
What would make you want to stop taking a medicine? (Further 
prompts: side effects, drug interactions) 
 
6 Have you ever tried to stop any of your medicines before?  
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Prompts:  
Situation: Have you ever taken any medicines in the past that made 
you feel unwell? 
Situation: Have you ever taken any medicines in the past that you 
didn’t like taking? 
What happened to these medicines – did you talk to anyone about 
them? 
What happened – who did you speak to?  Was it a positive or negative 
experience? 
7 If you wanted to stop some of your medicines, what would you do? 
Prompts:  
Situation: If you started a medicine and it made you feel unwell, what 
would you do? 
Who would you speak to?  (Further prompts: CH staff? Family? GP?)  
Would anyone try to stop you or help you? Why do you think they 
might do this?  (Further prompts: Family? GP?) 
What support would you need to help you stop taking a medicine – 
e.g. family, CH staff, GP, alternatives, “trial” 
 
8 Can you think of a time in the future where you might want to stop 
taking some medicines? 
Prompts:  
Situation: if in the future you became unwell or if you had difficulty 
swallowing and you found it difficult to take your medicines, how would 
you feel? 
What if you had to get your medicines by injection, or by swallowing 
liquids instead? 
Would you talk to your doctor about this? Or family/staff? 
Would you feel comfortable talking to the doctor/family etc about this? 
 
9 If your doctor suggested stopping some of your medicines they felt 
weren’t useful to you any more, how would that make you feel? 
Prompts:  
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Are there any medicines you wouldn’t want the doctor to stop? 
What would you do if they suggested stopping that? 
Would you agree or disagree? 
Would it make you feel worried/scared/sad/happy/relieved? 
Would you be worried about withdrawal/your condition getting worse? 
How do you think your family would feel about this? Explore – 
supportive? Unhappy? 
12 If a pharmacist or nurse suggested stopping some medicines they felt 
weren’t useful to you any more, how would that make you feel? 
Prompts:  
Explore beneficial medicines again. 
Would you agree or disagree? 
Would you want a second opinion or to speak to anyone else about 
this? 
Would it make you feel worried/scared/sad/happy/relieved? 
How do you think your family would feel about this?  Supportive?  Not 
happy? Why? 
Explore if different to a doctor. 
 
10 Have you ever talked to your doctor about your medicines? 
Prompts: Has anyone spoken to you about them or explained why 
you need them?  Would you find that useful? 
If your doctor wanted to change your medicines, would you want them 
to discuss that with you?   
Would you feel comfortable talking to the doctor about changing your 
medicines? 
How would you feel if your doctor changed your medicines without 
talking to you? 
Do you think you are the best person for the doctor to talk to about 
your medicines? Explore – why?  If not, who should the doctor speak 
to? 
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Would you like/prefer your doctor to talk to anyone else about your 
medicines? 
Can you think of a time when a decision was made about your 
medicines?  Were you involved?   
 
   
13 Do you ever talk to the staff about your medicines? 
Prompts:  
Do you feel they can advise you? 
If you haven’t, do you think you could? Explore. 
If you have, what did you talk about? Were you happy with the 
conversation? 
Do you feel in control of your medicines? 
How did you manage your medicines before you lived here? 
If they self-managed: Were you managing?  Did that stop when you 
came here?  Were you involved in that decision? How did it make you 
feel to stop managing them?   
Do you feel like you have a choice of whether to take your medicines 
or not?  Do they ask them if you want to take them? 
If not asked, would you like to be asked?  
 
 
14 If the patient has family: 
 
Have you ever spoken to your family about your medicines? 
Prompts:  
If yes – what do you talk about?  Are you comfortable talking to them 
about your medicines/do you like them to be involved?  Do you think 
they know what you take? 
If no – why not?  Are you not comfortable/don’t like them to be 
involved etc – explore.   
Do your family speak to the staff/your doctor about your medicines? 
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16 Is there anything else you would like to add to our conversation?  
 
 
Thank you for talking to me today, your answers have been very helpful.   
Are you still happy for me to use our conversation as part of my research?   
OK, just to let you know that you have two weeks to let me know if you want to change 
anything you have said to me or add anything you have forgotten – XX/XX/XXXX.  You also 
have two weeks, until XX/XX/XXX to decide if you no longer want to be a part of the study.  
Just let me know (provide contact details). 
Do you have any other questions? 
Please do not hesitate to get in touch if you have any questions, wish to change your 
answers or leave the study.
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Interview schedule: Healthcare professionals and care home staff 
Hello, my name is Emma.  I’m a PhD student at the University of Leeds.  Thank you for 
agreeing to take part in the study.  Today, I’d like to talk to you about the process of 
deprescribing unnecessary medicines for care home residents. 
Firstly, please can I confirm that you consent to be a part of this research project? 
The interview will be recorded [show dictaphone] and transcribed.  Do you consent to this? 
We can end the interview at any point, and you do not have to answer any question that you 
do not want to.  Just let me know during our conversation.  
The interview is confidential and the data will be anonymised, however if you reveal anything 
which raises safeguarding or similar concerns I may have to discuss this with appropriate 
people.  I will also have to speak to the appropriate authorities if it is revealed that you have 
breached your duty of care.  I will discuss this with you before doing so. 
Before we start, do you have any other questions? 
1 
Knowledge  
Are you aware of the concept of deprescribing? (The process of a trial 
of inappropriate medicines) 
Prompts:  
What do you understand it to mean? 
Have you heard the term before? 
Do you, or anyone you know, use the term? 
Do you know any evidence about deprescribing? 
Do you know of any deprescribing procedures? 
 
2 
Intentions 
Do you want to reduce the amount of medicines care home residents 
take?  
Prompts:   
Do you think this is important? 
How much – is it a priority? 
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3 
Skills 
Have you ever been involved in deprescribing for a resident? Or How 
often are you involved in deprescribing for care home residents? 
Prompts:  
What happened?  Was this easy? 
If not, why haven’t you been? Do you think it would be easy? 
Do you think all the medicines residents in your care take are useful to 
them? 
What happens when a pharmacist or nurse suggests deprescribing – 
is this helpful to you? 
Would pharmacist and nurse prescribers help with this process? 
 
4 
Memory, attention and decision process 
What would you do if you thought a resident would benefit from 
stopping a medicine?  
Prompts:  
How does it usually come about – routine review or ad-hoc? 
Who would you speak to? Resident/relative/care home staff/other 
HCP? 
Would anything interfere with this process for you? 
Would anything make this process easier? 
What would you do if a resident or relative told you they wanted to 
stop one of their medicines? 
Is this the sort of thing you would make a priority to deal with? 
 
5 
Memory, attention and decision process 
Are there any scenarios where you might decide not to proceed with 
the deprescribing process for a resident? 
Prompts:  
How would you feel if: 
- The resident has dementia,  
- Their family could not be reached, 
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- You were unsure about the potential consequences? 
6 
Knowledge 
Do you feel you have the knowledge to recognise medicines which 
may be inappropriate for care home residents? 
Prompts:  
Would training help?  If so, what in? 
What do you think you need to know to be involved in deprescribing? 
Do you feel your knowledge is lacking in any area? 
 
7 
Beliefs about capabilities 
Do you feel able to stop medicines for relatives in your care? 
Prompts: 
Do you feel confident deprescribing for residents? 
Is there anything that would help you feel more confident making 
these suggestions? 
How do you think these suggestions would be received by the 
resident/their relatives/CH staff/other healthcare professionals? 
 
8 
Social and professional role and identity 
Who do you think is responsible for deprescribing in care homes?  
You may think it is one person, or more than one person. 
Prompts:  
Do you think you have a role in deprescribing for care home 
residents? 
Do you think you should have a role in deprescribing? 
How do you find working with the multi-disciplinary team in care 
homes? 
What do you think the role of CH staff/GPs/relatives/the resident or 
other HCPs is? 
Do you feel comfortable talking to other healthcare professionals/care 
home staff/residents/relatives about the medicines taken by the 
resident? 
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Do you think that other healthcare professionals, such as nurses and 
pharmacists, can play a bigger role in the process than they do now?  
Would a prescribing qualification be necessary? 
9 
Reinforcement 
Is there anything stopping you from being involved in deprescribing? 
Prompts: 
Is there anything that could encourage you to be involved in 
deprescribing? 
If they are regularly involved in deprescribing: What do you think may 
stop others from being involved in deprescribing? 
CQUIN 
Specialists 
 
10 
Environmental consequences and resources 
Are there any competing tasks or time constraints that stop you being 
involved in deprescribing? 
Prompts:  
Do you think any of these are specific to care homes? 
Do these things stop you discussing a resident’s medicines with them 
and/or their relatives, or are there other tasks that prevent this?  
 
11 
Environmental consequences and resources 
Do you have the resources available to help you to reduce the number 
of medicines care home residents take? 
Prompts:  
What would help? 
How much does any perceived lack of resource impact on your 
deprescribing behaviour? 
If you had the right resources, would you suggest deprescribing for 
your residents more regularly? 
Anything specific to care homes? 
 
12 
Behavioural regulation  
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What do you feel you need to enable you to assist with deprescribing 
in care homes?  
Prompts:  
What barriers have you encountered?  What barriers do you think you 
might encounter? 
What would facilitate the process? 
How could you change your working practices? 
What could you do to do more deprescribing in care homes? 
What could other people in the multi-disciplinary team do? 
13 
Optimism  
Do you think that deprescribing will become a routine part of the care 
you and other GPs offer to residents? 
Prompts: 
Do you think that deprescribing should become a routine part of the 
care offered to residents? 
 
14 
Beliefs about consequences 
What do you think about the potential consequences of deprescribing 
for care home residents might be? 
Prompts:  
Do you think it’s worth doing? 
Do the potential consequences concern you?  Or do you think they 
would be positive? 
What about consequences for the resident/their relatives/colleagues 
care homes/NHS? 
If they only highlight positive consequences, suggest some negative 
ones and vice versa to see how they would feel about that. 
 
15 
Emotion 
How does the prospect of deprescribing in care homes make you 
feel? 
Prompts:  
How do you feel about the medicines taken by care home residents? 
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Do you feel like it’s too much/not enough? 
Do you feel responsible at all for the medicines taken by the residents 
in your care? 
How does that make you feel? 
What could help you overcome this? 
16 
Is there anything else that you would like to add?  
 
Thank you for taking part in the interview, your answers will be very useful and will help us to 
gain insight into deprescribing behaviours in care homes.  Are you still happy to be a part of 
the study? 
You have a period of two weeks, until XX/XX/XXX, to think about the interview and get in 
touch to amend your responses, add something or withdraw from the study. 
Do you have any other questions? 
Please do not hesitate to get in touch if you have any questions, wish to change your 
responses or leave the study. 
Provide contact details. 
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Appendix J:The frameworks developed during framework analysis 
During framework analysis, the resident and relative interview data were analysed together, 
and the GP, pharmacist and care home staff interview data were also analysed together thus 
forming two analysis groups.  As described in Chapter 3, section 3.8, themes and 
subthemes were developed from the data and utilised to create frameworks into which the 
data was sorted.  Three frameworks for each analysis group were created, one for each 
theme developed.  The subthemes developed formed the columns, and the participants the 
rows, of the frameworks as demonstrated in Figure 11. 
Below in tables 54 and 55 are the themes and subthemes which formed each of the 
frameworks utilised during framework analysis. 
Table 54: Frameworks developed during the analysis of the resident and relative 
interview data 
Frameworks, based on themes 
developed 
Columns of the framework matrices, 
based on the subthemes developed 
Life as a care home resident Being a care home resident 
Being involved in care 
The future 
Medicines and health Concerns about medicines 
Making sense of medicines 
Navigating ill health 
Response to medicines change 
Roles and relationships Managing views and information 
Perceptions of staff and systems 
Trust in others 
314 
 
 
Table 55: Frameworks developed during the analysis of the GP, pharmacist and care 
home staff interview data 
Frameworks, based on themes 
developed 
Columns of the framework matrices, 
based on the subthemes developed 
Environmental context and resources Healthcare systems 
Skills and knowledge 
Tools and resources 
Making sense of medicines Attitudes to deprescribing 
Deprescribing in practice 
Understanding of medicines taken by care 
home residents 
Social influences Residents and relatives 
Roles and responsibilities 
Working with others 
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Appendix L: Training attended by the author during the research 
programme 
General training 
Training attended Date 
Word for Thesis Part 2 (Final Year)  23.11.18 
Word for Thesis Part 1  30.10.18 
Maintaining Motivation Workshop  18.09.18 
The Finishing Thesis Writer  22.03.18 
NVivo Part 2  21.03.18 
Safeguarding Data 14.11.17 
NVivo Part 1  07.11.17 
Intro to Data Protection & GDPR Research  17.11.16 
NHS Ethical Approval Process 11.11.16 
Vulnerable Research Participants & Mental Capacity  09.11.16 
Word for Thesis Part 1  25.05.16 
NVivo Part 1  03.05.15 
Research with Human Participants  15.01.16 
6th Postgraduate Researcher Conference  08.12.15 
Project Managing Your Research Degree  02.12.15 
Ethics & Ethical Review  24.11.15 
Faculty of Medicine and Health Literature Searching  04.11.15 
Faculty of Medicine and Health Starting your Research Degree 13.10.15 
 
Training specific for the PhD 
Training attended Date 
Consulting with older people CCPE workshop 05.07.17 
Safeguarding children and vulnerable adults level 2 CPPE training 13.04.17 
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NHS ethical approval process 11.11.16 
Vulnerable people and the mental capacity act 09.11.16 
IRAS e-learning course 12.09.2016 
Sense about Science: Voice of Young Science Media Workshop 08.04.2016 
CPPE The mental capacity act (2005) and covert administration of 
medication 
20.01.2015 
Care home visit with a practice pharmacist 01.12.2015 
 
Other training activities 
Participation in University groups such as the Early Careers Research Network and the 
medicines optimisation research theme group. 
I continued to locum throughout my PhD to maintain my skills in practice, and took part in 
teaching opportunities within the school.
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Appendix L: Abstracts presented at conferences throughout the 
course of the research programme 
Abstract for presentation at FIP conference 2018, Glasgow 
Deprescribing: barriers and facilitators to stopping inappropriate medicines in long-
term care facilities 
Bolton E.V, Easthall C, Spilsbury K, Alldred DP 
School of Healthcare, University of Leeds 
Background information 
Millions of older people globally live in long-term care and inappropriate polypharmacy is 
prevalent in this context which can lead to adverse drug events, hospital admissions and 
poorer quality of life.1,2  Reducing inappropriate prescribing is an international priority and 
deprescribing (the cessation of inappropriate medicines) is a potential solution. 
Purpose 
To gain an understanding of barriers and facilitators to deprescribing for older people living 
in care homes to inform development of a novel intervention. 
Method 
Semi-structured interviews were conducted with care home residents and relatives. 
Interviews were audio-recorded and transcribed. Themes and explanations were developed 
using framework analysis. 
Results 
11 residents and 4 relatives were interviewed from 8 homes. Analysis revealed themes of: 
making decisions; medicines and health; roles and relationships; passivity. Barriers to 
deprescribing included: difficulties communicating with residents and healthcare 
professionals; concerns about stopping medicines, e.g. recurrence of the condition the 
medicine was being used to treat. Facilitators included having good relationships with 
healthcare professionals. 
Conclusion 
There is a paucity of research on the views of this vulnerable population about 
deprescribing. Practitioners involved in deprescribing should involve and empower residents 
and relatives to make informed decisions about residents’ care. The results will be used to 
create a behaviour change intervention to facilitate deprescribing in care homes. 
